

Sunday, 30. March 2025*Non-Profit Symposium*

08:30 - 10:00

R2

IS01 - Steroid-resistant GVHD: A discussion about complex cases | SFGM-TC

Stéphanie Nguyen (France)

Anne HUYNH (France)

IS01-1	Clinical cases of Acute graft-versus-host disease Florent Malard (Paris, France) Maud D'Aveni (France)	08:30 - 09:10
IS01-2	Clinical cases of Chronic graft-versus-host disease Edouard Forcade (Pessac, France) Etienne Daguindau (France)	09:10 - 09:50
IS01-3	Questions & Discussion - All the speakers of the session	09:50 - 10:00

Non-Profit Symposium

08:30 - 10:00

R3

IS02 - Optimizing outcomes in allogeneic stem cell transplantation | ATERHIT / Sorbonne

Arnon Nagler (Tel Aviv, Israel)

Eolia Brissot (Paris, France)

IS02-1	The ideal donor for haploidentical HCT Annalisa Ruggeri (Italy)	08:30 - 08:45
IS02-2	PTCy compared to ATG as GVHD prophylaxis with sibling and unrelated donors in AML Arnon Nagler (Tel Aviv, Israel)	08:45 - 09:00
IS02-3	Management of acute GVHD Yishan Ye (Hangzhou, China)	09:00 - 09:15
IS02-4	Maintenance therapy after allogeneic HCT in AML Ali Bazarbachi (Beirut, Lebanon)	09:15 - 09:30
IS02-5	Role of MRD in the allogeneic HCT setting Eolia Brissot (Paris, France)	09:30 - 09:45
IS02-6	Long-term complications of haplo-identical allogeneic HCT Bipin Savani (United States of America (the))	09:45 - 10:00

Non-Profit Symposium

08:30 - 10:00

R4

IS03 - What's new in myeloma?: the IFM perspective - With the institutional support of H.A.C. Pharma | IFM

Mohamad Mohty (Paris, France)

IS03-1	State of the art therapy of elderly but fit patients Thierry Facon (Lille, France)	08:30 - 08:50
IS03-2	Role of MRD as a pre-requisite for cure Jean-Luc Harousseau (France)	08:50 - 09:10
IS03-3	From auto-SCT to CAR-T cells: 40 years of progress Mohamad Mohty (Paris, France)	09:10 - 09:30
IS03-4	Toxicities of CAR-T cells in myeloma Zinaida Peric (Rijeka, Croatia)	09:30 - 09:50
IS03-5	Round table discussion - All Speakers	09:50 - 10:00

Non-Profit Symposium

08:30 - 10:00

R5

IS04 - GMMG symposium

Hartmut Goldschmidt (Heidelberg, Germany)

Hans Salwender (Hamburg, Germany)

IS04-1	Therapy of newly-diagnosed multiple myeloma patients Hartmut Goldschmidt (Heidelberg, Germany)	08:30 - 08:43
IS04-2	Treatment of high-risk multiple myeloma Lisa Leypoldt (Hamburg, Germany)	08:43 - 08:56
IS04-3	Role of CART therapy and bispecific Antibody in multiple myeloma Christof Scheid (Cologne, Germany)	08:56 - 09:09
IS04-4	Therapy of relapsed multiple myeloma patients outside immunotherapies Hans Salwender (Hamburg, Germany)	09:09 - 09:22
IS04-5	Immune deficiencies and prophylactic strategies during immunotherapies Igor-Wolfgang Blau (Berlin, Germany)	09:22 - 09:35
IS04-6	Update on Amyloidosis	09:35 - 09:35
IS04-7	Q&A	09:35 - 09:55

Nurses Group

08:30 - 10:00

R7

NG01 - Nurses Education Day 1 | The four pillars of transplant and cell therapy nursing care: Clinical practice

Claudia Boglione (Florence, Italy)

Marijke Quaghbeur (Ghent, Belgium)

NG01-1	Developing excellence in identifying the unwell patient Chiara Cannici (Alessandria, IT, Italy)	08:30 - 08:51
NG01-2	Developing excellence in identifying acute GVHD Sophie Van Lancker (Gent, Belgium)	08:51 - 09:12
NG01-3	Developing excellence in pain assesment and management Sarah Jayne Liptrott (Bellinzona, Switzerland)	09:12 - 09:33
NG01-4	Developing excellence in understanding conditioning toxicities Anna Serrahima (BARCELONA, Spain)	09:33 - 09:54
NG01-5	Q&A	09:54 - 10:00

Non-Profit Symposium

08:30 - 10:00

R9

IS00 - Challenges in Stem Cell Transplantation for Myelofibrosis | University Medical Center Hamburg-Eppendorf

Nicolaus Kröger (Hamburg, Germany)

Alessandro Rambaldi (Bergamo, Italy)

IS00-1	Welcome Nicolaus Kröger (Hamburg, Germany) Nico Gagelmann (Hamburg, Germany)	08:30 - 08:35
IS00-2	Splenectomy vs Spleen irradiation in JAKi refractory patients prior to transplantation Maria Chiara Finazzi (Bergamo, Italy)	08:35 - 08:50
IS00-3	ATG or PTCy to facilitate engraftment and prevent GvHD	08:50 - 09:00

	Patrizia Chiusolo (Roma, Italy)	
IS00-4	Individual timing of reducing Immunosuppression and start DLI Nico Gagelmann (Hamburg, Germany)	09:00 - 09:15
IS00-5	Genomics to optimize decision making regarding transplant indication Marie Robin (Paris, France)	09:15 - 09:30
IS00-6	Allograft for accelerate and blastic phase Kordelia Barbullushi (Milan, Italy)	09:30 - 09:40
IS00-7	Podium Discussion - All	09:40 - 10:00
<i>Statistics</i>		
08:30 - 12:00		R12
STATS-C1 - Basic course in Statistics 1		
Jacques - Emmanuel Galimard (Paris, France)		
STATS-C1-1	Protocol of a study: A study from the "idea" to the analysis plan	08:30 - 08:30
STATS-C1-2	Data collection and checking	08:30 - 08:30
STATS-C1-3	Descriptive statistics	08:30 - 08:30
STATS-C1-4	Comparison of groups for continuous data	08:30 - 08:30
STATS-C1-5	Comparison of groups for qualitative data	08:30 - 08:30
STATS-C1-6	Correlation and linear regression analyses	08:30 - 08:30
STATS-C1-7	Logistic regression	08:30 - 08:30
STATS-C1-8	Description for time to event outcome (without competition): The Kaplan Meier method	08:30 - 08:30
STATS-C1-9	Comparison of time to event outcome (without competition): The logrank test	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Haematopoietic Stem Cells		
A001	MYELODYSPLASIA-RELATED GENETIC MUTATIONS ARE ASSOCIATED WITH IMPROVED SURVIVAL FOLLOWING HMA MAINTENANCE TREATMENT AFTER ALLO-HSCT IN ADULT AML PATIENTS WITH ADVERSE-RISK Luxiang Wang (Shanghai, China)	08:30 - 08:30
A002	MULTICENTER VALIDATION OF THE NEWLY DEVELOPED CONCISE OBJECTIFIABLE RISK EVALUATION (CORE) SCORE FOR NON-RELAPSE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Gunnar Weise (Hamburg, Germany)	08:30 - 08:30
A003	IMPACT OF FLT3-INHIBITOR MAINTENANCE POST ALLOGENEIC STEM CELL TRANSPLANT ON ACUTE MYELOID LEUKEMIA PATIENTS WITH FLT3-ITD AND ASSOCIATED NPM1/DNMT3A MUTATIONS - MULTI-CENTER RETROSPECTIVE STUDY Dennis Dong Hwan Kim (Toronto, Canada)	08:30 - 08:30
A004	PHARMACOLOGICAL SUPPRESSION OF SEX HORMONES PROMOTES LYMPHOPOIESIS AND MEGAKARYOPOIESIS IN A LUTEINIZING HORMONE-DEPENDENT MANNER	08:30 - 08:30

	Enrico Velardi (Rome, Italy)	
A005	DEEP IMMUNOPHENOTYPING EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION REVEALS NOVEL ASSOCIATIONS BETWEEN FUNCTIONAL IMMUNE CELL RECONSTITUTION, IMMUNE-STIMULATED WHOLE BLOOD FUNCTION AND CLINICAL OUTCOMES Patrick Terrence Brooks (Copenhagen, Denmark)	08:30 - 08:30
A006	POST-TRANSPLANT MAINTENANCE THERAPY IN WILD-TYPE FLT3 ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: A BICENTRIC REAL-LIFE EXPERIENCE Alessandra Cipiciani (Ancona, Italy)	08:30 - 08:30
A007	EARLY B CELL IMMUNE RECONSTITUTION AS A PREDICTOR OF NON-RELAPSE MORTALITY IN T CELL DEPLETED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Alexandre G. Troullioud Lucas (New York, United States of America (the))	08:30 - 08:30
A008	HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER CAR19 T-CELL THERAPY IN B-ALL: A GOCART COALITION STUDY ON BEHALF OF THE PDWP, ALWP, AND CTIWP OF THE EBMT Adriana Balduzzi (Monza, Italy)	08:30 - 08:30
A009	EARLY SECONDARY CANCERS AFTER HAPLO-IDENTICAL ALLOGRAFT TRANSPLANTATION: RETROSPECTIVE MULTICENTER STUDY BY THE SFGM-TC Thomas Fatrara (Saint-Etienne, France)	08:30 - 08:30
A010	GERIATRIC ASSESSMENT SCORE FOR PREDICTING THE OUTCOME FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS AGED OVER 50 YEARS: RESULTS FROM A PROSPECTIVE ITALIAN SINGLE-CENTER STUDY Eugenia Accorsi Buttini (Brescia, Italy)	08:30 - 08:30
A011	EVOLVING TRENDS IN MORBIDITY AND MORTALITY OF IDIOPATHIC PNEUMONIA SYNDROME AND DIFFUSE ALVEOLAR HEMORRHAGE IN POST-STEM CELL TRANSPLANT PATIENTS WITH PRE-EXISTING PULMONARY DISEASE Samridhi Sinha (Brooklyn, United States of America (the))	08:30 - 08:30
A012	THE INFLUENCE OF BONE DISEASES ON MORBIDITY, MORTALITY, AND HEALTHCARE COSTS IN POST-STEM CELL TRANSPLANT PATIENTS Samridhi Sinha (Brooklyn, United States of America (the))	08:30 - 08:30
A013	THE IMPACT OF HLA-DQ8 HAPLOTYPE ON RELAPSE RISK AND GRAFT-VERSUS-LEUKEMIA EFFECT FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER ANALYSIS ON 400 PATIENTS Giulia Losi (Pavia, Italy)	08:30 - 08:30
A015	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH MDS AND AML SECONDARY TO INHERITED BONE MARROW FAILURE SYNDROMES AND INBORN ERRORS OF IMMUNITY Tatiana Bykova (Saint-Petersburg, Russian Federation (the))	08:30 - 08:30
A016	NON-REMOVAL DSA PROTOCOL PROMOTES HEMATOPOIETIC RECONSTRUCTION IN HAPLOIDENTICAL AND MMUD HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH POSITIVE DSA: A RETROSPECTIVE MULTICENTER CASE-CONTROL STUDY Jian Zhou (Zhengzhou, China)	08:30 - 08:30
A017	PREDICTIVE FACTORS AND IMPACT OF MIXED CHIMERISM ON	08:30 - 08:30

	OUTCOME AFTER ALLOGENEIC HSCT FOR ACQUIRED APLASTIC ANEMIA: A RETROSPECTIVE MULTICENTRIC STUDY Flore Sicre de Fontbrune (Paris, France)	
A019	SHAPING THE FUTURE OF FRAILTY CARE IN ALLO-HCT CANDIDATES: A PROSPECTIVE TELE-PREHABILITATION PROJECT Raquel Salinas González (Barcelona, Spain)	08:30 - 08:30
A021	DETERMINATION OF THE CORRELATION BETWEEN SERUM VCAM-1, ANGPT-1, ANGPT-2, S1P AND OPN LEVELS AND ENGRAFTMENT AFTER AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION Nur Soyer (Izmir, Turkey)	08:30 - 08:30
A022	LONG-TERM EFFICACY AND SAFETY OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL). REAL-WORLD REPORT OF POLISH LYMPHOMA RESEARCH GROUP (PLRG) Beata Ostrowska (Warsaw, Poland)	08:30 - 08:30
A023	THE DIRE NEED OF ESTABLISHING ADULT AND PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER IN A RESOURCE LIMITED SETUP: A NEEDS ASSESSMENT STUDY Eden Biltibo (Nashville, United States of America (the))	08:30 - 08:30
A025	OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION IN TP53-MUTATED MYELOID MALIGNANCIES: A MULTICENTER CANADIAN STUDY Jonas Mattsson (Toronto, Canada)	08:30 - 08:30
A026	IMPACT OF INCREASING DOSES OF TREOSULFAN IN DOUBLE-ALKYLATING CONDITIONING REGIMEN ON LONG TERM OUTCOME IN ABTCR/CD19 DEPLETED HAPLOIDENTICAL HSCT IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES Lucia Prezioso (Parma, Italy)	08:30 - 08:30
A027	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) IN ADULTS WITH HEREDITARY MYELOID MALIGNANCIES, A SINGLE-CENTER STUDY Alejandro Morales Curbelo (Las Palmas de Gran Canaria, Spain)	08:30 - 08:30
A028	A COMPARATIVE STUDY OF THE EFFECT ON THE OUTCOMES OF HAPLO_HSCT USING HEMATOPOIETIC STEM CELL MOBILIZING REGIMENS CONTAINING PLERIXAFOR PLUS G-CSF VERSUS G-CSF ALONE Jing Long (Beijing, China)	08:30 - 08:30
A030	OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN PATIENTS WITH CHEDIAK HIGASHI SYNDROME ON BEHALF OF IEWP: PRELIMINARY REPORT Reem Elfeky (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
A031	GOLD STANDARD UNDER PRESSURE: THE UKRAINIAN EXPERIENCE OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS Nazarii Shokun (Kyiv, Ukraine)	08:30 - 08:30
A032	COMPARATIVE OUTCOMES OF AIRBORNE INFECTION CONTROL IN HEPA-FILTERED ROOMS WITHOUT POSITIVE PRESSURE VERSUS POSITIVE PRESSURE ROOMS FOR STEM CELL TRANSPLANTATION Michael W. Sunga (Taguig, Philippines (the))	08:30 - 08:30
A033	LONG-TERM SURVIVAL AFTER SEQUENTIAL CONDITIONING WITH FLAMSA AND TOTAL BODY IRRADIATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA	08:30 - 08:30

	Paula Kessler (Düsseldorf, Germany)	
A034	COMPARISON OF SEQUENTIAL CONDITIONING REGIMENS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA - A MULTICENTER RETROSPECTIVE STUDY OF THE SFGM-TC Victoria Volpari (Grenoble, France)	08:30 - 08:30
A035	LONG-TERM SURVIVAL POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: ASSESSING PREDICTIVE RISK TOOLS IN A COLOMBIAN COHORT Claudia Sossa-Melo (Floridablanca, Colombia)	08:30 - 08:30
A036	LONG-TERM OUTCOMES OF PATIENTS WITH CALM::MLLT10 POSITIVE HEMATOLOGICAL MALIGNANCIES FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Gai ling Zhang (Langfang, China)	08:30 - 08:30
A037	NOVEL FLOW CYTOMETRIC KIT FOR THE IDENTIFICATION, CHARACTERIZATION AND ENUMERATION OF HEMATOPOIETIC STEM CELLS FROM DIFFERENT BLOOD SOURCES Julia Dzionek (Bergisch Gladbach, Germany)	08:30 - 08:30
A038	VALIDATION AND CLINICAL APPLICATION OF GELOFUSINE AS AN ALTERNATIVE TO DEXTRAN40-BASED SOLUTIONS FOR WASHING CRYOPRESERVED HEMATOPOIETIC STEM CELLS Stefania Nappo (Naples, Italy)	08:30 - 08:30
A040	RISK ASSESSMENT AND SURVIVAL IN AUTO-HCT: 13-YEAR EXPERIENCE IN A COLOMBIAN CENTRE Claudia Sossa-Melo (Floridablanca, Colombia)	08:30 - 08:30
A041	PATIENT'S OUTCOME AFTER DONOR LYMPHOCYTE INFUSION ACCORDING TO DIFFERENT INDICATION: SAFETY AND FEASIBILITY Micheline Karam (Lille, France)	08:30 - 08:30
A042	AUTOLOGOUS VS. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOBLASTIC LYMPHOMA:ALLOGENEIC TRANSPLANTATION---A PREFERENTIAL SELECTION, BUT NO SIGNIFICANT ADVANTAGES Qian Cheng (Suzhou, China)	08:30 - 08:30
A043	FEASIBILITY AND TOLERABILITY OF FLT3 INHIBITORS AS MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN AML WITH MUTATED FLT3 Rosa Plos (Udine, Italy)	08:30 - 08:30
A044	EFFICACY OF A PHARMACOKINETICS-GUIDED BUSULFAN-CONTAINING CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH MYELOID HEMATOLOGIC MALIGNANCIES Cristina Astrid Tentori (Milano, Italy)	08:30 - 08:30
A045	THE SHORT-TERM CARDIOTOXICITY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER EXPERIENCE Jean El Cheikh (Beirut, Lebanon)	08:30 - 08:30
A047	IMPACT OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE ON GUT MICROBIOTA AND IMMUNE RECONSTITUTION: A COMPARATIVE ANALYSIS WITH MATCHED DONOR TRANSPLANTS Su-Peng Yeh (Taichung, Taiwan (Province of China))	08:30 - 08:30
A048	COMPARING THE CLINICAL OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS IN	08:30 - 08:30

	PATIENTS WITH APLASTIC ANEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Sirichai Puttirangsan (Chiangmai, Thailand)	
A049	EFFECT OF DONOR AND RECIPIENT HLA GENOTYPE ON GVHD (GRAFT VERSUS HOST DISEASE) AND RELAPSE-FREE SURVIVAL (GRFS) IN MYELODYSPLASTIC SYNDROME AND ACUTE LEUKEMIA Meltem Kurt Yüksel (Ankara, Turkey)	08:30 - 08:30
P001	MIXED CHIMERISM IN HAPLOIDENTICAL RELATED DONOR STEM CELL TRANSPLANTATION IN CHILDREN WITH ACUTE LEUKEMIA: DOES IT PREDICT THE RELAPSE OF PRIMARY DISEASE? Abdulmalik Al-Ghamdi (Riyadh, Saudi Arabia)	08:30 - 08:30
P002	CLINICAL PICTURE AND IMMUNE RECONSTITUTION POST-HAEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH WISKOTT ALDRICH SYNDROME - LATIN AMERICAN SINGLE CENTER EXPERIENCE María Pilar Tejada (Ciudad Autónoma de Buenos Aires, Argentina)	08:30 - 08:30
P003	TRENDS AND DEMOGRAPHICS OF STEM CELL TRANSPLANTATION IN THE UNITED ARAB EMIRATES: A RETROSPECTIVE ANALYSIS FROM THREE MAJOR TERTIARY CARE HOSPITALS (2009-2023) Naveed Syed (Abu Dhabi, United Arab Emirates (the))	08:30 - 08:30
P005	RESTING ENERGY EXPENDITURE MEASURED BY INDIRECT CALORIMETRY IN ADULTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION Anne Marte Gudmundstuen (Oslo, Norway)	08:30 - 08:30
P006	BUSULFAN PHARMACOKINETIC-GUIDED CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION: RESULTS FROM A SINGLE CENTER Cristina Rotolo (Palermo, Italy)	08:30 - 08:30
P007	AN ORAL MUCOSITIS-BASED CLASSIFICATION OF CONDITIONING TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Nicolas Simon (Lille, France)	08:30 - 08:30
P008	LONG-TERM OUTCOMES AND LATE-ONSET COMPLICATIONS IN PAEDIATRIC CHRONIC GRANULOMATOUS DISEASE (CGD) POST-HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) Valentina Guarnieri (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P009	EFFECTS OF AN EXERCISE PROGRAM PRE-ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION OVER PHYSICAL CONDITION AND BODY COMPOSITION IN PATIENTS WITH HEMATOLOGIC CANCER Javier Cornago Navascués (Madrid, Spain)	08:30 - 08:30
P010	NO CRYOPRESERVED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY MULTIPLE MYELOMA PATIENTS AGED ≥ 65 YEARS: A SINGLE CENTER EXPERIENCE FROM ORAN, ALGERIA Amal Bendimerad (Oran, Algeria)	08:30 - 08:30
P011	NO CRYOPRESERVED AUTOLOGOUS TRANSPLANTATION WITH A LOW CD34 + CELL &LT; 2 X 10⁶ IN MULTIPLE MYELOMA PATIENTS: A SINGLE CENTER EXPERIENCE FROM ORAN. ALGERIA Soraya Beichou (Oran, Algeria)	08:30 - 08:30

P013	OUTCOMES AND EARLY COMPLICATIONS OF ALLOGENEIC STEM CELL TRANSPLANT FOR HEMATOLOGIC MALIGNANCIES IN PATIENTS OVER 65 YEARS Selene Guerzoni (Ancona, Italy)	08:30 - 08:30
P014	SUCCESSFUL HAPLOIDENTICAL ALPHA-BETA TCR DEPLETION PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH HAPLOIDENTICAL ALPHA-BETA TCR DEPLETION FOR DADA2 DEFICIENCY: A CASE REPORT Raed ALZYOUN (Amman, Jordan)	08:30 - 08:30
P015	EFFICACY OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION IN PEDIATRIC MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE ANALYSIS Fang Liu (Tianjin, China)	08:30 - 08:30
P017	ORAL MUCOSITIS: INCIDENCE, PREVENTION, AND MANAGEMENT IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION Isaak Achach (Mexico City, Mexico)	08:30 - 08:30
P018	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SICKLE CELL DISEASE, EXPERIENCE OF A LOW-INCOME COUNTRY PRIVATE SERVICE Victor Zecchin (Sao Paulo, Brazil)	08:30 - 08:30
P019	THE EFFECT OF LONG-TERM CRYOPRESERVATION ON CORD AND PERIPHERAL BLOOD HEMOPOIETIC STEM CELLS Iordanis Pelagiadis (Heraklion, Greece)	08:30 - 08:30
P020	NUTRITIONAL PARAMETERS AS PREDICTORS OF COMPLICATIONS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION Javier Cornago Navascués (Madrid, Spain)	08:30 - 08:30
P021	OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A 14-YEAR RETROSPECTIVE ANALYSIS Joud Zanabali Al-Sibai (Oviedo, Spain)	08:30 - 08:30
P023	REAL-LIFE EXPERIENCE OF LETERMОВIR USE WITH ANTIFUNGAL TRIAZOLES IN A HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER: PREDICTING INTERACTIONS, OVERCOMING OBSTACLES, AND EVALUATING OUTCOMES Nicolas Simon (Lille, France)	08:30 - 08:30
P024	FEASIBILITY AND MORBIDITY-MORTALITY OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN OLDER ADULTS: INSIGHTS FROM A GERIATRIC ASSESSMENT Javier Cornago Navascués (Madrid, Spain)	08:30 - 08:30
P025	ESTABLISHING ALLOGENEIC STEM CELL TRANSPLANTATION AT THE UKRAINIAN NATIONAL CANCER INSTITUTE DURING WARTIME: A CASE REPORT ON OVERCOMING CHALLENGES AND GLOBAL COLLABORATION Nazarii Shokun (Kyiv, Ukraine)	08:30 - 08:30
P026	EXCELLENT OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SEVERE APLASTIC ANEMIA, A SINGLE CENTRE EXPERIENCE; 15 YEARS RESULTS Kent Mun Loh (Singapore, Singapore)	08:30 - 08:30
P027	OUTCOMES OF CHILDREN, ADOLESCENTS AND YOUNG ADULTS (CAYA) PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AHCT)	08:30 - 08:30

Khalid Halahleh (Amman, Jordan)

ePoster

08:30 - 18:00

R18

Infectious Complications

- | | | |
|------|--|---------------|
| A178 | INVESTIGATIONAL LIVE BIOTHERAPEUTIC SER-155 : BIOMARKER INSIGHTS FROM A PHASE 1B STUDY IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT)
Meghan Chafee (Cambridge, United States of America (the)) | 08:30 - 08:30 |
| A179 | AN EVALUATION OF LATE CMV REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS RECEIVING LETERMIVIR PROPHYLAXIS
Jessica Pealing (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A180 | EFFICACY AND SAFETY OF PRIMARY LETERMIVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTION IN PAEDIATRIC PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTRE, RETROSPECTIVE, REAL-WORLD ANALYSIS
Ye Guo (Tianjin, China) | 08:30 - 08:30 |
| A182 | CASE SERIES OF INVASIVE FUSARIOSIS IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH HIGHLY FAVORABLE OUTCOMES IN SETTING OF TREATMENT WITH FOSMANOGEPIX: A SINGLE-CENTER EXPERIENCE
Avneet Kaur (Duarte, United States of America (the)) | 08:30 - 08:30 |
| A183 | CMV INFECTIONS AND LETERMIVIR RESISTANCE IN FRANCE. DATA FROM THE NAVIRE, STEM-CELL RECIPIENTS REAL-LIFE COHORT
Pascal Turlure (Limoges, France) | 08:30 - 08:30 |
| A185 | HIGH CMV IGG TITERS PRE-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ARE ASSOCIATED WITH CMV INFECTIONS WITH OR WITHOUT LETERMIVIR PROPHYLAXIS
Léna Royston (Geneva, Switzerland) | 08:30 - 08:30 |
| A186 | EPSTEIN-BARR VIRUS-RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) IN SPAIN: TRENDS, CHARACTERISTICS, AND OUTCOMES IN A MULTICENTER GETH-TC STUDY
Irene García-Cadenas (Barcelona, Spain) | 08:30 - 08:30 |
| A187 | USE OF LETERMIVIR IN PAEDIATRIC AND YOUNG ADULT PATIENTS. A RETROSPECTIVE STUDY ON BEHALF OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH-TC)
Maria Trabazo del Castillo (Barcelona, Spain) | 08:30 - 08:30 |
| A188 | IMPLIED PHYSICIAN PREFERENCES FOR MARIBAVIR VS VALGANCICLOVIR FOR TREATMENT OF POST-HCT CMV: RESULTS FROM A MULTI-CRITERIA DECISION ANALYSIS
Miguel-Angel Perales (New York, United States of America (the)) | 08:30 - 08:30 |
| A189 | HUMORAL VACCINE RESPONSES IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES FOLLOWING CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
Sigrun Einarsdottir (New York, United States of America (the)) | 08:30 - 08:30 |
| A191 | NEGLECTED TROPICAL DISEASES (NTD) AND RELATED INFECTIONS IN HAEMATOPOIETIC CELLULAR THERAPY (HCT) IN ADULTS AND CHILDREN: A SURVEY FROM THE EBMT INFECTIOUS DISEASES WORKING PARTY | 08:30 - 08:30 |

	John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	
A193	EFFECT OF LETERMIVIR ON CMV INFECTION AND IMMUNE RECONSTITUTION AFTER PTCY-BASED HAPLOIDENTICAL TRANSPLANTATION Su-Peng Yeh (Taichung, Taiwan (Province of China))	08:30 - 08:30
A194	CMV REACTIVATIONS AFTER LETERMIVIR PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE Anna Grassi (Bergamo, Italy)	08:30 - 08:30
A195	THE ROLE OF T-CELL RECOVERY AND CMV-SPECIFIC IMMUNE RECONSTITUTION THROUGH QUANTIFERON- CMV TEST IN PATIENTS RECEIVING LETERMIVIR PROPHYLAXIS Rosa Plos (Udine, Italy)	08:30 - 08:30
A196	CMV REACTIVATION IN PATIENTS WITH LYMPHOMA AFTER CAR-T THERAPY: INTERNATIONAL STUDY ON BEHALF OF IDWP, LWP, AND CTIWP OF EBMT Dina Averbuch (Jerusalem, Israel)	08:30 - 08:30
A197	TWO-STEP SCREENING STRATEGY FOR EARLY DETECTION OF VIRAL RESPIRATORY INFECTIONS IN PATIENTS UNDERGOING CAR T-CELL THERAPY. IS IT JUSTIFIED? Marina Sorribes Portella (Barcelona, Spain)	08:30 - 08:30
A198	INCIDENCE AND RISK FACTORS FOR LATE CYTOMEGALOVIRUS INFECTION DEVELOPMENT BEYOND DAY 100 POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WHO HAVE NOT RECEIVED EXTENDED LETERMIVIR PROPHYLAXIS Israel Henig (Haifa, Israel)	08:30 - 08:30
A199	PROGRESSIVE SUPPORTIVE CARE IMPROVEMENTS AND LETERMIVIR PROPHYLAXIS NEUTRALIZES THE HISTORICALLY INCREASED NON-RELAPSE MORTALITY ASSOCIATED WITH CMV SEROPOSITIVITY IN ALLOGENEIC STEM CELL TRANSPLANTATION Radwan Massoud (Hamburg, Germany)	08:30 - 08:30
A200	VIRAL ECHOES: NAVIGATING CMV AND EBV REACTIVATION IN THE LANDSCAPE OF STEM CELL TRANSPLANTS FOR AUTOIMMUNE DISEASES Michele Dicataldo (Torino, Italy)	08:30 - 08:30
A201	IMMUNE RECONSTITUTION ASSOCIATED WITH CMV REACTIVATION AFTER THE DISCONTINUATION OF LETERMIVIR PROPHYLAXIS - A PROSPECTIVE STUDY ON BEHALF OF THE POLISH ADULT LEUKEMIA GROUP Agnieszka Piekarska (Gdansk, Poland)	08:30 - 08:30
A202	SURVEILLANCE AND PROPHYLAXIS OF INFECTIONS FOLLOWING CAR-T CELL THERAPY: INTERNATIONAL SURVEY ON BEHALF OF THE INFECTIOUS DISEASES WORKING PARTY AND GOCART COALITION EBMT Dina Averbuch (Jerusalem, Israel)	08:30 - 08:30
A203	TIME EXPLORATION OF INITIATING LETERMIVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Ran Zhang (Zhengzhou, China)	08:30 - 08:30
A204	INCIDENCE OF HERPES ZOSTER VIRUS INFECTION AFTER HZV VACCINATION IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER HZV VACCINATION	08:30 - 08:30

	María Suárez-Lledó (Barcelona, Spain)	
A205	LETERMOVIR PROVIDES PROTECTION AGAINST CLINICALLY SIGNIFICANT CMV INFECTIONS IN CMV-SERONEGATIVE RECIPIENTS OF AN ALLOTRANSPLANT FROM A CMV-SEROPOSITIVE DONOR Patrice Chevallier (Nantes, France)	08:30 - 08:30
A207	EPIDEMIOLOGY OF BLOODSTREAM INFECTIONS IN ITALIAN PEDIATRIC HCT CENTERS: A NATIONWIDE OBSERVATIONAL ANALYSIS BY INFECTION WORKING GROUP OF THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION Francesco Baccelli (Bologna, Italy)	08:30 - 08:30
A208	A MONOCENTRIC RETROSPECTIVE STUDY OF BREAKTHROUGH CANDIDEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, AND CORRELATION WITH GUT COLONIZATION Alienor Xhaard (Paris, France)	08:30 - 08:30
A209	COST-EFFECTIVENESS OF LETERMOVIR PROPHYLAXIS IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANTATION: INSIGHTS FROM AN ITALIAN MONOCENTRIC EXPERIENCE Leonardo Amato (Pisa, Italy)	08:30 - 08:30
A210	THE ROLE OF THE HUMORAL RESPONSE, MEMORY-LIKE NK CELLS, AND GAMMA-DELTA T CELLS IN HCMV CONTROL IN THE LETERMOVIR ERA Hannah Görge (Wuerzburg, Germany)	08:30 - 08:30
A212	CLINICAL AND MICROBIOLOGICAL FEATURES OF <i>FUSARIUM</i> INFECTIONS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Krischan Braitsch (Munich, Germany)	08:30 - 08:30
A213	IS PREEMPTIVE RITUXIMAB FOR EBV REACTIVATION POST-ALLOGENEIC TRANSPLANT BENEFICIAL? A COMPARATIVE STUDY OF CLINICAL OUTCOMES Eshrak Al-Shaibani (Toronto, Canada)	08:30 - 08:30
A214	CLINICAL BURDEN OF LATE-ONSET CLINICALLY SIGNIFICANT CMV INFECTION AFTER LETERMOVIR CMV PROPHYLAXIS AMONG ALLOGENIC STEM CELL TRANSPLANT PATIENTS IN JAPAN Rika Ohkubo (Chiyoda, Japan)	08:30 - 08:30
A215	ASSOCIATION BETWEEN COLONIZATION AND MULTIDRUG-RESISTANT BACTEREMIA IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CAR-T THERAPY: A SINGLE-CENTER EXPERIENCE Alejandro Morales Curbelo (Las Palmas de Gran Canaria, Spain)	08:30 - 08:30
A216	OPTIMIZATION OF PREVENTION STRATEGIES AGAINST SARS-COV2 INFECTION IN PATIENTS WITH HEMATOLOGIC DISEASES: AN EVIDENCE-BASED ANALYTIC HIERARCHY PROCESS. Corrado Girmenia (Rome, Italy)	08:30 - 08:30
A217	INCIDENCE AND RISK FACTORS OF EBV REACTIVATION AND PTLD AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Yeqian Zhao (Hangzhou, China)	08:30 - 08:30
A219	INCREASING INCIDENCE OF MULTIDRUG-RESISTANT (MDR) INFECTIONS IN PAEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE DEVELOPING WORLD Santanu Sen (Mumbai, India)	08:30 - 08:30

A220	RECTAL COLONIZATION BY MULTIDRUG-RESISTANT BACTERIA IN ADULT ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT ON INFECTION RATE, GHVD INCIDENCE AND NONRELAPSE MORTALITY Edoardo Tamellini (Verona, Italy)	08:30 - 08:30
A221	CHARACTERISTICS AND KEY DETERMINANTS OF RESPIRATORY SYNCYTIAL VIRUS SYMPTOMS DURATION IN POST-ALLOGENEIC STEM CELL TRANSPLANT Mireia Micó Cerdà (Valencia, Spain)	08:30 - 08:30
A222	BURDEN OF ACYCLOVIR RESISTANT MUCOCUTANEOUS HUMAN HERPES SIMPLEX VIRUS INFECTION POST HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER US STUDY Genovefa Papanicolaou (New York, United States of America (the))	08:30 - 08:30
A223	MONITORING AND MANAGEMENT OF EBV-ASSOCIATED COMPLICATIONS IN ALLOGENEIC TRANSPLANT RECIPIENTS: PRACTICES AND ACCESS TO ADOPTIVE CELLULAR THERAPY - 2024 SURVEY BY THE SPANISH GETH-TC GROUP Irene García-Cadenas (Barcelona, Spain)	08:30 - 08:30
A224	AN 11-YEAR RETROSPECTIVE STUDY OF PNEUMOCYSTIS JIROVECHII PNEUMONIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Alienor Xhaard (Paris, France)	08:30 - 08:30
A225	CHAGAS' DISEASE IN HAEMATOPOIETIC CELL TRANSPLANTATION PATIENTS AND DONORS Gregorio Jaimovich (Buenos Aires, Argentina)	08:30 - 08:30
A226	DENGUE VIRUS INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION Martin Eduardo Castro (Buenos Aires, Argentina)	08:30 - 08:30
A227	PARADIGM SHIFT IN POST ALLOGENEIC-HSCT VIRAL INFECTIONS IN THE WIDESPREAD USE OF LETERMIVIR PROPHYLAXIS ERA. ONE SPANISH CENTER EXPERIENCE C. Blanco-Montes (Badalona, Spain)	08:30 - 08:30
A228	FINAL ANALYSIS OF OUTCOMES IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH REFRACTORY CYTOMEGALOVIRUS INFECTION OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS TREATMENTS IN EUROPE, CANADA AND ISRAEL Johan Maertens (Leuven, Belgium)	08:30 - 08:30
A229	IMPACT OF CYTOMEGALOVIRUS VIREMIA CLEARANCE ON OUTCOMES IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH REFRACTORY OR RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS TREATMENTS Tien Bo (Lexington, United States of America (the))	08:30 - 08:30
A230	A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Anna Nordlander (Stockholm, Sweden)	08:30 - 08:30
A231	CD45RA-DEPLETED DLI FOR REFRACTORY CMV INFECTION IN PEDIATRIC HSCT RECIPIENTS: A PROMISING THERAPEUTIC STRATEGY Ho Joon Im (Seoul, Korea (the Republic of))	08:30 - 08:30
A232	IMPACT OF LETERMIVIR PROPHYLAXIS ON CYTOMEGALOVIRUS	08:30 - 08:30

	OUTCOMES AND RESOURCE USE IN HIGH- RISK ALLOGENEIC HSCT RECIPIENTS ACCORDING TO THE REIMBURSEMENT CRITERIA IN SPAIN Carlos de Miguel (Madrid, Spain)	
A233	TRENDS IN ICU ADMISSIONS FOR ALLOGENEIC HEMATOPOIETIC TRANSPLANT RECIPIENTS: PATIENT PROFILES AND OUTCOMES Camilla Dao Vo (Oslo, Norway)	08:30 - 08:30
A234	LETERMOVIR PRIMARY PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) REACTIVATION IN EX-VIVO TCRAB-DEPLETED HAPLOIDENTICAL ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION WITH MEMORY T CELL ADD-BACK Ao Ran Boo (Singapore, Singapore)	08:30 - 08:30
A235	ASSESSMENT OF INACTIVATED VACCINE COVERAGES IN THE REVACCINATION PROGRAM OF HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AFTER THE SECOND YEAR OF TRANSPLANTATION Clarisse Machado (São Paulo, Brazil)	08:30 - 08:30
A236	CLINICAL VALIDATION OF A URINARY ANTIGEN TEST AS AN AID TO DIAGNOSE INVASIVE ASPERGILLOSIS IN HEMATOLOGY PATIENTS Yuri Vanbiervliet (Leuven, Belgium)	08:30 - 08:30
A237	IMPACT OF PROPHYLACTIC GRANULOCYTE TRANSFUSIONS ON REDUCING BLOOD CULTURE POSITIVITY AND TRANSPLANT-RELATED MORTALITY IN PAEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTS Anjali Yadav (Gurugram, India)	08:30 - 08:30
A238	NGS-BASED PATHOGEN DETECTION IN BRONCHOALVEOLAR LAVAGE FLUID OBTAINED FROM PATIENTS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION WITH PULMONARY INFECTIONS Anna Ruckdeschel (Würzburg, Germany)	08:30 - 08:30
A239	PRE-TRANSPLANT POSITIVE CMV PCR IS ASSOCIATED WITH POST-TRANSPLANT CMV INFECTIONS WITH OR WITHOUT LETERMOVIR PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Léna Royston (Geneva, Switzerland)	08:30 - 08:30
A240	SURVEY ON THE INCIDENCE AND MANAGEMENT OF TOXOPLASMOSIS AMONG THE CENTERS OF ITALIAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (GITMO) Katia Perruccio (Perugia, Italy)	08:30 - 08:30
A242	CLINICAL SIGNIFICANCE OF REACTIVATION OF HUMAN HERPESVIRUS 6 IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS M. Emilia Mas (Córdoba, Argentina)	08:30 - 08:30
A243	INFLUENCE OF GRAFT IMMUNE CELL COMPOSITION AND IMMUNE RECONSTITUTION ON CMV REACTIVATION AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION Valle Gómez García de Soria (Madrid, Spain)	08:30 - 08:30
A244	IDENTIFICATION OF PRIORITIZED HIGH-RISK CRITERIA AND PATIENT POPULATION SIZES FOR EXTENDED CMV PROPHYLAXIS IN ALLO-HSCT PATIENTS Maša Morsan (Zagreb, Croatia)	08:30 - 08:30
A245	ASSESSMENT OF T-CELL-MEDIATED, SARS-COV-2-SPECIFIC IMMUNE RESPONSES IN PATIENTS AFTER ALLOGENEIC	08:30 - 08:30

	HAEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE DIAGNOSTIC STUDY	
	Anna Ruckdeschel (Würzburg, Germany)	
A246	IMPACT OF LETERMIVIR PROPHYLAXIS ON CMV REACTIVATION AND IMMUNE RECONSTITUTION IN CMV-SEROPOSITIVE ALLOGENEIC HSCT RECIPIENTS: A SINGLE-CENTRE ANALYSIS	08:30 - 08:30
	Ilaria Cutini (Florence, Italy)	
A247	INVASIVE FUNGAL DISEASES CAUSED BY RARE PATHOGENS IN ADULT PATIENTS AFTER HEMATOPOIETIC CELL TRANSPLANTATION AND CHEMOTHERAPY	08:30 - 08:30
	Marina Popova (Saint Petersburg, Russian Federation (the))	
A248	COLONIZATION BY CARBAPENEM-RESISTANT BACTERIA IS ASSOCIATED WITH CARBAPENEM-RESISTANT BLOODSTREAM INFECTIONS WITH DISMAL OUTCOME IN THE IMMEDIATE POST-TRANSPLANT PHASE	08:30 - 08:30
	Francesco Baccelli (Bologna, Italy)	
A249	NEW INSIGHTS IN CURRENT PRACTICE IN THE MANAGEMENT OF DNA VIRUSES IN CHILDREN FOLLOWING ALLOGENEIC HSCT AT EBMT CENTERS	08:30 - 08:30
	Jan Styczynski (Bydgoszcz, Poland)	
A250	INSIGHTS FROM A DISCRETE CHOICE EXPERIMENT: HOW BENEFITS AND RISKS AFFECT PHYSICIAN PREFERENCES FOR PRE-EMPTIVE CMV TREATMENT IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS	08:30 - 08:30
	Miguel-Angel Perales (New York, United States of America (the))	
A251	SEPSIS AND ORGAN FAILURE REMAIN THE MAJOR RISK FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE POST- OR LATE ENGRAFTMENT PHASE ADMITTED TO THE INTENSIVE CARE UNIT	08:30 - 08:30
	Michael Serries (Bonn, Germany)	
A252	RESPIRATORY TRACT INFECTIONS CAUSED BY RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA VIRUS TREATED WITH RIBAVIRIN IN PATIENTS THAT HAVE UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Maria Stamouli (Athens, Greece)	
A253	TOO MUCH ANTIBIOTIC USE IN ALLO-HCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE DURING THE CRS-RISK PERIOD?	08:30 - 08:30
	Björn Reijnders (Nijmegen, Netherlands (the))	
A254	MOBILIZED GRANULOCYTES TRANSFUSION FOR SEVERE INFECTIONS IN NEUTROPENIC PEDIATRIC PATIENTS	08:30 - 08:30
	Federica Galaverna (Roma, Italy)	
A256	SAFETY AND EFFECTIVENESS OF THE RECOMBINANT ZOSTER VACCINE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL-WORLD SETTING	08:30 - 08:30
	Isabel Izquierdo (Zaragoza, Spain)	
A257	IMPACT OF LEVOFLOXACIN PROPHYLAXIS ON BLOODSTREAM INFECTION, CLOSTRIOIDES DIFFICILE INFECTION AND 30-DAY MORTALITY IN RECIPIENTS OF HEMATOPOIETIC CELL TRANSPLANTATION - A SINGLE CENTER EXPERIENCE	08:30 - 08:30
	Taylor Ackling (Duarte, United States of America (the))	
A258	CMV RNA MONITORING IN HEMATOPOIETIC STEM CELL TRANSPLANT	08:30 - 08:30
	Giovanna Travi (Milan, Italy)	

A259	SYMPTOMATIC HEPATITIS E VIRUS INFECTION IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Martina Crysandt (Aachen, Germany)	08:30 - 08:30
A261	CMV RETINITIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN Musa Karakukcu (Kayseri, Turkey)	08:30 - 08:30
A262	IMPACT OF LETERMIVIR PROPHYLAXIS AND VALIDATION OF CMV SCORE RISK IN ALLOGENEIC STEM CELL PATIENTS Cristina Rotolo (Palermo, Italy)	08:30 - 08:30
A263	INCIDENCE AND RISK FACTORS FOR INFECTION WITHIN THE FIRST 5 DAYS AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION USING CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS Marjorie Batista (Sao Paulo, Brazil)	08:30 - 08:30
A264	THE RELATIONSHIP BETWEEN BLOOD CONCENTRATION OF ISAVUCONAZOLE AND TREATMENT EFFICACY AND ADVERSE EVENTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Asami Kataoka (Kyoto, Japan)	08:30 - 08:30
A265	USE OF ANIDULAFUNGIN AS ANTIFUNGAL PROPHYLAXIS IN MISMATCHED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A PROSPECTIVE SINGLE TRANSPLANT PROGRAM EXPERIENCE Angela Carobene (Napoli, Italy)	08:30 - 08:30
A266	ADENOVIRUS INFECTION IN ADULT PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT: INCIDENCE AND OUTCOME DURING THE COVID-19 AND POST-COVID-19 YEARS Malgorzata Mikulska (Genoa, Italy)	08:30 - 08:30
A267	USEFULNESS OF WHOLE BLOOD MULTIPLEX REAL-TIME PCR IN PATIENTS WITH SUSPECTED SEPSIS: AN EXPERIENCE FROM A TERTIARY PEDIATRIC HEMATOLOGY-ONCOLOGY AND TRANSPLANT CENTER IN SOUTH INDIA Stalin Ramprakash (Bangalore, India)	08:30 - 08:30
A268	INCIDENCE, TYPE AND OUTCOME OF HEMORRHAGIC CYSTITIS (HC) AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A SURVEY OF INFECTIOUS DISEASES WORKING PARTY OF EBMT Simone Cesaro (Verona, Italy)	08:30 - 08:30
A269	POOLED BUFFY COAT PREPARATION AS A COST-EFFECTIVE METHOD OF GRANULOCYTE TRANSFUSION IN MANAGING INFECTIONS POST HSCT: AN EFFICACY ANALYSIS Rakesh Reddy Boya (Visakhapatnam, India)	08:30 - 08:30
A270	LEVERAGING FRENCH COMPASSIONATE PROGRAM DATA IN REFRACTORY CMV TO FURTHER DESCRIBE MARIBAVIR EFFECTIVENESS AND RESISTANCE PROFILE Catherine Cordonnier (Créteil, France)	08:30 - 08:30
A271	COMPARATIVE GENOMIC PROFILING OF SEVERE BACTERIAL INFECTIONS IN IMMUNOCOMPROMISED BONE MARROW TRANSPLANT RECIPIENTS AT A TERTIARY REFERRAL CENTER Marat Kazanov (Moscow, Russian Federation (the))	08:30 - 08:30
A272	PREVALENCE OF CLINICALLY SIGNIFICANT VIRAL AND BACTERIAL ENTERIC PATHOGENS IN HAEMOPOIETIC STEM CELL TRANSPLANT RECIPIENTS AND ALLOGENIC DONORS FROM	08:30 - 08:30

LOW AND MIDDLE INCOME COUNTRY		
	Manaswinee Mallik (Chandigarh, India)	
P138	THE EFFECT OF PERIPHERAL VASCULAR CATHETERS ON THE INCIDENCE OF CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTIONS (CLABSIS) IN PATIENTS UNDERGOING AUTO- AND ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Sławomir Milczarek (Szczecin, Poland)	
P139	VARIATIONS IN ABSOLUTE LYMPHOCYTE COUNT RECOVERY POST-HSCT IN RELATION TO TYPE OF DONOR AND GVHD PROPHYLAXIS	08:30 - 08:30
	Stalin Ramprakash (Bangalore, India)	
P140	MANAGEMENT OF CYTOMEGALOVIRUS REACTIVATION IN HIGH-RISK HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS BY USING CYTOMEGALOVIRUS-SPECIFIC IMMUNOGLOBULINS	08:30 - 08:30
	Ignas Gaidamavičius (Kaunas, Lithuania)	
P141	ISAVUCONAZOLE THERAPY OF INVASIVE FUNGAL DISEASE IN CHILDREN UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION	08:30 - 08:30
	Tatiana Bykova (Saint-Petersburg, Russian Federation (the))	
P142	IMPACT OF HLA MISMATCHES ON CMV REACTIVATION AND TRANSPLANT OUTCOMES IN HAPLOIDENTICAL HSCT WITH REDUCED-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE: A SINGLE-CENTER EXPERIENCE	08:30 - 08:30
	Mohammad Tarek (Cairo, Egypt)	
P143	EFFICACY AND SAFETY OF ABCD FIRST-LINE TREATMENT OF PATIENTS WITH HAEMATOLOGICAL DISORDERS COMBINED WITH INVASIVE FUNGAL DISEASE	08:30 - 08:30
	Qifa Liu (Guangzhou, China)	
P144	TO SEE IS TO BELIEVE: A CASE OF INFECTIOUS CEREBRAL VASCULITIS SECONDARY TO LATENT CYTOMEGALOVIRUS REACTIVATION IN AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENT	08:30 - 08:30
	Jovito Balbosa (Taguig, Philippines (the))	
P145	BK POLYOMAVIRUS DNA POSITIVITY IN URINE AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND ITS ASSOCIATION WITH CYSTITIS	08:30 - 08:30
	Fang Liu (Tianjin, China)	
P146	PARVOVIRUS B19 INFECTION IN ADULT PATIENTS AFTER AUTOLOGOUS-ALLOGENEIC STEM CELL TRANSPLANTATION OR CAR-T THERAPY: SINGLE CENTER EXPERIENCE	08:30 - 08:30
	Maria Caterina Mico' (Reggio Calabria, Italy)	
P147	REAL-WORLD DATA: PROLONGED USE OF CMV PROPHYLAXIS WITH LETERMOVIR SIGNIFICANTLY REDUCES THE RISK FOR CMV REACTIVATION IN PROLONGED IMMUNOCOMPROMISED ALLOGENEIC STEM CELL RECIPIENTS	08:30 - 08:30
	Katrin Koch (Munich, Germany)	
P149	INCREASED RISK OF INFECTION IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A SINGLE-CENTER STUDY	08:30 - 08:30
	Paula Mazorra Roig (Barcelona, Spain)	
P150	MONITORING SPECIFIC T-CELL RESPONSE TO VZV POST-VACCINATION IN HEMATOPOIETIC TRASPLANT RECIPIENTS: EXPERIENCE FROM A SINGLE CENTER TO GUIDE PROPHYLAXIS DISCONTINUATION	08:30 - 08:30

	Natalia Egri (Barcelona, Spain)	
P153	REACTIVATION AND RISK: A CASE SERIES ON TUBERCULOSIS IN POST-ALLOGENEIC HSCT PATIENTS IN A TERTIARY CARE CENTER IN THE PHILIPPINES Camille Pestaño (Taguig, Philippines (the))	08:30 - 08:30
P154	HUMORAL AND CELLULAR IMMUNE RESPONSE TO ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS VACCINE RSVREF3 IN ADULTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Jonas Lötscher (Basel, Switzerland)	08:30 - 08:30
P155	IMPACT OF EARLY CLINICALLY SIGNIFICANT CMV INFECTION IN HAPLOIDENTICAL HCT NOT RECEIVING LETERMIVIR PROPHYLAXIS Clarisse Machado (São Paulo, Brazil)	08:30 - 08:30
P156	INVASIVE FUNGAL INFECTIONS AND AZOLE PROPHYLAXIS DURING APLASIA: 8-YEAR OBSERVATION OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Sinem Civriz Bozdag (Istanbul, Turkey)	08:30 - 08:30
P158	LOW DOSE RITUXIMAB FOR PRE-EMPTIVE TREATMENT OF EPSTEIN BARR VIRUS REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER STUDY Jiejing Qian (Hangzhou, China)	08:30 - 08:30
P159	A SINGLE-CENTER PROSPECTIVE STUDY ON THE PREVENTION OF CYTOMEGALOVIRUS INFECTION IN CMV SEROPOSITIVE PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING LETERMIVIR Yanling Ren (Hangzhou, China)	08:30 - 08:30
P160	NEURO-TOXOPLASMOSIS IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT - A CASE REPORT TO RAISE THE AWARENESS FOR A RARE BUT NOT IMPOSSIBLE COMPLICATION Vera Radici (Brescia, Italy)	08:30 - 08:30
P162	SAFETY AND EFFICACY OF BEZLOTOXUMAB PLUS FIDAXOMICIN IN <i>C. DIFFICILE</i> INFECTION TREATMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTED PATIENTS Matteo Fanin (Udine, Italy)	08:30 - 08:30
P164	REAL-WORLD LETERMIVIR PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A BRAZILIAN MULTICENTER STUDY Carolina Perrone Marques (São Paulo, Brazil)	08:30 - 08:30
P165	REAL-WORLD EXPERIENCE WITH LETERMIVIR AS PRIMARY PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Lucía González Rodríguez (Vigo, Spain)	08:30 - 08:30
P166	ANNUAL AUDIT OF CENTRAL VENOUS ACCESS DEVICE INFECTION: A QUALITY IMPROVEMENT PROJECT IN A DISTRICT GENERAL HOSPITAL JACIE CENTRE Elizabeth Farnworth (Bath, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P167	DIAGNOSTIC IMPACT OF GASTROINTESTINAL PANELS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS IN A PRIVATE TERTIARY HOSPITAL IN THE PHILIPPINES: A CASE SERIES Camila Louise Cabalo-Alves (Manila, Philippines (the))	08:30 - 08:30

P168	COMPLICATIONS OF SARS-COV-2 REACTIVATION IN A PATIENT WITH A RELAPSED DIFFUSE LARGE B CELL LYMPHOMA UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT: A CASE REPORT Chennie Ongkingco (Makati, Philippines (the))	08:30 - 08:30
P169	A CASE REPORT ON ACUTE MYELOID LEUKEMIA COMPLICATED BY CYTOMEGALOVIRUS PNEUMONIA: DIAGNOSTIC CHALLENGES AND THERAPEUTIC APPROACHES THROUGH METAGENOMIC NEXT-GENERATION SEQUENCING Lingling Liu (Guangzhou, China)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		R18
Graft-versus-host Disease - Clinical		
B030	EFFICACY AND SAFETY OF BELUMOSUDIL FOR TREATMENT OF CGVHD: MULTICENTER RETROSPECTIVE ANALYSIS OF THE FRENCH COHORT OF THE COMPASSIONATE USE PROGRAM Michael Loschi (Nice, France)	08:30 - 08:30
B031	CLINICALLY MEANINGFUL IMPROVEMENT OF MODIFIED LEE SYMPTOM SCALE IN PATIENTS TREATED WITH BELUMOSUDIL FOR STEROID-REFRACTORY CHRONIC GVHD: EVIDENCE FROM REAL-WORLD OUTCOMES Dennis Dong Hwan Kim (Toronto, Canada)	08:30 - 08:30
B032	SPANISH REAL WORLD EXPERIENCE (GETH-TC) OF BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER 2 OR MORE PRIOR LINES OF THERAPY Mi Kwon (., Spain)	08:30 - 08:30
B033	MESENCHYMAL STROMAL CELLS AS A SAFE AND EFFECTIVE TREATMENT OPTION FOR HEAVILY PRE-TREATED AGVHD PATIENTS IN A REAL-WORLD SETTING Robert Zeiser (Freiburg, Germany)	08:30 - 08:30
B034	IMPACT OF BELUMOSUDIL TREATMENT IN ADVANCED CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): INSIGHTS INTO RESPONSE-BASED T- AND B-CELL SUBPOPULATION DYNAMICS Doris Ponce (New York, United States of America (the))	08:30 - 08:30
B035	CORRELATIONS OF CLINICIAN-REPORTED RESPONSES WITH OTHER RESPONSE MEASURES IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE: AN ANALYSIS FROM THE AGAVE-201 TRIAL Annie Im (Pittsburgh, United States of America (the))	08:30 - 08:30
B036	IMPACT OF TGF-FSMP AND MICROBIOME IN OBESE ALLO-HSCT PATIENTS: POSSIBLE REDUCTION OF GASTROINTESTINAL ACUTE GVHD RISK AND IMPROVEMENT OF OS Enrico Morello (Brescia, Italy)	08:30 - 08:30
B037	ASSESSING PRACTICE PATTERNS AND FUTURE PARADIGMS IN GRAFT VERSUS HOST DISEASE PROPHYLAXIS Brittany Knick Ragon (Charlotte, United States of America (the))	08:30 - 08:30
B038	DEVELOPMENT OF A VALIDATED CLINICAL RISK SCORE TO PREDICT ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A CIBMTR ANALYSIS Wael Saber (Milwaukee, United States of America (the))	08:30 - 08:30
B039	THE EFFECTS OF PRIOR LINES OF THERAPY ON CLINICAL OUTCOMES FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-	08:30 - 08:30

	HOST DISEASE RECEIVING AXATILIMAB: A POST HOC ANALYSIS OF AGAVE-201	
	John Galvin (Wilmington, United States of America (the))	
B040	DYNAMICS OF OVERALL AND ORGAN-SPECIFIC RESPONSES TO AXATILIMAB IN CHRONIC GRAFT-VERSUS-HOST DISEASE: ANALYSIS FROM THE AGAVE-201 STUDY	08:30 - 08:30
	Amandeep Salhotra (Duarte, United States of America (the))	
B041	A PROSPECTIVE OBSERVATIONAL STUDY USING BUDESONIDE, ADDED TO PTCY-BASED GVHD PROPHYLAXIS, FOR PREVENTION OF ACUTE GI GVHD AFTER ALLOGENEIC TRANSPLANTATION AND COMPARISON WITH CIBMTR CONTROL	08:30 - 08:30
	Stefan Ciurea (Orange, United States of America (the))	
B042	POST-TRANSPLANT TELOMERE LENGTH IS ASSOCIATED WITH CHRONIC GVHD IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS	08:30 - 08:30
	Kirk Schultz (Vancouver, Canada)	
B043	HLA-DRB1 ALLELE MISMATCH IS ASSOCIATED WITH ENGRAFTMENT AND ACUTE GVHD AFTER HLA-HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A NATIONWIDE RETROSPECTIVE ANALYSIS IN JAPAN	08:30 - 08:30
	Hiroyuki Muranushi (Kurashiki, Japan)	
B044	PRECISION DOSING OF PREEMPTIVE ADD-ON PROPHYLACTIC MEDICATION AGAINST SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE: A PROSPECTIVE INTERVENTIONAL TRIAL OF A MACHINE LEARNING MODEL	08:30 - 08:30
	Erlie Jiang (Tianjin, China)	
B045	THIRD-PARTY FECAL MICROBIOTA TRANSPLANTATION AS ADDITIONAL TREATMENT TO STANDARD THERAPY EARLY IN THE COURSE OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST-DISEASE	08:30 - 08:30
	Olga Pankratova (Helsinki, Finland)	
B046	RESULTS OF HOVON 112 TRIAL RANDOMIZING MSC VS PLACEBO IN SEVERE ACUTE GVHD AS FIRST-LINE TREATMENT	08:30 - 08:30
	L.E. van der Wagen (Utrecht, Netherlands (the))	
B047	PRE-TRANSPLANT HLA AND TISSUE RESIDENT MEMORY NK/T EXTRACELLULAR VESICLES ASSOCIATE WITH GVHD IN PEDIATRIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Francesca Gottardi (Bologna, Italy)	
B048	40 MG/KG/DAY CYCLOPHOSPHAMIDE: A STEP FORWARD IN REDUCING TOXICITY IN GVHD PROPHYLAXIS FOR ALLO-HCT FROM HLA-MATCHED DONORS	08:30 - 08:30
	Filipe R. Pinto (Porto, Portugal)	
B049	POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT, AND SHORT COURSE TACROLIMUS AS GVHD PROPHYLAXIS IN MATCHED, MISMATCHED UNRELATED DONOR AND HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT - MAYO CLINIC EXPERIENCE	08:30 - 08:30
	Hassan Alkhateeb (Rochester, United States of America (the))	
B050	SHORT-TERM SUBSTITUTION OF CALCINEURIN INHIBITORS (CNIS) WITH RECOMBINANT HUMANIZED ANTI-CD25 MONOCLONAL ANTIBODY (DACLIZUMAB) AS AGVHD PROPHYLAXIS IN CNIS INTOLERANT PATIENTS AFTER ALLO-HSCT	08:30 - 08:30
	Shan Shao (Shanghai, China)	

B051	ASSESSING THE CLINICAL AND ECONOMIC IMPACT OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ENGLAND: A RETROSPECTIVE COHORT ANALYSIS Francesca Kinsella (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
B052	LETMOVIR PROPHYLAXIS MAY INCREASE THE RISK OF GVHD AND DECREASE GRFS IN PATIENTS AFTER EX-VIVO AB⁺T-CELL DEPLETED HAPLOHCT Dominik Turkiewicz (Lund, Sweden)	08:30 - 08:30
B053	DESLOSINE AS A NOVEL BIOMARKER FOR PULMONARY AND CUTANEOUS MANIFESTATIONS IN CHRONIC GRAFT-VERSUS-HOST DISEASE Noa G. Holtzman (Miami, United States of America (the))	08:30 - 08:30
B054	CLUSTER ANALYSIS IDENTIFIES THREE DISTINCT BIOLOGIC SUBTYPES OF CHRONIC GVHD IN A LARGE PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION COHORT Kirk Schultz (Vancouver, Canada)	08:30 - 08:30
B055	THE MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM (MAGIC) COMPOSITE RESPONSE: A NOVEL ENDPOINT INTEGRATING CLINICAL AND BIOMARKER PARAMETERS FOR ACUTE GVHD James Ferrara (United States of America (the))	08:30 - 08:30
B056	REAL-WORLD OUTCOMES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN FOR GVHD PROPHYLAXIS Cornelia Baden (Kiel, Germany)	08:30 - 08:30
B057	PHASE 1 STUDY OF PACRITINIB, A CSF1R/JAK2/IRAK1 INHIBITOR, FOR REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: A PRELIMINARY ANALYSIS Noa G. Holtzman (Miami, United States of America (the))	08:30 - 08:30
B058	BARICITINIB IN THE GVHD PREVENTION REGIMEN WITH REDUCED DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT AND VEDOLIZUMAB IN CHILDREN WITH ACUTE LEUKEMIA: RESULTS OF A PROSPECTIVE STUDY Margarita Perminova (Moscow, Russian Federation (the))	08:30 - 08:30
B059	NOVEL QUADRUPLET GVHD PROPHYLAXIS WITH RABBIT ATG, PTCY, TACROLIMUS, AND MMF IN RIC ALLOGENEIC HSCT: A REAL WORLD DATA FROM A SINGLE CENTER IN INDIA Ganesh Jaishetwar (Hyderabad, India)	08:30 - 08:30
B061	NOVEL GVHD PROPHYLAXIS COMBINING REDUCED DOSE CYTOXAN AND ABATACEPT RESULTS IN LOW RATES OF ACUTE AND CHRONIC GVHD AND LOW TRANSPLANT RELATED TOXICITY Yuliya Shestovska (Philadelphia, United States of America (the))	08:30 - 08:30
B062	BELUMOSUDIL IS EFFICACIOUS FOR THE MANAGEMENT OF HEAVILY PRETREATED AND PROLONGED CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE MULTI-CENTER STUDY BY THE ISRAEL BONE MARROW TRANSPLANTATION ASSOCIATION Tsila Zuckerman (Haifa, Israel)	08:30 - 08:30
B064	ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) AS A RISK FACTOR OF RUXOLITINIB FAILURE FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE TREATMENT Nihar Desai (Toronto, Canada)	08:30 - 08:30

B065	THE EASIX SCORE IN PEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE COHORT ANALYSIS Francesco Baccelli (Bologna, Italy)	08:30 - 08:30
B066	VALIDATION OF MANHATTAN RISK SCORE TO PREDICT AGVHD SEVERITY IN PTCY-BASED PROPHYLAXIS: A STUDY ON 459 CONSECUTIVE HSCT PATIENTS Alessandro Criscimanna (Milan, Italy)	08:30 - 08:30
B067	DIFFERENT MONOCYTE SUBPOPULATIONS IN ALLOGENEIC STEM TRANSPLANTATION RECIPIENTS WITH AND WITHOUT GVHD: IMMUNOPHENOTYPES AND THE EXPRESSION OF HLA-DR AND CD300E Igor Age Kos (Homburg, Germany)	08:30 - 08:30
B068	EFFICACY AND SAFETY OF RUXOLITINIB IN CHILDREN WITH ACUTE AND CHRONIC STEROID-REFRACTORY OR STEROID-DEPENDENT GVHD Maria Gabelli (Padova, Italy)	08:30 - 08:30
B070	GRADE YOUR GVHD YOURSELF - DEVELOPMENT OF AN APP TO DOCUMENT CHRONIC GRAFT-VERSUS-HOST DISEASE BY PATIENTS AND CAREGIVERS Alexander Denk (Regensburg, Germany)	08:30 - 08:30
B073	A SINGLE-CENTER PROSPECTIVE STUDY OF SOLUBLE CHRONIC GRAFT-VERSUS-HOST DISEASE BIOMARKERS EVALUATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS Giorgos Karavalakis (Thessaloniki, Greece)	08:30 - 08:30
B074	REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE WHO RECEIVED 3 OR MORE LINES OF TREATMENT IN THE UNITED STATES Jingbo Yu (Wilmington, United States of America (the))	08:30 - 08:30
B075	CALCINEURIN INHIBITOR ALONE OR IN COMBINATION WITH METHOTREXATE FOR GVHD PROPHYLAXIS IN ACQUIRED APLASTIC ANEMIA: A REPORT ON BEHALF OF PAKISTAN BLOOD AND MARROW TRANSPLANT GROUP Natasha Ali (Karachi, Pakistan)	08:30 - 08:30
B076	ROLE OF PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES IN GRAFT-VERSUS-HOST DISEASE AFTER CORD BLOOD TRANSPLANTATION - A RETROSPECTIVE STUDY Harish Selvaraj (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
B079	THE IMPACT OF RUXOLITINIB ON STEROID-REFRACTORY CGVHD: ASSESSING CUTANEOUS RESPONSES AND LONG-TERM PROGNOSTIC FACTORS ACROSS PHENOTYPES Maria Helena Parrinello (Milano, Italy)	08:30 - 08:30
B080	COMPARATIVE SINGLE CENTRE OBSERVATIONAL ANALYSIS OF GVHD PROPHYLAXIS WITH GRAFALON (RATLG) AND THYMOGLOBULIN (RATG) IN THALASSEMIA MAJOR PATIENTS UNDERGOING STEM CELL TRANSPLANTATION Santanu Sen (Mumbai, India)	08:30 - 08:30
B081	AGVHDTRACKR AND CGVHDTRACKR: SHINY APPLICATIONS FOR GRAFT VERSUS HOST DISEASE MANAGEMENT AND CLINICAL DATA COLLECTION Silvia Nucera (Monza, Italy)	08:30 - 08:30
B082	PHENOTYPIC CHANGES IN SYSTEMIC IMMUNE CELLS IN RESPONSE TO AXATILIMAB IN HEALTHY MALE JAPANESE VOLUNTEERS	08:30 - 08:30

	Michael Pratta (Wilmington, United States of America (the))	
B084	TRANSPORTABILITY TO THE EU POPULATION OF EFFICACY OF BELUMOSUDIL AS COMPARED WITH BEST AVAILABLE THERAPY FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE Daniel Wolff (Regensburg, Germany)	08:30 - 08:30
B085	ANTI-CD25 MONOCLONAL ANTIBODY AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA Jian Zhou (Zhengzhou, China)	08:30 - 08:30
B086	EXTRACORPOREAL PHOTOPHERESIS TREATMENT IN PEDIATRIC PATIENTS WITH GVHD: INSIGHTS FROM A CASE SERIES Marina Rierola (Barcelona, Spain)	08:30 - 08:30
B087	SAFETY AND EFFICACY OF REDUCED-DOSE POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN HLA-IDENTICAL RELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: A COHORT STUDY Alejandro Luna de Abia (Madrid, Spain)	08:30 - 08:30
B088	GUT MICROBIOTA AND IMMUNOSUPPRESSION DOSING AFTER ALLO-HSCT Mikhail Uss (Minsk, Belarus)	08:30 - 08:30
B089	EFFICACY OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM AN UNRELATED MISMATCHED DONOR Lea Jukić (Zagreb, Croatia)	08:30 - 08:30
B090	EFFICACY AND SAFETY OF REDUCED-DOSES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED (10/10) PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Irene García-Cadenas (Barcelona, Spain)	08:30 - 08:30
B091	THE IMPACT OF MDSCS IN PBSC ON THE OCCURRENCE OF PATIENT GVHD Man Chen (Langfang, China)	08:30 - 08:30
B093	LIVER BIOPSY IN THE DIFFERENTIAL DIAGNOSIS OF LIVER TOXICITY AFTER TRANSPLANTATION: A CLINICO-PATHOLOGICAL STUDY OF 43 CONSECUTIVE PATIENTS Maria Teresa Lupo-Stanghellini (Milano, Italy)	08:30 - 08:30
B094	DOES THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION AFFECT UNRELATED DONOR ALLO-HCT OUTCOMES? A RETROSPECTIVE ANALYSIS ON BEHALF OF THE POLISH ADULT LEUKEMIA GROUP Ugo Giordano (Wrocław, Poland)	08:30 - 08:30
B096	IS IT POSSIBLE TO REDUCE THE DOSE OF CYPT IN <u>HLA-IDENTICAL</u> DONOR HSCT IN A SAFE WAY? RETROSPECTIVE UNICENTRE EXPERIENCE Marta Luque Garrido (Málaga, Spain)	08:30 - 08:30
B097	REAL-WORLD PATIENT CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE RECEIVING BELUMOSUDIL IN THE UNITED STATES Jingbo Yu (Wilmington, United States of America (the))	08:30 - 08:30
B098	POST-TRANSPLANT CYCLOPHOSPHAMIDE AND CARDIOTOXICITY: INSIGHTS FROM A RETROSPECTIVE STUDY IN ALLOGENEIC HSCT PATIENTS	08:30 - 08:30

	Claudia Sossa-Melo (Floridablanca, Colombia)	
B099	TREG SELECTION FROM G-CSF STIMULATED DONORS IMPROVES OUTCOMES OF IMMUNE-SUPPRESSION FREE HLA-HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH T CELL ADOPTIVE IMMUNOTHERAPY Rebecca Sembenico (Perugia, Italy)	08:30 - 08:30
B100	SUBSTANTIAL REDUCTION IN THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE WITH THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN MATCHED UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: A COMPARATIVE CASE-CONTROL STUDY Sotirios Bristogiannis (Athens, Greece)	08:30 - 08:30
B101	GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE STUDY Omur Gokmen Sevindik (Istanbul, Turkey)	08:30 - 08:30
B102	ASSESSMENT OF GASTROINTESTINAL GRAFT VERSUS HOST DISEASE USING ¹⁸F-FDG PET-CT AND SELECTED BIOMARKERS Joanna Kujawska (Poznan, Poland)	08:30 - 08:30
B103	IMPACT OF GRAFT CD3 AND CD34 CELL DOSES ON ACUTE GVHD RISK AND OUTCOMES: INSIGHTS FROM A SINGLE-CENTRE STUDY Alina Daniela Tanase (Bucharest, Romania)	08:30 - 08:30
B104	SINGLE CENTRE OBSERVATIONAL ANALYSIS OF GVHD PROPHYLAXIS WITH ANTI HUMAN T LYMPHOCYTE IMMUNOGLOBULIN (RATLG) IN THALASSEMIA MAJOR PATIENTS UNDERGOING STEM CELL TRANSPLANTATION Santanu Sen (Mumbai, India)	08:30 - 08:30
B105	EFFICACY AND SAFETY OF RUXOLITINIB FOR THERAPY OF CHRONIC STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN Nikita Levkovsky (Saint Petersburg, Russian Federation (the))	08:30 - 08:30
P109	EFFICACY ANALYSIS OF 33 PATIENTS WITH STEROID-RESISTANT GRADE III/IV ACUTE LIVER GRAFT-VERSUS-HOST DISEASE TREATED WITH PLASMA EXCHANGE, SEQUENTIAL LOW-DOSE CYCLOPHOSPHAMIDE AND ANTI-THYMOCYTE GLOBULIN Juan Wang (Zhengzhou, China)	08:30 - 08:30
P110	IMPACT OF HLA MISMATCHES AT MOLECULAR LEVEL ON THE CLINICAL EVOLUTION OF HAPLOIDENTICAL HSCT BASED ON POST-TRANSPLANT CYCLOPHOSPHAMIDE: EXPERIENCE OF A SINGLE CENTER Estefania Perez-Lopez (Salamanca, Spain)	08:30 - 08:30
P111	POST-TRANSPLANT CYCLOPHOSPHAMIDE IN OLDER ADULTS UNDERGOING MATCHED SIBLING DONOR ALLOGENEIC TRANSPLANTATION Nihar Desai (Toronto, Canada)	08:30 - 08:30
P112	TREATMENT OF ACUTE AND CHRONIC GVHD WITH EXTRACORPOREAL PHOTOPHERESIS (ECP): EVIDENCE-BASED RECOMMENDATIONS BY THE ITALIAN SOCIETY OF HEMAPHERESIS AND CELL MANIPULATION (SIDEM) Massimo Martino (Reggio Calabria, Italy)	08:30 - 08:30
P113	GRAFT VERSUS HOST DISEASE PROPHYLAXIS WITH ATG OR PTCY AFTER ALLOGENEIC TRANSPLANTATION FROM VOLUNTEER UNRELATED DONORS. A SINGLE CENTER RETROSPECTIVE PSEUDO-RANDOMIZED ANALYSIS	08:30 - 08:30

	Maria Liga (Patras, Greece)	
P115	ENHANCED OUTCOMES WITH PTCY IN REDUCED-INTENSITY TRANSPLANTATION FOR OLDER ADULTS: MYTH OR REALITY? Seongkyu Park (Bucheon-Si, Korea (the Republic of))	08:30 - 08:30
P116	MESENCHYMAL STROMAL CELLS IN TREATMENT OF GRAFT VERSUS HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN - SINGLE CENTER EXPERIENCE Peter Svec (Bratislava, Slovakia)	08:30 - 08:30
P117	THE IMPACT OF EXTRACORPOREAL PHOTOPHERESIS AND RUXOLITINIB ON THE OUTCOME OF CHRONIC GVHD: A RETROSPECTIVE REAL LIFE ANALYSIS Salvatore Leotta (Catania, Italy)	08:30 - 08:30
P118	EXTRACORPOREAL PHOTOPHERESIS FOR ACUTE AND CHRONIC GVHD IN PEDIATRIC HCTS RECIPIENTS: INSIGHTS FROM KING HUSSEIN CANCER CENTER Rawad Rihani (Amman, Jordan)	08:30 - 08:30
P120	SALVAGE TREATMENT OF PROGRESSIVE STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE BY IMMUNOABLATIVE THERAPY WITHOUT STEM CELL SUPPORT IN PEDIATRIC PATIENTS Jaspar Kloehn (Hamburg, Germany)	08:30 - 08:30
P121	ENHANCED GVHD PROPHYLAXIS WITH LOW-DOSE GRAFALON® AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL AND MISMATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION Alessandra Cipiciani (Ancona, Italy)	08:30 - 08:30
P122	A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF TREATMENT OUTCOMES IN APLASTIC ANAEMIA AT APOLLO HOSPITAL, HYDERABAD, INDIA Padmaja Lokireddy (Hyderabad, India)	08:30 - 08:30
P123	VEDOLIZUMAB FOR CHILDREN WITH INTESTINAL GRAFT-VERSUS-HOST DISEASE: SINGLE CENTER EXPERIENCE Işik Odaman Al (İstanbul, Turkey)	08:30 - 08:30
P124	A PHASE 2 STUDY OF FRONT LINE IBRUTINIB WITHOUT CORTICOSTEROIDS FOR NEWLY DIAGNOSED CHRONIC GRAFT-VERSUS-HOST DISEASE Noa G. Holtzman (Miami, United States of America (the))	08:30 - 08:30
P125	IMMUNE-MEDIATED COMPLICATIONS OF THE CENTRAL NERVOUS SYSTEM AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Jenny Miethke (Jena, Germany)	08:30 - 08:30
P128	RETROSPECTIVE ANALYSIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - INCIDENCE AND CORRELATION WITH RELAPSE AND NON-RELAPSE MORTALITY Iveta Oravcova (Bratislava, Slovakia)	08:30 - 08:30
P129	REDUCED DOSE POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (40 MG/KG) AS GVHD PROPHYLAXIS Jacob Alex (Portland, United States of America (the))	08:30 - 08:30
P130	EXTRACORPORAL PHOTOPHERESIS (ECP) IN STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): EFFICACY AND SAFETY PROFILE. Sabrina Giammarco (Rome, Italy)	08:30 - 08:30

P131	EXTENSIVE TUBULAR BASEMENT MEMBRANE (TBM) DEPOSIT ASSOCIATE WITH MEMBRANOUS NEFROPATHY (MN) AND TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) AS RARE BUT PECULIAR MANIFESTATION OF CGVHD AFTER HSCT Amelia Rinaldi (Parma, Italy)	08:30 - 08:30
P132	COMPARING THE EFFICACY AND SAFETY OF ATLG AND ATG IN ALLO - HSCT FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE STUDY Xiangzhong Zhang (Guangzhou, China)	08:30 - 08:30
P133	USE OF VEDOLIZUMAB IN CHILDREN WITH STEROID-REFRACTORY GASTRO-INTESTINAL GRAFT-VERSUS-HOST DISEASE Joanna Cisek (Bydgoszcz, Poland)	08:30 - 08:30
P134	EARLY START OF CYCLOSPORINE A COMBINED WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PATIENTS UNDERGOING HSCT FROM HAPLOIDENTICAL DONORS: A SINGLE-CENTER EXPERIENCE Giorgia Battipaglia (Naples, Italy)	08:30 - 08:30
P135	EPIDEMIOLOGY AND REAL-WORLD STUDY OF GRAFT-VERSUS-HOST DISEASE POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT): A RETROSPECTIVE ANALYSIS FROM A TERTIARY CENTRE IN SINGAPORE Victor Wei Teik Ling (Singapore, Singapore)	08:30 - 08:30
P136	CASE SERIES: CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER HAEMOPOIETIC STEM CELL TRANSPLANT Marzia Rahman (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		R18
Graft-versus-host Disease - Preclinical and Animal Models		
B019	TISSUE-ADAPTED TREGS HARNESS INFLAMMATORY SIGNALS TO PROMOTE INTESTINAL REPAIR FROM THERAPY-RELATED INJURY Sascha Göttert (Regensburg, Germany)	08:30 - 08:30
B020	GUT MICROBIOME ALTERATIONS AND FUNCTIONAL PATHWAYS ASSOCIATED WITH SEVERE AGVHD IN PEDIATRIC ALLO-HSCT RECIPIENTS: THE ROLE OF RUMINOCOCCUS GNAVUS AND LACTOBACILLUS RHAMNOSUS Francesco Baccelli (Bologna, Italy)	08:30 - 08:30
B021	MAST CELL DEFICIENCY IS ASSOCIATED WITH POOR GLUCOCORTICOID RESPONSE IN ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE Lukas Gaksch (Graz, Austria)	08:30 - 08:30
B022	TREGS DERIVED EXTRACELLULAR VESICLES ARE ASSOCIATED WITH A STRONG IMMUNOSUPPRESSIVE ACTIVITY AND PREVENT GVHD IN MURINE MODELS Francesco Guardalupi (Chieti, Italy)	08:30 - 08:30
B023	POST-TRANSPLANT CYCLOPHOSPHAMIDE FACILITATES PRESERVATION OF TISSUE-RESIDENT IL-22-PRODUCING LYMPHOCYTES AND INTESTINAL STEM CELLS Guillermo Ortí (New York City, United States of America (the))	08:30 - 08:30
B024	NON-RADIOACTIVE METABOLIC IMAGING OF GRAFT-VERSUS HOST DISEASE BY DEUTERIUM MAGNETIC RESONANCE	08:30 - 08:30

SPECTROSCOPY

Nataliya Buxbaum (Buffalo, United States of America (the))

B025	TIMED INHIBITION OF THE STING PATHWAY IMPROVES TISSUE REGENERATION AND PREVENTS GVHD FOLLOWING ALLO-HSCT Chiara Suriano (Regensburg, Germany)	08:30 - 08:30
B027	DYNAMIC CHANGES OF EXTRACELLULAR VESICLES ORIGINATED FROM PLATELETS, ENDOTHELIAL CELLS AND LEUKOCYTES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CORRELATION WITH ACUTE GVHD Federica Ferrando (Torino, Italy)	08:30 - 08:30
B028	MICROBIOME CHIMERISM - A NEW FRONTIER IN GVHD PATHOGENESIS? Anna Li (Adelaide, Australia)	08:30 - 08:30
B029	SERUM EXTRACELLULAR VESICLES AND MIRNA CARGO AS PREDICTIVE MARKERS FOR ACUTE-GRAFT-VS.-HOST DISEASE Federica Ferrando (Torino, Italy)	08:30 - 08:30
P108	AXATILIMAB ABROGATES INFLAMMATORY CYTOKINES AND CHEMOKINES AND INTERRUPTS THE DIFFERENTIATION OF MONOCYTES TO MACROPHAGES, A PATHOGENIC DRIVER OF INFLAMMATION AND FIBROSIS IN CGVHD Chryssa Kanellopoulou (Wilmington, United States of America (the))	08:30 - 08:30

ePoster

08:30 - 18:00

R18

Stem Cell Donor

B002	PEPTIDE BINDING MOTIF MISMATCHES AND OUTCOME IN EX-VIVO T-CELL DEPLETED HLA-HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC PATIENTS AFFECTED BY ACUTE LEUKEMIA Pietro Merli (Rome, Italy)	08:30 - 08:30
B003	HAPLOIDENTICAL VS MISMATCHED UNRELATED DONOR HCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE PROPHYLAXIS: DONOR AGE MATTERS MORE THAN DONOR TYPE Yosra Aljawai (Houston, United States of America (the))	08:30 - 08:30
B005	HAPLOIDENTICAL TRANSPLANT USING SELECTIVE EX-VIVO TCR-AB DEPLETED AND UPFRONT MEMORY T-CELL ADD-BACK YIELDS COMPARABLE OUTCOME AS MATCHED RELATED AND UNRELATED DONOR TRANSPLANT FOR ELDERLY ADULTS Ian Wu (Singapore, Singapore)	08:30 - 08:30
B006	DROP-OUTS OF STEM CELL DONATION - AN ANALYSIS OF THE AUSTRIAN STEM CELL REGISTER Sophia Oesterreicher (Vienna, Austria)	08:30 - 08:30
B007	ALTERNATIVE DONOR SELECTION FOR PTCY HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT Jaime Sanz (Valencia, Spain)	08:30 - 08:30
B008	CHANCES OF FINDING MATCHED RELATED DONORS AND UNDERGOING TRANSPLANT FOR SAUDI PATIENTS WITH SICKLE CELL DISEASE IN NEED OF HEMATOPOIETIC STEM CELL TRANSPLANTATION Mohsen Alzahrani (Riyadh, Saudi Arabia)	08:30 - 08:30
B009	OUTCOMES OF SECOND-DEGREE RELATIVE HAPLOIDENTICAL	08:30 - 08:30

	DONORS FOR ALLOGENEIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR HEMATOLOGICAL MALIGNANCIES	
	Shukaib Arslan (Duarte, United States of America (the))	
B010	COMPARISON OF THE RESULTS OF HSCT BETWEEN UNRELATED CORD BLOOD DONORS AND HAPLOIDENTICAL DONORS FOR THE TREATMENT OF APLASTIC ANEMIA IN PEDIATRIC PATIENTS	08:30 - 08:30
	Zhang Jianping (Langfang, China)	
B012	BUILDING RECOMMENDATIONS FOR RELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A DELPHI STUDY BY THE LATIN AMERICAN BONE MARROW TRANSPLANTATION GROUP (LABMT)	08:30 - 08:30
	Cristobal Frutos-Ortiz (Asuncion, Paraguay)	
B013	DISTRIBUTION OF GRAFT TYPES AND TIME TO HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA (AML) IN DIFFERENT ETHNIC GROUPS IN ISRAEL	08:30 - 08:30
	Shlomo Elias (Jerusalem, Israel)	
B014	HEALING BONDS: THE COMPLEX EXPERIENCES OF PEDIATRIC SIBLING STEM CELL DONORS	08:30 - 08:30
	Victoria Bordon (Ghent, Belgium)	
B015	SAFETY OF HEMATOPOIETIC STEM CELL DONATION FROM YOUNG RELATED DONORS DUE TO THE LOWERED ADULT AGE IN JAPAN	08:30 - 08:30
	Tsuneaki Hirakawa (Tokyo, Japan)	
B016	THE EFFECT OF ABO INCOMPATIBILITY BETWEEN DONOR AND RECIPIENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, SINGLE CENTER STUDY	08:30 - 08:30
	Mohammed Essa (Riyadh, Saudi Arabia)	
B017	DOES ONE HLA MISMATCH INFLUENCE TRANSPLANT SUCCESS? A COMPARATIVE ANALYSIS ON GVHD AND MORTALITY	08:30 - 08:30
	Mehmet Sinan Dal (Ankara, Turkey)	
P100	EVALUATION OF HLA HAPLOTYPE HOMOZYGOSITY IN THE PORTUGUESE BONE MARROW DONOR REGISTRY FOR ALLOGENEIC T-CELL PRODUCT PRODUCTION	08:30 - 08:30
	Eduardo Espada (Lisbon, Portugal)	
P101	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER RETROSPECTIVE ANALYSIS FROM SLOVAKIA	08:30 - 08:30
	Iveta Oravcova (Bratislava, Slovakia)	
P103	DKMS ACCESS TO TRANSPLANTATION (ATT) PROGRAM: GIVING HOPE FOR A HEALTHY FUTURE	08:30 - 08:30
	Nitin Agarwal (Bangalore, India)	
P104	LOW MCV IN HEALTHY VOLUNTEER DONORS: THE HARVESTING CHALLENGE	08:30 - 08:30
	Angeliki Karagiannidou (Chaidari, Greece)	
P106	CASE SERIES REPORT ON PAEDIATRIC SIBLING DONOR OUTCOMES	08:30 - 08:30
	James Celaire (Leeds, United Kingdom of Great Britain and Northern Ireland (the))	
P107	ANTI-MYELOMA TREATMENT IMPACTS ON SYNTHESIS OF ANTI-HLA ANTIBODIES AND MIGHT BE CONSIDERED FOR DESENSITIZATION PROTOCOLS IN PATIENTS WITH DSA BEFORE	08:30 - 08:30

HSCT

Roberto Crocchiolo (Milano, Italy)

ePoster

08:30 - 18:00

R18

Stem Cell Source

- A171 **THE APPLICATION OF UMBILICAL CORD BLOOD TRANSPLANTATION IN PAEDIATRIC INBORN ERRORS OF IMMUNITY** 08:30 - 08:30
Xiaowen Zhai (Shanghai, China)
- A172 **ADHERENCE TO CB GUIDELINES IMPROVES TRANSPLANT OUTCOMES IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES** 08:30 - 08:30
Filippo Milano (Seattle, United States of America (the))
- A173 **THE COMPARISON OF BONE MARROW (BM) PLUS PERIPHERAL BLOOD (PB) VERSUS PB AS GRAFT SOURCE IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR ELDERLY PATIENTS** 08:30 - 08:30
Wei Zhao (Beijing, China)
- A174 **THE HAPLOID HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH UMBILICAL CORD BLOOD TRANSFUSION IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES - A MULTICENTER, SINGLE-ARM PROSPECTIVE TRIAL** 08:30 - 08:30
Jiejing Qian (Hangzhou, China)
- A175 **ADAMII™-CD34: INSTRUMENTAL QUALIFICATION IN THE CHARACTERIZATION PROCESS OF THE LEUKAPHERESIS PRODUCT FOR HSC TRANSPLANTATION** 08:30 - 08:30
Serena Urbani (Firenze, Italy)
- A176 **EARLY LOW-DOSE ATG CONDITIONING FOR SINGLE UNIT CORD BLOOD TRANSPLANT IN HIGH-RISK MALIGNANCIES: GOOD ENGRAFTMENT, REDUCED GVHD, AND LOW NRM** 08:30 - 08:30
Marta Castelli (Bergamo, Italy)
- A177 **COMPARATIVE ANALYSIS OF STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH HLA-HOMOZYGOUS HAPLOTYPES** 08:30 - 08:30
Noriyoshi Yoshinaga (Kyoto, Japan)
- P097 **COMPARISON OF QUALITY ASSESSMENT OF LEUKOCYTE SUBPOPULATIONS OF AN UMBILICAL CORD BLOOD UNIT BETWEEN CONTIGUOUS SEGMENT AND CRYOVIAL** 08:30 - 08:30
Ines Bojanić (Zagreb, Croatia)
- P098 **ASSESSMENT OF PERIPHERAL STEM CELL GRAFT FUNCTION TO PREDICT THE INCIDENCE OF INFECTIOUS COMPLICATIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
Anna Söderström (Stockholm, Sweden)
- P099 **THE FACTORS INFLUENCING THE IMMUNE REGULATORY PHENOTYPIC CHANGES OF UMBILICAL CORD BLOOD-DERIVED MESENCHYMAL STEM CELLS BASED ON CELL DIMENSIONALITY AND SCAFFOLD PRESENCE** 08:30 - 08:30
Jun Eun Park (Seoul, Korea (the Republic of))

ePoster

08:30 - 18:00

R18

Non-haematopoietic Stem Cells and Regenerative Medicine

- B001 **EFFECT OF CONDITIONING TOXICITY ON THE BONE MARROW MESENCHYMAL STROMA CELL-NICHE AND ITS IMPACT ON ENGRAFTMENT AND RELAPSE OF MYELOID NEOPLASIA** 08:30 - 08:30

Sara Garaali (Halle (Saale), Germany)

ePoster

08:30 - 18:00

R18

New Drugs and Cell-based Immune Therapies

A162	BONE MARROW TRANSPLANTATION AND MITOCHONDRIAL TRANSFER ALLEVIATE THE SYMPTOMS OF LEIGH SYNDROME Takafumi Yokota (Osaka, Japan)	08:30 - 08:30
A163	SYNERGIZING MDM2 INHIBITION WITH ANTI-TIM-3 ANTIBODY THERAPY TO ENHANCE THE GRAFT-VERSUS-LEUKEMIA EFFECT Andrea Acerbis (Freiburg, Germany)	08:30 - 08:30
A164	T CELL RECEPTOR GENE THERAPY TARGETING MUTANT NPM1 IN ACUTE MYELOID LEUKEMIA Eva Argiro (Leiden, Netherlands (the))	08:30 - 08:30
A165	EBV INFECTION RISK OF BLINATUMOMAB IN B-ALL PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Hailu Sun (Beijing, China)	08:30 - 08:30
A166	A NOVEL SKP2 INHIBITOR TRIGGERS PYROPTOSIS IN PH⁺ ALL VIA DYSREGULATION OF GLYCEROPHOSPHOLIPID METABOLISM Xiaolong Tian (Chongqing, China)	08:30 - 08:30
A167	PREVENTION OF RELAPSE WITH ORAL AZACITIDINE AND VENETOCLAX AFTER ALLO-HCT FOR AML AND MDS Antoine Capes (Paris, France)	08:30 - 08:30
A169	A SINGLE CENTRE EXPERIENCE WITH DARATUMUMAB IN RELAPSED REFRACTORY T-ALL Sandra Easdale (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
A170	LUSPATERCEPT TREATMENT FOR ERYTHROID POOR GRAFT FUNCTION OCCURRING POST HEMATOPOIETIC STEM CELL TRANSPLANTATION Qing Zhao (Shanghai, China)	08:30 - 08:30
P089	GLOFITAMAB COMBINED WITH SALVAGE THERAPY FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: INSIGHTS FROM A REAL-WORLD PROSPECTIVE OBSERVATIONAL STUDY IN CHINESE PATIENTS Haiwen Huang (Suzhou, China)	08:30 - 08:30
P090	DONOR CD45 RA DEPLETED CELLS FOR THE TREATMENT OF SEVERE CRYPTOSPORIDIOSIS FOLLOWING HAPLOIDENTICAL HSCT Rakefet Sidlik Muskatel (Petach Tikva, Israel)	08:30 - 08:30
P091	REAL-WORLD EXPERIENCE: TABELCLEUCEL FOR EBV-POSITIVE POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Kiavasch Mohammad Nejad Farid (Heidelberg, Germany)	08:30 - 08:30
P092	ANALYSIS OF DONORS AND STARTING MATERIAL TO MANUFACTURE OPTIMAL BATCHES OF VIRAL-SPECIFIC T-CELLS Sara Vallejo-Diez (Cantabria, Spain)	08:30 - 08:30
P094	SUCCESSFUL TREATMENT OF POST-TRANSPLANT AUTOIMMUNE NEUTROPENIA AND SECONDARY GRAFT FAILURE WITH RITUXIMAB AND DARATUMUMAB Mehtap Sirin (Ulm, Germany)	08:30 - 08:30

ePoster

08:30 - 18:00

R18

Experimental Transplantation and Gene Therapy

- A156 **BASE EDITING OF HEMATOPOIETIC STEM CELLS AND T CELLS RESTORES PI3K SIGNALLING IN APDS1 AND APDS2 PATIENTS** 08:30 - 08:30
Kate Orf (London, United Kingdom of Great Britain and Northern Ireland (the))
- A157 **GENE THERAPY FOR SICKLE CELL DISEASE AND TRANSFUSION DEPENDENT BETA THALASSEMIA: REAL WORLD DATA, SINGLE CENTER EXPERIENCE** 08:30 - 08:30
Mohammed Essa (Riyadh, Saudi Arabia)
- A159 **CHARACTERISATION OF THE DIFFERENTIAL B CELL TRANSCRIPTOME EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WHO DEVELOP CHRONIC GVHD OR DISEASE RELAPSE** 08:30 - 08:30
Ali Gazwani (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))
- A161 **ALLOGENEIC HSCT FOLLOWING LUNG TRANSPLANT: SECOND REPORTED CASE IN THE LITERATURE** 08:30 - 08:30
Irene Bernareggi (Siena, Italy)

ePoster

08:30 - 18:00

R18

Cellular Therapies other than CARs

- A135 **ADOPTIVE CELL THERAPY WITH MEMORY T LYMPHOCYTES TO TREAT INFECTIOUS DISEASES IN IMMUNOCOMPROMISED PATIENTS** 08:30 - 08:30
Karima Al-Akioui Sanz (Madrid, Spain)
- A136 **UTILIZING T REGULATORY AND T MEMORY CELL PRODUCTS IN THE TREATMENT OF PATIENTS WITH GVHD AND ASSOCIATED INFECTIOUS COMPLICATIONS: INSIGHTS FROM A CLINICAL EXPERIENCE** 08:30 - 08:30
Dmitry Pershin (Moscow, Russian Federation (the))
- A139 **ADOPTIVE IMMUNOTHERAPY WITH DONOR-DERIVED VIRUS-SPECIFIC T LYMPHOCYTE FOR THE TREATMENT OF SEVERE, TREATMENT-REFRACTORY VIRAL INFECTIONS IN CHILDREN UNDERGOING HLA-HAPLOIDENTICAL T-ALPHA/BETA AND B-DEPLETED TRANSPLANTATION** 08:30 - 08:30
Federica Galaverna (Roma, Italy)
- A140 **AN INNOVATIVE PLATFORM APPROACH FOR THE PARALLEL DEVELOPMENT OF HEMATOPOIETIC STEM AND PROGENITOR CELL-GENE THERAPIES (HSPC-GT) FOR RARE/ULTRA-RARE LYSOSOMAL STORAGE DISORDERS WITH SEVERE SKELETAL MANIFESTATIONS** 08:30 - 08:30
Maria Ester Bernardo (Milano, Italy)
- A141 **T- AND B-CELL NEOGENESIS RECOVERS EFFICIENTLY IN CHILDREN WITH ACUTE LEUKEMIA GIVEN AN ALPHA-BETA T-CELL DEPLETED HAPLO-HSCT FOLLOWED BY INFUSION OF GENETICALLY MODIFIED DONOR T-CELLS** 08:30 - 08:30
Marialuigia Catanoso (Rome, Italy)
- A142 **POST-TRANSPLANT MAINTENANCE THERAPY WITH AZACITIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) IN PATIENTS WITH JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) AT HIGH RISK OF RELAPSE** 08:30 - 08:30
Luca Vinci (Freiburg, Germany)
- A143 **DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A SINGLE CENTER LONGITUDINAL** 08:30 - 08:30

	RETROSPECTIVE STUDY Veronika Valkova (Prague 2, Czechia)	
A144	MERIT OF A HIGH-VOLUME DONOR LYMPHOCYTE INFUSION PRACTICE IN MODERN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION Micheal Brennan (Dublin, Ireland)	08:30 - 08:30
A145	SAFETY AND EFFICACY OF AN ADVANCED THERAPY PROPHYLAXIS WITH CMV-SPECIFIC CYTOTOXIC T LYMPHOCYTES AFTER FAMILIAL ALLOGENEIC TRANSPLANTATION Arancha Bermudez (Santander, Spain)	08:30 - 08:30
A147	FEASIBILITY OF GENERATION AND EXPANSION OF HEMATOPOIETIC STEM CELL-DERIVED NATURAL KILLER CELLS FOR A POTENTIAL ALTERNATIVE CELL SOURCE OF CANCER IMMUNOTHERAPY Suppanut Komjakraphan (Hat Yai, Thailand)	08:30 - 08:30
A148	IMPLEMENTING A DATABASE ON ATMP-RELATED TRIALS IN EUROPE - INSIGHTS FROM THE JOIN4ATMP PROJECT Stephanie Winter (Vienna, Austria)	08:30 - 08:30
A149	DONOR-DERIVED ANTI-LEUKEMIA CTL FOR THE CONTROL OF LEUKEMIA RELAPSE IN HIGH-RISK CHILDREN AFTER HAPLO-HSCT Daniela Montagna (Pavia, Italy)	08:30 - 08:30
A150	ABATACEPT(CTLA4-IG) PRIMING AND ITS ROLE IN MODULATING NKCELL FUNCTION AND GRAFT-VERSUS-LEUKEMIA EFFECT IN PATIENTS UNDERGOING HAPLOIDENTICAL HCT: A PROMISING APPROACH TO DISSOCIATE GVH AND GVL Sarita Jaiswal (New Delhi, India)	08:30 - 08:30
A152	LEUKAPHERESIS FOR CD45RA-DEPLETED DONOR LYMPHOCYTE INFUSIONS: REPORT FROM A SINGLE PEDIATRIC CENTER Blanca Molina (Madrid, Spain)	08:30 - 08:30
A153	2 YEARS OF CAR-T IN A TERTIARY PEDIATRIC CENTER: RESULTS AND RESPONSE TO TREATMENT Antonella Zanette (Curitiba, Brazil)	08:30 - 08:30
A154	THE ADDITION OF CD28 SIGNALLING MOTIFS TO CD3Z ENHANCES TCR T CELL FUNCTION Emma Morris (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
A155	SUCCESSFUL LONG-TERM USE OF DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD Bernd Gruhn (Jena, Germany)	08:30 - 08:30
P082	THE USE OF MESENCHYMAL STROMAL CELLS FOR THE TREATMENT STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN Krzysztof Czyzewski (Bydgoszcz, Poland)	08:30 - 08:30
P083	VIRUS SPECIFIC T-CELL THERAPY IS EFFECTIVE IN TREATING CHILDREN WITH REFRACTORY VIRAL INFECTIONS POST HEMATOPOIETIC STEM CELL TRANSPLANT OR SOLID ORGAN TRANSPLANT Satya Prakash Yadav (Gurgaon, India)	08:30 - 08:30
P084	STUDY ON THE EFFICACY AND SAFETY OF THE VENAZA REGIMEN AND DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA POST-TRANSPLANT	08:30 - 08:30

	Maria Izquierdo Montagut (Badalona, Spain)	
P085	TRANSFER OF HERPES SIMPLEX VIRUS TYPE 1 (HSV1)-SPECIFIC T CELLS IN A PEDIATRIC PATIENT POST-HSCT WITH SEVERE, ACICLOVIR-RESISTANT HSV1 INFECTION Ariana de Oliveira Mekonnen (Hannover, Germany)	08:30 - 08:30
P086	INTRATHECAL DONOR LYMPHOCYTE INFUSION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM VIRAL INFECTIONS IN PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Juan Wang (Zhengzhou, China)	08:30 - 08:30
P087	TREATMENT WITH ATMP CLASSIFIED BK-VIRUS SPECIFIC T-CELLS - A CASE REPORT Rebecca Axelsson Robertson (Stockholm, Sweden)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Autoimmune Diseases		
B299	BONE MARROW HEMOPOIESIS IN PRE-TREATED MULTIPLE SCLEROSIS BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION Edoardo Simonetti (Florence, Italy)	08:30 - 08:30
B300	HIGH DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS: QUALITY OF LIFE ANALYSIS Denis Fedorenko (Moscow, Russian Federation (the))	08:30 - 08:30
B301	EARLY THERAPEUTIC RESPONSE AS A PROGNOSTIC INDICATOR IN AUTOLOGOUS HSCT FOR MULTIPLE SCLEROSIS Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	08:30 - 08:30
B302	IMPACT OF BMI ON HEMATOPOIETIC STEM CELL TRANSPLANT OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	08:30 - 08:30
B303	ASSOCIATION OF SMOKING WITH DISEASE PROGRESSION IN PERSONS WITH MULTIPLE SCLEROSIS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	08:30 - 08:30
P306	CYCLOPHOSPHAMIDE (CP)-FREE MOBILIZATION OF HEMATOPOIETIC STEM CELLS (HSC) IN PATIENTS WITH AUTOIMMUNE DISEASE (AD) UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AUTOHCT) Ernesto Ayala (Jacksonville, United States of America (the))	08:30 - 08:30
P307	INDUCTION OF B CELL DEPLETION IN THE BONE MARROW THROUGH ANTI-CD19 CAR T CELL THERAPY IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES Ioanna Minopoulou (Berlin, Germany)	08:30 - 08:30
P308	EVALUATION OF THE EFFECT OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT ON SYMPTOM SEVERITY USING MSWS-12, ARMSQ AND SYMPTOMSCREEN IN MULTIPLE SCLEROSIS PATIENTS Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	08:30 - 08:30
P309	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC SCLEROSIS - A SINGLE CENTER EXPERIENCE OF UNIVERSITY HOSPITAL CENTER ZAGREB, ZAGREB, CROATIA	08:30 - 08:30

Krešimir Rukavina (Zagreb, Croatia)

ePoster

08:30 - 18:00

R18

Aplastic Anaemia

- B285 **COMPARISON OF OUTCOMES OF IMMUNOSUPPRESSIVE THERAPY WITH RABBIT VS. HORSE ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE A IN PATIENTS WITH REFRACTORY CYTOPENIA OF CHILDHOOD** 08:30 - 08:30
Ayami Yoshimi (Freiburg,, Germany)
- B286 **THE DOSE OPTIMIZATION OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE+PTCY IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR APLASTIC ANEMIA PATIENTS** 08:30 - 08:30
Na Wang (Wuhan, China)
- B287 **MIXED T-CELL CHIMERISM IN SAA HSCT RECIPIENTS IS LINKED TO VIRUS INFECTION, DOES NOT PREDICT GRAFT FAILURE, AND REQUIRES NO PROLONGED IMMUNOSUPPRESSION OR DLI** 08:30 - 08:30
Kainat Memon (Manchester, United Kingdom of Great Britain and Northern Ireland (the))
- B288 **ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR VEXAS SYNDROME: INTERIM RESULTS FROM A PHASE II STUDY** 08:30 - 08:30
Emma Groarke (Bethesda, United States of America (the))
- B289 **DANICOPAN AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: LONG-TERM PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 ALPHA TRIAL** 08:30 - 08:30
Hubert Schrezenmeier (Ulm, Germany)
- B290 **IN VIVO EFFECTS AND PHARMACODYNAMICS OF ATGAM IN ACQUIRED APLASTIC ANEMIA PATIENTS** 08:30 - 08:30
Emma Pool (Leiden, Netherlands (the))
- B291 **ASSESSMENT OF CHARACTERISTICS AND TREATMENT PATTERNS OF ADULT PATIENTS WITH ACQUIRED APLASTIC ANAEMIA IN TURKIYE (PLANE-TR STUDY)** 08:30 - 08:30
Mehmet Sinan Dal (Ankara, Turkey)
- B292 **LOW-DOSE TREOSULFAN-BASED CONDITIONING WITH PTCY GVHD PROPHYLAXIS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SEVERE APLASTIC ANEMIA** 08:30 - 08:30
Anna Lifshits (Moscow, Russian Federation (the))
- B293 **OUTCOME OF ACQUIRED APLASTIC ANAEMIA IN CHILDREN UNDER SIX YEARS: A STUDY FROM A COHORT ON BEHALF OF THE FRENCH REFERENCE CENTER FOR APLASTIC ANEMIA** 08:30 - 08:30
Cecile Renard (Lyon, France)
- B294 **EVALUATION OF HAEMATOLOGY PHYSICIANS' AWARENESS OF AND REFERRAL TO APLASTIC ANAEMIA PATIENT ADVOCACY GROUPS** 08:30 - 08:30
Raj Gokani (Walton Oaks, United Kingdom of Great Britain and Northern Ireland (the))
- B295 **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACQUIRED APLASTIC ANEMIA WITH CYCLOPHOSPHAMIDE AND ANTI-THYMOCYTE GLOBULIN CONDITIONING REGIMEN** 08:30 - 08:30
Malek Benakli (Algiers, Algeria)
- B296 **OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR BONE MARROW FAILURE SYNDROMES IN PAEDIATRIC POPULATION - A RESOURCE-LIMITED COUNTRY - SRI LANKA** 08:30 - 08:30

	Shanika Vitharana (Colombo, Sri Lanka)	
B297	OUTCOME AFTER AUTOLOGOUS CORD BLOOD TRANSPLANTATION FOR PEDIATRIC ACQUIRED APLASTIC ANEMIA:A RETROSPECTIVE ANALYSIS OF MULTICENTER STUDY IN CHINA Jiao Chen (Beijing, China)	08:30 - 08:30
P305	EXCELLENT OUTCOME OF UPFRONT HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SEVERE APLASTIC ANEMIA:A SINGLE CENTER EXPERIENCE FROM JORDAN Ayad Ahmed Hussein (Amman, Jordan)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Acute Leukaemia		
B216	SAFETY, EFFICACY AND CAR T-CELL PERSISTENCE OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PATIENTS ≥55 YEARS OLD, WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL) Deborah Yallop (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
B217	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH NUP98-REARRANGED ACUTE MYELOID LEUKEMIA: A REAL-WORLD MULTICENTER EXPERIENCE Shixuan Zhang (Hangzhou, China)	08:30 - 08:30
B218	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SHOULD BE OFFERED TO OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION: A STUDY FROM THE EBMT ALWP Ali Bazarbachi (Beirut, Lebanon)	08:30 - 08:30
B219	HAPLOIDENTICAL VERSUS MUD HCT FOR ADULT PATIENTS WITH R/R ALL: A STUDY FROM THE GLOBAL COMMITTEE AND THE ALWP OF THE EBMT Yuhua Ru (Suzhou, China)	08:30 - 08:30
B220	ALLOGENEIC TRANSPLANTATION OUTCOMES OF MDS/AML: A MULTICENTER STUDY OF RISK VERIFICATION AND MATCHED ANALYSIS Yuhua Ru (Suzhou, China)	08:30 - 08:30
B221	CLONAL EVOLUTION IN AML PATIENTS AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Olga Blau (Berlin, Germany)	08:30 - 08:30
B222	PROGNOSTIC SIGNIFICANCE OF CYTOGENETIC RISK SCORE IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC TRANSPLANTATION FROM HLA MATCHED DONORS: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Tel Aviv, Israel)	08:30 - 08:30
B223	SAFETY AND EFFICACY OF AFM28, A CD123-TARGETING INNATE CELL ENGAGER IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKAEMIA: INTERIM RESULTS FROM A PHASE 1 STUDY Lydia Wunderle (Mannheim, Germany)	08:30 - 08:30
B224	HYPOMETHYLATING AGENTS AND VENETOCLAX WITH OR WITHOUT DLI IN RELAPSED AML AND MDS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REAL LIFE MULTICENTRIC STUDY	08:30 - 08:30

	Patrizia Chiusolo (Roma, Italy)	
B225	CONSOLIDATIVE ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION VS. WATCH AND WAIT APPROACH FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH EARLY LOSS OF B-CELL APLASIA AFTER CAR T-CELL THERAPY Sergi Camarillas (Barcelona, Spain)	08:30 - 08:30
B226	AUTO-HCT IN CR1 VERSUS ALLO-HCT IN CR2 FOR ADULT PATIENTS WITH INTERMEDIATE-RISK AML. ON BEHALF OF THE EBMT GLOBAL COMMITTEE AND ACUTE LEUKEMIA WORKING PARTY Jia Chen (Suzhou, China)	08:30 - 08:30
B227	ALLOGENEIC TRANSPLANTATION FOR WILMS TUMOR 1 (WT1) MUTATED COMPARED TO NON-MUTATED ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Tel Aviv, Israel)	08:30 - 08:30
B228	OUTCOMES OF MIXED PHENOTYPE ACUTE LEUKEMIA IN THE POST-TRANSPLANT CYCLOPHOSPHAMIDE ERA: A RETROSPECTIVE STUDY OF THE ALWP OF EBMT Annalisa Paviglianiti (Barcelona, Spain)	08:30 - 08:30
B229	ALLOGENEIC STEM CELL TRANSPLANTATION AFTER CAR-T CELL FOR R/R B-ALL IN PAEDIATRIC AND YOUNG ADULT PATIENTS. A RETROSPECTIVE STUDY ON BEHALF OF THE SPANISH GETH-TC Júlia Marsal-Ricomà (Barcelona, Spain)	08:30 - 08:30
B230	VENETOCLAX PLUS HYPOMETHYLATING AGENT COMBINATION AS EFFECTIVE BRIDGE THERAPY TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AML PATIENTS: A SUB-ANALYSIS OF THE AVALON STUDY Elisabetta Todisco (Busto Arsizio, Italy)	08:30 - 08:30
B233	ENDOTHELIAL DYSFUNCTION IN AML PATIENTS PREVAILS FROM INITIAL DIAGNOSIS AND ASSOCIATES WITH OUTCOME Thomas Luft (Heidelberg, Germany)	08:30 - 08:30
B234	OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ADULTS WITH INHERITED MYELOID MALIGNANCIES - A MULTICENTER ANALYSIS ON BEHALF OF THE GERMAN COOPERATIVE TRANSPLANT STUDY GROUP Tim Lohmann (Essen, Germany)	08:30 - 08:30
B235	EXPRESSION OF BONE MARROW INFILTRATING NK CELLS (BINK) AND PERIPHERAL BLOOD NK CELL (PBNK) RECEPTORS IN PAEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA Carmen Mestre Durán (Madrid, Spain)	08:30 - 08:30
B237	VENETOCLAX-DECITABINE FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANT IMPROVES THE OUTCOME OF ELDERLY HIGH-RISK ACUTE MYELOID LEUKAEMIA: VEN-DEC-GITMO STUDY MID-TERM UPDATE OF ALLO-TRANSPLANTED PATIENTS Daniele Avenoso (Brescia, Italy)	08:30 - 08:30
B238	ALLO-HCT OUTCOMES FOR AML PATIENTS WITH TP53 MUTATIONS IN ACTIVE DISEASE: A STUDY ON BEHALF OF THE GLOBAL COMMITTEE AND THE ALWP OF THE EBMT Yishan Ye (Hangzhou, China)	08:30 - 08:30
B239	FLT3-ITD MRD MEASUREMENT WITH A SENSITIVE NGS-BASED METHOD IN AML PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30

	Adriane Halik (Berlin, Germany)	
B240	LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA Maria Klimentova (Moscow, Russian Federation (the))	08:30 - 08:30
B241	DECREASING RISK TO DIE FROM ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS Jochen J. Frietsch (Jena, Germany)	08:30 - 08:30
B242	INVESTIGATING THE ROLE OF BONE MARROW MICROENVIRONMENT IN LEUKEMIA RELAPSE AFTER ALLOGENEIC TRANSPLANTATION Cristina Toffalori (Milano, Italy)	08:30 - 08:30
B243	RELAPSED/REFRACTORY ACUTE MYELOBLASTIC LEUKEMIA:HIGH EFFICIENCY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING SALVAGE THERAPY COMBINING 7 DAYS VENETOCLAX AND G-CSF, FLUDARABINE, HIGH-DOSE CYTARABINE, AND MITOXANTRONE Ahmad Ibrahim (Beirut, Lebanon)	08:30 - 08:30
B244	IMPACT OF TP53 MUTATION ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MDS/AML NOT IN COMPLETE REMISSION Normann Steiner (Innsbruck, Austria)	08:30 - 08:30
B245	ALLOGENEIC STEM CELL TRANSPLANTATION IN DE NOVO CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA IN ACTIVE DISEASE: A STUDY FROM THE ALWP OF THE EBMT Sara Tarantino (Milan, Italy)	08:30 - 08:30
B246	ACUTE MYELOID LEUKEMIA (AML) BLASTS IMPAIR HUMAN MAIT CELL FUNCTION Charlotte Calvo (Paris, France)	08:30 - 08:30
B250	OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PRIMARY REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE ANALYSIS FROM THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION REGISTRY Gloria Catalano (Milan, Italy)	08:30 - 08:30
B251	COMPARING THE EFFICACY AND SAFETY OF VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY AS INDUCTION THERAPY IN CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA PATIENTS Jingyi Shen (Suchow, China)	08:30 - 08:30
B253	IMPACT OF MUTATED TP53 ALLELIC BURDEN ON OUTCOMES OF ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A STUDY FROM THE ALWP OF THE EBMT Xavier Poiré (Brussels, Belgium)	08:30 - 08:30
B254	OPTIMIZATION STRATEGIES FOR TRANSPLANT RECOMMENDATION FOR ADULT AML PATIENTS WITH <i>CBFB::MYH11</i> FUSION Luxiang Wang (Shanghai, China)	08:30 - 08:30
B255	COMPARATIVE OUTCOMES OF AZACITIDINE-VENETOCLAX VERSUS LENALIDOMIDE-AZACITIDINE AS SALVAGE THERAPY IN RELAPSED MYELOID MALIGNANCIES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION Inna Shaforostova (Muenster, Germany)	08:30 - 08:30
B256	LONG-TERM OUTCOME OF DLI-BASED TREATMENT STRATEGY IN	08:30 - 08:30

	PATIENTS WITH RELAPSED AML AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	
	Jule Bergsma (Leiden, Netherlands (the))	
B258	REAL-WORLD ANALYSIS OF FLT3 INHIBITOR MAINTENANCE THERAPY ON POST-TRANSPLANT OUTCOMES IN FLT3-MUTATED AML PATIENTS FROM THE GERMAN HEMATOPOIETIC STEM CELL TRANSPLANTATION REGISTRY (DRST)	08:30 - 08:30
	Radwan Massoud (Hamburg, Germany)	
B259	B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH RELAPSED/REFRACTORY OR PERSISTENT MRD BENEFIT FROM BLINATUMOMAB BRIDGING PRIOR TO ALLO-HSCT	08:30 - 08:30
	Luxiang Wang (Shanghai, China)	
B260	IMPACT OF COMPLETE REMISSION WITH PARTIAL AND INCOMPLETE HEMATOLOGIC RECOVERY AFTER VENETOCLAX-BASED THERAPY ON ALLOHCT OUTCOMES IN AML PATIENTS	08:30 - 08:30
	Dmitrii Zhogolev (St. Petersburg, Russian Federation (the))	
B261	A PHASE I/II STUDY OF TAFASITAMAB FOR THE PREVENTION OF RELAPSE AFTER STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ALL	08:30 - 08:30
	Peter Lang (Tübingen, Germany)	
B263	FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN OLDER AML AND MDS PATIENTS: A SINGLE-CENTER EXPERIENCE	08:30 - 08:30
	Anna Grassi (Bergamo, Italy)	
B264	SORAFENIB MAINTENANCE MODULATES IMMUNE RECONSTITUTION AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION REDUCING PD-1 EXPRESSION ON CD8 T CELLS	08:30 - 08:30
	Sarah Morin (Geneva, Switzerland)	
B265	KAT6A INHIBITION AS A NOVEL STRATEGY TO OVERCOME IDH INHIBITOR RESISTANCE IN ACUTE MYELOID LEUKEMIA	08:30 - 08:30
	Mengbao Du (Hangzhou, China)	
B266	DONOR LYMPHOCYTE INFUSIONS FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS	08:30 - 08:30
	Fabio Serpenti (Milano, Italy)	
B267	SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE SINGLE CENTER ANALYSIS	08:30 - 08:30
	Michalis Kastamoulas (Athens, Greece)	
B268	CLINICAL OUTCOMES OF AZACITIDINE AND VENETOCLAX TREATMENT WITH OR WITHOUT CELLULAR THERAPY IN RELAPSED AML POST-ALLOHCT	08:30 - 08:30
	Candela Ceballos (San Sebastian, Spain)	
B269	EFFICACY AND SAFETY OF AZACITIDINE AND VENETOCLAX IN RELAPSED ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES POST-ALLO-HCT: A POLISH ACUTE LEUKEMIA GROUP (PALG) ANALYSIS	08:30 - 08:30
	Agnieszka Szeremet (Wroclaw, Poland)	
B270	DAY +100 BONE MARROW MEGAKARYOCYTE RESERVE PREDICTS SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ACUTE LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Zeynep Arzu Yegin (Ankara, Turkey)	

B271	PREEMPTIVE DONOR LYMPHOCYTE INFUSION FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA - AN ANALYSIS ON BEHALF OF POLISH ACUTE LEUKEMIA GROUP (PALG) Anna Lojko-Dankowska (Poznan, Poland)	08:30 - 08:30
B272	PRE-TRANSPLANT MRD DOUBLE POSITIVE DETECTION BY MOLECULAR AND MFC WERE THE INDEPENDENT DISMAL PROGNOSTIC FACTOR IN KMT2A-TRANSLOCATION PARTNER GENES AND KMT2A-PTD AML IN CR1 Na Zhang (Hebei, China)	08:30 - 08:30
B274	MO-TRANS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE III STUDY OF MOCRAVIMOD (MOC) AS ADJUNCTIVE AND MAINTENANCE TREATMENT IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Elisabeth Kueenburg (Saint-Louis, France)	08:30 - 08:30
B275	A SOUTH WALES PERSPECTIVE OF OUTCOMES IN ACUTE MYELOID LEUKAEMIA (AML) IN FIRST COMPLETE REMISSION (CR1): A RETROSPECTIVE ANALYSIS OF PRE-TRANSPLANT BONE MARROW ASSESSMENT Abigail Downing (Cardiff, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
B276	EFFICACY AND SAFETY OF REDUCED DOSE POST TRANSPLANT CYCLOPHOSPHAMIDE REGIMES IN HAPLOIDENTICAL STEM CELL TRANSPLANT IN PATIENTS WITH ACUTE LEUKAEMIA, A SINGLE CENTRE STUDY Tien Gen Wong (Ampang Jaya, Malaysia)	08:30 - 08:30
B277	IMPACT OF T(9;11) AND DEL(7Q) AS INTERMEDIATE-RISK ABNORMALITIES IN AML AFTER ALLO-TRANSPLANT: ANALYSIS BASED ON THE ELN 2022 CLASSIFICATION - AN EBMT ALWP STUDY Iman Abou Dalle (Beirut, Lebanon)	08:30 - 08:30
B278	AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS MAINTENANCE THERAPY AS A POST-CONSOLIDATION THERAPY IN PATIENTS WITH STANDARD RISK ACUTE LYMPHOBLASTIC LEUKEMIA Sebastian Giebel (Gliwice, Poland)	08:30 - 08:30
B279	OUTCOME OF AML PATIENTS WITH POSTTRANSPLANT EXTRAMEDULLARY RELAPSE Cort Hendrik Claassen (Essen, Germany)	08:30 - 08:30
B281	IMPLEMENTATION OF CLINICAL ROUTINE USE OF NEXT-GENERATION SEQUENCING AND VENETOCLAX IN ACUTE MYELOID LEUKAEMIA TREATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION, A REAL-LIFE SINGLE-CENTRE STUDY Riccardo Boncompagni (Florence, Italy)	08:30 - 08:30
B282	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN CHILDREN WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: AMBULATORY OR IN-HOSPITAL? Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	08:30 - 08:30
B283	CONDITIONING REGIMEN COMBINING LOW DOSE TBI, POST TRANSPLANTATION CYCLOPHOSPHAMIDE AND STANDARD PROPHYLACTIC DLI LEADS TO EXCELLENT 2 YEARS OUTCOME IN FRAIL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS Constantijn Halkes (Leiden, Netherlands (the))	08:30 - 08:30
B284	IMPACT OF TACROLIMUS EXPOSURE ON CLINICAL OUTCOMES IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL	08:30 - 08:30

	TRANSPLANTATION	
	Andreas Ralfs (Düsseldorf, Germany)	
P277	LONG-TERM OUTCOMES OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED ALLOGENEIC STEM CELL TRANSPLANTATION Dong Won Baek (Daegu, Korea (the Republic of))	08:30 - 08:30
P278	CHALLENGES AND RESULTS OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TP53-ALTERED MYELOID NEOPLASMS: A SINGLE CENTER EXPERIENCE María Oviedo (Santander, Spain)	08:30 - 08:30
P279	OUTCOMES OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS: A RETROSPECTIVE STUDY ON BEHALF OF PAKISTAN BLOOD AND MARROW TRANSPLANT (PBMT) GROUP Saima Humayun Toor (Rawalpindi, Pakistan)	08:30 - 08:30
P280	DRUG SENSITIVITY AND CLINICAL APPLICATIONS BASED ON CUPROPTOSIS-ASSOCIATED LNCRNA PROGNOSTIC IMPACT IN ACUTE MYELOID LEUKEMIA Yaoyao Shen (Suzhou, China)	08:30 - 08:30
P281	CR STATUS BEFORE TRANSPLANTATION WAS THE INDEPENDENT FACTOR THAT PREDICTED SURVIVAL AND RELAPSE RISK IN MIXED PHENOTYPE ACUTE LEUKEMIA: A SINGLE-CENTER LONG-TERM FOLLOW-UP STUDY Yue Lu (Hebei, China)	08:30 - 08:30
P283	PROGNOSTIC IMPACT OF CD135 EXPRESSION ON BLASTS IN ADULT ACUTE MYELOID LEUKEMIA (AML): A NEW BIOMARKER FOR IMPROVEMENT OF AML RISK STRATIFICATION Lu Gao (Soochow, China)	08:30 - 08:30
P284	MATCHED SIBLING HEMATOPOIETIC STEM CELL TRANSPLANTATION VS TKI COMBINED WITH CHEMOTHERAPY FOR ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: PERUVIAN REAL-WORLD DATA STEM CELL TRANSPLANT CENTER Cindy Alcarraz Molina (Lima, Peru)	08:30 - 08:30
P285	HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOME IN BCR/ABL POSITIVE-PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITHOUT POST-HSCT TYROSINE KINASE INHIBITORS Amir Ali Hamidieh (Tehran, Iran (Islamic Republic of))	08:30 - 08:30
P286	HMA PLUS VENETOCLAX AS FRONT-LINE OR SALVAGE THERAPY FOR AML PATIENTS PRIOR TO STEM CELL TRANSPLANT Bana Antonios (Pittsburgh, United States of America (the))	08:30 - 08:30
P287	REAL-WORLD DATA ON MAINTENANCE THERAPY POST ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A SURVEY FROM GETH-TC (SPANISH TRANSPLANT GROUP) Estefania Perez-Lopez (Salamanca, Spain)	08:30 - 08:30
P288	HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADOLESCENTS AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA: A RETROSPECTIVE SINGLE CENTRE SERIES Sabrina Akhrouf (Algiers, Algeria)	08:30 - 08:30
P290	QUANTUM-WILD: PHASE 3, RANDOMIZED, DOUBLE-BLIND QUIZARTINIB STUDY IN NEWLY DIAGNOSED, FLT3 -ITD-NEGATIVE ACUTE MYELOID LEUKEMIA	08:30 - 08:30

	Esther Natalie Oliva (London, United Kingdom of Great Britain and Northern Ireland (the))	
P292	EFFICACY AND SAFETY OF VENETOCLAX-BASED SALVAGE THERAPY AS BRIDGE-TO-TRANSPLANT IN PATIENTS WITH REFRACTORY/RELAPSE AML- PERUVIAN EXPERIENCE Shirley Quintana (Lima, Peru)	08:30 - 08:30
P293	INOTUZUMAB OZOGAMICIN IN CHILDREN WITH B-ALL, SINGLE CENTER EXPERIENCE Murat Elli (Istanbul, Turkey)	08:30 - 08:30
P294	TRANSPLANTATION OUTCOMES FOR ADULTS WITH HYPODIPLOIDY IN ACUTE LYMPHOBLASTIC LEUKEMIA Francisco Javier Gutierrez-Ramirez (Mexico City, Mexico)	08:30 - 08:30
P297	AN UNCOMMON CASE OF SECOND ALLOGENEIC HSCT FOR DONOR CELL LEUKEMIA: FEASIBILITY AND OUTCOME Margherita Malchiodi (Siena, Italy)	08:30 - 08:30
P298	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN A PATIENT WITH FANCONI ANEMIA-ASSOCIATED AML: A CASE REPORT Andriyana Bankova (Sofia, Bulgaria)	08:30 - 08:30
P299	DRUG RESPONSE PROFILING AS A BRIDGE TO ALLOGENEIC STEM CELL TRANSPLANTATION IN A RELAPSED IMMATURE T-ALL WITH CONCOMITANT AML CLONE Amelia Rinaldi (Parma, Italy)	08:30 - 08:30
P301	EFFICACY AND SAFETY OF TBI+THIOTEPA+ATG BASED CONDITIONING REGIMEN FOR HAPLOIDENTICAL HSCT IN 5 CASES OF AGGRESSIVE T-ALL COMBINED CNS INVOLVEMEN Ying Jiang (Shanghai, China)	08:30 - 08:30
P302	A CASE OF HLA-ESCAPE IN A PEDIATRIC CASE OF ACUTE MYELOID LEUKEMIA SUBJECTED TO HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION Manuela Tumino (Padua, Italy)	08:30 - 08:30
P303	ACUTE MYELOID LEUKEMIA - NEVER-ENDING BATTLE WITH A FORMIDABLE FOE - A CASE REPORT Krasen Venkov (Sofia, Bulgaria)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Paediatric Issues		
B168	CUMULATIVE INCIDENCE AND OUTCOME OF SECONDARY NEOPLASMS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN. A SINGLE CENTER EXPERIENCE Daria Pagliara (Roma, Italy)	08:30 - 08:30
B169	LONG-TERM OUTCOMES OF HSCT FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA, SINGLE CENTER EXPERIENCE. L. Shelikhova (Moscow, Russian Federation (the))	08:30 - 08:30
B170	DISRUPTION OF THE GUT MICROENVIRONMENT AND BLOOD-BRAIN BARRIER PREDICTS COGNITIVE IMPAIRMENT IN PAEDIATRIC HSCT Maya Davies (Adelaide, Australia)	08:30 - 08:30
B171	HEPATIC VENO-OCCLUSIVE DISEASE IN PATIENTS UNDER 3	08:30 - 08:30

	YEARS OLD RECEIVING A HSCT. A MULTICENTER SURVEY STUDY OF SPANISH GROUP FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (GETH-TC)	
	Iván López-Torija (Barcelona, Spain)	
B172	VEDOLIZUMAB PREVENTS LOWER GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC NON-MALIGNANT DISEASE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Karin Toews (Berlin, Germany)	
B173	SPECIFIC HLA CLASS I GENOTYPES DO NOT PREDICT PROGNOSIS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC APLASTIC ANEMIA	08:30 - 08:30
	Kotaro Narita (Nagoya, Japan)	
B174	PROSPECTIVE EVALUATION OF TREOSULFAN EXPOSURE IMPACT ON THE OUTCOMES OF PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	08:30 - 08:30
	Francesco Delle Cave (Pavia, Italy)	
B175	EASIX SCORE PREDICTS OVERALL SURVIVAL, EVENT-FREE SURVIVAL AND NON-RELAPSE MORTALITY FOR PEDIATRIC PATIENTS AFTER ALLOSCT	08:30 - 08:30
	Burak Caliskan (Vienna, Austria)	
B176	AGE IS A STRONG INFLUENCE ON THE GUT MICROBIOME IN CHILDREN UNDERGOING HEMATOPOIETIC CELL TRANSPLANT	08:30 - 08:30
	Pooja Khandelwal (Cincinnati, United States of America (the))	
B177	FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR DECOLONIZATION OF MULTI-DRUG RESISTANT MICROORGANISMS (MDRO) OR GVHD TREATMENT IN CHILDREN: A MULTICENTER RETROSPECTIVE ANALYSIS ON SAFETY AND EFFICACY	08:30 - 08:30
	Pietro Merli (Rome, Italy)	
B178	DEVELOPMENT AND VALIDATION OF A PREDICTION MODEL FOR SEVERE PES DURING THE TREATMENT OF UNRELATED UCBT IN PEDIATRIC PATIENTS	08:30 - 08:30
	Fang Liu (Tianjin, China)	
B179	OUTCOMES OF PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES GIVEN SECOND HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH EITHER TCRAB/CD19 DEPLETION OR POST-TRANSPLANT CYCLOPHOSPHAMIDE	08:30 - 08:30
	Riccardo Masetti (Bologna, Italy)	
B180	HAPLOIDENTICAL SIBLING DONOR FOR PEDIATRIC PATIENTS: THE PERFECT MISMATCH?	08:30 - 08:30
	Marta Gonzalez Vicent (Madrid, Spain)	
B181	LONG-TERM OUTCOMES IN PATIENTS WITH HURLER SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Melissa Panesso (Barcelona, Spain)	
B182	PAEDIATRIC APHERESIS PROCEDURES USING HICKMAN CATHETERS: EXPERIENCE OF A UK CENTRE	08:30 - 08:30
	Gemma Barnard (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	
B183	OUTCOMES OF THE FIRST COMPREHENSIVE PEDIATRIC PRIVATE HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER IN JORDAN: EXPERIENCE FROM A DEVELOPING COUNTRY.	08:30 - 08:30

	Ayad Ahmed Hussein (Amman, Jordan)	
B184	NUTRITIONAL EVALUATION AND SUPPORT IN PEDIATRIC ALLO-HSCT: AN EXPERT CONSENSUS ON BEHALF OF THE INFECTIOUS DISEASE, NURSES, AND HEMATOPOIETIC CELL TRANSPLANT WORKING GROUPS OF AIEOP Francesco Baccelli (Bologna, Italy)	08:30 - 08:30
B185	HIGH TACROLIMUS TROUGH CONCENTRATIONS IS AN EARLY PREDICTOR OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN Rajinder Bajwa (Columbus, United States of America (the))	08:30 - 08:30
B186	USE OF ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION IN PEDIATRIC PATIENTS: A RETROSPECTIVE MULTICENTER STUDY Filomena Pierri (Genova, Italy)	08:30 - 08:30
B187	MULTICENTER REPORT ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH TRISOMY 21 AND ACUTE LEUKEMIAS IN CHILE, 2000-2024 Paula Catalán (Santiago, Chile)	08:30 - 08:30
B188	ENHANCING PEDIATRIC OUTCOMES IN STEM CELL TRANSPLANTATION: INTEGRATING SCREENING TOOLS FOR COMPREHENSIVE QUALITY OF LIFE ASSESSMENT Flannery Bowman (Durham, United States of America (the))	08:30 - 08:30
B189	EFFICACY OF AUTOLOGOUS CORD BLOOD TRANSPLANTATION IN TREATING CHILDREN WITH ACQUIRED APLASTIC ANEMIA: A SINGLE-CENTER COMPARATIVE STUDY AND INDIVIDUAL PATIENT DATA META-ANALYSIS Ye Guo (Tianjin, China)	08:30 - 08:30
B190	PHYSICAL CAPACITY AND METABOLIC SYNDROME IN LONG-TERM SURVIVORS OF PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - THE IMPACT OF LIFESTYLE Anne Nissen (Copenhagen, Denmark)	08:30 - 08:30
B191	THE USE OF CONTINUOUS MILRINONE THERAPY AS A HEMODYMANIC BRIDGE TO ALLOGENEIC HEMATOPOEITIC CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ANTHRACYCLINE-RELATED CARDIOTOXICITY Deepak Chellapandian (St Petersburg, United States of America (the))	08:30 - 08:30
B192	ARTIFICIAL INTELLIGENCE HELPS IN THE EARLY DIAGNOSIS OF VENO-OCCLUSIVE DISEASE IN CHILDREN WITH 100% ACCURACY Rajinder Bajwa (Columbus, United States of America (the))	08:30 - 08:30
B193	TCI-SCORE: EXPLORATION FOR FUTURE VALIDATION IN A PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION COHORT, FIRST REPORT Paula Catalán (Santiago, Chile)	08:30 - 08:30
B194	EFFICACY AND SAFETY ASSESSMENT OF ANTIFUNGAL PROPHYLAXIS WITH POSACONAZOLE USING THERAPEUTIC DRUG MONITORING IN PEDIATRIC PATIENTS WITH ONCOHEMATOLOGICAL DISORDERS - A SINGLE-CENTRE STUDY Karolina Liszka (Wrocław, Poland)	08:30 - 08:30
B195	IMPACT OF THE DASATINIB USED BEFORE ALLOHCT ON THE OUTCOME OF CHILDREN WITH CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA Fang Liu (Tianjin, China)	08:30 - 08:30

B196	SEVERE VANISHING BILE DUCT SYNDROME IN PEDIATRIC PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Maura Faraci (Genova, Italy)	08:30 - 08:30
B197	OUTCOMES OF AB T CELL DEPLETED HAPLO-HSCT FOR PEDIATRIC MDS Sung Han Kang (Seoul, Korea (the Republic of))	08:30 - 08:30
B198	IMPACT OF ABO MISMATCH ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS Luiz Guilherme Darrigo Junior (Ribeirão Preto, Brazil)	08:30 - 08:30
B199	ELEVATED PLASMA CXCL9 AND CHI3L1 PRIOR TO HCT PREDICTS POST-HCT PULMONARY COMPLICATIONS IN CHILDREN Hannah Walker (Parkville, Australia)	08:30 - 08:30
B200	MACROPHAGE ACTIVATION SYNDROME WITH POOR GRAFT FUNCTION OR REJECTION AS INDICATION FOR SECOND ALLOGENEIC HCT FROM HAPLOIDENTICAL DONOR IN CHILDREN WITH HIGH RISK ACUTE LEUKEMIA Polina Kozhokar (Saint-Petersburg, Russian Federation (the))	08:30 - 08:30
B201	THE USE OF POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN PEDIATRIC UNRELATED DONOR HEMATOPOETIC STEMCELL TRANSPLANTATION Luca Marie Beermann (Hamburg, Germany)	08:30 - 08:30
B202	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM UNRELATED DONOR VERSUS HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK HEMATOLOGICAL MALIGNANCIES Maura Faraci (Genova, Italy)	08:30 - 08:30
B203	OUTCOME OF SECOND ALLOGENEIC STEM CELL TRANSPLANTATION OR BOOST FOR PEDIATRIC BONE MARROW FAILURE DISORDERS Alice Morin (Paris, France)	08:30 - 08:30
B204	CHARACTERIZING OUTCOMES AND RESOURCE UTILIZATION IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS MEETING ENHANCED CARE CRITERIA: A SINGLE CENTER EXPERIENCE Lev Gorfinkel (Boston, United States of America (the))	08:30 - 08:30
B205	HEMATOPOIETIC STEM CELL TRANSPLANTATION DISRUPTS AGE-RELATED GUT MICROBIOTA SIGNATURES IN PEDIATRIC AND ADULT PATIENTS Francesco Baccelli (Bologna, Italy)	08:30 - 08:30
B207	SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOLLOWING GRAFT FAILURE IN CHILDREN Eun Sang Yi (Seoul, Korea (the Republic of))	08:30 - 08:30
B208	SECOND ALLOHCT FOR RELAPSES OF ACUTE LEUKEMIA ASSOCIATED WITH HLA LOSS OF HETEROZYGOSITY IN CHILDREN Polina Kozhokar (Saint-Petersburg, Russian Federation (the))	08:30 - 08:30
B210	USE OF SOMATIC NEXT-GENERATION SEQUENCING PANELS: NEW OPPORTUNITIES TO OPTIMIZE THE INDICATION FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION Aurora Pescini (Pisa, Italy)	08:30 - 08:30
B211	OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30

	IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH DOWN SYNDROME AND ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GETH-TC	
	Mercedes Plaza Fornieles (Murcia, Spain)	
B212	ETHNIC DISPARITIES IN RESPONSE TO CMV IMMUNOTHERAPY USING INTRAVENOUS CMV HYPERIMMUNE GLOBULIN IN PEDIATRIC ALLO-HSCT RECIPIENTS	08:30 - 08:30
	Natalia Maximova (Trieste, Italy)	
B213	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MALIGNANT NEOPLASMS IN CHILDREN: SINGLE CENTER EXPERIENCE FOR 560 PEDIATRIC PATIENTS	08:30 - 08:30
	Teimur Aliev (Moscow, Russian Federation (the))	
B215	PHOTOBIO-MODULATION FOR PREVENTION AND TREATMENT OF MUCOSITIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE RESEARCH PROTOCOL AND PRELIMINARY RESULTS	08:30 - 08:30
	Giovanna Lucchini (Monza, Italy)	
P240	HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PAEDIATRIC ACUTE MYELOID LEUKEMIA: CHALLENGES AND OUTCOMES IN A RESOURCE-LIMITED SETTING - THE SRI LANKAN PERSPECTIVE	08:30 - 08:30
	Prabani Shiromala Maddumarachchi (Maharagama, Sri Lanka)	
P241	TCRAB T AND B CELL DEPLETED HLA MISMATCHED TRANSPLANT IN CHILDREN WITH NON-MALIGNANT INDICATIONS USING TREOSULFAN, FLUDARABINE, THIOTEPA, RITUXIMAB AND THYMOGLOBULIN BASED CONDITIONING: SINGLE CENTER EXPERIENCE	08:30 - 08:30
	Ravi Shah (Calgary, Canada)	
P242	IDENTIFYING GAPS IN PARENT KNOWLEDGE SURROUNDING STEM CELL TRANSPLANTS FOR THALASSAEMIA IN PAEDIATRIC PATIENTS: WHAT INFORMATION NEEDS TO BE ADDRESSED?	08:30 - 08:30
	Jessica Jaffrey (Leeds, United Kingdom of Great Britain and Northern Ireland (the))	
P243	EVALUATION OF DENTAL HEALTH TRENDS IN PAEDIATRIC PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	James Celaire (Leeds, United Kingdom of Great Britain and Northern Ireland (the))	
P244	A NOVEL PRE-BONE MARROW TRANSPLANT PAIN MANAGEMENT CLINIC APPROACH AT THE CHILDREN'S HOSPITAL AT WESTMEAD	08:30 - 08:30
	Caroline Wells (Sydney, Australia)	
P245	EASIX SCORE IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS IN A LATIN AMERICAN CENTRE	08:30 - 08:30
	Pablo Hayler (Santiago, Chile)	
P246	OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN INFANTS : A SINGLE-CENTER RETROSPECTIVE STUDY	08:30 - 08:30
	Mohammed Essa (Riyadh, Saudi Arabia)	
P247	TREOSULFAN BASED CONDITIONING FOR PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A 10-YEAR EXPERIENCE IN A SINGLE CENTRE	08:30 - 08:30
	Paula Catalán (Santiago, Chile)	
P248	OUTCOMES FOLLOWING A THIRD HSCT IN CHILDREN: A RETROSPECTIVE ANALYSIS ON BEHALF OF GETH PEDIATRIC SUBCOMMITTEE	08:30 - 08:30

	Luisa Sisinni (Madrid, Spain)	
P249	GRAFT REJECTION AFTER EX-VIVO T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: ANALYSIS OF INCIDENCE, SURVIVAL, RISK FACTORS, AND ASSOCIATION WITH BIOMARKERS OF INFLAMMATION Ladislav Krol (Lund, Sweden)	08:30 - 08:30
P250	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC NEUROBLASTOMA: FIRST REPORT FROM THE RUSSIAN MULTICENTER GROUP Teimur Aliev (Moscow, Russian Federation (the))	08:30 - 08:30
P251	IMMUNE DYSREGULATION AND AUTOIMMUNITY POST-HSCT IN RAG1-SCID: A CHALLENGING CASE REPORT Camilla Visconti (Milan, Italy)	08:30 - 08:30
P252	IMPACT OF BODY MASS INDEX ON OUTCOMES IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY Natalia Maximova (Trieste, Italy)	08:30 - 08:30
P254	ESTABLISHING & DELIVERING A NEW PAEDIATRIC BONE MARROW TRANSPLANT SERVICE Gemma Barnard (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P255	REPORT OF PEDIATRIC HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN THE 1ST CENTER OF EXCELLENCE IN THE UAE Mansi Sachdev (Abu Dhabi, United Arab Emirates (the))	08:30 - 08:30
P256	OFF-LABEL USE OF LETERMOVIR FOR PROPHYLACTIC, PREEMPTIVE AND THERAPEUTIC TREATMENT OF CYTOMEGALOVIRUS IN PAEDIATRIC HSCT PATIENTS Daniela S. Kohlfürst (Graz, Austria)	08:30 - 08:30
P257	HIGH-RISK NEUROBLASTOMA TREATED WITH AUTOLOGOUS STEM CELL TRANSPLANT - EXPERIENCE FROM A TERTIARY CANCER CENTRE IN INDIA Maharshi Trivedi (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P258	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN TYROSINE KINASE INHIBITOR ERA Hyoung Soo Choi (Seongnam, Korea (the Republic of))	08:30 - 08:30
P259	COMPARISON OF TWO STRATEGIES FOR REDUCING T CELL ALLOREACTIVITY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTER EXPERIENCE Grigory Tsaur (Ekaterinburg, Russian Federation (the))	08:30 - 08:30
P260	TANDEM AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IS SAFE AND EFFECTIVE FOR TREATMENT OF PEDIATRIC SOLID TUMORS: RESULTS OF MULTICENTRE RETROSPECTIVE STUDY IN RUSSIA Kirill Kirgizov (Moscow, Russian Federation (the))	08:30 - 08:30
P261	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE FOR 150 PEDIATRIC HSCT IN 2021-2023 Irina Kostareva (Moscow, Russian Federation (the))	08:30 - 08:30
P263	LETERMOVIR PROPHYLAXIS IN PAEDIATRIC PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION Gemma Barnard (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P264	FAVORABLE OUTCOMES OF CENTRAL VENOUS CATHETERS	08:30 - 08:30

	UTILIZATION IN PEDIATRIC ONCOLOGY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM JORDAN.	
	Ayad Ahmed Hussein (Amman, Jordan)	
P265	A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF TRANSPLANTATION OUTCOMES IN PATIENTS WITH JUVENILE MYELOMONOCYTIC LEUKEMIA	08:30 - 08:30
	Fang Liu (Tianjin, China)	
P266	DONOR LYMPHOCYTE INFUSION WITH ZOLEDRONATE AFTER AB-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA	08:30 - 08:30
	Ho Joon Im (Seoul, Korea (the Republic of))	
P267	PROLONGED HYPOGAMMAGLOBULINEMIA IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. ONE-CENTER EXPERIENCE	08:30 - 08:30
	Susanna Arakelyan (Moscow, Russian Federation (the))	
P268	LONG-ACTING ANTIEMETICS FOR PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM JORDAN	08:30 - 08:30
	Ayad Ahmed Hussein (Amman, Jordan)	
P271	IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT AT NEW PAEDIATRIC HSCT CENTRE	08:30 - 08:30
	Catherine O'Sullivan (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	
P272	IMPROVED OUTCOMES FOR PEDIATRIC PATIENTS WITH DE NOVO CHRONIC MYELOID LEUKEMIA IN BLAST PHASE BY EARLY STAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Fang Liu (Tianjin, China)	
P273	ANNUAL (2023) EPIDEMIOLOGICAL ANALYSIS OF A DEVELOPING PEDIATRIC TRANSPLANT CENTER	08:30 - 08:30
	Paulina Formińska (Warsaw, Poland)	
P274	ENTEROCOLITIS SECONDARY TO HERPES HUMAN VIRUS 6 (HHV-6) IN THE CONTEXT OF HEMATOPOIETIC STEM CELL TRANSPLANT. CLINICAL CASE REPORT OF A PEDIATRIC PATIENT	08:30 - 08:30
	Iván López-Torija (Barcelona, Spain)	
P275	THE FIRST TEN: REPORTING THE INCIDENCE OF INFECTION AND INFECTION RELATED MORTALITY IN A NEW PAEDIATRIC HSCT SERVICE	08:30 - 08:30
	Thomas McGrath (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	
P276	ALLOGENEIC PERIPHERAL BLOOD HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN A 2-MONTH-OLD PATIENT WITH FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (FHL) TYPE II AND RSV INDUCED RESPIRATORY FAILURE	08:30 - 08:30
	Daniela S. Kohlfürst (Graz, Austria)	
<i>ePoster</i>		
08:30 - 18:00		R18
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution		
B140	PREDICTORS FOR THYMIC RECONSTITUTION AFTER PEDIATRIC AND YOUNG ADULT HCT: A MULTICENTER ANALYSIS	08:30 - 08:30

	Devin McAvoy (New York, United States of America (the))	
B141	PROTECTIVE ROLE OF NAÏVE VD2 GD T-CELL AGAINST RELAPSE IN ABHAPLO-HSCT Giulia Barbarito (Palo Alto, United States of America (the))	08:30 - 08:30
B144	ATLG IMPAIR CD4+ NAÏVE T CELLS AFTER HEMATOPOIETIC STEM CELL TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA Silvia Nucera (Monza, Italy)	08:30 - 08:30
B145	DECIPHERING THE IMPACT OF LETERMIVIR ON THE IMMUNE-RECONSTITUTION OF CMV-SPECIFIC T LYMPHOCYTES REVEALED BY DEXTRAMERS IN THE PT-CY ERA Elena Tassi (Milan, Italy)	08:30 - 08:30
B147	THE IMPACT OF VITAMIN D RECEPTOR POLYMORPHISMS AND PRE-TRANSPLANT VITAMIN D STATUS ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML, MDS, AND ALL PATIENTS Lina Kolloch (Muenster, Germany)	08:30 - 08:30
B148	DISTINCT IMMUNE RECONSTITUTION PATTERNS CORRELATE WITH OUTCOMES FOLLOWING PEDIATRIC AB T-CELL/CD19 B-CELL DEPLETED HAPLOIDENTICAL HSCT Linda Oppizzi (Palo Alto, United States of America (the))	08:30 - 08:30
B149	RECONSTITUTION AND LICENSING OF NATURAL KILLER CELLS FOLLOWING T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN Maxime Jullien (Nantes, France)	08:30 - 08:30
B151	THE IMPACT OF MONOCYTE RECOVERY ON OUTCOMES OF MATCHED UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS Nihar Desai (Toronto, Canada)	08:30 - 08:30
B152	IMPLEMENTATION OF FLOW CYTOMETRY IN MONITORING POST-HSCT CHIMERISM IN PATIENTS WITH CERTAIN INBORN ERRORS OF IMMUNITY (IEI) Dmitry Pershin (Moscow, Russian Federation (the))	08:30 - 08:30
B153	RETROSPECTIVE ANALYSIS OF CHIMERISM MONITORING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: EVALUATION OF THE PREDICTIVE VALUE OF ULTRA-LOW THRESHOLDS FOR EARLY RELAPSE DETECTION Karolin Weber (Munich, Germany)	08:30 - 08:30
B154	REDUCED-INTENSITY POST-CYCLOPHOSPHAMIDE DECREASED EARLY IMMUNE REACTIONS IN UNRELATED CORD BLOOD TRANSPLANTATION Yuntian Ding (Shenzhen, China)	08:30 - 08:30
B155	DIAGNOSTIC NGS PANEL-BASED SERIAL MRD MONITORING AS A PROGNOSTIC TOOL IN ACUTE MYELOID LEUKEMIA Hyeoung-Joon Kim (Jeollanam-do, Korea (the Republic of))	08:30 - 08:30
B156	DISTINCT PATTERNS OF CHIMERISM DYNAMICS IN THE PATIENTS RECEIVED POST-TRANSPLANT CYCLOPHOSPHAMIDE GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS BASED REGIMEN FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) Majed Altareb (Toronto, Canada)	08:30 - 08:30

B157	CD4⁺ T-CELL RECONSTITUTION AT DAY 90 PREDICTS FAVORABLE OUTCOMES AFTER CONVENTIONAL T-CELL REPLETE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS Milena Todorović Balint (Belgrade, Serbia)	08:30 - 08:30
B158	CHARACTERIZATION OF IMMUNE CELL SUBPOPULATIONS IN PATIENTS WITH RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Wei Zhao (Beijing, China)	08:30 - 08:30
B159	ALLOGENEIC STEM CELL TRANSPLANTATION AFTER BRIDGING WITH AZACITIDINE[CT1] - VENETOCLAX FOR MOLECULAR RELAPSE OF NPM1 MUTATED AML Martina Crysandt (Aachen, Germany)	08:30 - 08:30
B160	PHENOTYPIC AND GENOTYPIC PROFILES OF PERSISTENT GRAFT T CELLS MAY IMPACT THE POST-TRANSPLANT RELAPSES IN PATIENTS WITH AML Evgeny Klyuchnikov (Hamburg, Germany)	08:30 - 08:30
B161	DONOR LYMPHOCYTE INFUSIONS FOR RECURRENCE OF MYELOID NEOPLASMS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF HYPOMETHYLATING AGENTS AND BCL2 INHIBITORS Miriam Mozaffari Jovein (Freiburg im Breisgau, Germany)	08:30 - 08:30
B162	IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS AFFECTED BY ACUTE MYELOID LEUKEMIA: ROLE OF GVHD PROPHYLAXIS Domenico D'Agostino (Verona, Italy)	08:30 - 08:30
B163	DETAILED FLOW CYTOMETRY-BASED ASSESSMENT OF EARLY B-CELL RECONSTITUTION DYNAMICS IN ACUTE LEUKEMIA PEDIATRIC PATIENTS AFTER HSCT Dmitry Pershin (Moscow, Russian Federation (the))	08:30 - 08:30
B164	DELAYED CD4 IMMUNE RECONSTITUTION ASSOCIATION WITH ACUTE GRAFT-VERSUS-HOST DISEASE AND NON-RELAPSE MORTALITY FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Benjamin McCormick (Birmingham, United States of America (the))	08:30 - 08:30
B165	INCREASING UTILITY OF MOLECULAR MRD MONITORING BY RT-QPCR IN PAEDIATRIC AML PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT Poulami Das (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
B166	MEASUREMENT OF ACTIVE ANTI-THYMOCYTE GLOBULIN (AATG) CONCENTRATION IN ALLOGENIC BONE MARROW TRANSPLANTATION (ABMT) OF PATIENTS WITH INBORN ERRORS OF IMMUNITY (IEI) BY FLOW CYTOMETRY (FC) Tatiana Sozonova (Moscow, Russian Federation (the))	08:30 - 08:30
B167	DISEASE STATUS AT ALLOGENEIC TRANSPLANT AFFECTS THE PROGNOSTIC VALUE OF POST-TRANSPLANT MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA Chiara Camerini (Florence, Italy)	08:30 - 08:30
P231	MEASURABLE RESIDUAL DISEASE ASSESSMENT PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: A 20-YEAR MONOCENTRIC STUDY Alexandre-Raphael Wery (Bruxelles, Belgium)	08:30 - 08:30

P233	SUCCESSFUL MANAGEMENT OF MIXED DONOR CHIMERISM AND LOW-LEVEL BCR-ABL POSITIVITY IN A PAEDIATRIC BCR-ABL POSITIVE AML POST-TRANSPLANT USING DONOR LYMPHOCYTE INFUSION AND TYROSINE KINASE INHIBITOR Nida Malik (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P234	DONOR HYPO-RESPONSIVENESS AFTER NAÏVE T CELL DEPLETED GRAFT AS A STRATEGY TO INDUCE SOLID ORGAN TRANSPLANT TOLERANCE MEDIATED BY MIXED TRANSIENT CHIMERISM Antonio Pérez-Martínez (Madrid, Spain)	08:30 - 08:30
P235	LINEAGE-SPECIFIC CHIMERISM AND IMMUNOSURVEILLANCE IN PEDIATRIC PATIENTS WITH MIXED CHIMERISM POST-HSCT Francesco Paolo Tambaro (Naples, Italy)	08:30 - 08:30
P237	IMMUNE RECONSTITUTION AND ITS IMPACT ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE (CIC 1085) Yavor Petrov (Varna, Bulgaria)	08:30 - 08:30
P238	IMMUNE CELL RECONSTITUTION AND HLA CLASS I EXPRESSION LEVEL AFTER ALLOGENEIC HSC TRANSPLANTATION IN A PATIENT AFFECTED BY ACUTE MYELOID LEUKEMIA: ONE YEAR REPORT Francesca Toraldo (Siena, Italy)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Conditioning Regimens		
B107	VENETOCLAX AND CLADRIBINE-BASED DEBULKING CHEMOTHERAPY SEQUENTIAL OR BRIDGING WITH REDUCED-INTENSITY CONDITIONING FOLLOWED BY ALLO-TRANSPLANTATION IN REFRACTORY MYELOID MALIGNANCIES: A SINGLE ARM PROSPECTIVE PHASE II STUDY Ling Wang (Shanghai, China)	08:30 - 08:30
B108	IN ALLOGENEIC TRANSPLANTATION WITH REDUCED DOSE POSTTRANSPLANTATION-CYCLOPHOSPHAMIDE NON-RELAPSE MORTALITY RISK-SCORES HAVE LIMITED (PATIENTS >=65 YEARS) OR NO VALUE (PATIENTS <65 YEARS) IN TRANSPLANTATION ELIGIBILITY PREDICTION P.A. von dem Borne (Leiden, Netherlands (the))	08:30 - 08:30
B109	PERIPHERAL BLOOD STEM CELL GRAFT BUT NOT CONDITIONING IMPROVES SIBLING OR UNRELATED DONOR TRANSPLANTATION OUTCOMES IN PATIENTS WITH AML ≥65YEARS. A STUDY OF EBMT ALWP Alexandros Kanellopoulos (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
B110	CHOICE AND OUTCOME OF CONDITIONING REGIMENS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMA: AN ANALYSIS OF THE EBMT-LYMPHOMA WORKING PARTY Evgenii Shumilov (Münster, Germany)	08:30 - 08:30
B111	TREOSULFAN VS BUSULFAN AS PART OF CLOFARABINE-BASED REDUCED-INTENSITY CONDITIONING REGIMEN BEFORE ALLOTRANSPLANT FOR MYELOID MALIGNANCIES Patrice Chevallier (Nantes, France)	08:30 - 08:30
B112	BUSULFAN LEVELS MONITORING IN ADULTS ENHANCING DOSING ADJUSTMENTS AND STEM CELL TRANSPLANTATION OUTCOMES	08:30 - 08:30

	Shlomo Elias (Jerusalem, Israel)	
B113	COMPARISON OF <i>IN VIVO</i> GVHD PROPHYLAXIS REGIMENS IN PATIENTS WITH AML UNDERGOING ALLO-HCT WITH INTERMEDIATE TOXICITY PROTOCOLS: A STUDY ON BEHALF OF THE EBMT ALWP Jesus Duque-Afonso (Freiburg, Germany)	08:30 - 08:30
B114	COMPARABLE OS AND GFFS OF ATLG VS. RATG FOR GVHD PROPHYLAXIS IN PEDIATRIC AA PATIENTS UNDERGOING TRANSPLANTATION Li Nannan (Langfang, China)	08:30 - 08:30
B115	COMPARATIVE OUTCOMES OF CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A CIBMTR ANALYSIS Amy K. Keating (Boston, United States of America (the))	08:30 - 08:30
B116	GENOTYPE-SPECIFIC CYTOKINE PROFILES AND ENGRAFTMENT OUTCOMES IN REDUCED-TOXICITY HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PRE-TRANSPLANT IMMUNOSUPPRESSION FOR SICKLE CELL DISEASE Anna B. Pawlowska (Duarte, United States of America (the))	08:30 - 08:30
B117	CONDITIONING REGIMEN FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN ACUTE LEUKEMIA: EVIDENCE BASED GUIDELINES ON BEHALF OF THE ITALIAN STEM CELL TRANSPLANT GROUP (GITMO) Alessandra Picardi (Naples, Italy)	08:30 - 08:30
B118	TREOSULFAN/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMAS IN THE POST-TRANSPLANT CYCLOPHOSPHAMIDE ERA: A STUDY ON BEHALF OF GETH-TC Lorenzo Lazzari (Milano, Italy)	08:30 - 08:30
B119	OPTIMIZATION OF TBI-BASED MYELOABLATIVE REGIMEN INCORPORATING ATG AND PTCY IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: HISTORICAL COMPARISON WITH TBI/CY Jae Ho Yoon (Seoul, Korea (the Republic of))	08:30 - 08:30
B120	ALEMTUZUMAB-BASED ONE-DAY NONMYELOABLATIVE CONDITIONING REGIMEN FOR GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Nihar Desai (Toronto, Canada)	08:30 - 08:30
B121	FLUDARABINE AND TREOSULFAN CONDITIONING IS FEASIBLE AND LEADS TO HIGH OS AND LOW NRM Chiara Bernardi (Geneva, Switzerland)	08:30 - 08:30
B122	IMPACT OF GVHD PROPHYLAXIS WITH <i>IN VIVO</i> T-CELL DEPLETION ON HEMATOPOIETIC AND IMMUNE SYSTEM RECONSTITUTION IN PATIENTS WITH AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Thomas Meyer (Freiburg, Germany)	08:30 - 08:30
B123	HOSPITAL BASED OUTPATIENT ADMINISTRATION OF ONCE DAILY DOSING MYELOABLATIVE INTRAVENOUS PHARMACOKINETICALLY TARGETED BUSULFAN BASED CONDITIONING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT - SINGLE CENTER EXPERIENCE Hassan Alkhateeb (Rochester, United States of America (the))	08:30 - 08:30

B124	TBI-ATG BASED CONDITIONING REGIMEN IS A PROMISING APPROACH FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED PERIPHERAL T-CELL LYMPHOMA TREATED WITH ALLOGENEIC SCT Chuxian Zhao (Shanghai, China)	08:30 - 08:30
B125	ATG FREE CONDITIONING REGIMEN USING FLUDARABINE, BUSULFAN AND CYCLOPHOSPHAMIDE IN SIBLING DONOR TRANSPLANTATION FOR THALASSEMIA MAJOR AT A TERTIARY CENTRE IN INDIA D M Mohana Reddy (Bengaluru, India)	08:30 - 08:30
B126	LOW INCIDENCE OF GRAFT-VERSUS-HOST DISEASE AND SATISFACTORY EFFICACY OF VFM CONDITIONING REGIMEN FOR PATIENTS > 50 YEARS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLO-HSCT Yi Luo (Hangzhou, China)	08:30 - 08:30
B127	POST-TRANSPLANT IMMUNOMODULATION WITH 5-AZACITIDINE-DLI IMPROVES SURVIVAL IN SEQUENTIAL CONDITIONING HSCT FOR HIGH-RISK AML AND MDS Audrey Da Rocha (Amiens, France)	08:30 - 08:30
B128	OPTIMIZED ALEMTUZUMAB DOSING AND ROUTE OF ADMINISTRATION MAY IMPROVE OUTCOMES IN PRIMARY HEMANGIOPATHIC LYMPHOHISTIOCYTOSIS Aaron Ross (Houston, United States of America (the))	08:30 - 08:30
B129	TANDEM CONDITIONING-BASED MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH MYELOID MALIGNANCIES NOT IN REMISSION Jae Won Yoo (Seoul, Korea (the Republic of))	08:30 - 08:30
B131	PROPORTIONAL BUT NOT EQUAL RELATION BETWEEN BUSULFAN DOSE ADJUSTMENTS AND RESULTING EXPOSURE VARIATIONS Daniele Canarutto (Milan, Italy)	08:30 - 08:30
B132	IMPACT OF IMMUNOSUPPRESSION INTENSIFIED CONDITIONING REGIMEN FOR PATIENTS WITH STRONG POSITIVE PRE-TRANSPLANTATION DONOR SPECIFIC ANTI-HLA ANTIBODIES (DSAs) UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION Huixia Liu (Shanghai, China)	08:30 - 08:30
B134	THIOTEPA ADDITION TO TREOSULFAN-FLUDARABINE REGIMEN EXHIBITED EFFECTIVENESS AND TOLERABILITY IN ELDERLY AND UNFIT PATIENTS UNDERGOING HSCT WITH ACTIVE MYELOID DISEASES: A REAL-WORLD STUDY Luca Tosoni (Udine, Italy)	08:30 - 08:30
B135	REAL WORLD EXPERIENCE OF TREOSULFAN IN ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH HEMATOLOGICAL DISEASES. THE SPANISH GROUP OF SCT AND CELL THERAPY (GETH-TC) Juan Manuel Cerezo Martín (Santander, Spain)	08:30 - 08:30
B136	OUTCOMES OF SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH TOTAL MARROW AND LYMPHOID IRRADIATION WITH FLUDARABINE AND MELPHALAN Janny Yao (Duarte, United States of America (the))	08:30 - 08:30
B137	IMPACT OF ABSOLUTE LYMPHOCYTE COUNT AT ATG ADMINISTRATION ON OUTCOMES IN HAPLOIDENTICAL HSCT FOR ADULT AML	08:30 - 08:30

	Byung-Sik Cho (Seoul, Korea (the Republic of))	
B138	TREOSULFAN CONDITIONING IN ALLO-HSCT AND DOSE CAPPING ACCORDING TO BODY SURFACE AREA Katerina Nezvalova Henriksen (Oslo, Norway)	08:30 - 08:30
B139	TOTAL MARROW AND LYMPHOID IRRADIATION VERSUS TOTAL BODY IRRADIATION AS CONDITIONING REGIMENS IN ALLOGENIC STEM CELL TRANSPLANTATION: TOXICITY AND OUTCOMES María Panizo-Inogés (Pamplona, Spain)	08:30 - 08:30
P201	CONDITIONING WITH HIGH-DOSE MITOXANTRONE AND MELPHALAN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA Galina Petrova (Moscow, Russian Federation (the))	08:30 - 08:30
P202	MODIFIED CONDITIONING REGIMEN BASED ON MITOXANTRONE HYDROCHLORIDE LIPOSOME AND BUSULFAN/CYCLOPHOSPHAMIDE FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA Chen Liang (Tianjin, China)	08:30 - 08:30
P203	SAFETY AND EFFICACY OF ALLO-HSCT WITH TENIPOSIDE CONTAINING CONDITIONING REGIMEN FOR PATIENTS WITH NK/T CELL LYMPHOMA Zhihui Li (Beijing, China)	08:30 - 08:30
P204	UPFRONT TRANSPLANTATION USING A MELPHALAN-BASED SEQUENTIAL CONDITIONING IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES Artur Schneider (Essen, Germany)	08:30 - 08:30
P206	EVALUATION OF THIOTEPA, BUSULFAN, AND FLUDARABINE (TBF) CONDITIONING REGIMEN AS AN ALTERNATIVE APPROACH FOR HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC ACUTE LEUKEMIA Hasan Hashem (Amman, Jordan)	08:30 - 08:30
P208	EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ASCT IN PATIENTS WITH LOW-OR INTERMEDIATE-RISK AML Erlie Jiang (Tianjin, China)	08:30 - 08:30
P210	PTCY BASED GVHD PROPHYLAXIS IN MISMATCHED UNRELATED DONORS: A REAL LIFE RETROSPECTIVE SINGLE CENTER ANALYSIS Cristina Rotolo (Palermo, Italy)	08:30 - 08:30
P211	TREOSULFAN VERSUS BUSULFAN CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE Dalila Salvatore (San Giovanni Rotondo, Italy)	08:30 - 08:30
P213	ALLO-HCT FOR YOUNGER PATIENTS WITH MULTIPLE MYELOMA - STILL A GOOD TREATMENT OPTION Malgorzata Sobczyk-Kruszelnicka (Gliwice, Poland)	08:30 - 08:30
P214	IMPROVED LONG TERM SURVIVAL OF PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES AFTER UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION WITH SEQUENTIAL CONDITIONING - ADDITION OF VENETOCLAX PROLONGS RFS Felicitas Schulz (Düsseldorf, Germany)	08:30 - 08:30
P215	ANTITHYMOCYTE GLOBULIN WITH LOW DOSE POST-	08:30 - 08:30

	TRANSPLANT CYCLOPHOSPHAMIDE IMPROVES OUTCOME OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS	
	Hee Young Ju (Seoul, Korea (the Republic of))	
P216	ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FOR PATIENTS WITH MYCOSIS FUNGOIDES/SEZARY SYNDROME IN SINGLE-CENTER EXPERIENCE - GLIWICE, POLAND	08:30 - 08:30
	Wlodzimierz Mendrek (Gliwice, Poland)	
P217	THE SAFETY AND EFFICACY OF LIPOSOMAL MITOXANTRONE (LIPO-MIT) COMBINED WITH TBI-BASED CONDITIONING FOR ALLO-HSCT IN RELAPSED/REFRACTORY T-LBL AND T-ALL	08:30 - 08:30
	Deyan Liu (Langfang, China)	
P218	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR GERM CELL TUMORS: A SINGLE CENTER EXPERIENCE IN UNITED ARAB EMIRATES	08:30 - 08:30
	Basmah Al-Charfli (Abu Dhabi, United Arab Emirates (the))	
P219	EFFICACY OF A SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN MYELOID HEMATOLOGIC MALIGNANCIES	08:30 - 08:30
	Daolin Wei (Shanghai, China)	
P220	A SINGLE-CENTER COMPARISON OF THIOTEPA-TREOSULFAN VERSUS THIOTEPA-BUSULFAN BASED CONDITIONING REGIMENS IN ADULTS WITH HAEMATOLOGICAL MALIGNANCIES UNDERGOING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT	08:30 - 08:30
	Yeow Tee Goh (Singapore, Singapore)	
P221	4-GY RADIOTHERAPY BOOST PLUS 2-GY TMI WITHIN NON-MYELOABLATIVE BALTIMORE CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN LYMPHOMA PATIENTS IN PARTIAL REMISSION	08:30 - 08:30
	Daniele Mannina (Rozzano, Italy)	
P222	TREOSULFAN-BASED CONDITIONING FOR PEDIATRIC AND YOUNG ADULT ALL: UKRAINIAN SINGLE CENTER EXPERIENCE	08:30 - 08:30
	Olha Veremiichyk (Kyiv, Ukraine)	
P223	THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH ATG/PTCY-BASED GVHD PROPHYLAXIS AS PROMISING APPROACH FOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER, OPEN-LABEL, PROSPECTIVE STUDY	08:30 - 08:30
	Jiejing Qian (Hangzhou, China)	
P227	CURATIVE EFFICACY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTION USING TBI/BU FOR REFRACTORY OR RELAPSED LEUKEMIA PATIENTS	08:30 - 08:30
	Wenya Liu (中国, China)	
P228	ASSESSING THE NEED FOR BUSULFAN THERAPEUTIC DRUG MONITORING DURING REDUCED-INTENSITY CONDITIONING FOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION	08:30 - 08:30
	Umberto Pizzano (Treviso, Italy)	
P229	USE OF A SEQUENTIAL REGIMEN FOR PATIENTS WITH MYELOID MALIGNANCIES AND ACTIVE DISEASE AT TIME OF TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE	08:30 - 08:30
	Giorgia Battipaglia (Naples, Italy)	
P230	DONOR-SPECIFIC ANTIBODIES AGAINST HUMAN LEUKOCYTE ANTIGENS: BANE OF MISMATCHED TRANSPLANTS	08:30 - 08:30

Shreyas Hanmantgad (London, United Kingdom of Great Britain and Northern Ireland (the))

ePoster

08:30 - 18:00

R18

Non-infectious Late Effects, Quality of Life and Fertility

- | | | |
|------|--|---------------|
| A308 | <p>COMPREHENSIVENESS VS SIMPLICITY VS OBJECTIVITY: A COMPARISON OF DIFFERENT COMORBIDITY INDICES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT)</p> <p>Lorenzo Iovino (Seattle, United States of America (the))</p> | 08:30 - 08:30 |
| A309 | <p>SECOND CANCERS IN PATIENTS RECEIVING RUXOLITINIB FOR STEROID-REFRACTORY GVHD: IMPACT OF ACTIVE SURVEILLANCE IN 76 PATIENTS WITH 4 YEARS FOLLOW-UP</p> <p>Daniele Sannipoli (Milano, Italy)</p> | 08:30 - 08:30 |
| A310 | <p>DONOR CD8+ T CELLS DRIVE ATHEROSCLEROSIS IN MICE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</p> <p>Haroon Shaikh (Würzburg, Germany)</p> | 08:30 - 08:30 |
| A311 | <p>BONE HEALTH MONITORING AND FRACTURE RISK IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS</p> <p>Nabanita Bhunia (Columbus, United States of America (the))</p> | 08:30 - 08:30 |
| A312 | <p>DYNAMIC EASIX-DRI MODEL PREDICTS POST-TRANSPLANT SURVIVAL IN PATIENTS RECEIVING PTCY OR METHOTREXATE FOR GVHD PROPHYLAXIS</p> <p>Hassan Alkhateeb (Rochester, United States of America (the))</p> | 08:30 - 08:30 |
| A313 | <p>DETERMINANTS OF OUTCOMES AFTER ALLOGENEIC TRANSPLANTATION (ALLOHCT) IN PATIENTS ≥70 YEARS OF AGE - SINGLE CENTRE ANALYSIS</p> <p>Pavel Jindra (Pilsen, Czechia)</p> | 08:30 - 08:30 |
| A314 | <p>SECOND MALIGNANT NEOPLASMS INCIDENCE FOR CHILDREN UNDERGOING CYCLOPHOSPHAMIDE AND TBI CONDITIONED HSCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA OVER 10 YEARS FOLLOW-UP - A SINGLE CENTER EXPERIENCE</p> <p>Maharshi Trivedi (Bristol, United Kingdom of Great Britain and Northern Ireland (the))</p> | 08:30 - 08:30 |
| A315 | <p>RURAL/REGIONAL PLACE OF RESIDENCE IMPACTS POST ALLOGENEIC BONE MARROW TRANSPLANT OVERALL SURVIVAL OF AUSTRALIAN PATIENTS WITH ACUTE MYELOID LEUKAEMIA: AN ANZTCT REGISTRY STUDY</p> <p>Zulekha Khan (Sydney, Australia)</p> | 08:30 - 08:30 |
| A316 | <p>SUCCESSFUL FERTILITY PRESERVATION IN PATIENTS WITH SICKLE CELL DISEASE PREPARING FOR HSCT AND GENE THERAPY: OOCYTE RETRIEVAL OUTCOMES AND ATTRITION RATES</p> <p>Hannah Maher (New York City, United States of America (the))</p> | 08:30 - 08:30 |
| A317 | <p>LONG-TERM METABOLIC DERANGEMENTS FOLLOWING HSCT IN PEDIATRICS: THE SIBLING DONOR-RECIPIENT DYAD AS AN IDEAL MODEL TO ASSESS THE DETRIMENTAL ROLE OF TBI ON IMMUNE-METABOLIC PATHWAYS</p> <p>Alessandro Cattoni (Monza, Italy)</p> | 08:30 - 08:30 |
| A318 | <p>STUDY PRESENTATION: TREATMENT ADHERENCE IN PATIENTS WITH STEM CELL TRANSPLANTATION FOR HEMATOLOGIC CANCER (TASK): A BICENTER OBSERVATIONAL STUDY</p> <p>Anne-Kathrin Köditz (Leipzig, Germany)</p> | 08:30 - 08:30 |

A319	IMPACT OF A LONG-TERM FOLLOW-UP PROGRAM ON ADHERENCE TO SCREENING AND PREVENTION GUIDELINES IN SURVIVORS OF ALLOGENEIC BONE MARROW TRANSPLANTATION Vanderson Rocha (São Paulo, Brazil)	08:30 - 08:30
A320	FERRITIN AS A BIOMARKER FOR RELAPSE, MORTALITY AND GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC STEM CELL TRANSPLANTATION Caden Chiarello (Toronto, Canada)	08:30 - 08:30
A321	CENTRAL NERVOUS SYSTEM RELAPSE AFTER ALLOGENEIC TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS: INCIDENCE AND PROGNOSTIC FACTORS Brenda Lizeth Acosta-Maldonado (Ciudad de México, Mexico)	08:30 - 08:30
A322	ACCESS TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN A TRADITIONALLY AGE-INELIGIBLE POPULATION Dana Platt (Duarte, United States of America (the))	08:30 - 08:30
A323	WHICH CRITERIA FOR RETURN TO WORK AFTER ALLOGENIC TRANSPLANTATION SHOULD BE RECOMMENDED? MIXED-METHODS SURVEY AMONG HEMATOLOGISTS OF AN ALLOGENIC STEM CELL TRANSPLANTATION NETWORK IN GERMANY Martina Crysandt (Aachen, Germany)	08:30 - 08:30
A324	POST-ALLO HSCT ANXIETY, DEPRESSION AND COGNITIVE FUNCTIONS: CORRELATIONS WITH RETURN TO WORK AND DAILY LIVING ACTIVITIES - INSIGHTS FROM THE "SOPRALLO PROJECT" Fabio Andreozzi (Brussels, Belgium)	08:30 - 08:30
A325	PATIENT REPORTED OUTCOMES IN AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS, PROSMM. SINGLE CENTRE PILOT STUDY Jose María Aspa Cilleruelo (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
A326	MONOCLONAL GAMMOPATHY AFTER ALLO-HSCT: A SINGLE CENTER EXPERIENCE IN T-CELL DEPLETED TRANSPLANTS WITH TREG/TCON ADOPTIVE IMMUNOTHERAPY Valerio Viglione (Perugia, Italy)	08:30 - 08:30
A327	PATIENT REPORTED OUTCOMES IN LONG TERM SURVIVORS POST-ALLOGENEIC STEM CELL TRANSPLANT WITH CD34+ POSITIVE SELECTION Alba Puyuelo (Barcelona, Spain)	08:30 - 08:30
P191	BCR::ABL NEGATIVE B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA, NOT ANYMORE Candela Ceballos (San Sebastian, Spain)	08:30 - 08:30
P192	AT-HOME ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE Ignacio Gómez-Centurión (Madrid, Spain)	08:30 - 08:30
P193	PRE-TRANSPLANT FUNCTIONAL STATUS IMPACTS LENGTH OF HOSPITAL STAY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS IN AN OUTPATIENT TRANSPLANT PROGRAM Lizamarie Bachier-Rodriguez (Atlanta, United States of America (the))	08:30 - 08:30
P194	THE OUTCOME OF SECOND HEMATOPOIETIC STEM CELL TRANSPLANTATIONS IS NOT INFERIOR TO A SINGLE TRANSPLANT IN HEMATOLOGIC PATIENTS - A SINGLE INSTITUTE EXPERIENCE Tran-Der Tan (Taipei, Taiwan (Province of China))	08:30 - 08:30

P195	THE IMPACT OF ANTECEDENT AND POST-TRANSPLANT MALIGNANCIES ON THE OUTCOMES OF PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA IN NEW ZEALAND Xiaobin Zhan (Auckland, New Zealand)	08:30 - 08:30
P196	EARLY AND LATE INTEGRATION OF PALLIATIVE CARE IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) OR CAR-T THERAPY: A SINGLE-CENTER EXPERIENCE Enrico Morello (Brescia, Italy)	08:30 - 08:30
P197	SNAPSHOT OF PREHABILITATION SCREENING TOOLS FOR FUNCTIONAL ASSESSMENT PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION Alejandro Luna de Abia (Madrid, Spain)	08:30 - 08:30
P198	ACUTE FIBRINOUS AND ORGANIZING PNEUMONIA AND NONSPECIFIC INTERSTITIAL PNEUMONIA ASSOCIATED WITH ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. CASES REPORT Larisa Kuzmina (Moscow, Russian Federation (the))	08:30 - 08:30
P199	LATE EFFECTS IN MULTIPLE MYELOMA: A SINGLE-CENTRE FOCUSED CLINIC EXPERIENCE Jose María Aspa Cilleruelo (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P200	A COMPARISON BETWEEN STANDARD GRANULOCYTE COLONY STIMULATING FACTOR (GCSF) AND PEGYLATED GCSF POST AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PLASMA CELL DISORDERS Basmah Al-Charfli (Abu Dhabi, United Arab Emirates (the))	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		R18
Nurses Posters - Research		
NP042	RECOVERY IN A HOMELIKE ENVIRONMENT-PATIENTS' EXPERIENCES WITH HOSPITAL AT HOME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A QUALITATIVE STUDY Sigrid Cecilie Tinglum Skøyeneie (Oslo, Norway)	08:30 - 08:30
NP043	EFFICACY OF A COMPLEX LYSOSTAPHIN GARGLE IN THE PREVENTION OF ORAL MUCOSITIS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY Xiaoyu Zhou (Hangzhou, China)	08:30 - 08:30
NP044	CONSTRUCTION OF QUALITY EVALUATION SYSTEM FOR PREVENTION AND NURSING OF DRUG RESISTANT BACTERIAL INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS Erjie Jiang (Tianjin, China)	08:30 - 08:30
NP045	STRESS PERCEIVED LEVELS BETWEEN PHYSICIANS AND NURSES IN COMMUNICATING BAD NEWS IN STEM CELL TRANSPLANTATION SETTINGS: A NATIONWIDE SURVEY BY THE GITMO NG Stefano Botti (Reggio Emilia, Italy)	08:30 - 08:30
NP046	ENHANCING OUTCOMES AFTER CAR-T THERAPY: A PATIENT SUPPORT INITIATIVE Luminita Keating (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30

NP047	BREAKING BARRIERS: A SCOPING REVIEW OF FACTORS INFLUENCING WORK PARTICIPATION AFTER HEMATOPOIETIC CELL TRANSPLANTATION Karine Bilodeau (Montreal, Canada)	08:30 - 08:30
NP048	EXPERIENCES OF PATIENTS DEALING WITH CRS AND/OR ICANS DURING HOSPITALIZATION FOLLOWING CAR-T THERAPY Amaia Urcelay Ganzabal (Barcelona, Spain)	08:30 - 08:30
NP117	FRAILITY IN PATIENTS WITH MALIGNANT BLOOD DISEASE AND PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SYSTEMATIC REVIEW Marit Bakken (Oslo, Norway)	08:30 - 08:30
NP118	EFFICACY AND SAFETY OF INTERLEUKIN-11 IN THE TREATMENT OF ORAL MUCOSITIS RELATED TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Huanfeng Liu (Chongqing, China)	08:30 - 08:30
NP119	PATIENT-REPORTED HEALTH CARE UTILIZATION AND PRODUCTIVITY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE Samer Ghazi (Toronto, Canada)	08:30 - 08:30
NP120	SAFE PRACTICES IN NURSING CARE FOR PATIENTS SUBMITTED TO BONE MARROW TRANSPLANTATION - SCOPING REVIEW Isabel Rocha (Oporto, Portugal)	08:30 - 08:30
NP121	IMPROVEMENT EFFECT OF STRUCTURED FAMILY THERAPY MODEL ON BEHAVIOURAL COMPETENCE OF CHILDREN WITH HAEMATOPUIETIC STEM CELL TRANSPLANTATION Tianwen Zhang (Chongqing, China)	08:30 - 08:30
NP122	THE VALIDITY OF GLIM-DEFINED MALNUTRITION IN COMBINATION WITH CALF CIRCUMFERENCE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION Liyuan Qin (Shanghai, China)	08:30 - 08:30
NP123	PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE AMONG RECIPIENTS OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE Samer Ghazi (Toronto, Canada)	08:30 - 08:30
NP124	THE APPLICATION OF A SYMPTOM CLUSTER MANAGEMENT MODEL BASED ON THE KNOWLEDGE-ATTITUDE-PRACTICE THEORY IN THE PERIOPERATIVE PERIOD OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Lixue Zhang (Tianjin, China)	08:30 - 08:30
NP126	ENHANCING EDUCATION IN AN ONCOLOGY ENVIRONMENT Emily Bentley (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP127	A STUDY OF THE QUESTION PROMPT CHECKLIST IN PATIENTS TREATED WITH CAR-T CELLS FOR MULTIPLE MYELOMA Manli Chen (Chongqing, China)	08:30 - 08:30
NP128	CONSTRUCTION OF HOME LONG-TERM CARE SERVICE SYSTEM FOR PATIENTS WITH HEMATOLOGICAL TUMOR AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION Li Wang	08:30 - 08:30
NP129	CLINICAL CHARACTERISTICS AND NURSING COUNTERMEASURES OF HOSPITAL-ACQUIRED INFECTIONS IN	08:30 - 08:30

	PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	
	Yuqiu Liu (Tianjin, China)	
NP130	STERILIZATION EFFECT OF PLASMA AIR DISINFECTION MACHINE IN STEM CELL TRANSPLANTATION NON-LAMINAR FLOW WARD	08:30 - 08:30
	Jie Yan (Tianjin, China)	
NP131	CURRENT SITUATION AND INFLUENCING FACTORS OF RECURRENCE FEAR IN PATIENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Yan Zhou (Tianjin, China)	
NP132	THE EFFECT OF ELASTIC BAND RESISTANCE EXERCISE IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RANDOMIZED CONTROLLED STUDY	08:30 - 08:30
	Jianli Zhang (Hangzhou, China)	
NP133	QUALIFICATION OF A NETWORK OF HOSPITALS IN BRAZIL FOR THERAPY WITH CAR T CELLS	08:30 - 08:30
	Francisca Santos (São Paulo, Brazil)	
NP134	SILTUXIMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME	08:30 - 08:30
	Cristina Martin Benito (Salamanca, Spain)	
NP135	BRAZIL'S CHALLENGES IN THE SEARCH FOR FACT CERTIFICATION	08:30 - 08:30
	Francisca Santos (São Paulo, Brazil)	
NP136	POMALIDOMIDE: THE NEW OPTION FOR PREVENT RELAPSE OF PH CHROMOSOME NEGATIVE ACUTE B-LYMPHOCYTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Lidan Zhu (Chongqing, China)	
NP137	THE EXPLORATION OF NURSING CARE FOR COMPLICATIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CAR-T CELL THERAPY	08:30 - 08:30
	Xu Mingyue (Tianjin, China)	
NP138	PEGYLATED LIPOSOMAL MITOXANTRONE-EAC PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN T/NK NON-HODGKIN LYMPHOMA	08:30 - 08:30
	Jiali Li (Chongqing, China)	
<i>ePoster</i>		
08:30 - 18:00		R18
Nurses Posters - Adult		
NP001	SCHOOL OF HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS BASED ON PEER-TO-PEER EDUCATION METHOD	08:30 - 08:30
	María Soledad Jiménez Picazo (Córdoba, Spain)	
NP002	ADVANCE CARE PLANNING IN CAR-T THERAPY PATIENTS: DEMOGRAPHIC INFLUENCES AND ENGAGEMENT RATES - A RETROSPECTIVE SINGLE-CENTRE STUDY	08:30 - 08:30
	Andres Sebastian Moya Davila (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP003	ADHERENCE TO IMMUNOSUPPRESSORS AFTER HSCT: A CROSS-SECTIONAL STUDY	08:30 - 08:30
	Chiara Visintini (Udine, Italy)	

NP004	IMPLEMENTATION OF USE OF PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) FOR ADMINISTRATION OF PERIPHERAL BLOOD STEM CELLS (PBSC) IN PATIENTS RECEIVING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) Yu Ting Ngo (Singapore, Singapore)	08:30 - 08:30
NP005	NURSE LED PRE-HABILITATION FOR PATIENTS UNDERGOING STEM CELL TRANSPLANTATION Jo Preston (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP006	PATIENT FEEDBACK ON LYMPHOMA END OF TREATMENT SESSION Katherine Taylor (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP007	PROPHYLACTIC NASOGASTRIC TUBE FEEDING IN MYELOABLATIVE STEM CELL TRANSPLANT: A SERVICE EVALUATION Julie Beckerson (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP008	'BACK TO SCHOOL': CAN A STEM CELL TRANSPLANT EDUCATION PROGRAM ENHANCE PATIENT EXPERIENCES? Christina Paula Tejada (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP009	HAEMATOLOGY EMERGENCY DEPARTMENT UTILIZATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE Cristina Canaleta (Barcelona, Spain)	08:30 - 08:30
NP010	NURSE LED CLINIC HAEMATOLOGY: DREAMWORK OR TEAMWORK Maaike de Ruijter (Haarlem, Netherlands (the))	08:30 - 08:30
NP011	IMPROVING HAEMATOLOGY ONCOLOGY PATIENT'S TREATMENT RECALL PRIOR TO STARTING CONDITIONING PRE-AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT AND PRIMARY SYSTEMIC ANTI-CANCER THERAPY: IMPLEMENTATION OF "TEACH-BACK METHOD" Ana Goncalves (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP012	IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY (ICAH) FOLLOWING CD19 CAR T-CELL THERAPY IN LBCL, A SINGLE CENTER EXPERIENCE Nicole O'Leary (Melbourne, Australia)	08:30 - 08:30
NP013	HOW DOES PREMATURE OVARIAN INSUFFICIENCY AFFECT QUALITY OF LIFE IN WOMEN THAT HAVE RECEIVED A HAEMATOPOIETIC STEM CELL TRANSPLANT? A LITERATURE REVIEW Francesca Toselli (Oxford, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP014	HOME SELF-ADMINISTRATION IN PATIENTS RECEIVING CELL THERAPY AND INTENSIVE CHEMOTHERAPY. A UNICENTRIC EXPERIENCE Marta Torres Torres (Barcelona, Spain)	08:30 - 08:30
NP015	FEASIBILITY ASSESSMENT OF IMPLEMENTING AN EARLY WARNING SYSTEM FOR VENO-OCCLUSIVE DISEASE IN ALLOGENIC STEM CELL TRANSPLANTATION: A PILOT STUDY Angela Rodriguez-Rodriguez (Salamanca, Spain)	08:30 - 08:30
NP016	AN OCCUPATIONAL SAFETY PROJECT FOR CANCER CARE NURSES, USING SURFACE WIPE SAMPLING FOR HAZARDOUS DRUGS IN A HAEMATOLOGY AND ONCOLOGY SETTING Audrey O'Halloran (Dublin, Ireland)	08:30 - 08:30
NP017	ADDRESSING BARRIERS IN ACCESSING SUITABLE STEM CELL	08:30 - 08:30

	DONORS: HAEMATOLOGY NURSE'S PERSPECTIVE ON SOUTH ASIAN DONOR AWARENESS IN THE UK	
	Sinju Thomas (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP019	OPTIMIZING STEM CELL HARVESTING FOR MYELOMA PATIENTS: REDUCING NHS COSTS AND ENHANCING PATIENT EXPERIENCE THROUGH SINGLE TRANSPLANT STRATEGY	08:30 - 08:30
	Annabelle Annis (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	
NP020	THE ROLE AND IMPACT OF NURSE SPECIALISTS IN THE ASSESSMENT AND MANAGEMENT OF GRAFT VERSUS HOST DISEASE AT THE GVHD CLINIC	08:30 - 08:30
	Mohsen Alzahrani (Riyadh, Saudi Arabia)	
NP021	IMPROVING THE ADMINISTRATION OF ALEMTUZUMAB FOR THE CONDITIONING OF ALLOGENEIC TRANSPLANT PATIENTS	08:30 - 08:30
	Sara Rush (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
NP022	COMPARISON OF HOSPITALIZATIONS IN PATIENTS UNDERGOING REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT BASED ON GVHD PROPHYLAXIS (PTCY VS METHOTREXATE) IN HOSPITAL BASED OUTPATIENT PRACTICE	08:30 - 08:30
	Kendall Solinger (Rochester, United States of America (the))	
NP023	BONE MARROW TRANSPLANTATION IN COVID-19 PATIENTS: A QUALITATIVE STUDY ON THE HEALTHCARE PROFESSIONALS' EXPERIENCE	08:30 - 08:30
	Nicole Cassinari (Piacenza, Italy)	
NP024	DELAYED ADMISSION MODEL IN THE WARD EVALUATING THE SAFETY AND EFFICACY OF OUTPATIENT LYMPHODEPLETING CHEMOTHERAPY: AN ANALYSIS IN PATIENTS UNDERGOING CAR-T THERAPY	08:30 - 08:30
	Sabrina Castiglione (Firenze, Italy)	
NP025	'WHERE NOW': A HEALTH AND WELLBEING COURSE SUPPORTING THE NEEDS OF SURVIVORS POST ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Janet O'Doherty (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP026	NURSING CARE IN CAR-T THERAPY FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	08:30 - 08:30
	Laura Tierno Marti (Barcelona, Spain)	
NP027	MOBILE HEALTH TECHNOLOGIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SCOPING REVIEW	08:30 - 08:30
	Zhengwen Pan (Hangzhou, China)	
NP028	A QUALITY IMPROVEMENT PROJECT TO REDUCE 'TEMPERATURE SPIKE TO NEEDLE TIME' FOR FIRST DOSE ANTIBIOTICS TO WITHIN 60 MINUTES ON AN INPATIENT HAEMATOLOGY/AUTOLOGOUS TRANSPLANT UNIT	08:30 - 08:30
	Allison Ponsford (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	
NP029	THE TRANSPLANT COORDINATOR: A NEW APPROACH OF ORGANIZATION AND MANAGEMENT IN HSCT AND CELLULAR THERAPIES	08:30 - 08:30
	Roberta Lepori (Florence, Italy)	
NP030	EMBEDDING PASTORAL SUPPORT NURSING IN CLINICAL HAEMATOLOGY: OUR EXPERIENCE	08:30 - 08:30
	Manelyn Castaneda (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP031	NURSE LED IMMUNE EFFECTOR CELL ENCEPHALOPATHY (ICE) SCORING: ADAPTING TO MEET THE INDIVIDUAL NEEDS OF	08:30 - 08:30

	PATIENTS RECEIVING CAR T-CELL THERAPY	
	Emily John (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP032	IMPLEMENTATION OF GROUP AND SAVE & BLOOD TRANSFUSION PRODUCTS ORDERED NOTEBOOK TO REDUCE THE WASTAGE OF BLOOD COMPONENTS IN HAEMATOLOGY AND TRANSPLANT DAY UNIT (HTDU)	08:30 - 08:30
	Judith Lee (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
NP033	EFFECT OF CELLULAR THERAPY ON PATIENTS' QUALITY OF LIFE, A COHORT STUDY AT ABU DHABI STEM CELL CENTER, UAE CENTER OF EXCELLENCE FOR HSCT	08:30 - 08:30
	Dina El Mouzain (Abu Dhabi, United Arab Emirates (the))	
NP049	VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) COLONIZATION IN ASCT RECIPIENTS: DOES IT PREDICT WORSE OUTCOMES? A PROSPECTIVE SINGLE CENTRE STUDY	08:30 - 08:30
	Benedetta Scaioli (Meldola, Italy)	
NP050	BED DAYS SAVED, HOTBED USAGE AND PATIENT EXPERIENCE OF AMBULATORY CARE AT THE CHRISTIE	08:30 - 08:30
	Ruth Bull (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
NP051	OPTIMAL TIMING OF NASOGASTRIC TUBE INSERTION PRIOR TO MUCOSITIS IN PATIENTS RECEIVING HAPLO-IDENTICAL ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS: A SERVICE EVALUATION	08:30 - 08:30
	Julie Beckerson (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP052	NASOGASTRIC TUBE INSERTION AFTER REDUCED INTENSITY CONDITIONED ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: A SERVICE EVALUATION OF MUCOSITIS AND ARTIFICIAL NUTRITIONAL SUPPORT	08:30 - 08:30
	Julie Beckerson (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP053	OSTEOPOROSIS	08:30 - 08:30
	Serpil Vieira (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP054	THIOTEPA CONTAINING HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR CNS LYMPHOMA - NURSING CHALLENGE AND EXPERIENCES IN ENHANCING PATIENT SAFETY AND CARE STRATEGIES	08:30 - 08:30
	Hsin-Ju Yeh (Taipei City, Taiwan (Province of China))	
NP055	BLOOD TRANSFUSIONS IN HOSPITAL-AT-HOME FOR PATIENTS UNDERGOING STEM CELL TRANSPLANTATION AT OSLO UNIVERSITY HOSPITAL: THE IMPORTANCE OF PROACTIVE PLANNING!	08:30 - 08:30
	Ellen Hammering (Oslo, Norway)	
NP056	NURSING CONSULTATION FOR HEALTHY SEXUALITY POST HSCT	08:30 - 08:30
	Cláudia Silva (Lisbon, Portugal)	
NP057	EXPLORING THE UNMET NEED OF FINANCIAL SUPPORT FOR PATIENTS GOING THROUGH CAR T-CELL THERAPY: ANTHONY NOLAN'S PERSPECTIVE	08:30 - 08:30
	Emily John (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP058	CANCER TREATMENT IN AMBULATORY CARE: AN INNOVATION TO THE EMERGING CHALLENGES OF IN-PATIENT BED CAPACITY	08:30 - 08:30
	Naida Abasta (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP059	USE OF ULTRASOUND-GUIDED PERIPHERAL VENOUS CANNULATION IN PATIENTS WITH POOR PERIPHERAL ACCESS UNDERGOING APHERESIS	08:30 - 08:30
	Loredana Oraka (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	

NP060	SETTING UP AND ADAPTING AMBULATORY CARE FOR SCT PATIENTS IN A DISTRICT GENERAL NHS HOSPITAL Gail Rawbone (Somerset, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP061	CAR-T CCU ADMISSIONS 2019-2023: TRENDS AND OUTCOMES AT THE CHRISTIE HSCT & CELLULAR THERAPY UNIT Elleanor Dickinson-Symes (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP062	EDUCATION: THE KEY TO EXCELLENT PATIENT CARE Nicola Knightly (Swindon, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP063	USE OF CENTRAL VENOUS ACCESS PORTS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION. RESULTS OF A SINGLE CENTER SERIES Nuria Ballestar (Barcelona, Spain)	08:30 - 08:30
NP064	SOCIOCULTURAL DETERMINANTS OF SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NIGERIAN CASE STUDY Blessing Nkeiruka Aziken-john (Lagos, Nigeria)	08:30 - 08:30
NP065	THE IMPACT OF ANTHONY NOLAN FUNDED, POST-TRANSPLANT SPECIALIST NURSES ON PATIENT AND FAMILY WELLBEING Rachel Miller (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP066	APHERESIS EXAGAMLOGENE AUTOTEMCEL, EXA-CEL, (CASGEY) GENE THERAPY IN TRANSFUSION DEPENDENT THALASSEMIA (TDT): FIRST UK EXPERIENCE Jaya Sudhir (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP067	NURSE LED LATE EFFECTS CLINIC - FINDINGS FROM ONE YEAR OF DATA COLLECTION Laura Hazlett (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP068	OPTIMISING CAR-T THERAPY: AN EVALUATION OF THE PARTNERSHIP BETWEEN THE CAR-T SPECIALIST NURSING TEAM AND INTENSIVE CARE Daveen Kay (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP069	EXTRACORPOREAL PHOTOCHEMOTHERAPY SESSIONS AND NURSING ASSESSMENT OF ACUTE CUTANEOUS GRAFT-VERSUS-HOST DISEASE: EVALUATION AND SUPPORTIVE CARE Antonio Magaro (Milan, Italy)	08:30 - 08:30
NP071	ANALYSIS OF RISK FACTORS FOR HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION □□ □ (□□, China)	08:30 - 08:30
NP072	STANDARDISATION IN ORAL MUCOSITIS ASSESSMENT: INSIGHTS FROM IMPLEMENTATION OF BEST PRACTICE Gabriella Rennick (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP073	IMPLEMENTATION OF A PROJECT TO CHECK THE STRESS AND OVERLOAD OF PRIMARY CAREGIVERS OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE OF A CENTER Sara Marcos Asensio (Salamanca, Spain)	08:30 - 08:30
NP074	ADDRESSING NURSING CHALLENGES IN TOXIC EPIDERMAL NECROLYSIS POST-TRANSPLANT CARE Job Rexal Perez Gaddi (Zagreb, Croatia)	08:30 - 08:30
NP075	THE TOXIC EFFECTS CYTOKINE RELEASE SYNDROME (CRS) AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) POST CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY: REVIEW OF INCIDENCE RATES	08:30 - 08:30

	Kevin Aguilar (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP076	FECAL MICROBIAL THERAPY IN A PATIENT AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Klára Kabátová Maxová (Pilsen, Czechia)	08:30 - 08:30
NP077	NURSING EXPERIENCE OF CAR-T CELL THERAPY FOR DLBCL PATIENTS WITH PSEUDOMONAS AERUGINOSA INFECTION IN SKIN WOUNDS Yabin Wang (Beijing, China)	08:30 - 08:30
NP078	CATHETER-ASSOCIATED BACTERIAL INFECTIONS IN PATIENTS POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION: PATHOGEN ISOLATION AND TRENDS OBSERVED IN 2023-2024 AT A SINGLE-CENTER STUDY (CIC 1085) Zornitsa Zlateva (Varna, Bulgaria)	08:30 - 08:30
NP079	PATIENT DIARY AS A TOOL FOR EARLY SYMPTOM DETECTION AND FOSTERING PATIENT ENGAGEMENT IN ONCO-HEMATOLOGICAL POPULATION: A SCOPING REVIEW Silvia Gnechi (Milan, Italy)	08:30 - 08:30
NP080	MALNUTRITION PREVENTION IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION THROUGH NUTRITIONAL SUPPORT: NURSES ROLE AND IMPLICATIONS OF A MULTIDISCIPLINARY TEAM APPROACH Carmine Colella (Napoli, Italy)	08:30 - 08:30
NP081	REDUCING NURSE STRESS AND ANXIETY LEVELS ON A BMT UNIT USING COMMERCIALY AVAILABLE VIRTUAL REALITY (VR) TECHNOLOGY Jason Fletcher (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP082	ADVANCING CAR-T CELL THERAPY IN UNIVERSITY HOSPITAL CENTRE ZAGREB: A NURSING PERSPECTIVE ON CHALLENGES AND ACHIEVEMENTS (2019-2024) Zvonimir Kralj (Zagreb, Croatia)	08:30 - 08:30
NP083	THE CRUCIAL ROLE OF ADVANCED NURSE PRACTITIONERS IN EARLY DETECTION, INTERVENTION, AND MANAGEMENT OF THROMBOTIC MICROANGIOPATHY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Wan Hua Chou (Beitou District, Taiwan (Province of China))	08:30 - 08:30
NP085	NURSING OF A PATIENT WHO WAS TREATED WITH CD33-CART AND COMPLICATED WITH MULTI-DRUG RESISTANT PSEUDOMONAS AERUGINOSA ORAL MUCOSITIS Yan Xu (Beijing, China)	08:30 - 08:30
NP086	ENHANCING NURSING CARE FOR MS PATIENTS UNDERGOING STEM CELL TRANSPLANTATION: DEVELOPMENT AND EVALUATION OF A TARGETED EDUCATIONAL RESOURCE Jackie Horder (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP087	EVALUATION OF A NURSE PRACTITIONER LED INDUCTION PROGRAMME FOR MEDICAL TRAINEES Rebecca Williams (Cardiff, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP088	BELUMOSUDIL: A MIRACLE? Serpil Vieira (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP089	TRADITIONAL OR DIGITAL SCT WORKBOOK? DESIGNING AND DEVELOPMENT OF AN EDUCATIONAL WORKBOOK Theresa Peters (Bath, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP090	DELIVERY OF STEM CELL TRANSPLANTS (SCT) IN PRIVATE HEALTH CARE RESULTS IN EQUAL OUTCOMES. JOINT-VENTURE	08:30 - 08:30

	BETWEEN THE CHRISTIE PRIVATECARE (TCPC) AND THE CHRISTIE NHS (CNHSFT)	
	Lisa Deavall (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
NP091	FERTILITY OUTCOMES AFTER FLUDARABINE/BUSULFAN AND ANTITHYMOCYTE GLOBULIN AS REDUCED TOXICITY MYELOABLATIVE CONDITIONING FOR MATCHED RELATED DONOR ALLO-HCT : EXPERIENCE FROM EHU 1ER NOVEMBER D'ORAN, ALGERIA	08:30 - 08:30
	Meriem Belabbes (Oran, Algeria)	
NP092	NURSING EXPERIENCE OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA COMPLICATED WITH COLD AGGLUTININ DISEASE RECEIVING CAR-T THERAPY	08:30 - 08:30
	Yabin Wang (Beijing, China)	
NP093	HSCT UNIT ON THE MOVE	08:30 - 08:30
	Cláudia Silva (Lisbon, Portugal)	
NP094	NURSING CARE OF 4 PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME ASSOCIATED SWEET SYNDROME	08:30 - 08:30
	□□ □ (Tianjin, China)	
NP095	INTEGRATIVE NURSING EXPERIENCE IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CD19+ CART THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE STUDY	08:30 - 08:30
	Xiaoxu Ren (Tian Jin, China)	
NP096	ESTIMATED CREATININE CLEARANCE VS 24 HOUR URINE CREATININE CLEARANCE/EDTA	08:30 - 08:30
	Sophie Bertorelli (Cardiff, United Kingdom of Great Britain and Northern Ireland (the))	
NP097	NURSING CARE FOR ALL PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CD19+	08:30 - 08:30
	Congcong Lv (Tianjin, China)	
NP098	FEAR OF CANCER RECURRENCE IN PRE-HEMATOPOIETIC STEM CELLTRANSPLANTATION (HSCT) FOR HEMATOLOGICAL MALIGNANCY: THE SAME PERIOD OF NETWORK ANALYSIS	08:30 - 08:30
	Fangfang Wu (Chongqing, China)	
<i>ePoster</i>		
08:30 - 18:00		R18
Patient Advocacy: Patients' Reported Outcome and Expectations		
P414	EXPLORING THE IMPACT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ON HEALTH-RELATED QUALITY OF LIFE OF PATIENTS AND CAREGIVERS: A QUANTITATIVE SURVEY-BASED STUDY IN FRANCE	08:30 - 08:30
	Darko Kiprijanovski (Paris, France)	
P415	EXPLORING THE IMPACT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ON THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS AND CAREGIVERS: A QUALITATIVE SURVEY-BASED STUDY IN FRANCE	08:30 - 08:30
	Darko Kiprijanovski (Paris, France)	
P416	BRIDGING THE GAP: CO-DEVELOPMENT OF STRUCTURED PATIENT PARTNER SUPPORT PATHWAYS FOR CELLULAR THERAPY PATIENTS	08:30 - 08:30
	Karine Bilodeau (Montreal, Canada)	

P417	PERSPECTIVES AND EXPERIENCES OF ADULT PATIENTS UNDERGOING CAR T-CELL THERAPY IN THE NHS: QUALITATIVE EVIDENCE FROM THE UK Caitlin Farrow (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P418	SCALING SOCIOECONOMIC AND QUALITY OF LIFE DATA COLLECTION AMONG HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS IN THE UK: PROGRESS AND LESSONS LEARNED Gemma Pugh (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P419	THE SAFETY AND EFFICACY OF INTRA GENICULAR ARTERY MESENCHYMAL STEM CELL INJECTION IN THE TREATMENT OF KNEE OSTEOARTHRITIS; A ONE-YEAR FOLLOW-UP STUDY Maedeh Rouzbahani (Tehran, Iran (Islamic Republic of))	08:30 - 08:30
P420	UMBILICAL-DERIVED MESENCHYMAL STEM CELL INFUSION VIA MEDIAL CIRCUMFLEX FEMORAL ARTERY FOR EARLY-STAGE OSTEONECROSIS OF THE FEMORAL HEAD: A PILOT STUDY Maedeh Rouzbahani (Tehran, Iran (Islamic Republic of))	08:30 - 08:30
P421	CIBMTR ACCESS CLINICAL TRIAL EXPANDS TRANSPLANTATION TO A DIVERSE AND SOCIALLY VULNERABLE COHORT OF PATIENTS Rachel Cusatis (Milwaukee, United States of America (the))	08:30 - 08:30
P422	THE EBMT TRAINEE COMMITTEE SURVEY RESULTS: EDUCATIONAL NEEDS IN PALLIATIVE CARE FOR HEMATOLOGY, HEMATOPOIETIC CELL TRANSPLANTATION AND CELLULAR THERAPY Esra Gülderen (Bursa, Turkey)	08:30 - 08:30
P423	TREATING C1 CHRONIC VENOUS DISEASE AFTER TARGETED ENDOVASCULAR STEM CELL THERAPY FOR KNEE OSTEOARTHRITIS: AN INCIDENTAL FINDING Maedeh Rouzbahani (Tehran, Iran (Islamic Republic of))	08:30 - 08:30
P424	INNOVATIVE IMMUNOASSAY FOR THE RELIABLE AND RAPID MEASUREMENT OF ALEMTUZUMAB LEVELS Susanne Kricke Orszulik (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P425	BASELINE ASSESSMENT OF STRENGTH, FITNESS, NUTRITIONAL STATUS AND QUALITY OF LIFE IN ADULTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE FOR PREHABILITATION? Lauren Blackburn (Sutton, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P426	A SINGLE-CENTRE STUDY ON LONGITUDINAL CHANGES IN QUALITY OF LIFE AFTER CAR-T THERAPY IN PATIENTS WITH NON-HODGKIN LYMPHOMA Bethany Rendell (Swansea, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P427	INADEQUACY OF COUNSELLING OF PAEDIATRIC SIBLING STEM CELL DONORS Serena Sen (Mumbai, India)	08:30 - 08:30
P428	PATIENT REPORTED FATIGUE AND THE EFFECT OF STEM CELL TRANSPLANT IN THE SETTING OF MANTLE CELL OR DIFFUSE LARGE B-CELL LYMPHOMAS - A LONGITUDINAL ANALYSIS Natacha Bolaños (Madrid, Spain)	08:30 - 08:30

ePoster

08:30 - 18:00

R18

Quality Management

P388	WHAT TO DO WITH HEMATOPOIETIC STEM CELL LEFTOVERS FOLLOWING TRANSPLANTATION? Irit Pevzner-Melamed (Haifa, Israel)	08:30 - 08:30
P389	QUALITY ASSURANCE IN CRYOPRESERVATION FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN A RESOURCE-CONSTRAINED SETTING: A SINGLE-CENTER EXPERIENCE Divya Setya (Ghaziabad, India)	08:30 - 08:30
P390	EVALUATION OF THE EFFECTIVENESS OF AN ELECTRONIC QUALITY MANAGEMENT SYSTEM ACCORDING TO THE LEAN IT METHODOLOGY Giorgia Battipaglia (Naples, Italy)	08:30 - 08:30
P391	THE QUALITY MANAGER IN STEM CELL TRANSPLANT CENTERS: DEVELOPMENT OF A COMPETENCY ASSESSMENT TOOL IN COMPLIANCE WITH JACIE STANDARDS Vincenzo Iaconianni (Sesto San Giovanni, Italy)	08:30 - 08:30
P392	DOING TOO MUCH? A QUALITY ASSESSMENT OF ICANS RISK OPTIMIZATION FOR CAR-T THERAPIES Sara Young (Charlottesville, United States of America (the))	08:30 - 08:30
P393	UNCOMMON CONFIGURATION OF JACIE ACCREDITED PROCESSING FACILITY FOR THE POLICLINICO TOR VERGATA HEMATOPOIETIC STEM CELL TRANSPLANT PROGRAM OF ROME Antonio Bruno (Rome, Italy)	08:30 - 08:30
P394	STAND-ALONE ACCREDITATION OF A CLINICAL UNIT: THE BENEFITS OF JACIE ACCREDITATION Giuseppe Pietrantuono (Rionero in Vulture, Italy)	08:30 - 08:30
P395	QUALITY INDICATORS TO EVALUATE THE QUALITY OF THE STEM CELL COLLECTION AND PROCESSING SYSTEM AT THE SOUTH AFRICAN NATIONAL BLOOD SERVICE Laurel Anderson (Johannesburg, South Africa)	08:30 - 08:30
P396	VALIDATION OF LONG-TERM STORAGE OF PBSC SUPPLEMENTED WITH 7% DMSO DILUTED IN SALINE WITHOUT ADDED PROTEINS Francesco Lanza (ravenna, Italy)	08:30 - 08:30
P397	USING LEAN SIX SIGMA METHODOLOGY TO REDUCE THE TURNAROUND TIME FOR BLOOD PRODUCTS (PRBCS) IN HOSPITALIZED PATIENTS: A SINGLE CENTER TRANSFUSION DELAY STUDY Affaf Sheikh (Karachi, Pakistan)	08:30 - 08:30
P398	THE TRANSPLANT PROGRAM QUALITY COUNCIL MEETINGS AS THE EFFECTIVE TOOL FOR THE QMS INTRODUCTION AND MAINTENANCE AND THE IMPLEMENTATION OF NEW REQUIREMENTS Marie Dobrovolna (Prague, Czechia)	08:30 - 08:30
P399	REVIEW OF THE FINAL REVIEW (FR): AN AUDIT ON SURVIVAL OUTCOME COMPARING PATIENTS WITH AND WITHOUT REVIEW PRIOR TO CONDITIONING AND STEM CELL TRANSPLANTATION (HSCT) Mark Barrios (St Leonards, Australia)	08:30 - 08:30
P400	SURVEY OF UK TRAINING ACCESSIBILITY AND RESOURCES FOR HSCT QUALITY MANAGEMENT Eleanor Leaney (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P401	PILOT PROJECT OF PRE-REHABILITATION IN PEDIATRIC PATIENTS BEFORE HEMATOPOIETIC STEM CELL	08:30 - 08:30

TRANSPLANTATION IN THE REPUBLIC OF BELARUS

Volha Mishkova (Borovlyany, Belarus)

- P403 **ASSESSMENT METHODS FOR STANDARD OPERATING PROCEDURE (SOP) COMPETENCIES AT SOUTH WEST PENINSULA TRANSPLANT SERVICE - ONLINE SOLUTIONS** 08:30 - 08:30
Rob Wosley (Plymouth, United Kingdom of Great Britain and Northern Ireland (the))
- P405 **SUCCINYLATED GELATIN QUALIFICATION AS ALTERNATIVE SOLUTION TO HES FOR WASHING/DILUTION OF CORD BLOOD UNITS FOR INFUSION AND SATELLITE SAMPLES FOR QUALITY CONTROLS** 08:30 - 08:30
Serena Urbani (Firenze, Italy)
- P406 **OUTPATIENT CARE DYNAMICS AFTER ALLOGENEIC TRANSPLANTATION: REASONS FOR HOSPITALIZATION AND EARLY MORTALITY IN A LATIN AMERICAN TRANSPLANT CENTER** 08:30 - 08:30
Alejandra De Las Fuentes Cepeda (Monterrey, Mexico)
- P407 **TAILORED ASSESSMENT OF HPC-A COLLECTION, PROCESSING AND STEM CELL GRAFT QUALITY** 08:30 - 08:30
Gabriella Peluso Cassese (Rome, Italy)
- P409 **CAR-T EXPANSION: A HISTORY OF MULTI-PARTNERSHIP BASED ON QUALITY** 08:30 - 08:30
Alessandro Busca (Turin, Italy)
- P410 **EVALUATION OF THE EFFECTIVENESS OF PRE TRANSPLANT EDUCATIONAL SEMINAR, ON FUNCTIONAL CAPACITY OF STEM CELL TRANSPLANTATION PATIENTS** 08:30 - 08:30
Eoin Glynn (London, United Kingdom of Great Britain and Northern Ireland (the))
- P411 **CHALLENGES OF IMPLEMENTING A NEW QUALITY MANAGEMENT SYSTEM** 08:30 - 08:30
Samah Alimam (London, United Kingdom of Great Britain and Northern Ireland (the))
- P412 **NATIONAL IMPLEMENTATION OF A PHARMACEUTICAL HANDOVER TOOL FOR ADULT HSCT AND CAR-T PATIENTS BETWEEN THE NATIONAL SCOTTISH TRANSPLANT CENTRE AND LOCAL HAEMATOLOGY TEAMS** 08:30 - 08:30
Sarah Mitchell (Glasgow, United Kingdom of Great Britain and Northern Ireland (the))
- P413 **MEET ME HALFWAY: UTILIZING IA INTERIM AUDIT TOWARD THE PATHWAY TO ACCREDITATION - A SINGLE CENTRE EXPERIENCE** 08:30 - 08:30
Antonette Geraldine Amao (Bath, United Kingdom of Great Britain and Northern Ireland (the))

ePoster

08:30 - 18:00

R18

Inborn Errors, Granulocyte and Osteoclast Disorders

- B313 **TREATMENT EFFECT OF ATIDARSAGENE AUTOTEMCEL (ARSA-CEL) IN AGE-MATCHED TREATED VS. UNTREATED SIBLING PAIRS WITH EARLY-ONSET METACHROMATIC LEUKODYSTROPHY (MLD)** 08:30 - 08:30
Valeria Calbi (Milan, Italy)
- B314 **HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC NON-MALIGNANT DISEASES** 08:30 - 08:30
Tatiana Bykova (Saint-Petersburg, Russian Federation (the))
- B315 **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR OSTEOPEetrosis: A SINGLE-CENTER EXPERIENCE** 08:30 - 08:30
Etai Adam (Ramat Gan, Israel)

B316	ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND 12-YEARS FOLLOW-UP IN TWO SIBLINGS AFFECTED BY FUCOSIDOSIS Virginia Meda Spaccamela (Zurich, Switzerland)	08:30 - 08:30
B317	PULMONARY COMPLICATIONS FOLLOWING ALLOGENIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCIES Victoria Bloch Blytt Sandstad (Copenhagen, Denmark)	08:30 - 08:30
P321	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TREATMENT OF SHWACHMAN- DIAMOND SYNDROME: A REPORT OF 19 PEDIATRIC CASES FROM A SINGLE CENTER Jiao Chen (Beijing, China)	08:30 - 08:30
P322	A SUCCESSFUL TREATMENT OF A PATIENT WITH HIGH-RISK NEUROBLASTOMA AND OSTEOGENESIS IMPERFECTA TYPE XV ASSOCIATED WITH A NOVEL HOMOZYGOUS VARIANT OF THE WNT1 GENE Ayad Ahmed Hussein (Amman, Jordan)	08:30 - 08:30
P323	T-REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRE-SYMPTOMATIC X-LINKED ADRENOLEUKODYSTROPHY PATIENT: ADDING THIOTEPA TO CONDITIONING REGIMEN Ayad Ahmed Hussein (Amman, Jordan)	08:30 - 08:30
P324	FEATURES OF IMMUNE RESTORATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH IEI IN THE REPUBLIC OF BELARUS Volha Mishkova (Borovlyany, Belarus)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		R18
Lymphoma and Chronic Lymphocytic Leukaemia		
B339	LONG-TERM FOLLOW-UP RESULTS OF NONREMISSION RELAPSED/REFRACTORY DLBCL WITH CAR T-CELL COCKTAIL THERAPY ALONE OR IN COMBINATION WITH ASCT Xiaoying Zhang (Wuhan, China)	08:30 - 08:30
B340	IMPROVEMENTS IN OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOMA BETWEEN 2002-2022: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY Evgenii Shumilov (Münster, Germany)	08:30 - 08:30
B341	UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK T-CELL LYMPHOMA: INTERIM ANALYSIS OF A PROSPECTIVE STUDY FengRong Wang (Beijing, China)	08:30 - 08:30
B342	INTERIM ANALYSIS OF SECOND-LINE PROLGOLIMAB THERAPY IN CLASSIC HODGKIN LYMPHOMA: A STEP TOWARD TRANSPLANT-FREE TREATMENT (PROLGO-HL) Liudmila Fedorova (Saint Petersburg, Russian Federation (the))	08:30 - 08:30
B343	CLINICAL OUTCOMES OF HTLV-1-ASSOCIATED ADULT T-CELL LEUKEMIA/LYMPHOMA (ATL) PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION (SCT): AN EBMT LWP RETROSPECTIVE ANALYSIS Patricia López-Pereira (Barcelona, Spain)	08:30 - 08:30
B344	CAR-T AND ALLOGENIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-	08:30 - 08:30

	CELL LYMPHOMA (THRLBCL): AN EBMT LYMPHOMA WORKING PARTY STUDY	
	Simon Renders (Heidelberg, Germany)	
B345	LONG-TERM SURVIVAL OUTCOMES OF T-CELL LYMPHOMAS: NATIONWIDE STATISTICAL ANALYSIS OF KOREA	08:30 - 08:30
	Dong Won Baek (Daegu, Korea (the Republic of))	
B346	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR RELAPSED AND/OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA, A SINGLE CENTER 21-YEAR EXPERIENCE	08:30 - 08:30
	André Antunes (Funchal, Portugal)	
B347	FRAILTY TRANSITIONS AND THEIR PROGNOSTIC SIGNIFICANCE IN CAR T-CELL THERAPY FOR NON-HODGKIN LYMPHOMA. PRELIMINARY RESULTS FROM A MULTICENTER STUDY CONDUCTED ON BEHALF OF THE GETH-TC	08:30 - 08:30
	María Queralt Salas (Barcelona, Spain)	
B348	OUTCOMES OF PATIENTS WITH HODGKIN LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN LATIN AMERICA: A MULTICENTER ANALYSIS BY GELL-LABMT	08:30 - 08:30
	Cristobal Frutos-Ortiz (Asuncion, Paraguay)	
B349	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND ABATACEPT GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS SHOWS IMPROVED OUTCOMES IN NORTH AMERICAN ADULT T-CELL LEUKEMIA/LYMPHOMA	08:30 - 08:30
	Alex Sica (New York, United States of America (the))	
B350	PATHWAY INHIBITOR-REFRACTORY HIGH-RISK CLL: WHICH CELLULAR THERAPY FIRST? A SINGLE-CENTER RETROSPECTIVE STUDY	08:30 - 08:30
	Michael Schmitt (Heidelberg, Germany)	
B351	IMPACT OF CENTER-EXPERIENCE ON TRANSPLANT OUTCOMES IN ADULT PATIENTS WITH LYMPHOMAS	08:30 - 08:30
	Mizuki Watanabe (Tokyo, Japan)	
B352	HIGH DOSE GEMCITABINE, BUSULFAN, AND THIOTEPA WITH AUTOLOGOUS STEM CELL TRANSPLANTATION SIGNIFICANTLY IMPROVE THE OUTCOME OF PRIMARY OR RELAPSED CENTRAL NERVOUS SYSTEM LYMPHOMA	08:30 - 08:30
	Jie Ji (Chengdu, China)	
B353	CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF 104 CASES OF EXTRANODAL NK/T-CELL LYMPHOMA UNDERGOING PRIMARY TREATMENT IN NOVEL AGENTS ERA	08:30 - 08:30
	Haiwen Huang (Suzhou, China)	
B354	BISPECIFIC ANTIBODIES FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: REAL-LIFE EXPERIENCE IN CART AND TARGET THERAPY ERA	08:30 - 08:30
	Gabriele Facchin (Udine, Italy)	
B355	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA: EFFECTIVE CONSOLIDATION POST-PD-1 INHIBITORS IN THIRD- AND FOURTH-LINE TREATMENT	08:30 - 08:30
	Liudmila Fedorova (Saint Petersburg, Russian Federation (the))	
P325	GIVING IMMUNE CHECKPOINTS INHIBITORS BEFORE AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION MODIFIES ITS COURSE WITH OCCURRENCE OF ENGRAFTMENT	08:30 - 08:30

	SYNDROME IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA Ahmad Ibrahim (Beirut, Lebanon)	
P326	OUTCOMES OF PATIENTS WITH RELAPSED HODGKIN'S LYMPHOMA AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION Natalya Milanovich (Minsk, Belarus)	08:30 - 08:30
P327	OUTCOME OF PATIENTS WITH REFRACTORY/RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION Mercedes de Jesús García (Córdoba, Argentina)	08:30 - 08:30
P330	ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY LYMPHOMAS: TWENTY YEARS OF EXPERIENCE FROM ASST SPEDALI CIVILI DI BRESCIA Daniele Avenoso (Brescia, Italy)	08:30 - 08:30
P331	EFFICACY AND SAFETY OF PD-1/PD-L1 INHIBITORS FOR NATURAL KILLER/T-CELL LYMPHOMA: A SINGLE-ARM META-ANALYSIS Jiao Yang (Sichuan, Chengdu, China)	08:30 - 08:30
P332	NIVOLUMAB-BASED BRIDGE FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH REFRACTORY AND RELAPSED PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA Liudmila Fedorova (Saint Petersburg, Russian Federation (the))	08:30 - 08:30
P333	OBSERVATIONAL STUDY ON THE EFFICACY OF ORT-M/A CHEMOTHERAPY REGIMEN IN UNFIT PCNSL PATIENTS IN CHINA Lingling Liu (Guangzhou, China)	08:30 - 08:30
P335	ROLE OF POLATUZUMAB VEDOTIN IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AS BRIDGING STRATEGY TO HAEMATOPOIETIC CELL TRANSPLANT IN THE PHILIPPINES: CASE SERIES AND LITERATURE REVIEW Jan Miko Aaron Baybay (Bonifacio Global City, Philippines (the))	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		R18
Haemoglobinopathy		
A328	TREOSULFAN, THIOTEPA AND FLUDARABIN REPRESENTS A SAFE AND EFFICIENT ALTERNATIVE CONDITIONING IN T CELL DEPLETED HAPLOIDENTICAL AND MSD HSCT FOR PATIENTS WITH TDT Anja Troeger (Regensburg, Germany)	08:30 - 08:30
A329	HAEMOPOIETIC CELL TRANSPLANTATION FOR TRANSFUSION DEPENDENT THALASSAEMIA: REAL WORLD DATA FROM 2010-2021. AGE , DONOR TYPE AND YEAR OF TRANSPLANT AFFECT THE OUTCOME Donatella Barionciani (Pesaro, Italy)	08:30 - 08:30
A330	RISK ADAPTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH HIGH-RISK HEMOGLOBINOPATHIES: INSIGHTS FROM KING HUSSEIN CANCER CENTER Rawad Rihani (Amman, Jordan)	08:30 - 08:30
A331	HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH TRANSFUSION DEPENDENT THALASSEMIA-COMPARISON BASED ON DIFFERENT DONOR TYPES	08:30 - 08:30

	Sunil Bhat (Bangalore, India)	
A332	PEDIATRIC TRANSPLANT AND CELLULAR THERAPY CONSORTIUM (PTCTC) SURVEY ASSESSING PRACTICE PREFERENCES FOR ALLOGENEIC STEM CELL TRANSPLANTATION OR GENE THERAPY FOR PATIENTS WITH SICKLE CELL DISEASE Niketa C. Shah (New Brunswick, United States of America (the))	08:30 - 08:30
A333	OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR TRANSFUSION-DEPENDENT ANAEMIAS IN HONG KONG Wilson Chan (Hong Kong, Hong Kong)	08:30 - 08:30
A334	FEASIBILITY OF SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH HEMOGLOBINOPATHIES Marco Zecca (Pavia, Italy)	08:30 - 08:30
A335	TERRITORY-WIDE RETROSPECTIVE REVIEW ON OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR HAEMOGLOBIN BART'S HYDROPS FETALIS SYNDROME IN HONG KONG Wilson Chan (Hong Kong, Hong Kong)	08:30 - 08:30
A337	DURABLE ENGRAFTMENT AFTER RADIATION FREE REDUCED INTENSITY CONDITIONING AND HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH SEVERE SICKLE CELL DISEASE Alexander Ngwube (Houston, United States of America (the))	08:30 - 08:30
A338	OUTCOME OF TCR ALPHA / BETA AND CD19⁺ DEPLETION VS. POST-TRANSPLANT CYCLOPHOSPHAMIDE HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT IN PATIENT WITH THALASSEMIA MAJOR : A COMPARATIVE ANALYSIS Anjali Yadav (Gurugram, India)	08:30 - 08:30
A339	REDUCED-TOXICITY MYELOABLATIVE CONDITIONING REGIMEN IN HLA-IDENTICAL SIBLING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE Thalita Cristina de Mello Costa (Ribeirão Preto, Brazil)	08:30 - 08:30
A340	FLUDARABINE/TREOSULFAN/THIOTEPA/ATG CONDITIONING FOR SIBLING TRANSPLANTATION TRANSFUSION DEPENDENT THALASSAEMIA LEADS TO EARLY AND SUSTAINED ENGRAFTMENT WITH LOW INCIDENCE OF VOD AND GVHD Leena Karnik (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
A341	SIGNIFICANT GROWTH IN HCT USE FOR HAEMOGLOBINOPATHIES IN THE LAST DECADE DRIVEN BY SICKLE CELL DISEASE ACROSS ALL AGES WITH EXCELLENT OUTCOMES: EBMT ANALYSIS Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
A342	EXCELLENT THALASSEMIA-FREE SURVIVAL IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN OLDER CHILDREN WITH ANTIBODIES AND TRANSFUSION-DEPENDENT THALASSEMIA Kavitha Ganesan (Chennai, India)	08:30 - 08:30
A344	HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS WITH SICKLE CELL DISEASE AND RECURRENT VASO-OCCLUSIVE CRISES OR BETA-THALASSEMIA WHO RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS IN THE US Duncan Brown (Boston, United States of America (the))	08:30 - 08:30
A345	GRAFT VS HOST DISEASE IN PATIENTS WITH BETA-THALASSEMIA MAJOR AFTER STEM CELL TRANSPLANTATION:	08:30 - 08:30

	SINGLE CENTER EXPERIENCE	
	Alphan Küpesiz (Antalya, Turkey)	
A346	MACHINE LEARNING INDIVIDUALIZED PREDICTION OF OUTCOMES OF HEMATOPOIETIC CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: RATIONALE FOR PROPOSED EXTERNAL VALIDATION WITH EBMT DATABASE	08:30 - 08:30
	Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the))	
P317	SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PATIENTS WITH THALASSEMIA MAJOR AFTER GRAFT REJECTION	08:30 - 08:30
	Michalis Kastamoulas (Athens, Greece)	
P318	ELUCIDATION OF FACTORS IN DELAYED PLATELET ENGRAFTMENT AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMIA	08:30 - 08:30
	Ülker Koçak (Ankara, Turkey)	
P319	ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION WITH GVHD PROPHYLAXIS BY POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN A PATIENT WITH MANUKAU HEMOGLOBINOPATHY: A CASE REPORT	08:30 - 08:30
	Tatiana Bykova (Saint-Petersburg, Russian Federation (the))	
P320	PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SICKLE CELL DISEASE: A CASE SERIES OF SINGLE CENTER EXPERIENCE	08:30 - 08:30
	Ali Bulent Antmen (Adana, Turkey)	
<i>ePoster</i>		
08:30 - 18:00		R18
Solid Tumours		
B363	EXTRAMEDULLARY DISEASE OF MYELOID MALIGNANCIES: A RELIABLE INDICATOR FOR TREATMENT WITH ALLOSCT AT ANY STAGE?	08:30 - 08:30
	Alexander Hölscher (Düsseldorf, Germany)	
B364	HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANTATION IN ADULT EWING SARCOMA PATIENTS - A RETROSPECTIVE EBMT REGISTRY STUDY	08:30 - 08:30
	Paolo Pedrazzoli (Pavia, Italy)	
<i>ePoster</i>		
08:30 - 18:00		R18
Nurses Posters - Paediatric		
NP034	UTILIZING DIGITAL THERAPEUTIC EDUCATION FOR ADOLESCENTS AND YOUNG ADULTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SCOPING REVIEW OF EVIDENCE AND STRATEGIES	08:30 - 08:30
	Simona Calza (Genoa, Italy)	
NP035	SHIFTING PARADIGMS: IMPLEMENTATION OF THE FIRST PAEDIATRIC BMT & CELLULAR THERAPIES NURSE PRACTITIONER ROLE IN AUSTRALIA	08:30 - 08:30
	Maddie Gilsenan (Melbourne, Australia)	
NP036	IMPLEMENTATION OF PATIENT SAFETY TOOLS AS A QUALITY STRATEGY IN A PEDIATRIC HEMATOPOIETIC STEM CELL, CELL THERAPY AND PEDIATRIC ONCOHEMATOLOGY UNIT	08:30 - 08:30
	Manuel Adrián Julbez Zamorano (Madrid, Spain)	

NP037	VIRTUAL REALITY AS A NON-PHARMACOLOGICAL INTERVENTION IN PEDIATRIC ONCOLOGY: TWO SCOPING REVIEWS ON CLINICAL OUTCOMES, CAREGIVER EXPERIENCES, AND HEALTHCARE PROFESSIONAL PERSPECTIVES Simona Calza (Genoa, Italy)	08:30 - 08:30
NP038	THE PSYCHOLOGICAL IMPACT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION ON CHILDREN AND ADOLESCENTS: A PROSPECTIVE SINGLE-ARM STUDY FROM A PEDIATRIC BMT UNIT IN INDIA Jerlin Robin (Chennai, India)	08:30 - 08:30
NP039	ESCAPING THE FEAR OF SIMULATION - UTILISING ESCAPE ROOMS IN BMT NURSING EDUCATION AND TEAM BUILDING Johanna Lee (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP040	DRINKING WATER FOR ADULT AND PAEDIATRIC STEM CELL TRANSPLANT PATIENTS IN THE UK - THE NEED FOR GUIDANCE Rachel Protheroe (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP041	DEVELOPMENT OF A NURSE-LED PAEDIATRIC PHOTOBIO-MODULATION SERVICE Eleanor Leaney (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP099	AN EXPLORATION OF RETURN TO SCHOOL PRACTICE FOR PATIENTS WHO HAVE HAD A STEM CELL TRANSPLANT AT GOSH Annette Hill (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP100	HICKMAN CATHETERS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: INFECTIOUS COMPLICATIONS, REMOVAL AND NURSING CARE; A SINGLE-CENTER EXPERIENCE Nihal Ozkan (Istanbul, Turkey)	08:30 - 08:30
NP101	OFFERING CHOICE OF IMMUNOGLOBULIN REPLACEMENT TREATMENT TO CHILDREN WITH SECONDARY IMMUNODEFICIENCY FOLLOWING CAR-T THERAPY - A CASE REPORT Saskia Burrige (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP102	NUTRITIONAL SCREENING IN PEDIATRIC PATIENTS UNDERGOING HSCT: A SPECIFIC FORM FOR MALNUTRITION RE-EVALUATION IN PEDIATRIC BONE MARROW TRANSPLANT CENTER OF A.S.S.T. SPEDALI CIVILI DI BRESCIA Ilaria Pedretti (Brescia, Italy)	08:30 - 08:30
NP103	PREPARING NURSING STAFF FOR THE ADMINISTRATION OF THE FIRST GENE-EDITED STEM CELL INFUSION: A COMPREHENSIVE APPROACH Rodaina Abujoub (Riyadh, Saudi Arabia)	08:30 - 08:30
NP104	INCREASING DIETETIC REVIEWS FOR PAEDIATRIC PATIENTS UNDERGOING AN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT TO REDUCE THE USE OF PARENTERAL NUTRITION Chloe Elliott (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP105	ALLOGENEIC BONE MARROW TRANSPLANTS IN FANCONI ANEMIA: THE STORY OF TWO SISTERS Yana Diamand (Haifa, Israel)	08:30 - 08:30
NP106	THE DAY AFTER THE SURPRISE: FIRST IMPRESSIONS ABOUT THE IMPACT OF THE GAMIFICATION AND HUMANIZATION INTERVENTIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) Victoria Molinillo Ponce (Barcelona, Spain)	08:30 - 08:30
NP107	EDUCATION FROM THE WALL: RESEARCH MEETS CARE	08:30 - 08:30

	Bart Maertzdorf (Utrecht, Netherlands (the))	
NP108	A PILOT STUDY AIMING TO IDENTIFY THE MOST EFFECTIVE MODALITY FOR ENGAGING AND EDUCATING INPATIENT NURSES IN RESEARCH Kristen Graham (Boston, United States of America (the))	08:30 - 08:30
NP109	ORAL MUCOSITIS IN PEDIATRIC HEMATO-ONCOLOGY PATIENTS: A PILOT STUDY ON SEVERITY, DURATION, AND PREVENTIVE MEASURES Nicole De Vita (Trieste, Italy)	08:30 - 08:30
NP110	PREVENTION AND MANAGEMENT OF COMPLICATED ORAL MUCOSITIS IN CHILDREN RECEIVING HSCT: A CASE FROM PAEDIATRIC BONE MARROW TRANSPLANT CENTRE OF A.S.S.T. SPEDALI CIVILI DI BRESCIA Alessandra Buccino (Brescia, Italy)	08:30 - 08:30
NP111	HOW CAN WE OPTIMISE THE SEARCH PATHWAY FOR CHILDREN WITH LEUKAEMIA WHO REQUIRE A STEM CELL TRANSPLANT? Annette Hill (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP112	CASE PRESENTATION: NURSING ASSESSMENT OF IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN PAEDIATRIC PATIENTS Irene Trueba Grande (Madrid, Spain)	08:30 - 08:30
NP113	PSYCHO-ONCOLOGICAL INTERVENTION FOR PEDIATRIC HEMATOPOIETIC STEM CELL SIBLING DONORS Marina Bonfill (Barcelona, Spain)	08:30 - 08:30
NP114	STANDARDISED PAEDIATRIC PARENTERAL NUTRITION (PN) "AN OPPORTUNITY TO PROVIDE BETTER EQUITY OF CARE, IMPROVE SAFETY AND REDUCE COSTS" Karen Jepson (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
NP115	EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN FROM MATCHED RELATED DONOR: EVIDENCE FROM A SINGLE CENTER IN AN EMERGING COUNTRY, UNITED ARAB EMIRATES Zainul Aabideen (Abu Dhabi, United Arab Emirates (the))	08:30 - 08:30
NP116	MANAGEMENT OF SEVERE CUTANEOUS GRAFT-VERSUS-HOST-DISEASE IN AN ADOLESCENT Veronica Fernandez-Angulo (Barcelona, Spain)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Data Management		
P368	IMPLICATIONS FOR NON-ADHERENCE TO IMWG RESPONSE CRITERIA FOR DEFINING CR IN MULTIPLE MYELOMA PRE-HSCT: A POTENTIAL ROLE FOR SUBDIVIDING VGPR INTO DETECTABLE VERSUS NON-DETECTABLE DISEASE Damith Nirmal Dhanasekara Dhanasekara Koralage (Cardiff, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P369	PREDICTIVE MODELING OF OUTCOMES IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING MACHINE LEARNING TECHNIQUES Maedeh Rouzbahani (Tehran, Iran (Islamic Republic of))	08:30 - 08:30
P370	IMPROVEMENT OF FINDING UNRELATED DONORS - HOW A MULTINATIONAL PATIENT REGISTRY SERVICE IS BRIDGING THE GAP IN SELECTING AND REQUESTING DONORS FOR HSCT	08:30 - 08:30

	Alice Nagel (Tübingen, Germany)	
P371	DESIGN AND INTEGRATION OF ELECTRONIC PROFORMAS INTO ELECTRONIC HEALTH RECORDS TO OPTIMIZE THE TIMELY AND ACCURATE COMPLETION, USABILITY AND UTILITY OF EBMT DATA COLLECTION FORMS	08:30 - 08:30
	Ioannis Peppas (London, United Kingdom of Great Britain and Northern Ireland (the))	
P372	ARTIFICIAL INTELLIGENCE FOR THE IDENTIFICATION OF CAR-T THERAPY CANDIDATES USING REAL-WORLD DATA: A PILOT STUDY OF THE SPANISH HEMATOPOIETIC TRANSPLANT AND CELLULAR THERAPY GROUP (GETH-TC)	08:30 - 08:30
	Leyre Bento (Palma, Spain)	
P373	THE UNFULFILLED PROMISE: UNDERSTANDING DONOR ATTRITION IN HEMATOPOIETIC STEM CELL DONATION FOR UNRELATED ALLOGENEIC BONE MARROW TRANSPLANTATION - WHEN YES TURNS TO NO	08:30 - 08:30
	Pinelopi Samara (Athens, Greece)	
P374	DATA MANAGEMENT GROUP: FROM CREATION TO COMMUNITY	08:30 - 08:30
	Catherine Grundy (Nottingham, United Kingdom of Great Britain and Northern Ireland (the))	
P375	MICROPARTICLES DERIVED FROM HEMATOPOIETIC CELLS IN UMBILICAL CORD BLOOD INDUCE AN ANTI-INFLAMMATORY RESPONSE IN THE HL60 CELL	08:30 - 08:30
	Angeliki Xagorari (Thessaloniki, Greece)	
P376	FROM EXCEL TABLE TO REDCAP BASED REGISTRY: SINGLE CENTER EXPERIENCE	08:30 - 08:30
	Nazarii Shokun (Kyiv, Ukraine)	
P377	QUALITY ASSESSMENT OF LEUKAPHERESIS PRODUCTS FOR FURTHER MANUFACTURING OF CAR-T CELLS - EXPERIENCE OF A SINGLE COLLECTION CENTER	08:30 - 08:30
	Fátima Amado (Porto, Portugal)	
P378	A NEW PAGE: A QUALITY IMPROVEMENT PROJECT TRANSITIONING TO PAPERLESS DOCUMENTATION TO ENHANCE SCT PATIENT CARE	08:30 - 08:30
	Antonette Geraldine Amao (Bath, United Kingdom of Great Britain and Northern Ireland (the))	
P379	THE IMPACT OF THE NEW EBMT DATA REGISTRY ON WORKLOAD AND PRODUCTIVITY OF BSBMTCT CERTIFIED USERS.	08:30 - 08:30
	Clementina Abamba (London, United Kingdom of Great Britain and Northern Ireland (the))	
P380	ANALYSIS OF ADVERSE EVENTS AND REACTIONS IN THE ITALIAN HEMATOPOIETIC STEM CELL TRANSPLANTATION NETWORK: 10 YEARS OF REPORTING TO THE NATIONAL COMPETENT AUTHORITY	08:30 - 08:30
	Benedetta Mazzanti (Rome, Italy)	
P381	DESCRIPTION OF PATIENTS AND MANAGEMENT OF CGVHD IN FRANCE BASED ON NATURAL LANGUAGE PROCESSING (NLP) FROM MEDICAL DOCUMENTS AVAILABLE IN HOSPITAL ELECTRONIC MEDICAL FILES	08:30 - 08:30
	Darko Kiprijanovski (Paris, France)	
P382	OVERCOMING DATA MANAGEMENT CHALLENGES IN DEVELOPING COUNTRIES: LESSONS FROM THE PAKISTAN BONE MARROW TRANSPLANT (PBMT) GROUP	08:30 - 08:30
	Shahid Iqbal (Rawalpindi, Pakistan)	
P383	DEVELOPMENT OF THE ALGORITHM FOR DELIVERING STEM CELLS FROM EUROPE TO THE REPUBLIC OF BELARUS UNDER EXISTING SOCIAL AND ECONOMIC RESTRICTIONS	08:30 - 08:30

Volha Mishkova (Borovlyany, Belarus)

ePoster

08:30 - 18:00

R18

Statistics

- P385 **PROBABILITIES OF TRANS-LOCATED MISMATCHES FOR HLA LOSS RELAPSE RISKS AFTER HCT: INTRODUCING THE HLA HAPLOTYPE MATCH CALCULATOR** 08:30 - 08:30
 Jürgen Sauter (Tübingen, Germany)
- P387 **DECISION MAKING IN HEMATOPOIETIC STEM CELL UNRELATED DONOR SEARCH** 08:30 - 08:30
 Yuval Nov (Haifa, Israel)

ePoster

08:30 - 18:00

R18

Immunodeficiency Diseases and Macrophages

- B318 **CLINICAL OUTCOME AND QUALITY OF LIFE IN PATIENTS WITH ARPC1B-DEFICIENCY MANAGED CONSERVATIVELY OR WITH ALLOGENEIC STEM CELL TRANSPLANTATION ON BEHALF OF INBORN ERRORS WORKING PARTY** 08:30 - 08:30
 Maura Faraci (Genova, Italy)
- B319 **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR VERY EARLY-ONSET INFLAMMATORY BOWEL DISEASE CAUSED BY INTERLEUKIN-10 RECEPTOR DEFICIENCY** 08:30 - 08:30
 Ping Wang (Shanghai, China)
- B320 **POST-TRANSPLANT AUTOIMMUNE DISORDERS IN PATIENTS TRANSPLANTED FOR PRIMARY IMMUNODEFICIENCY OR IMMUNE DYSREGULATION** 08:30 - 08:30
 Hannah Lust (Chicago, United States of America (the))
- B321 **EXPERIENCE WITH T-CELL DEPLETED ALLOGENEIC HSCT FOR REFRACTORY SJIA ASSOCIATED WITH LUNG DISEASE** 08:30 - 08:30
 Eleanor Cook (Cincinnati, United States of America (the))
- B322 **NEWBORN SCREENING SAVES LIVES, AND OTHER LESSONS LEARNED FROM ONE HUNDRED TRANSPLANTS IN SCID** 08:30 - 08:30
 Etai Adam (Ramat Gan, Israel)
- B323 **TREOSULFAN-BASED CONDITIONING REGIMEN WITH PLERIXAFOR AND G-CSF BEFORE TCRAB+/CD19+ GRAFT DEPLETED HSCT IN WISKOTT-ALDRICH SYNDROME PATIENTS: AN UPDATE OF 8 YEARS' EXPERIENCE** 08:30 - 08:30
 Evelina Lyudovskikh (Moscow, Russian Federation (the))
- B324 **EXCELLENT SURVIVAL AFTER ALLO-HSCT FROM ANY DONOR SOURCE IN SCREENED SCID PATIENTS - A SINGLE CENTER ANALYSIS** 08:30 - 08:30
 Kajetan Trojovsky (Düsseldorf, Germany)
- B325 **IMPROVED SURVIVAL AFTER ALLOGENEIC HSCT IN SCID PATIENTS AFTER INTRODUCTION OF NEWBORN SCREENING IN RUSSIA** 08:30 - 08:30
 Alexandra Laberko (Moscow, Russian Federation (the))
- B326 **IMPACT OF MIXED CHIMERISM ON DISEASE CONTROL IN PATIENTS WITH INBORN ERRORS OF IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
 Alexandra Laberko (Moscow, Russian Federation (the))

B327	EXPANDING THE LANDSCAPE OF INBORN ERRORS OF IMMUNITY IN HEMATOLOGICAL DISORDERS: A PROSPECTIVE STUDY ON HIDDEN IEI AND IEI PHENOCOPIES Eleonora Gambineri (Florence, Italy)	08:30 - 08:30
B328	THE JANUS KINASE INHIBITOR RUXOLITINIB RESOLVED RECURRENT CNS DISEASE POST-HEMATOPOIETIC STEM CELL TRANSPLANT IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS Yue Song (Suzhou, China)	08:30 - 08:30
B330	SECOND ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH INBORN ERRORS OF IMMUNITY Vedat Uygun (Istanbul, Turkey)	08:30 - 08:30
B331	ALLOPLUS: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV), UPDATE OF A RETROSPECTIVE STUDY OF THE SFGM TC Ana Berceanu (Reims, France)	08:30 - 08:30
B332	CLINICAL EFFICACY AND SAFETY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TREATING X-LINKED AGAMMAGLOBULINEMIA Jun Li Zhu (Beijing, China)	08:30 - 08:30
B335	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN FOR PRIMARY IMMUNE DEFICIENCIES: THE EXPERIENCE OF SINGLE CENTER Ilgen Sasmaz (Adana, Turkey)	08:30 - 08:30
B336	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR WISKOTT-ALDRICH SYNDROME - A REPORT FROM INDIA Satya Prakash Yadav (Gurgaon, India)	08:30 - 08:30
B337	HSCT IN CHILDREN WITH INBORN ERRORS OF IMMUNITY: A SINGLE-CENTER EXPERIENCE FROM SOUTHERN INDIA Sagar Bhattad (Bangalore, India)	08:30 - 08:30
B338	THE IMPACT OF PRE-TRANSPLANT COMORBIDITIES AND IMMUNE RECONSTITUTION ON HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN CHILDREN WITH INBORN ERRORS OF IMMUNITY Rafaella Muratori (Curitiba, Brazil)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		R18
Chronic Leukaemia and Other Myeloproliferative Disorders		
A364	DASATINIB AS TARGETED THERAPY FOR POST-TRANSPLANT EXTRAMEDULLARY RELAPSE. AN OBSERVATIONAL STUDY Isabel Cunningham (New York, United States of America (the))	08:30 - 08:30
P359	MUTANT SRSF2P95H SYNERGIZES WITH ONCOGENIC NRAS TO UPREGULATE EBP50 NETWORK AND PROMOTE AML Yubin Feng (Hefei, China)	08:30 - 08:30
P360	OUTCOMES OF HSCT IN CHRONIC MYELOID LEUKEMIA FROM LOW AND MIDDLE INCOME COUNTRY : A PAKISTAN BLOOD AND MARROW TRANSPLANT GROUP STUDY Saima Humayun Toor (Rawalpindi, Pakistan)	08:30 - 08:30
P361	AUTOLOGOUS HSCT ACTIVITIES IN THE ERA OF IEC THERAPY: REPORT FROM A SINGLE CENTER	08:30 - 08:30

	Sabrina Giammarco (Rome, Italy)	
P362	TRANSPLANT PRACTICE AND OUTCOMES FOR MYELODYSPLASTIC/MYELOPROLIFERATIVE OVERLAP NEOPLASMS (MDS/MPN) IN NORTH WEST ENGLAND Daniel Wiseman (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P363	TARGETING AUTOPHAGY AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME BCR-ABL-DEPENDENT AND -INDEPENDENT IMATINIB RESISTANCE THROUGH THE INHIBITION OF HISTONE DEACETYLASES Eun Sun Yoo (Seoul, Korea (the Republic of))	08:30 - 08:30
P364	THE OUTCOMES OF ALLOGENEIC TRANSPLANTATION IN MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS, A SINGLE CENTRE EXPERIENCE Marketa Stastna Markova (Praha 2, Czechia)	08:30 - 08:30
P365	OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOMONOCYTIC LEUKEMIA: INSIGHTS FROM THE LATIN AMERICA REGISTRY Fernando Barroso Duarte (Fortaleza, Brazil)	08:30 - 08:30
P366	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER FAILURE-INTOLERANCE TO SEVERAL TIROSIN KINASE INHIBITORS AND PONATINIB. EXPERIENCE OF ONE CENTER Amado Karduss-Urueta (Medellin (Ant), Colombia)	08:30 - 08:30
P367	ALLOGENEIC TRANSPLANTATION IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA Isabel Izquierdo (Zaragoza, Spain)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Multiple Myeloma		
A347	EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER RECEIVING CAR-T THERAPY: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA Martin Vogel (Neuss, Germany)	08:30 - 08:30
A348	MULTICENTER PROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF DARATUMUMAB INCLUDED IN A MELPHALAN 200 MG/M2 CONDITIONING REGIMEN IN PATIENTS WITH PLASMA CELL MYELOMA (PM) Denis Fedorenko (Moscow, Russian Federation (the))	08:30 - 08:30
A349	ANALYSIS OF DIFFERENT MODALITIES OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE PROVINCE OF GRANADA (SPAIN) Manuel Jurado Chacón (Granada, Spain)	08:30 - 08:30
A350	IMPROVED SURVIVAL IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT Victor Wei Teik Ling (Singapore, Singapore)	08:30 - 08:30
A351	AN ANALYSIS OF REAL-WORLD MEDICAL HISTORY, CILTACABTAGENE AUTOLEUCEL PRODUCT CHARACTERISTICS, AND PATIENT OUTCOMES Raphaëlle Parker (New Brunswick, United States of America (the))	08:30 - 08:30
A352	EXPLORATORY MULTIVARIABLE ANALYSES SHOW DIFFERENTIAL IMPACT OF DUFFY GENOTYPE ON PROGRESSION-	08:30 - 08:30

	FREE SURVIVAL (PFS) WITH LENALIDOMIDE-BORTEZOMIB-DEXAMETHASONE (RVD) ALONE OR RVD+ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)	
	Lauren E. Merz (Boston, United States of America (the))	
A353	DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: A POOLED ANALYSIS OF PATIENTS AGED \geq65 YEARS FROM PERSEUS AND GRIFFIN STUDIES	08:30 - 08:30
	Roberto Mina (Torino, Italy)	
A354	IMPACT OF DIFFERENT TREATMENT AND DISEASE CHARACTERISTICS ON ACHIEVING MINIMAL RESIDUAL DISEASE NEGATIVITY AFTER AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA	08:30 - 08:30
	Ana Pilar Gonzalez-Rodriguez (Oviedo, Spain)	
A355	AHSCT WITH NON-CRYOPRESERVED COMPARED TO CRYOPRESERVED HPSC YIELDS FASTER NEUTROPHIL ENGRAFTMENT AND LESS TRANSFUSION NEED AMONG PATIENTS WITH MULTIPLE MYELOMA	08:30 - 08:30
	Ramazan Öcal (Ankara, Turkey)	
A356	LENALIDOMIDE VS NO MAINTENANCE IN MULTIPLE MYELOMA POST-AUTOLOGOUS TRANSPLANT IN A REAL WORLD SETTING: A PROPENSITY SCORE MATCHING ANALYSIS IN A COHORT FROM LATAM	08:30 - 08:30
	Cristobal Frutos-Ortiz (Asuncion, Paraguay)	
A357	COMBINED MINIMAL RESIDUAL DISEASE EVALUATION IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION TO IMPROVE OUTCOME PREDICTION: BONE MARROW AND APHERESIS SAMPLES ANALYSIS	08:30 - 08:30
	Ludovica Pengue (Florence, Italy)	
A359	A SINGLE-CENTER EXPERIENCE OF ALLOGENEIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA OVER A PERIOD OF 20 YEARS	08:30 - 08:30
	Tim Mayer (Würzburg, Germany)	
A360	STRESS-INDUCED MITOPHAGY AND MITOCHONDRIAL DYSFUNCTION DRIVE NK CELL IMMUNE IMPAIRMENT IN MULTIPLE MYELOMA	08:30 - 08:30
	Katia Beider (Ramat Gan, Israel)	
A361	TREATMENT ATTRITION IN MYELOMA PATIENTS IN FINLAND: A REAL-WORLD STUDY	08:30 - 08:30
	Anu Partanen (Kuopio, Finland)	
A362	UP-FRONT AUTOLOGOUS TRANSPLANTATION IN STANDARD-RISK MULTIPLE MYELOMA: NO NEED FOR CRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS	08:30 - 08:30
	Ahmad Ibrahim (Beirut, Lebanon)	
P336	OUTCOMES OF TANDEM AUTOGRAFTS IN HIGH-RISK MYELOMA PATIENTS TRANSPLANTED AT A SINGLE CENTRE	08:30 - 08:30
	Jenny Byrne (Nottingham, United Kingdom of Great Britain and Northern Ireland (the))	
P337	FACTORS AFFECTING LONG-TERM DISEASE-FREE REMISSION IN PATIENTS OF MULTIPLE MYELOMA UNDERGOING SINGLE AUTOLOGOUS STEM CELL TRANSPLANT	08:30 - 08:30
	Sumeet Mirgh (Mumbai, India)	
P338	THE ROLE OF AUTOTRANSPLANTATION IN MULTIPLE MYELOMA IN THE AGE OF NEW DRUGS: A MULTICENTRIC RETROSPECTIVE	08:30 - 08:30

	ANALYSIS	
	Diana Marina Fortoes (Iasi, Romania)	
P339	HIGH-DOSE ERYTHROPOIETIN IMPROVES SURVIVAL IN MULTIPLE MYELOMA ASSOCIATED ANEMIA: A 15 YEARS SINGLE-CENTER AMBISPECTIVE COHORT STUDY	08:30 - 08:30
	Xinyu Xue (Chengdu, China)	
P340	30 YEARS OF AUTOGRAFTS FOR PATIENTS WITH PLASMA CELL DISORDERS IN A DGH SETTING AT THE ROYAL UNITED HOSPITAL BATH	08:30 - 08:30
	Josephine Crowe (Bath, United Kingdom of Great Britain and Northern Ireland (the))	
P341	CAR-TAL: GPRC5D AS A TARGET-SWITCHING TOOL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER BCMA-DIRECTED CAR-T CELL THERAPY - A RETROSPECTIVE, SINGLE-CENTER ANALYSIS	08:30 - 08:30
	Anca-Maria Albici (Kiel, Germany)	
P342	IMPACT OF DARATUMUMAB-BASED REGIMEN ON PNEUMONIA RISK IN TE-NDMM TREATED WITH D-VTD FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT: A MONOCENTRIC EXPERIENCE	08:30 - 08:30
	Ludovica Pengue (Florence, Italy)	
P343	IMPACT OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA AT THE NATIONAL CANCER INSTITUTE OF PERU	08:30 - 08:30
	Jule Vasquez (Lima, Peru)	
P345	SECOND AUTOLOGOUS TRANSPLANT AS AN OPTION FOR RELAPSED MULTIPLE MYELOMA. A SINGLE-CENTER EXPERIENCE IN URUGUAY	08:30 - 08:30
	Sebastian Galeano (Montevideo, Uruguay)	
P347	ANALYSIS OF THE HISTORICAL COHORT OF PATIENTS WITH MULTIPLE MYELOMA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Joud Zanabali Al-Sibai (Oviedo, Spain)	
P348	TALQUETAMAB IS AN EFFECTIVE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH PRIOR ALLOGENEIC STEM CELL TRANSPLANTATION: A TWO CASES REPORT	08:30 - 08:30
	Michele Wieczorek (Vicenza, Italy)	
P349	ALLOGENEIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA IN MALAYSIA -A SINGLE CENTRE EXPERIENCE	08:30 - 08:30
	Khaiteri Raghunathan (Ampang, Malaysia)	
P350	OUTCOMES OF COST-EFFECTIVE AUTOLOGOUS STEM CELL TRANSPLANT IN INDIAN PATIENTS -A RETROSPECTIVE STUDY	08:30 - 08:30
	Perraju Bhaskar Bhuvan Lagudu (Visakhapatnam, India)	
P351	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA IN KAZAKHSTAN: 10-YEAR SINGLE-CENTER EXPERIENCE	08:30 - 08:30
	Olga Kolesnikova (Astana, Kazakhstan)	
P352	OUTCOMES OF STEM CELL TRANSPLANTATION FROM A TIER 2 CITY IN LOWER MIDDLE INCOME COUNTRIES- A RETROSPECTIVE STUDY FROM A SINGLE CENTRE IN SOUTH INDIA	08:30 - 08:30
	Perraju Bhaskar Bhuvan Lagudu (Visakhapatnam, India)	
P353	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30

IN FILIPINO PATIENTS WITH MULTIPLE MYELOMA IN TWO PRIVATE TERTIARY HOSPITALS IN THE PHILIPPINES: A CASE SERIES

Tonee Ann Abella (Taguig, Philippines (the))

ePoster

08:30 - 18:00

R18

Pharmacology

- P443 **CYCLOSPORIN PHARMACOKINETICS FOR PAEDIATRIC PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
Iek Cheng (London, United Kingdom of Great Britain and Northern Ireland (the))
- P444 **AN EVALUATION OF A CLINICAL PHARMACY PRE-ADMISSION REVIEW SERVICE FOR PATIENTS UNDERGOING CAR-T CELL THERAPY** 08:30 - 08:30
Vaishali Dulobdas (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))
- P445 **DELAYED ACHIEVEMENT OF TARGET EXPOSURE WITH STANDARD CYCLOSPORINE DOSING PROTOCOLS IN CHILDREN UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT** 08:30 - 08:30
Tareq Artul (Haifa, Israel)
- P446 **SEIZURE PROPHYLAXIS WITH CAR-T PRODUCTS - A SURVEY OF UK PRACTICE** 08:30 - 08:30
Patrycja Kopec (Glasgow, United Kingdom of Great Britain and Northern Ireland (the))
- P447 **THE CYTOMEGALOVIRUS VIRAL LOAD SPIKE AFTER LETERMOVIR USE IN ASIAN PATIENTS** 08:30 - 08:30
Tsung-Yu Pai (Taipei, Taiwan (Province of China))
- P448 **DESENSITISATION PROGRAMMES - PHARMACY INVOLVEMENT IN CHILDREN PRESENTING WITH ALLERGIES HAVING AN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT** 08:30 - 08:30
Helen Young (Newcastle Upon Tyne, United Kingdom of Great Britain and Northern Ireland (the))
- P449 **THE PHARMACY WORKFORCE FOR ADULT ALLOGENEIC STEM CELL TRANSPLANT (SCT) AND ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) SERVICES: A NATIONAL BENCHMARKING SURVEY** 08:30 - 08:30
Elizabeth Davies (Manchester, United Kingdom of Great Britain and Northern Ireland (the))
- P450 **HIGH THROUGHPUT IMAGING OF SPHEROIDS FOR THE IN VITRO STUDY OF DRUG-DRUG INTERACTIONS IN CONDITIONING REGIMENS** 08:30 - 08:30
Yvonne Gloor (Geneva, Switzerland)
- P451 **FREQUENCY AND RISK OF DRUG-DRUG INTERACTIONS WITH LETERMOVIR DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A REAL-LIFE ASSESSMENT STUDY** 08:30 - 08:30
Nicolas Simon (Lille, France)
- P452 **EFFECT OF MAJOR LIVER GST ENZYMES ON HEPATIC CELLS' RESPONSE TO CONDITIONING DRUGS USED IN HEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
Vid Mlakar (Geneva, Switzerland)
- P453 **AN AUDIT ON THE INCIDENCE OF HYPOGAMMAGLOBULINEMIA AND INITIATION OF IMMUNOGLOBULIN REPLACEMENT IN MULTIPLE MYELOMA PATIENTS RECEIVING BISPECIFIC ANTIBODY TREATMENT** 08:30 - 08:30
Simran Kaur Dhadda (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))
- P454 **CLINICAL PRACTICE-ORIENTED TRAINING MODEL FOR** 08:30 - 08:30

	HEMATOLOGY SPECIALIST CLINICAL PHARMACISTS: EXPERIENCES FROM A HEMATOLOGY CENTER IN CHINA	
	Mi Zhou (Suzhou, China)	
P456	EFFICACY AND SAFETY OF LETERMОВIR IN THE PROPHYLAXIS OF CYTOMEGALOVIRUS IN HEMATOPOIETIC-CELL TRANSPLANTATION - A SINGLE CENTER EXPERIENCE	08:30 - 08:30
	Vera Pires (Lisboa, Portugal)	
<i>ePoster</i>		
08:30 - 18:00		R18
Non-infectious Early Complications		
A273	RETROSPECTIVE ANALYSIS OF VENO-OCCLUSIVE DISEASE IN ADULT PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION: EARLY DEFIBROTIDE THERAPY AND PREDICTIVE RISK FACTORS FOR VENO-OCCLUSIVE DISEASE	08:30 - 08:30
	Alfredo Pacheco Reyes (Cordoba, Spain)	
A274	CYTOKINE PROFILING FOR DIFFERENTIATING CYTOKINE RELEASE SYNDROME FROM SEPSIS IN POST T CELL REPLETE HAPLO-HSCT AND CAR-T THERAPY SETTING	08:30 - 08:30
	Shreya Agrawal (Kochi, India)	
A275	RE-EVALUATING VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME ADULT DIAGNOSTIC CRITERIA: CHARACTERISATION OF DEFIBROTIDE-TREATED PATIENTS IN THE DEFIFRANCE REGISTRY	08:30 - 08:30
	Mohamad Mohty (Paris, France)	
A276	ABATACEPT LOWERS ENDOTHELIAL ACTIVATION-RELATED SERIOUS EVENTS IN CHILDREN UNDERGOING ALLOGENEIC TRANSPLANT FOR TRANSFUSION DEPENDENT BETA THALASSEMIA VIA NOVEL MECHANISM OF INHIBITING NEUTROPHIL EXTRACELLULAR TRAPS	08:30 - 08:30
	Pooja Khandelwal (Cincinnati, United States of America (the))	
A277	EASIX AND ENGRAFTMENT SYNDROME AFTER AT-HOME AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOPROFERATIVE DISORDERS	08:30 - 08:30
	María Queralt Salas (Barcelona, Spain)	
A278	IMMUNE CYTOPENIA IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION - HALF MATCH LEADS TO DOUBLE THE TROUBLE	08:30 - 08:30
	Kavitha Ganesan (Chennai, India)	
A279	REAL LIFE MANAGEMENT OF VENO-OCCLUSIVE DISEASE POST ALLOGENEIC TRANSPLANTATION: A NATIONAL SURVEY BY GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO)	08:30 - 08:30
	Giorgia Mancini (Ancona, Italy)	
A280	PRE-TRANSPLANT T-CELL RECEPTOR EXCISION CIRCLES (TRECS) PREDICT CLINICAL OUTCOMES POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Noa G. Holtzman (Miami, United States of America (the))	
A281	EVALUATING THE EFFECT OF ENTERAL NUTRITION ON CLINICAL OUTCOMES AND MICROBIOME DYNAMICS IN HAEMATOPOIETIC TRANSPLANTATION RECIPIENTS	08:30 - 08:30
	Hannah Wardill (Adelaide, Australia)	
A283	SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE	08:30 - 08:30

	Aitana Balaguer Roselló (Valencia, Spain)	
A284	INCONSISTENT PRACTICE PATTERNS OF SGLT2 INHIBITOR USE ACROSS EBMT CELL THERAPY CENTERS: A SURVEY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY Christian Schultze-Florey (Hannover, Germany)	08:30 - 08:30
A285	OUTCOME OF PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC TRANSPLANTATION FROM UNRELATED DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Tel Aviv, Israel)	08:30 - 08:30
A286	FRAILTY SYNDROME AS A DETERMINANT OF ENDOTHELIAL ACTIVATION AND OUTCOMES IN ALLO-HCT PATIENTS María Queralt Salas (Barcelona, Spain)	08:30 - 08:30
A287	CARE BMT RISK SCORE: CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION, A REAL-LIFE EVALUATION Ambra Fumagalli (Milano, Italy)	08:30 - 08:30
A288	TRANSPLANT RELATED HEPATIC DYSFUNCTION AND MORTALITY AFTER MATCHED RELATED DONOR STEM CELL TRANSPLANT IN CHILDREN WITH ACUTE LEUKEMIA PREVIOUSLY TREATED WITH IMMUNOTHERAPY Aaron Ross (Houston, United States of America (the))	08:30 - 08:30
A289	ROOT CAUSE ANALYSIS OF GRAFT FAILURE IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT: A RETROSPECTIVE COHORT STUDY FROM A SINGLE CENTRE Gaurav Kharya (Delhi, India)	08:30 - 08:30
A290	CAN NEW HARMONIZED TA-TMA DIAGNOSTIC CRITERIA DISTINGUISH IT FROM OTHER ENDOTHELIAL INJURY SYNDROMES SUCH AS SOS/VOD? Carlos de Miguel (Madrid, Spain)	08:30 - 08:30
A291	PROGNOSTIC PLASMA BIOMARKERS FOR SINUSOIDAL OBSTRUCTION SYNDROME IN ALLOGENEIC HSCT WITH HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE Mi Kwon (., Spain)	08:30 - 08:30
A292	OUTPATIENT CARE REDUCES COMPLICATIONS IN STEM CELL TRANSPLANTATION Javier Cornago Navascués (Madrid, Spain)	08:30 - 08:30
A293	POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML PATIENTS UNDERGOING ALLO-HCT WITH CARDIAC MORBIDITY: IS IT SAFE? María Queralt Salas (Barcelona, Spain)	08:30 - 08:30
A294	IMPACT OF INOTUZUMAB OZOGAMICIN ON SINUSOIDAL OBSTRUCTION SYNDROME INCIDENCE AND IDENTIFICATION OF RISK FACTORS IN ALLOGENEIC HSCT RECIPIENTS: MATCHED CASE-CONTROL STUDY WITH PROSPECTIVE LABORATORY MONITORING Dmitrii Evstratov (Moscow, Russian Federation (the))	08:30 - 08:30
A295	REAL-WORLD OUTCOME OF DEFIBROTIDE FOR TREATMENT OF ADULT PATIENTS WITH SEVERE HEPATIC VOD/SOS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Jae Ho Yoon (Seoul, Korea (the Republic of))	08:30 - 08:30
A296	CD36 AND CD326/EPCAM EXTRACELLULAR VESICLES MARKERS ASSOCIATED TO PERIPHERAL NEUROPATHY ONSET IN	08:30 - 08:30

	CHILDREN UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	
	Francesca Gottardi (Bologna, Italy)	
A297	ENDOTHELIAL DYSFUNCTION IN PATIENTS BEFORE CELLULAR THERAPY - A PROSPECTIVE OBSERVATIONAL STUDY	08:30 - 08:30
	Laura Simons (Heidelberg, Germany)	
A298	EFFECT OF LUSPATERCEPT ON THE TREATMENT OF ANEMIA IN ALLO-HSCT FOR PATIENTS WITH HEMATOLOGICAL DISEASES	08:30 - 08:30
	Juan Wang (Zhengzhou, China)	
A299	STUDY OF PRIMARY GRAFT FAILURE AFTER A FIRST HSCT IN 10 PEDIATRIC UNITS: DO OUR PATIENTS SURVIVE ONE OF THE MOST FEARED COMPLICATIONS?	08:30 - 08:30
	Melissa Panesso (Barcelona, Spain)	
A300	HEMORRHAGIC CYSTITIS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN: A SINGLE PEDIATRIC CENTER EXPERIENCE	08:30 - 08:30
	Pauline Mazilier (Bruxelles, Belgium)	
A301	IDENTIFICATION OF VOD/SOS AND TMA RISK FACTORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE	08:30 - 08:30
	Aser Alonso (Palma, Spain)	
A302	CORTICAL BLINDNESS AND PROGRESSIVE TETRAPARESIS UNDER IMMUNOSUPPRESSION WITH THE CALCINEURIN INHIBITOR CICLOSPORIN A AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Anna Ruckdeschel (Würzburg, Germany)	
A303	A PROINFLAMMATORY TH1/TC1 ENVIRONMENT AND CYTOLYTIC ACTIVITY MEDIATE EARLY PULMONARY ENDOTHELIAL CELL (EC) APOPTOSIS AND DRIVE THE DEVELOPMENT OF EXPERIMENTAL IDIOPATHIC PNEUMONIA SYNDROME	08:30 - 08:30
	Kenneth Cooke (Baltimore, United States of America (the))	
A304	INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF TOXIC EPIDERMAL NECROLYSIS AND ACUTE GRAFT VERSUS HOST DISEASE OF THE SKIN IN A PEDIATRIC COHORT	08:30 - 08:30
	April Rahrig (Indianapolis, United States of America (the))	
A305	INCREASED FREQUENCY OF ENGRAFTMENT SYNDROME FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WHO RECEIVED NIVOLUMAB-CONTAINING SALVAGE THERAPY	08:30 - 08:30
	Aikaterini Benekou (Athens, Greece)	
A306	SAFETY AND EFFICACY OF ROMIPLOSTIM FOR THE TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Yunchao Su (Beijing, China)	
A307	VON WILLEBRAND FACTOR (VWF) AND ENDOTHELIAL DYSFUNCTION SYNDROMES FOLLOWING PEDIATRIC HSCT	08:30 - 08:30
	Denise Horan (Copenhagen OE, Denmark)	
P170	ERYTHROBLASTEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IS ASSOCIATED WITH DECREASED RELAPSE FREE SURVIVAL IN A CONTEMPORARY COHORT	08:30 - 08:30
	Sae Ushio (Yamagata, Japan)	
P171	DETERMINANTS OF TREATMENT OUTCOMES IN HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVE	08:30 - 08:30

	DISEASE IN ADULTS: A MULTICENTER RETROSPECTIVE STUDY BY THE POLISH ACUTE LEUKEMIA GROUP Patrycja Mensah-Glanowska (Kraków, Poland)	
P172	POORER SURVIVAL IN PATIENTS UNDERGOING APLASIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION DURING SUMMER Anders Eivind Myhre (Oslo, Norway)	08:30 - 08:30
P173	CURRENT TRENDS IN VENO-OCCLUSIVE DISEASE IN ADULT ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS James Dillon (Dublin 8, Ireland)	08:30 - 08:30
P175	UGT1A1 POLYMORPHISM AND TOXICITY RELATED TO ALLOGENEIC STEM CELL TRANSPLANTATION WITH BUSULFAN BASED REGIMEN Sabrina Giammarco (Rome, Italy)	08:30 - 08:30
P176	PLATELET REQUIREMENTS IN TWO STANDARDIZED AUTOLOGOUS STEM CELL TRANSPLANTATION PLATFORMS: TIME TO THINK ABOUT THROMBOPOIETIN AGONISTS? Beatrice Polito (Pisa, Italy)	08:30 - 08:30
P177	TWO CASES OF ISOLATED RENAL THROMBOTIC MICROANGIOPATHIES (TMA) POST HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) Megan Athersmith (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P178	OUTCOMES OF HEPATIC VENO-OCCLUSIVE DISEASE TREATMENT WITH N-ACETYLCYSTEINE IN ADULTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING REFINED EBMT CRITERIA 2023 Chantiya Chanswangphuwana (Bangkok, Thailand)	08:30 - 08:30
P179	LOW LEVELS OF INSULIN-LIKE GROWTH FACTOR-I ARE ASSOCIATED WITH INCREASED ENDOTHELIAL DAMAGE DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Maria Ebbesen Sørum (Copenhagen, Denmark)	08:30 - 08:30
P181	SUCCESSFUL POTENT REDUCTION OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES USING IMLIFIDASE IN A PATIENT UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION Li Yuan Chan (Sutton, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P183	ASSESSMENT OF NUTRITIONAL RISK IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION AND ITS ASSOCIATION WITH CHANGES IN PECTORAL MUSCLE DENSITY Sinem Civriz Bozdog (Istanbul, Turkey)	08:30 - 08:30
P185	BEVACIZUMAB FOR THE TREATMENT OF DIFFUSE GASTROINTESTINAL BLEEDING DUE TO SEVERE VENO-OCCLUSIVE DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Lydia Bussemer (Wuerzburg, Germany)	08:30 - 08:30
P186	THE CHARACTERISTICS AND IMPACT OF PERI-TRANSPLANT DIARRHEA IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION Panarat Noiperm (Hat Yai, Thailand)	08:30 - 08:30
P187	PRE-HSCT NUTRITIONAL SUPPORT AND ITS IMPACT ON POST-HSCT NUTRITIONAL OUTCOME Domas Vaitiekus (Kaunas, Lithuania)	08:30 - 08:30
P188	SUCCESSFUL ALLOGENIC STEM CELL TRANSPLANTATION IN HIGHLY HLA-IMMUNIZED PATIENT AND PRE-TREATMENT WITH	08:30 - 08:30

	RITUXIMAB FOLLOWED BY BORTEZOMIB AND DARATUMUMAB Martina Crysandt (Aachen, Germany)	
P189	EARLY DIAGNOSIS AND OUTCOMES OF VENO-OCCLUSIVE DISEASE IN CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE SERIES REPORT Thanh Liem Nguyen (Hanoi, Viet Nam)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Myelodysplastic Syndromes		
B356	OUTCOME OF PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MDS/MPN OVERLAP SYNDROMES - A REAL WORLD ANALYSIS ACROSS 12 CENTERS IN GERMANY Marek Werth (Frankfurt am Main, Germany)	08:30 - 08:30
B357	VALIDATION OF MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM FOR POST-TRANSPLANT PROGNOSIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION 2022 Yiming Cai (Suzhou, China)	08:30 - 08:30
B358	SEQUENTIAL FLAMSA-FB CONDITIONING IMPROVES PFS IN UNTREATED MDS PATIENTS UNDERGOING ALLOGENEIC HSCT COMPARED TO ALTERNATIVE REGIMENS Radwan Massoud (Hamburg, Germany)	08:30 - 08:30
B359	OUTCOMES OF ALLO-HCT PERFORMED WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED PROPHYLAXIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME. STUDY CONDUCTED ON BEHALF OF GETH-TC María Queralt Salas (Barcelona, Spain)	08:30 - 08:30
B360	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME ASSOCIATED WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - A STUDY ON BEHALF OF THE CMWP AND SAAWP OF THE EBMT Joanna Drozd-Sokolowska (Warsaw, Poland)	08:30 - 08:30
B362	INFLUENCE OF MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-M) STRATIFICATION ON BONE MARROW TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME(MDS): LATIN AMERICAN REGISTRY Fernando Barroso Duarte (Fortaleza, Brazil)	08:30 - 08:30
P356	10 YEARS OF EXPERIENCE WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OF MYELODYSPLASTIC NEOPLASMS: PREVENTION OF RELAPSE WITH AZACITIDINE László Gopcsa (Budapest, Hungary)	08:30 - 08:30
P357	ACCELERATION OF RECOVERY FROM LIFE-THREATENING MYELOSUPPRESSION AND ENHANCED ANTI-TUMOR EFFECTS IN ELDERLY PATIENTS WITH AML/MDS VIA UMBILICAL CORD BLOOD INFUSION Yuntian Ding (Shenzhen, China)	08:30 - 08:30
P358	SUCCESSFUL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR A PATIENT WITH VEXAS AND MYELODYSPLASTIC SYNDROMES Larisa Kuzmina (Moscow, Russian Federation (the))	08:30 - 08:30

ePoster

08:30 - 18:00

R18

CAR-based Cellular Therapy - Clinical

A082	THE OPTIMIZED HINGE CD19/20 CAR-T SHOWED DURABLE EFFICACY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA: INTERIM RESULTS FROM A MULTICENTER PHASE I/II TRIAL Jia Wei (Wuhan, China)	08:30 - 08:30
A083	THE ROLE OF FUNCTIONAL RESPIRATORY TESTS IN PRE-CAR T-CELL THERAPY SCREENING: NECESSITY OR REDUNDANCY? Giulia Losi (Pavia, Italy)	08:30 - 08:30
A085	EDITED ALLOGENEIC BCMA-CAR NK CELLS AS INNOVATIVE THERAPEUTIC CONCEPT FOR MULTIPLE MYELOMA Evelyn Ullrich (Frankfurt, Germany)	08:30 - 08:30
A086	PROLONGED CAR-T CELL EXPANSION AND STEMNESS IN HEAVILY PRETREATED RELAPSED/REFRACTORY B-ALL AND B-NHL PATIENTS TREATED WITH PSU CD19CAR INCORPORATED CD28/CD40 CO-STIMULATORY MOLECULE: A PRELIMINARY OUTCOME Jakrawadee Julamanee (Hat Yai, Thailand)	08:30 - 08:30
A087	ANALYSIS OF RESIDUAL CELLULAR AND HUMORAL VACCINE RESPONSE IN PATIENTS TREATED WITH ANTI-CD19 CAR-T CELLS Ana Llorens (Nantes, France)	08:30 - 08:30
A088	MOLECULAR TUMOR BURDEN AND CLONAL DYNAMICS ARE ASSOCIATED WITH TREATMENT FAILURE RISK IN LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH CAR-T CELL THERAPY Mariana Bastos Oreiro (Madrid, Spain)	08:30 - 08:30
A089	COMPARING T-CELL PHENOTYPE OF CD28 VS 4-1BB CD19 SPECIFIC CAR T-CELLS IN B-ALL PATIENTS Alexandre G. Troullioud Lucas (New York, United States of America (the))	08:30 - 08:30
A090	CAR-T CELL DYNAMICS AND MYELOID-CELL ALTERED PROFILE ARE ASSOCIATED WITH CLINICAL OUTCOME IN ANTI-CD19 CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL MALIGNANCIES: A REAL-LIFE COHORT STUDY Edoardo Campodonico (Milan, Italy)	08:30 - 08:30
A091	A RETROSPECTIVE STUDY OF RECIPIENT-DERIVED VERSUS DONOR-DERIVED CAR-T CELL THERAPY IN RELAPSED B-ALL PATIENTS AFTER TRANSPLANTATION Xiaoqi Wang (ChongQing, China)	08:30 - 08:30
A092	THE CD62L⁺ PROPORTION AND CD4/CD8 RATIO OF BCMA-CART PRODUCTS AS A PROGNOSTIC INDICATOR FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Longyuan Wu (Hangzhou, China)	08:30 - 08:30
A093	SIX-YEAR FOLLOW-UP INDICATES THE CURATIVE POTENTIAL OF COCKTAIL CAR-T OR IN COMBINATION WITH ASCT IN TP53-ALTERED RELAPSED/REFRACTORY B-NHL Jia Wei (Wuhan, China)	08:30 - 08:30
A094	HIGHER DOSES OF FLUCY LYMPHODEPLETION IN HIGH-RISK PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL) TREATED WITH TISAGENLEUCEL ARE ASSOCIATED WITH HIGHER CAR-T EXPANSION AND BETTER RESPONSE Marta Canelo-Vilaseca (Paris, France)	08:30 - 08:30
A095	DECIPHERING THE COMPLEX INTERTWINING BETWEEN	08:30 - 08:30

	CYTOPENIA AND TRANSFUSION NEEDS AFTER CAR T-CELL THERAPY FOR B-CELL MALIGNANCIES	
	Luciana Teofili (Rome, Italy)	
A097	PATIENTS WITH NON-REMISSION AT LYMPHODYPLETING CHEMOTHERAPY AND SEVERE CYTOKINE RELEASE SYNDROME AFTER TREATMENT WITH TISAGENLEUCEL SHOW HIGH RATES OF CD19-NEGATIVE RELAPSES AND POOR SURVIVAL	08:30 - 08:30
	Martin Hutter (Frankfurt am Main, Germany)	
A098	AUTOLOGOUS STEM CELL TRANSPLANTATION COMBINED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR REFRACTORY/RELAPSED B-CELL LYMPHOMA: SALVAGE THERAPY VS. CONSOLIDATION THERAPY	08:30 - 08:30
	Fan Yang (Beijing, China)	
A099	BCMA/CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ANTI-HLA ANTIBODY SENSITIZATION IN PATIENTS WITH ACUTE LEUKEMIA: A PILOT CLINICAL STUDY	08:30 - 08:30
	Houli Zhao (Hangzhou, China)	
A100	NOVEL SIGNATURE OF BASELINE INFLAMMATION IDENTIFIES PATIENTS AT HIGH RISK OF RELAPSE AFTER BCMA CAR-T IN MULTIPLE MYELOMA	08:30 - 08:30
	Eugene Brailovski (New York City, United States of America (the))	
A102	EFFICACY AND SAFETY OF CAR-T CELL THERAPY IN B-ALL PATIENTS PREVIOUSLY TREATED WITH BLINATUMOMAB	08:30 - 08:30
	Yurou Chu (Suzhou, China)	
A103	DISTINCT EXPANSION, PHENOTYPE, FUNCTION, AND TOXICITY OF CILTA-CEL VS. IDE-CEL CAR T CELLS IN THE REAL WORLD	08:30 - 08:30
	Djordje Atanackovic (Baltimore, United States of America (the))	
A104	CD19.CAR-T CELL THERAPY FOR PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS OR RHEUMATOID ARTHRITIS	08:30 - 08:30
	Michael Schmitt (Heidelberg, Germany)	
A105	VIRAL REACTIVATION IN MULTIPLE MYELOMA PATIENTS RECEIVING ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY	08:30 - 08:30
	Shlomo Elias (Jerusalem, Israel)	
A106	CAR-T CELL RECEPTOR ASSOCIATED TREMOR - AN OBSERVATIONAL STUDY	08:30 - 08:30
	Sara Lozano Cerrada (London, United Kingdom of Great Britain and Northern Ireland (the))	
A108	CLINICAL OUTCOMES OF PATIENTS WITH LYMPHOID BLASTIC PHASE OF CHRONIC MYELOID LEUKEMIA TREATED WITH CAR T-CELL THERAPY: A MULTICENTER REAL WORLD STUDY	08:30 - 08:30
	Yujie Liu (Suzhou, China)	
A109	LYMPHODEPLETION WITH SINGLE AGENT BENDAMUSTINE PRIOR TO CAR T-CELL THERAPY IN PATIENTS WITH IMPAIRED RENAL FUNCTION	08:30 - 08:30
	Georg-Nikolaus Franke (Leipzig, Germany)	
A110	UNLOCKING THE ROLE OF CRP AND IL-10 SERUM LEVELS ON CAR-T CELL THERAPY OUTCOME. A SINGLE CENTRE EXPERIENCE	08:30 - 08:30
	Ilaria Cutini (Florence, Italy)	
A111	ELECTROENCEPHALOGRAM FEATURES IN PATIENTS WITH IMMUNE EFFECTOR-CELL ASSOCIATED NEUROTOXICITY SYNDROME (ICANS): A MONOCENTRIC EXPERIENCE	08:30 - 08:30

	Michele Wieczorek (Vicenza, Italy)	
A112	CLINICALLY SIGNIFICANT HYPOFIBRINOGENEMIA AS A FREQUENT ADVERSE EVENT IN CAR-T-CELL THERAPY RECEPTORS WITH CYTOKINE RELEASE SYNDROME Maria Huguet (Badalona, Spain)	08:30 - 08:30
A113	ANALYSIS OF MAJOR ADVERSE CARDIAC EVENTS (MACE) AND SURVIVAL OUTCOMES BY CAR-T SUBTYPE: CD-19 VERSUS BCMA DIRECTED THERAPY IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS Anup Kumar Trikannad Ashwini Kumar (Little Rock, United States of America (the))	08:30 - 08:30
A114	INITIAL ANALYSIS OF TISAGENLEUCEL THERAPY USING FORMSNET3 IN JAPAN: REAL-WORLD EFFICACY AND SAFETY IN PEDIATRIC AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA Itaru Kato (Kyoto, Japan)	08:30 - 08:30
A115	SINGLE-CELL TRANSCRIPTOMICS UNCOVERS THE IMPACT OF IMMUNE RECONSTITUTION DYNAMICS ON EBV/CMV REACTIVATION IN RELAPSED/REFRACTORY T-ALL/LBL PATIENTS TREATED WITH AUTOLOGOUS NANOBODY-DERIVED FRATRICIDE-RESISTANT CD7 CAR-T THERAPY Meng Lv (Beijing, China)	08:30 - 08:30
A116	THE PATIENT JOURNEY AND TREATMENT OUTCOMES COMPARING INPATIENT VERSUS OUTPATIENT AXICABTAGENE CILOLEUCEL IN NON-HODGKIN'S LYMPHOMA (NHL) - A LARGE, MULTICENTER STUDY Minoo Battiwalla (Nashville, United States of America (the))	08:30 - 08:30
A117	CLINICAL RESOLUTION OF AUTOIMMUNE CHOROIDITIS AND MULTIORGAN INVOLVEMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT TREATED WITH CD19CAR-T INCORPORATED CD28/CD40 SIGNALING MOLECULES Jakrawadee Julamanee (Hat Yai, Thailand)	08:30 - 08:30
A118	EASIX SCORE AS PREDICTOR FOR SURVIVAL OUTCOMES AFTER ANTI-CD19 CAR-T CELL THERAPY: A STUDY ON BEHALF OF THE GRUPO ESPAÑOL DE TRASPLANTE Y TERAPIA CELULAR Alberto Mussetti (Barcelona, Spain)	08:30 - 08:30
A119	SERUM AMYLOID-A (SAA) IS AN OPTIMAL ACUTE PHASE PROTEIN FOR CYTOKINE RELEASE SYNDROME IN CAR-T PATIENTS EXPOSED TO TOCILIZUMAB Eugenio Galli (Rome, Italy)	08:30 - 08:30
A120	FIRST-LINE SALVAGE THERAPIES AFTER ANTI-BCMA CAR-T FAILURE IN PATIENTS WITH MULTIPLE MYELOMA: A META-ANALYSIS OF RESPONSE RATES Jaromir Tomasik (Warsaw, Poland)	08:30 - 08:30
A121	ICANS PREDICTORS IN CAR-T CELL THERAPY: BASELINE CLINICAL, BIOCHEMICAL, AND EEG FINDINGS Eugenio Galli (Rome, Italy)	08:30 - 08:30
A122	LOW DISEASE BURDEN BEFORE CAR-T CELL INFUSION HIGHLY REDUCES THERAPY-RELATED TOXICITIES Paweł Marschollek (Wrocław, Poland)	08:30 - 08:30
A123	INFECTIONS AFTER CAR T-CELL THERAPY WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA Ana Benzaquén (Valencia, Spain)	08:30 - 08:30
A124	DISEASE PATTERNS AND RESOURCE UTILIZATION OF LATE IMMUNE CELL-ASSOCIATED HEMATOLOGIC TOXICITY (ICAHT)	08:30 - 08:30

	AFTER CD19-DIRECTED CAR-T THERAPY Philippe Giguère (Ottawa, Canada)	
A125	IMPACT OF WEIGHT CHANGE ON OUTCOMES AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR B-CELL LYMPHOMAS Shaykhah Alotaibi (Jacksonville, United States of America (the))	08:30 - 08:30
A126	OUTCOMES AFTER CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELLS FOR B-CELL MALIGNANCIES: A SINGLE CENTER EXPERIENCE Giorgia Battipaglia (Naples, Italy)	08:30 - 08:30
A127	THIRD LINE (3L) CAR T-CELL THERAPY IN THE GOLDEN YEARS: A SINGLE-CENTER EXPERIENCE ON OUTCOMES FOR ELDERLY PATIENTS IN LARGE B-CELL LYMPHOMA Majed Altareb (Toronto, Canada)	08:30 - 08:30
A128	IMPORTANCE OF INFLAMMATORY BIOMARKERS ON PREDICTION OF RESPONSE TO CAR-T IN LYMPHOMA PATIENTS Nicolás De Lucas Torres (Oviedo, Spain)	08:30 - 08:30
A130	EXPANDING CAR T-CELL THERAPY BOUNDARIES: DEVELOPING A MIXED OUTPATIENT-AT HOME MODEL Beatriz Merchán Muñoz (Barcelona, Spain)	08:30 - 08:30
A131	ESTABLISHMENT OF THE FIRST PROGRAM FOR LOCAL CD19-CAR-T PRODUCTION AND TREATMENT OF LYMPHOMA IN THE UAE AND GULF REGION Inas El-Najjar (Abu-Dhabi, United Arab Emirates (the))	08:30 - 08:30
A132	SEQUENTIAL BCMA CAR-T CELL THERAPY IS SAFE AND EFFICACIOUS IN REFRACTORY MULTIPLE MYELOMA IN A REAL-WORLD SETTING Philipp Gödel (Cologne, Germany)	08:30 - 08:30
A133	CYTOKINE PROFILE AS A PREDICTOR OF CELLULAR EXPANSION AND ICANS IN CAR-T CELL THERAPY FOR B-CELL LYMPHOMAS Giuseppe Petruzzellis (Udine, Italy)	08:30 - 08:30
A134	USE OF RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IMPROVE THROMBOCYTOPENIA IN CAR-T CELL-TREATED PATIENTS Jia Wei (Wuhan, China)	08:30 - 08:30
P053	AUTOLOGOUS STEM CELL BOOST FOR PROLONGED CYTOPENIA AFTER CAR-T CELL: A SINGLE CENTER EXPERIENCE Michele Wieczorek (Vicenza, Italy)	08:30 - 08:30
P054	THE ROLE OF EEG IN THE PREDICTION AND MANAGEMENT OF IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN CAR-T THERAPY Alice Sumner (Cardiff, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P055	ANTI-CD19 CAR T-CELL THERAPY DURING COVID-19 INFECTION IS FEASIBLE AND SAFE: A SINGLE CENTRE EXPERIENCE OVER TWO YEARS Amrith Mathew (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P056	A BI-CENTER REAL-WORLD DATA OF TISAGENLEUCEL VERSUS ALLOGENEIC HSCT OUTCOMES IN LARGE B-CELL LYMPHOMAS Tong-Yoon Kim (Seoul, Korea (the Republic of))	08:30 - 08:30
P057	IGM RECOVERY AS A SURROGATE OF EFFECTIVENESS AFTER CAR-T THERAPY FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA - A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS	08:30 - 08:30

	Nobuhiro Tsukada (Tokyo, Japan)	
P058	T-CELL IMMUNOPHENOTYPING IN LEUKAPHERESIS PRODUCT APPLIED TO THE USE OF AXICABTAGENE CILOLEUCEL, A REAL-WORLD STUDY Ibrahim Yakoub-Agha (Lille, France)	08:30 - 08:30
P059	IMMUNE CELL-ASSOCIATED HEMATOTOXICITY (ICAH) AFTER CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T): APPLICATION OF THE NEW SCORING SYSTEM ON A SINGLE CENTER SERIES OF PATIENTS Maria Dimitrakoudi (Athens, Greece)	08:30 - 08:30
P060	FROM TUMOR BOARD DECISION TO INFUSION: ARE TIMELINES OF ANTI-CD19 DIRECTED CAR-T CELL THERAPY AFFECTING THE TREATMENT OUTCOME? Sophia Oesterreicher (Vienna, Austria)	08:30 - 08:30
P061	IMPACT OF SARCOPENIA AND CYTOKINES ON CAR T OUTCOMES IN ADULTS WITH R/R DLBCL TREATED WITH TISAGENLECLEUCE Rawan Faramand (Tampa, United States of America (the))	08:30 - 08:30
P063	POINT OF CARE DONOR-DERIVED ANTI-CD19 CAR T-CELLS FOR THE TREATMENT OF CHILDREN WITH CD19+ B-ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS Anna Komitopoulou (Athens, Greece)	08:30 - 08:30
P064	PATIENT JOURNEY FOR CAR-T IN FOLLICULAR LYMPHOMA: A SWOT ANALYSIS Paolo Corradini (Milan, Italy)	08:30 - 08:30
P065	MAPPING THE FIRST MONTH: CAR-T CELL EXPANSION AND TOXICITIES María Perera Álvarez (Las Palmas de Gran Canaria, Spain)	08:30 - 08:30
P066	MAINTENANCE THERAPY POST ANTI CD19 CHIMERIC ANTIGEN RECEPTOR(CAR) T CELL THERAPY - A SINGLE CENTRE PILOT STUDY Monisha Harimadhavan (Kochi, India)	08:30 - 08:30
P067	EVALUATING ACCESSIBLE BIOMARKER CUTOFFS IN RELATION TO RELAPSE AFTER CAR-T CELL THERAPY USING ROC CURVE ANALYSIS Alejandro Luna de Abia (Madrid, Spain)	08:30 - 08:30
P069	LEUKAPHERESIS FOR AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN A SINGLE PEDIATRIC CENTER Guzmán López de Hontanar Torres (Madrid, Spain)	08:30 - 08:30
P070	FIRST CASE IN SPAIN OF COMMERCIAL CAR-T THERAPY IN RELAPSED/REFRACTORY CLASSICAL MANTLE CELL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT Anabelle China Rodríguez (Madrid, Spain)	08:30 - 08:30
P071	MUCORMYCOSIS AS FATAL COMPLICATION AFTER CD19 CAR-T CELL THERAPY IN A PATIENT WITH DLBCL Johann Hempel (Kiel, Germany)	08:30 - 08:30
P072	BRAIN FDG-PET-MRI TO IDENTIFY NEUROTOXICITY AFTER CAR T-CELL THERAPY AND GUIDE TREATMENT: A PEDIATRIC CASE Maria Gabelli (Padova, Italy)	08:30 - 08:30
P073	CAR-T CELL THERAPY FOR LYMPHOMA AND ACUTE LEUKEMIA AT LOW COST IN A DEVELOPING COUNTRY Thanh Liem Nguyen (Hanoi, Viet Nam)	08:30 - 08:30

P074	DEXAMETHASONE PROPHYLAXIS TO REDUCE CRS OR ICANS AFTER AXICABTAGENE (AXICEL) INFUSION: REAL-LIFE EXPERIENCE AT A SINGLE CENTER Maria Isabel Sotelo Alva (L'Hospitalet de Llobregat, Spain)	08:30 - 08:30
P075	RISK-STRATIFIED PREEMPTIVE IMMUNE INTERVENTION FOR PREVENTION OF HIGHER GRADE ICANS IN HIGH RISK PATIENTS Jonas Wißkirchen (Mainz, Germany)	08:30 - 08:30
P076	EFFICACY OF CAR-T CELL THERAPY AND PROGNOSTIC FACTOR ANALYSIS FOR RELAPSED/REFRACTORY B-NHL: A SINGLE CENTRE REAL LIFE EXPERIENCE Maria Dimitrakoudi (Athens, Greece)	08:30 - 08:30
P077	SEVERE ICANS AND SECONDARY CHOLANGITIS POST CAR T-CELL THERAPY FOR MANTLE CELL LYMPHOMA Eugene Leung (Toronto, Canada)	08:30 - 08:30
P078	CAR T THERAPY IN SLOVAKIA: A SINGLE CENTRE EXPERIENCE Zuzana Rusinakova (Bratislava, Slovakia)	08:30 - 08:30
P079	BCMA CAR-T THERAPY AS SALVAGE THERAPY IN PATIENTS WITH PLASMABLASTIC MYELOMA Su Li (Shanghai, China)	08:30 - 08:30
P080	THE SIGNIFICANCE OF PERIPHERAL BLOOD CYTOMORPHOLOGIC SMEAR FOR LINEAGE SWITCHING IN IMMUNOTHERAPY Jiao Zong (Beijing, China)	08:30 - 08:30
P081	CART CELL THERAPY BASED ON ALLO-HSCT IN A PATIENT WITH RELAPSED DLBCL AFTER ASCT Shaomei Feng (Beijing, China)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		R18
CAR-based Cellular Therapy - Preclinical		
A073	THE EXPRESSION OF PD-1 ON T CELLS IN ACUTE GRAFT-VERSUS-HOST DISEASE AND PRELIMINARY EXPLORATION OF PD-1.ICAR-TREG CELLS IN THE TREATMENT OF AGVHD Xiaopeng Tian (Suzhou, China)	08:30 - 08:30
A074	QUINOLONES ENHANCE ANTI-TUMOR EFFICACY OF CAR T CELL THERAPY Qiqi Zhang (□□, China)	08:30 - 08:30
A076	LOW-AFFINITY ANTIHER2-CAR T CELLS EFFICIENTLY ERADICATE HER2+ AND HER2LOW CANCER CELLS WITH REDUCED TOXICITY ON HEALTHY TISSUE Markus Perl (Regensburg, Germany)	08:30 - 08:30
A077	CD19-CAR REDIRECTED NK CELLS SECRETE CYTOTOXIC EXTRACELLULAR VESICLES EXPRESSING CAR MOLECULES WITH A POWERFUL ANTI-LEUKEMIC ACTIVITY IN VIVO Giulia Corradi (Pescara, Italy)	08:30 - 08:30
A078	ON THE WAY TO IMPROVE NKG2D CAR-T AS A TREATMENT FOR PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS Karima Al-Akioui Sanz (Madrid, Spain)	08:30 - 08:30
A079	ENGINEERING CAR-T CELLS FOR EFFECTIVE THERAPY AMID JAK INHIBITION Alexandros Rampotas (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30

A080	ENHANCED LLAMA-DERIVED V_HH CLEC12A-CAR-NK CELLS FOR TREATMENT ACUTE MYELOID LEUKEMIA Evelyn Ullrich (Frankfurt, Germany)	08:30 - 08:30
A081	NEXT-DAY CAR-T MANUFACTURING: IMPROVING TRANSDUCTION EFFICIENCY AND CELL PHENOTYPE WITH MICROFLUIDIC SYSTEMS Marina Popova (Saint Petersburg, Russian Federation (the))	08:30 - 08:30
P047	SYNERGISTIC IMPACT OF APOPTOTIC CELLS AND CAR T CELL TREATMENTS ON PERITONEAL SOLID TUMORS Dror Mevorach (Jerusalem, Israel)	08:30 - 08:30
P049	THE USE OF ICASP9 SUICIDE GENE IS INCREASING THE SAFETY PROFILE OF ANTI ROR1 CAR T CELLS IN MANTLE CELL LYMPHOMA David Kegyes (Cluj Napoca, Romania)	08:30 - 08:30
P050	PRECLINICAL ASSESSMENT OF ANTI ROR1 CAR T CELLS FOR SOLID CANCERS Ionut Ciprian Tomuleasa (Cluj Napoca, Romania)	08:30 - 08:30
P051	CURRENT PRACTICES, TECHNOLOGIES, AND CHALLENGES IN DEVELOPING CELL-BASED ATMPs: A SURVEY AMONG CENTERS ASSOCIATED WITH CTIWP OF EBMT, NXTGEN HIGHTECH, DARE-NL, T2EVOLVE, AND GOCART COALITION Trudy Straetemans (Utrecht, Netherlands (the))	08:30 - 08:30
P052	THE FUTURE OF VIRAL VECTORS: A SURVEY AMONG CENTERS ASSOCIATED WITH CTIWP OF EBMT, NXTGEN HIGHTECH, DARE-NL, T2EVOLVE, AND GOCART COALITION Zsolt Sebestyen (Utrecht, Netherlands (the))	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		R18
Psychological Issues		
P432	MEDICAL CARE AGGRESSIVENESS AT THE END-OF-LIFE AFTER ALLOGENEIC TRANSPLANTATION FOR THE TREATMENT OF NON-CR ACUTE LEUKEMIA: A RETROSPECTIVE COHORT STUDY Loïc Bauschert (Nancy, France)	08:30 - 08:30
P434	PARENTAL DISTRESS AND CHALLENGES IN ACCEPTING THE TRANSITION FROM CURATIVE TO PALLIATIVE CARE FOR CHILDREN WITH ONCOLOGICAL/HEMATOLOGICAL DISEASES AFTER HSCT Natalia Klipinina (Moscow, Russian Federation (the))	08:30 - 08:30
P435	DEPRESSION IN PAEDIATRIC SIBLING STEM CELL DONORS Serena Sen (Mumbai, India)	08:30 - 08:30
P436	DESIGNING AND IMPLEMENTING A PREPARATION FOR STEM-CELL TRANSPLANT SEMINAR: PATIENT PERCEPTION AND IMPACT Jenna Love (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P437	ILLNESS PERCEPTIONS AS PREDICTORS OF MENTAL HEALTH AMONG HCT RECIPIENTS: CROSS-SECTIONAL AND LONGITUDINAL INVESTIGATIONS Małgorzata Sobczyk-Kruszelnicka (Gliwice, Poland)	08:30 - 08:30
P438	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA: POSITIVE IMPACT AFTER PSYCHOLOGICAL FOLLOW-UP, AND HETEROGENEOUS PSYCHOLOGICAL ASPECTS ACCORDING TO AGE	08:30 - 08:30

	Eliana Kachaamy (Beirut, Lebanon)	
P440	THE PILOT PROJECT FOR ASSESSMENT OF ANXIETY AND ADAPTATION DISORDERS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REPUBLIC OF BELARUS Volha Mishkova (Borovlyany, Belarus)	08:30 - 08:30
P441	IMPACT OF ANXIETY ON OVERALL SURVIVAL IN ALLO-HCT PATIENTS Larisa Kuzmina (Moscow, Russian Federation (the))	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Myeloproliferative Neoplasm		
B304	PREDICTORS OF SURVIVAL OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELOYDYSPLASTIC SYNDROME Nelli Bejanyan (Tampa, United States of America (the))	08:30 - 08:30
B305	CLINICAL IMPACT OF SPLANCHNIC VEIN THROMBOSIS IN PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Maria Chiara Finazzi (Bergamo, Italy)	08:30 - 08:30
B307	ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH MYELOFIBROSIS: THE DONOR TYPE EFFECT ON SURVIVAL Patrizia Chiusolo (Roma, Italy)	08:30 - 08:30
B308	DISRUPTION OF MECHANOTRANSDUCTION PATHWAY EFFICIENTLY INHIBITS FIBROTIC RESPONSE OF MESENCHYMAL STROMAL CELLS DERIVED FROM MYELOFIBROSIS PATIENTS Weronika Lebowa (Kraków, Poland)	08:30 - 08:30
B309	OVERALL SURVIVAL AND DURATION OF TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR BEST AVAILABLE THERAPY IN A REAL-WORLD SETTING Andreas Reiter (Mannheim, Germany)	08:30 - 08:30
B310	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS: A COMPARISON BETWEEN DONOR TYPES Ana Lisa Basquiera (Córdoba, Argentina)	08:30 - 08:30
B311	SPLENIC MANAGEMENT AND ITS IMPACT ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT OUTCOMES IN MYELOFIBROSIS Urmimala Bhattacharjee (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
B312	POST-TRANSPLANT SPLENECTOMY WAS A POTENTIAL EFFECTIVE OPTION TO TREATING POOR GRAFT FUNCTION IN PATIENTS WITH MYELOFIBROSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Yi Liao (Beijing, China)	08:30 - 08:30
P311	PTCY ENRICHED TRANSPLANT CONDITIONING INTENSITY SCORE FOR MYELOFIBROSIS, IN THE HAPLOIDENTICAL SETTING Massimiliano Gambella (Genova, Italy)	08:30 - 08:30
P312	AVAPRITINIB POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADVANCED SYSTEMIC MASTOCYTOSIS: A CASE SERIES Seok-Yun Lee (Bern, Switzerland)	08:30 - 08:30

P314	TREATMENT OF RELAPSE FOLLOWING ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS Patrizia Chiusolo (Roma, Italy)	08:30 - 08:30
P315	OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT IN MYELOFIBROSIS: REAL-WORLD EXPERIENCE IN NATIONAL TRANSPLANT CENTRE IN MALAYSIA Andy Tang Sing Ong (Selangor, Malaysia)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		R18
Stem Cell Mobilization, Collection and Engineering		
A050	DARATUMUMAB-CONTAINING INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EFFECTS ON STEM CELL MOBILIZATION, COLLECTION AND ENGRAFTMENT (DILEMMA STUDY) Luciana Teofili (Rome, Italy)	08:30 - 08:30
A051	TREATMENT STRATEGIES AIMED AT MOBILIZING ALLOGENEIC AND AUTOLOGOUS HSC IN ADULTS AND CHILDREN: EVIDENCE-BASED RECOMMENDATIONS BY THE GRUPPO ITALIANO TRAPIANTI MIDOLLO OSSEO (GITMO) Massimo Martino (Reggio Calabria, Italy)	08:30 - 08:30
A052	NEW METHOD FOR BONE MARROW SEPARATION AND BUFFY COAT ENRICHMENT: QUICK TO USE, SAFE AND COST-EFFECTIVE Martina Brandl (Gauting, Germany)	08:30 - 08:30
A053	INFANTS AND YOUNG CHILDREN PERIPHERAL BLOOD STEM CELL COLLECTION FOR EX-VIVO HEMATOPOIETIC STEM CELL GENE THERAPY: FEASIBILITY AND EFFICACY IN 37 PATIENTS WEIGHING 7-15 KG Alessia Orsini (Milan, Italy)	08:30 - 08:30
A054	POSITIVE SELECTION OF CD34+ FROM CRYOPRESERVED STEM CELL (SC) SOURCE TO TREAT POOR GRAFT FUNCTION (PGF): PRELIMINARY DATA FROM TWO ITALIAN TRANSPLANT CENTERS Giorgia Mancini (Ancona, Italy)	08:30 - 08:30
A055	IMPACT OF PREEMPTIVE USE OF PLERIXAFOR ON MOBILIZATION, GRAFT COMPOSITION AND CLINICAL OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER PROPENSITY SCORE MATCHING ANALYSIS Ling Wang (Shanghai, China)	08:30 - 08:30
A056	SAFETY, EFFICACY AND FEASIBILITY OF GCSF AND PLERIXAFOR BASED CD34 MOBILIZATION FOR AUTOLOGOUS BACKUP IN PATIENTS UNDERGOING ALTERNATE DONOR HSCT FOR SICKLE CELL DISEASE Vaibhav Chadha (Delhi, India)	08:30 - 08:30
A057	STEM CELL BOOST WITH IMMUNOMAGNETIC SELECTION IS SUCCESSFUL IN THE THERAPY OF 60% PATIENTS WITH ALLOGENEIC POOR GRAFT FUNCTION- RESULTS OF RETROSPECTIVE POLISH STUDY Jowita Frączkiewicz (Wroclaw, Poland)	08:30 - 08:30
A059	MACHINE LEARNING IDENTIFIES KEY FACTORS INFLUENCING APHERESIS YIELD FOR CAR-T CELL THERAPY IN B-CELL LYMPHOMA PATIENTS Natalia Lorente (Madrid, Spain)	08:30 - 08:30
A060	IMMUNOMAGNETIC SELECTION OF ALLOGENEIC CD34+ CELLS	08:30 - 08:30

	FOR STEM CELL BOOST - SINGLE CENTRE EXPERIENCE Darija Bogdanić (Zagreb, Croatia)	
A061	PREDICTIVE MODEL OF THE EFFICIENCY OF HAEMATOPOIETIC PROGENITOR CELL MOBILISATION FOR HEALTHY DONORS MOBILISED WITH G-CSF Tania Dexter (London, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
A062	IS EXCEPTIONALLY HIGH PRE-TRANSPLANT CD34+ CELL YIELD IN SINGLE APHERESIS PREDICTIVE OF POOR PROGNOSIS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION? Sinem Civriz Bozdog (Istanbul, Turkey)	08:30 - 08:30
A063	HEMATOPOIETIC STEM CELL COLLECTION IN HEALTHY PEDIATRIC ALLOGENEIC DONORS FOR ADULT RECIPIENTS: PREDICTING FACTORS FOR OPTIMAL CD34+ COLLECTION Mohammed Essa (Riyadh, Saudi Arabia)	08:30 - 08:30
A064	IMMUNOPHENOTYPIC ANALYSIS OF ANTI-CD38 TREATMENT ON HEMATOPOIETIC PROGENITOR CELLS DURING APHERESIS IN PATIENTS WITH PLASMA CELL DYSCRASIAS Natalia Lorente (Madrid, Spain)	08:30 - 08:30
A065	FROM DELHI TO TBILISI: A TALE OF TWO CITIES AND TWO TRANSPLANT PROGRAMS Maia Ananiashvili (Tbilisi, Georgia)	08:30 - 08:30
A066	SUBSTITUTION OF THE CLINIMACS PRODIGY TO THE CLINIMACS PLUS DEVICE SUPPORTS EQUIVALENT PERFORMANCES FOR THE IMMUNO-SELECTION OF CD34+ CELLS FROM FRESH OR THAWED APHERESIS PRODUCTS Boris Calmels (Marseille, France)	08:30 - 08:30
A067	DARATUMUMAB: DOES IT INFLUENCE AUTOLOGOUS STEM CELL COLLECTION AND ENGRAFTMENT? Raquel García-Talavera Hernández (Las Palmas de Gran Canaria, Spain)	08:30 - 08:30
A068	SAFETY OF BONE MARROW HARVESTING IN BONE MARROW SIBLING DONORS WITH THALASSEMIA CARRIER Pornpun Sripornsawan (Hat Yai, Thailand)	08:30 - 08:30
A069	OPERATOR AND NON-OPERATOR BASED FACTORS THAT AFFECT HEMATOPOIETIC STEM CELL COLLECTION EFFICIENCY Eleni Lalou (Athens, Greece)	08:30 - 08:30
A070	RETROSPECTIVE ANALYSIS TO EVALUATE MOBILISATION EFFECTIVENESS OF G-CSF + PLERIXAFOR VS G-CSF ± CHEMOTHERAPY IN PATIENTS WITH MULTIPLE MYELOMA Sung-Hoon Jung (Hwasun, Korea (the Republic of))	08:30 - 08:30
A071	THE IMPACT OF TOTAL HANDLING TIME AND SUBSEQUENT CRYOPRESERVATION OF ALLOGENEIC STEM CELLS ON ENGRAFTMENT KINETICS Malgorzata Sobczyk-Kruszelnicka (Gliwice, Poland)	08:30 - 08:30
A072	COMPLETE RECOVERY FROM CYTOPENIAS AFTER CHEMOTHERAPY, CART CELL INFUSION OR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CD34+ SELECTED STEM CELL BOOST Marta Pérez Laencina (Murcia, Spain)	08:30 - 08:30
P028	STEM CELL MOBILIZATION WITH PEGFILGRASTIM IN PEDIATRIC PATIENTS FOR AUTOLOGOUS INFUSION: SAFE AND EFFECTIVE A. Jaspers-Bakker (Utrecht, Netherlands (the))	08:30 - 08:30

P029	EXPANDING THE REACH. THE CITY OF HOPE MODEL TO EXPAND HIGH QUALITY CELLULAR THERAPY SERVICE ENABLES RAPID ACHIEVEMENT OF FACT ACCREDITATION Jeff Schriber (Goodyear, United States of America (the))	08:30 - 08:30
P030	HEMATOPOIETIC STEM CELL MOBILIZATION USING PEG-G-CSF EMPEGFILGRASTIM (EXTIMIA®) IN PATIENTS WITH LYMPHOPROLIFERATIVE DISEASES: EXPERIENCE OF SEVERAL CENTERS IN THE RUSSIAN FEDERATION Ekaterina Nesterova (Moscow, Russian Federation (the))	08:30 - 08:30
P031	OUTCOME OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CRYOPRESERVED STEM CELLS IN PEDIATRIC PATIENTS DURING COVID-19 PANDEMIC: A SINGLE CENTER EXPERIENCE Amir Ali Hamidieh (Tehran, Iran (Islamic Republic of))	08:30 - 08:30
P032	APHERESIS OUTCOMES IN A COHORT OF PATIENTS WITH MS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION Yandy Marx Castillo-Aleman (Abu Dhabi, United Arab Emirates (the))	08:30 - 08:30
P034	MOBILIZATION AND COLLECTION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS IN PATIENTS WITH A HIGH RISK NEUROBLASTOMA Tomáš Sýkora (Bratislava, Slovakia)	08:30 - 08:30
P035	COMPARISON OF HEMATOPOIETIC STEM CELL MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTS: VINORELBINE, CYCLOPHOSPHAMIDE, AND G-CSF FOR OPTIMAL CD34+ CELL YIELD Yavor Petrov (Varna, Bulgaria)	08:30 - 08:30
P036	EFFECTS OF G-CSF ALONE AND COMBINED WITH CYCLOPHOSPHAMIDE OR PLERIXAFOR ON THE INTRA-APHERESIS RECRUITMENT OF CD34⁺ HEMATOPOIETIC STEM CELLS Yandy Marx Castillo-Aleman (Abu Dhabi, United Arab Emirates (the))	08:30 - 08:30
P037	CD34 REMOBILISATION AFTER 1ST TRANSPLANT IN MYELOMA PATIENTS-A SINGLE CENTRE STUDY Kikaiweji Liley (Leicester, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P038	OPTIMIZING LEUKAPHERESIS FOR CAR-T MANUFACTURING: VARIABILITY IN CD3+ T CELL COLLECTION EFFICIENCY WITH INTERMITTENT MNC COLLECTION Katja Kimberger (Leeds, United Kingdom of Great Britain and Northern Ireland (the))	08:30 - 08:30
P039	EFFECT OF PLERIXAFOR ON NEUTROPHIL AND PLATELET ENGRAFTMENT IN PATIENTS UNDERGOING STEM CELL TRANSPLANT WITH PREHARVEST CD34 COUNT ABOVE 20 CELLS/MM³ Perraju Bhaskar Bhuvan Lagudu (Visakhapatnam, India)	08:30 - 08:30
P040	A COLOMBIAN CENTER EXPERIENCE OF AUTOMATED CLINICAL- GRADE PERIPHERAL BLOOD STEM CELL ISOLATION AND PROCESSING FOR HEMATOLOGICAL CLINICAL APPLICATIONS Claudia Sossa-Melo (Floridablanca, Colombia)	08:30 - 08:30
P042	TACKLING THE PROBLEM OF FALSE-NEGATIVE RESULTS OF CD34+ CELL ENUMERATION IN PEDIATRIC NEUROBLASTOMA PATIENTS PLANNED FOR STEM CELL COLLECTION: INSIGHTS FROM TWO CASES Tami Katz (Haifa, Israel)	08:30 - 08:30
P043	PREHARVEST PLATELET COUNTS ARE A PREDICTOR OF	08:30 - 08:30

	RESPONSE TO PLERIXAFOR IN PEDIATRIC PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT	
	Aditya Gupta (New Delhi, India)	
P044	POLYURETHANE DOUBLE LUMEN 14.5 FR TUNNELED CATHETER FOR BOTH CENTRAL VENOUS ACCESS AND APHERESIS IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT	08:30 - 08:30
	Disha Satya (Jaipur, India)	
P046	ANALYSIS OF FACTORS AFFECTING THE EFFICIENCY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION BEFORE APHERESIS IN PEDIATRIC PATIENTS WITH MALIGNANT NEOPLASMS	08:30 - 08:30
	Nara Stepanyan (Moscow, Russian Federation (the))	
<i>ePoster</i>		
08:30 - 18:00		R18
ePoster Viewing		
<i>Patient, Family, and Donor Day</i>		
09:00 - 10:15		R15
PFDD1 - Patient, Family, and Donor Day 1 Harmonisation of GVHD care and patient reported outcomes		
	Riikka-Leena Manninen (Ylöjärvi, Finland)	
	Andrea Linke (Berlin, Germany)	
PFDD1-1	Welcome to the PFDD	09:00 - 09:05
	Natacha Bolaños (Madrid, Spain)	
PFDD1-2	Introduction by the Chairs	09:05 - 09:10
PFDD1-3	The Alarm: Chimera by Mike Peters	09:10 - 09:15
PFDD1-4	A patient journey with GvHD	09:15 - 09:30
	Tone Hansen (Tønsberg, Norway)	
PFDD1-5	GVHD care for HSCT patients in Europe	09:30 - 09:45
	Katharina Egger-Heidrich (Dresden, Germany)	
	Daniel Wolff (Regensburg, Germany)	
PFDD1-6	Integration of PRO on GVHD in daily practice	09:45 - 10:00
	Maria Teresa Lupo-Stanghellini (Milano, Italy)	
PFDD1-7	Q&A - Discussion	10:00 - 10:15
<i>Breaks</i>		
10:00 - 10:30		R1
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>Meetings</i>		
10:00 - 12:30		R8
IM-1 - EBMT Exam		
<i>Industry Symposium</i>		
10:30 - 12:00		R1
IS05 - What's new in GvHD in 2025? SANOFI		
	Mohamad Mohty (Paris, France)	
	Franco Locatelli (Rome, Italy)	
IS05-1	Welcome and introduction	10:30 - 10:35

	Mohamad Mohty (Paris, France) Franco Locatelli (Rome, Italy)	
IS05-2	Sourcing signals: Treatment signalling pathways in GvHD	10:35 - 10:50
	Franco Locatelli (Rome, Italy)	
IS05-3	Calibrating the scales: GvHD classification in trials and practice	10:50 - 11:05
	Daniel Wolff (Regensburg, Germany)	
IS05-4	Fresh approaches: Advances in GvHD treatment	11:05 - 11:20
	Mohamad Mohty (Paris, France)	
IS05-5	Management of GvHD: Real-life cases	11:20 - 11:45
	Daniele Avenoso (Brescia, Italy)	
IS05-6	Q&A and closing remarks	11:45 - 12:00
	Mohamad Mohty (Paris, France) Franco Locatelli (Rome, Italy)	

Industry Symposium

10:30 - 12:00

R2

IS06 - Different Patients, Different Constellations: How Patient-Specific Factors Can Guide Practical CMV Management | TAKEDA

Johan Maertens (Leuven, Belgium)

IS06-1	Welcome and Introductions	10:30 - 10:35
	Johan Maertens (Leuven, Belgium)	
IS06-2	The Stars: Patient, Virus and Treatment Factors	10:35 - 10:45
	Johan Maertens (Leuven, Belgium)	
IS06-3	Identifying Constellations	10:45 - 11:05
	Francesca Bonifazi (BOLOGNA, Italy)	
IS06-4	Expanding the star charts	11:05 - 11:25
	Maria Calbacho (Madrid, Spain)	
IS06-5	Panel Discussion and Q&A - Chair and Speakers	11:25 - 11:55
IS06-6	Concluding Remarks	11:55 - 12:00
	Johan Maertens (Leuven, Belgium)	

Nurses Group

10:30 - 12:00

R7

NG02 - Nurses Education Day 2 | The four pillars of transplant and cell therapy nursing care: Leadership

Claudia Boglione (Florence, Italy)

Marijke Quaghbeur (Ghent, Belgium)

NG02-1	What does leadership look like as a nurse in direct patient care	10:30 - 10:51
	María Paz Manzanares (Madrid, Spain)	
NG02-2	Leading the patient and caregivers towards empowerment	10:51 - 11:12
	Anke Jaehnke (Stuttgart, Germany)	
NG02-3	Leading quality and patient safety at the bedside	11:12 - 11:33
	Elin Ofverberg (Gothenburg, Sweden)	
NG02-4	Leading change in daily practice	11:33 - 11:54
	Catriona Gahan (London, United Kingdom of Great Britain and Northern Ireland (the))	
NG02-5	Q&A	11:54 - 12:00

Trainee Day

10:30 - 11:45

R10

TD1 - Trainee Day 1 | Bloody Science

TD1-1	Welcome Nico Gagelmann (Hamburg, Germany) Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	10:30 - 10:35
TD1-2	Marrow: just a niche? Zoe Wong (Oxford, United Kingdom of Great Britain and Northern Ireland (the))	10:35 - 10:50
TD1-3	Posttransplant Cyclophosphamide: from mice to standard of care Leo Luznik (Houston, United States of America (the))	10:50 - 11:05
TD1-4	Blood and bone marrow differentials: just an algorithm? Torsten Haferlach (Munich, Germany)	11:05 - 11:20
TD1-5	Case 1: The Many Faces of Posttransplant Complications with Reduced-Dose Posttransplant Cyclophosphamide (PTCy): A Case of Haploidentical HSCT in Aplastic Anemia Alejandra De Las Fuentes Cepeda (Monterrey, Mexico)	11:20 - 11:25
TD1-6	Discussion	11:25 - 11:45

Psy Day

10:30 - 11:45

R11

Psy1 - Psy Day Session 1 | Preparation for transplant & cellular therapy

Emanuela Mencaglia (Rozzano - Milan, Italy)

PSY1-1	Patients' and caregivers' perspectives on preparedness for and experience with CAR-T therapy Anna Barata (Boston, United States of America (the))	10:30 - 10:50
PSY1-2	Psychological Assessment Practices for Hematopoietic Stem Cell Transplantation Hermioni Amonoo (Boston, United States of America (the))	10:50 - 11:10
PSY1-3	Assessing distress before HSCT: working on multidisciplinary team for the best clinical and psychosocial practice Elisa Scaburri (Milan, Italy)	11:10 - 11:30
PSY1-4	Q&A	11:30 - 11:45

Patient, Family, and Donor Day

10:45 - 12:00

R15

PFDD2 - Patient, Family, and Donor Day 2 | Taboos and unspoken subjects

Jacqueline Del Castillo (London, United Kingdom of Great Britain and Northern Ireland (the))

Peter Feenstra (BARJAC, GARD, France)

PFDD2-1	Introduction	10:45 - 10:50
PFDD2-2	Emotional regulation Robin Muir (Mance, United Kingdom of Great Britain and Northern Ireland (the))	10:50 - 11:05
PFDD2-3	Caregiving and partnership Hans Kouwenberg (BARJAC, GARD, France)	11:05 - 11:20
PFDD2-4	Social relationships Gabriele Alzati (Besnate, Italy)	11:20 - 11:35
PFDD2-5	Q&A and Wrap-up	11:35 - 12:00

Breaks

12:00 - 12:30

R1

Break, ePoster Viewing, Visit Exhibition*Industry Symposium*

12:30 - 14:00

R2

IS07 - Past, present and future: why hypervigilance for hepatic VOD remains critical | JAZZ PHARMACEUTICALS

Mohamad Mohty (Paris, France)

IS07-1 **Past, present and future: refining hepatic VOD management** 12:30 - 12:40
Mohamad Mohty (Paris, France)

IS07-2 **Where are we today: how can we improve hepatic VOD management and how can the refined EBMT 2023 criteria help?** 12:40 - 12:55
Tony Pagliuca (London, United Kingdom of Great Britain and Northern Ireland (the))

IS07-3 **Where are we today: how have the refined EBMT 2023 criteria been validated?** 12:55 - 13:05
Monica Cabrero (Salamanca, Spain)

IS07-4 **Where are we today: the ElastoVOD study - how can elastography be used to identify hepatic VOD patients?** 13:05 - 13:15
Francesca Bonifazi (BOLOGNA, Italy)

IS07-5 **Audience discussion and Q&A** 13:15 - 13:25
Mohamad Mohty (Paris, France)
Tony Pagliuca (London, United Kingdom of Great Britain and Northern Ireland (the))
Monica Cabrero (Salamanca, Spain)
Francesca Bonifazi (BOLOGNA, Italy)
Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))
Selim Corbacioglu (Regensburg, Germany)

IS07-6 **Remaining vigilant through MDT collaboration: discussing the future landscape of hepatic VOD management** 13:25 - 13:55
Mohamad Mohty (Paris, France)
Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))
Selim Corbacioglu (Regensburg, Germany)

IS07-7 **Past, present and future learnings: summary and close** 13:55 - 14:00
Mohamad Mohty (Paris, France)

Industry Symposium

12:30 - 14:00

R3

IS08 - It takes a village: embracing a multidisciplinary approach to optimize cGvHD management | NOVARTIS

Nicola Polverelli (Pavia, Italy)

IS08-1 **Welcome & Introduction** 12:30 - 12:35
Nicola Polverelli (Pavia, Italy)

IS08-2 **Improving survivorship in cGvHD: current challenges and guidelines** 12:35 - 12:50
Meng Lv (Beijing, China)

IS08-3 **Enhancing patient outcomes through early diagnosis and multidisciplinary approaches** 12:50 - 13:10
Nicola Polverelli (Pavia, Italy)
Daniel Wolff (Regensburg, Germany)
Meng Lv (Beijing, China)
Anne Bergeron (Geneva, Switzerland)
Giulio Ferrari (Milan, Italy)
Brigitte Frey (Liestal, Switzerland)

IS08-4	Management of cGvHD and best practices for optimizing care Nicola Polverelli (Pavia, Italy) Daniel Wolff (Regensburg, Germany) Meng Lv (Beijing, China) Anne Bergeron (Geneva, Switzerland) Giulio Ferrari (Milan, Italy) Brigitte Frey (Liestal, Switzerland)	13:10 - 13:30
IS08-5	cGvHD management: advances and future directions Daniel Wolff (Regensburg, Germany)	13:30 - 13:45
IS08-6	Q&A and Closing remarks Nicola Polverelli (Pavia, Italy)	13:45 - 14:00

Industry Symposium

12:30 - 14:00

R4

IS09 - A Vision Forward for EBV+ PTLD: Clinical Perspectives and Collaborative Care for EBV-specific T-cell Immunotherapy | PIERRE FABRE

Anna Sureda (Barcelona, Spain)

IS09-1	Welcome and Introduction Anna Sureda (Barcelona, Spain)	12:30 - 12:40
IS09-2	Integrating Perspectives on Unmet Needs in EBV+ PTLD: An Uncertain Treatment Path Jean-Hugues Dalle (Paris, France)	12:40 - 12:55
IS09-3	Transforming the Outlook on R/R EBV+ PTLD: Clinical data with EBV-specific T-cell Immunotherapy Patrizia Comoli (Pavia, Italy)	12:55 - 13:20
IS09-4	A Vision Forward for R/R EBV+ PTLD Management and Care: Patient Selection for T-cell Immunotherapy Michael Schmitt (Heidelberg, Germany)	13:20 - 13:35
IS09-5	Future Directions and the Potential for Transforming Patient Care • Patients Perspectives • Panel Discussion Anna Sureda (Barcelona, Spain) Lorna Warwick (Mississauga, Canada)	13:35 - 13:55
IS09-6	Q&A and Closing Anna Sureda (Barcelona, Spain)	13:55 - 14:00

Industry Symposium

12:30 - 14:00

R5

IS10 - What the guidelines do or do not say about antifungal treatments in patients with haematological malignancies | Gilead & Kite

Olaf Penack (Berlin, Germany)

Alessandro Busca (Turin, Italy)

IS10-1	Introduction and housekeeping Olaf Penack (Berlin, Germany) Alessandro Busca (Turin, Italy)	12:30 - 12:35
IS10-2	Challenges for patients with haematological malignancies receiving antifungal treatments Johan Maertens (Leuven, Belgium)	12:35 - 12:55
IS10-3	Reasons for stopping and when to stop antifungal treatment Dionysios Neofytos (Geneva, Switzerland)	12:55 - 13:15

IS10-4	Breakthrough and elusive infections in patients with haematological malignancies Marie-Pierre Ledoux (Strasbourg, France)	13:15 - 13:35
IS10-5	Audience Q&A - All Olaf Penack (Berlin, Germany) Alessandro Busca (Turin, Italy)	13:35 - 13:55
IS10-6	Meeting close Olaf Penack (Berlin, Germany) Alessandro Busca (Turin, Italy)	13:55 - 14:00

Industry Symposium

12:30 - 13:30

R7

IS11 - Delivering Therakos ECP: Best Practice in 2025| THERAKOS

Tuula Rintala (London, United Kingdom of Great Britain and Northern Ireland (the))

IS11-1	Introduction Tuula Rintala (London, United Kingdom of Great Britain and Northern Ireland (the))	12:30 - 12:35
IS11-2	Best practices for nurses - Venous access options for ECP Nina Worel (Vienna, Austria)	12:35 - 12:50
IS11-3	ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults - The importance of nurse involvement Saskia Bos (Leuven, Belgium)	12:50 - 13:05
IS11-4	The Italian SIdEM / GITMO guidelines - Best practice for nurses Anna Colpo (Padua, Italy)	13:05 - 13:20
IS11-5	Q&A session	13:20 - 13:30

Trainee Day

12:30 - 13:45

R10

TD2 - Trainee Day 2 | One does not simply: treat children with cellular therapies

Manuela Spadea (Turin, Italy)

Kath Colman (Melbourne, Australia)

TD2-1	CAR-T in Paediatrics 2025 Matthias Eyrich (Würzburg, Germany)	12:30 - 12:50
TD2-2	Are gene editing and gene addition therapy the new black for a curative approach in haemoglobinopathies? Franco Locatelli (Rome, Italy)	12:50 - 13:10
TD2-3	Fertility preservation - what do we need to consider today? Tamara Diesch-Furlanetto (BASEL, Switzerland)	13:10 - 13:25
TD2-4	Case 2: Busulfan alone as conditioning for second allogenic hematopoietic stem cell transplantation for infantile malignant osteopetrosis with isolated poor myeloid chimerism - an unusual strategy Akshay Deshpande (United Kingdom of Great Britain and Northern Ireland (the))	13:25 - 13:30
TD2-5	Discussion	13:30 - 13:45

Psy Day

12:30 - 13:45

R11

Psy2 - Psy Day Session 2 | Supporting patients with psychological issues during and post-transplant

Stefania Spina (Milano, Italy)

PSY2-1	Managing Anticipatory Nausea & Vomiting (ANV)	12:30 - 12:50
	Clare McGowan (GLASGOW, United Kingdom of Great Britain and Northern Ireland (the))	
PSY2-2	The complex process of "positive risk-taking" as patients transition from isolation back to 'normality'	12:50 - 13:10
	Helen Aiston (Southampton, United Kingdom of Great Britain and Northern Ireland (the))	
PSY2-3	Efficacy of psychodynamic short-term psychotherapy for Hematological cancer patients with comorbid depression and anxiety: preliminary data	13:10 - 13:30
	Vezio Savoia (Rome, Italy)	
PSY2-4	Q&A	13:30 - 13:45

Statistics

12:30 - 16:00

R12

STATS-C2 - Basic course in Statistics 2

Jacques - Emmanuel Galimard (Paris, France)

STATS-C2-1	Theory: The survival function and the hazard function	12:30 - 12:30
	Jacques - Emmanuel Galimard (Paris, France)	
STATS-C2-2	The Cox model and multivariable methods	12:30 - 12:30
	Luuk Gras (Leiden, Netherlands (the))	
STATS-C2-3	Competing events and the cumulative incidence method	12:30 - 12:30
	Luuk Gras (Leiden, Netherlands (the))	
STATS-C2-4	Comparison of time to event outcome with competition: The Gray test	12:30 - 12:30
	Luuk Gras (Leiden, Netherlands (the))	
STATS-C2-5	Stat issues in Hematologic Studies	12:30 - 12:30
	Matthieu Resche-Rigon (Paris, France)	

Patient, Family, and Donor Day

13:30 - 14:45

R15

PFDD3 - Patient, Family, and Donor Day 3 | Navigating Survivorship: Addressing Long-Term Needs and Challenges

Andrea Linke (Berlin, Germany)

Guy Bouguet (Paris, France)

PFDD3-1	Introduction	13:30 - 13:35
PFDD3-2	Navigating an Immunocompromised Life as a Survivor	13:35 - 13:50
	Rachel Phelan (Milwaukee, United States of America (the))	
PFDD3-3	Referencing the latest research and patient stories, I plan to focus on the tight rope patients must walk between being vigilant to avoid infections and the need to not stay cloistered at home.	13:50 - 14:05
	Brian Koffman (Claremont, United States of America (the))	
PFDD3-4	Post-traumatic growth patient and expert	14:05 - 14:20
	Guy Tavori (Kefar Vitkin, Israel)	
PFDD3-5	Q&A - Discussion	14:20 - 14:45

Breaks

14:00 - 14:30

R1

Break, ePoster Viewing, Visit Exhibition*Industry Symposium*

14:30 - 16:00

R2

IS12 - Expanding treatment options: ex vivo T cell depletion and point-of-care manufacturing of CAR T cell therapies | MILTENYI BIOTEC

Franco Locatelli (Rome, Italy)

IS12-1	Welcome & introduction Franco Locatelli (Rome, Italy)	14:30 - 14:40
IS12-2	Is a TCRα/β-depleted haploidentical transplant regimen a curative treatment option for sickle cell disease and transfusion-dependent thalassemia, and is it comparable to matched donor transplants? Selim Corbacioglu (Regensburg, Germany)	14:40 - 15:00
IS12-3	CD45RA+ TN depletion of PBSC grafts for prevention of chronic GVHD - results from clinical trials and laboratory studies Marie Bleakley (United States of America (the))	15:00 - 15:20
IS12-4	TCRα/ CD19 depleted grafts in allogeneic hematopoietic stem cell transplantation combined with personalized immune interventions to optimize GVHD-relapse-free survival in adults with Myelofibrosis and Inborn Errors of Immunity Moniek de Witte (Utrecht, Netherlands (the))	15:20 - 15:40
IS12-5	Academic model for CAR T development in multiple myeloma: clinical results with ARI0002h and future plans Carlos Fernández de Larrea (Barcelona, Spain)	15:40 - 16:00

Industry Symposium

14:30 - 16:00

R3

IS13 - Is transplant suitable for my patient? Optimizing treatment success in FLT3-AML | DAIICHI SANKYO

Adriano Venditti (Rome, Italy)

IS13-1	Welcome and Introduction Adriano Venditti (Rome, Italy)	14:30 - 14:35
IS13-2	Navigating FLT3-mutated AML: Evolving treatment landscape Michael Heuser (Germany)	14:35 - 14:55
IS13-3	How can we determine which FLT3-AML patients should receive allo-HCT? Charles Craddock (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	14:55 - 15:15
IS13-4	Co-ordinating treatment decisions: A real-world patient pathway Hildegard T. Greinix (Graz, Austria)	15:15 - 15:35
IS13-5	Panel discussion - All	15:35 - 15:55
IS13-6	Wrap-up and close Adriano Venditti (Rome, Italy)	15:55 - 16:00

Industry Symposium

14:30 - 16:00

R4

IS14 - Updates in the Management of CMV in HSCT | MSD

Per Ljungman (Stockholm, Sweden)

IS14-1	Opening Per Ljungman (Stockholm, Sweden)	14:30 - 14:35
--------	--	---------------

IS14-2	Contemporary CMV Management: State of the Art Update Per Ljungman (Stockholm, Sweden)	14:35 - 14:50
IS14-3	Advancements in CMV Management in Pediatric HSCT: Evidence Based Insights and Latest Clinical Data Jan Styczynski (Bydgoszcz, Poland)	14:50 - 15:05
IS14-4	Addressing Real World Challenges and Controversies in CMV Management with special focus on Immune Monitoring Raffaella Greco (Milano, Italy)	15:05 - 15:20
IS14-5	The Future of CMV in HSCT: Where Does Emerging New Data Point Us? Genovefa Papanicolaou (New York, United States of America (the))	15:20 - 15:40
IS14-6	Panel Q&A - All speakers	15:40 - 15:59
IS14-7	Closing Per Ljungman (Stockholm, Sweden)	15:59 - 16:00

Nurses Group

14:30 - 16:00

R7

NG03 - Nurses Education Day 3 | The four pillars of transplant and cell therapy nursing care: Research

Claudia Boglione (Florence, Italy)

Marijke Quaghbeur (Ghent, Belgium)

NG03-1	Using evidence in CVC care Sandra Schoenfeld (Basel, Switzerland)	14:30 - 14:51
NG03-2	Using evidence in infection prevention and control Maria Finch (London, United Kingdom of Great Britain and Northern Ireland (the))	14:51 - 15:12
NG03-3	Using evidence in oral care Stefano Botti (Reggio Emilia, Italy)	15:12 - 15:33
NG03-4	Using evidence in long term follow up Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))	15:33 - 15:54
NG03-5	Q&A	15:54 - 16:00

Lab Scientists Day

14:30 - 15:45

R9

LS1 - Lab Scientists Day 1 | Joint EBMT & AIBT session | HLA typing and anti-HLA antibodies: when the bench supports the bedside

Annamaria Pasi (Italy)

Katharina Fleischhauer (Essen, Germany)

LS1-1	Antibodies (DSA) and mean fluorescence intensity (MFI): the laboratory perspective Giovanni Rombolà (Parma, Italy)	14:30 - 14:50
LS1-2	Next-generation sequencing in HLA typing and the importance of being over the second field Sharon Vivers (London, United Kingdom of Great Britain and Northern Ireland (the))	14:50 - 15:10
LS1-3	Is there a clinical impact of non donor-specific anti-HLA antibodies? Roberto Crocchiolo (Milano, Italy)	15:10 - 15:30
LS1-4	Q&A	15:30 - 15:45

Trainee Day

14:30 - 15:45

R10

TD3 - Trainee Day 3 | Going viral: an educated gameshow

Vera Radici (Brescia, Italy)

Rafaella Muratori (Curitiba, Brazil)

TD3-1	EBV-infections and PTLD Nina Khanna (Basel, Switzerland)	14:30 - 14:45
TD3-2	CMV-infections with and without letermovir Rafael de la Camara (Madrid, Spain)	14:45 - 15:00
TD3-3	Multi-drug resistant infections worldwide in allogeneic HCT recipients Dionysios Neofytos (Geneva, Switzerland)	15:00 - 15:15
TD3-4	Gameshow Lars Klingen Gjørde (Copenhagen, Denmark) Kath Colman (Melbourne, Australia)	15:15 - 15:45

Psy Day

14:30 - 15:45

R11

Psy3 - Psy Day Session 3 | Support & consideration of caregivers

Anna Barata (Boston, United States of America (the))

PSY3-1	The patient, his family and caregivers in the context of death within a Pediatric Immunology department Elodie Jacquelet (Vincennes, France)	14:30 - 14:50
PSY3-2	Psychosocial Intervention for Caregivers of Hematopoietic Stem Cell Transplant Survivors Hermioni Amonoo (Boston, United States of America (the))	14:50 - 15:10
PSY3-3	New ethical issues regarding patients and related donors' care Alice Polomeni (PARIS 12alic, France)	15:10 - 15:30
PSY3-4	Q&A	15:30 - 15:45

Patient, Family, and Donor Day

15:00 - 16:15

R15

PFDD4 - Patient, Family, and Donor Day 4 | Patient Voice Matters: Patient Reported Outcomes (PROs) to improve the patient Journey

Noelle Tassy (Marseilles, France)

Maria Teresa Lupo-Stanghellini (Milano, Italy)

Paola Zarantin (Genoa, Italy)

PFDD4-1	Introduction	15:00 - 15:05
PFDD4-2	Patient with multiple sclerosis Reported Outcomes during and after autologous HSCT Noelle Tassy (Marseilles, France)	15:05 - 15:20
PFDD4-3	aHSCT for people with relapsing multiple sclerosis: a testimonial 10 years post Susanne Baerlin (Berlin, Germany)	15:20 - 15:30
PFDD4-4	The Global Patient Reported Outcomes for Multiple Sclerosis Initiative (PROMS) Paola Zarantin (Genoa, Italy)	15:30 - 15:40
PFDD4-5	Patient involvement in designing PRO measures Esther Natalie Oliva (London, United Kingdom of Great Britain and Northern Ireland (the))	15:40 - 15:55

PFDD4-6	Q&A - Discussion	15:55 - 16:15
<i>Breaks</i>		
16:00 - 16:30		R1
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>Industry Symposium</i>		
16:30 - 18:00		R2
IS15 - Navigating the evolving haemoglobinopathy transplant journey VERTEX		
Fabio Ciceri (Milano, Italy)		
IS15-1	Welcome and introduction Fabio Ciceri (Milano, Italy)	16:30 - 16:40
IS15-2	Reviewing options in an evolving treatment landscape Roland Meisel (Düsseldorf, Germany)	16:40 - 16:55
IS15-3	Troubleshooting the transplant process Fabio Ciceri (Milano, Italy) Roland Meisel (Düsseldorf, Germany) Mohsen Alzahrani (Riyadh, Saudi Arabia) Eleni Tholouli (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) Mattia Algeri (Rome, Italy)	16:55 - 17:25
IS15-4	Optimising post-transplant monitoring and follow-up Mattia Algeri (Rome, Italy)	17:25 - 17:40
IS15-5	Panel discussion and Q&A - All faculty, moderated by Chair	17:40 - 17:55
IS15-6	Summary and close Fabio Ciceri (Milano, Italy)	17:55 - 18:00
<i>Industry Symposium</i>		
16:30 - 18:00		R3
IS16 - Therakos ECP: A Backbone for GvHD Therapy THERAKOS		
Massimo Martino (Reggio Calabria, Italy)		
IS16-1	Introduction Massimo Martino (Reggio Calabria, Italy)	16:30 - 16:35
IS16-2	Treatment of GvHD using non-pharmacological extracorporeal therapies - update of the Italian SIDEM / GITMO guidelines based on best available evidence Maria Teresa Lupo-Stanghellini (Milano, Italy)	16:35 - 16:50
IS16-3	Evidence for treatment of chronic GvHD using ECP - A future backbone for GvHD Therapy Zachariah DeFilipp (Boston, United States of America (the))	16:50 - 17:20
IS16-4	ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD - improved long-term outcomes Nicolaus Kröger (Hamburg, Germany)	17:20 - 17:50
IS16-5	Q&A session	17:50 - 18:00
<i>Industry Symposium</i>		
16:30 - 18:00		R4
IS17 - Transforming Treatment Paradigms With CAR T Cell Therapy: Clinical and Real-World Management of Lymphoma and Multiple Myeloma BRISTOL MYERS SQUIBB		
Paolo Corradini (Milan, Italy)		

IS17-1	Welcome and introductions Paolo Corradini (Milan, Italy)	16:30 - 16:40
IS17-2	CAR T cell therapy and the evolving lymphoma treatment landscape Jeremy Abramson (Boston, United States of America (the))	16:40 - 17:10
IS17-3	Optimizing patient outcomes in earlier lines of treatment: CAR T in RRMM Elena Zamagni (Bologna, Italy)	17:10 - 17:40
IS17-4	Interactive session and Q&A - All faculty	17:40 - 18:00

Industry Symposium

16:30 - 18:00

R5

IS18 - Optimizing Conditioning Regimens for HSCT in AML/MDS: Balancing Strategies for Improved Outcome | MEDAC

Mohamad Mohty (Paris, France)

IS18-1	Welcome and Intro Mohamad Mohty (Paris, France)	16:30 - 16:35
IS18-2	Setting the Stage: Decoding the Conditioning Spectrum Mohamad Mohty (Paris, France)	16:35 - 16:40
IS18-3	The Conditioning Renaissance: New Data Reshaping Transplant Preparation Friedrich Stölzel (Germany)	16:40 - 16:55
IS18-4	Half-Match, Full Potential: Optimizing Haploidentical HSCT with RTC Regimens Raynier Devillier (France)	16:55 - 17:10
IS18-5	Bridging Insights: A US Perspective on Conditioning Regimens in HSCT Filippo Milano (Seattle, United States of America (the))	17:10 - 17:25
IS18-6	Flip the Coin: RIC, RTC, or MAC? - All faculty	17:25 - 17:55
IS18-7	Charting the Course: Future Horizons in Conditioning Regimens Mohamad Mohty (Paris, France)	17:55 - 18:00

Nurses Group

16:30 - 18:00

R7

NG04 - Nurses Education Day 4 | The four pillars of transplant and cell therapy nursing care: Education

Claudia Boglione (Florence, Italy)

Marijke Quaghbeur (Ghent, Belgium)

NG04-1	Knowledge and experience sharing by patient peers Judith Timmermans (Voorhout, Netherlands (the))	16:30 - 16:51
NG04-2	Teaching pre-transplant admission Emma Kane (London, United Kingdom of Great Britain and Northern Ireland (the))	16:51 - 17:12
NG04-3	Learning how to be safe at home Lidia Hurtado (Barcelona, Spain)	17:12 - 17:33
NG04-4	Enhancing adherence after transplant : example of the ETOILE program Aurélie Esteve (PARIS, France)	17:33 - 17:54
NG04-5	Q&A	17:54 - 18:00

Lab Scientists Day

16:30 - 17:45

R9

LS2 - Lab Scientists Day 2 | Gene Therapy: patient and product

Carlijn Voermans (amsterdam, Netherlands (the))

- | | | |
|-------|---|---------------|
| LS2-1 | Indications and outcomes: inborn errors of immunodeficiencies
Claire Booth (London, United Kingdom of Great Britain and Northern Ireland (the)) | 16:30 - 16:55 |
| LS2-2 | Indications and outcomes: sickle cell disease
Akshay Sharma (Memphis, United States of America (the)) | 16:55 - 17:20 |
| LS2-3 | CRISPR gene editing tools: novel developments
Iris Hagemans (Nijmegen, Netherlands (the)) | 17:20 - 17:45 |

Psy Day

16:30 - 17:45

R11

Psy4 - Psy Day Session 4 | Long term care post-transplant

Surabhi Chaturvedi (London, United Kingdom of Great Britain and Northern Ireland (the))

- | | | |
|--------|--|---------------|
| PSY4-1 | Psychosocial development in BMT survivors: how BMT patients cope during the post transplant years
Stefania Spina (Milano, Italy) | 16:30 - 16:50 |
| PSY4-2 | Communication deficits in long-term care after allogeneic hematopoietic stem cell transplantation - results from a single center interview study

Daniel Wolff (Regensburg, Germany)
Guy Tavori (Kefar Vitkin, Israel) | 16:50 - 17:10 |
| PSY4-3 | The role of Post-Traumatic Growth (PTG) in recovery post-transplant
Kathleen McHugh (Glasgow, United Kingdom of Great Britain and Northern Ireland (the)) | 17:10 - 17:30 |
| PSY4-4 | Q&A | 17:30 - 17:45 |

Nurses Group

16:30 - 18:00

R12

NG05 - Skills Lab | Research workshop

Annika Kisch (Lund, Sweden)

Lynn Leppla (Freiburg, Germany, Germany)

- | | | |
|--------|--|---------------|
| NG05-1 | Guidelines for the use of AI and AI-assisted technologies in research
Ozgun Gokmen Kaya (Istanbul, Turkey) | 16:30 - 16:55 |
| NG05-2 | The ethical and legal concerns of using AI in research
Isabel Salcedo (Madrid, Spain) | 16:55 - 17:20 |
| NG05-3 | Embracing the challenge for literature searches: a hands-on workshop
Simona Calza (Genoa, Italy) | 17:20 - 18:00 |

Pharmacists Day

16:30 - 18:00

R13

Pharm5 - Pharmacists Training Session

Nick Duncan (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))

Patient, Family, and Donor Day

16:45 - 17:45

R15

PFDD5 - Patient, Family, and Donor Day 5 | Building a Sustainable Future for CAR-T Cell Therapy

Natacha Bolaños (Madrid, Spain)

Guy Bouguet (Paris, France)

PFDD5-1	Introduction	16:45 - 16:50
PFDD5-2	The challenges of CAR-T therapy trials for Myositis: A MIHRA initiative to respond to patient needs and safety concerns Karen Cheng (Basel, Switzerland)	16:50 - 17:05
PFDD5-3	CAR-T patients' experiences, quality of life and supportive care needs Elise Pennings (Amsterdam, Netherlands (the))	17:05 - 17:20
PFDD5-4	Patient experience on CAR-T cell therapy (title TBC) Silvio Giancesella (Bergamo, Italy)	17:20 - 17:35
PFDD5-5	Discussion - Q&A	17:35 - 17:45

Breaks

18:00 - 18:15

R1

Break*General*

18:15 - 19:45

R1

GS1 - Opening Ceremony

Anna Sureda (Barcelona, Spain)

Fabio Ciceri (Milano, Italy)

GS1-1	Welcome and introduction Anna Sureda (Barcelona, Spain)	18:15 - 18:20
GS1-2	Welcome and introduction to the conference Fabio Ciceri (Milano, Italy)	18:20 - 18:25
GS1-3	EBMT Patient Advocacy Committee: Welcome note Natacha Bolaños (Madrid, Spain)	18:25 - 18:30
GS1-4	Welcome from the Nurses Group Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))	18:30 - 18:35
GS1-5	Honorary Members 2025 Catherine Cordonnier (Créteil, France) Myriam Labopin (Paris, France) Norbert Schmitz (Hamburg, Germany) Gerard Socie (France)	18:35 - 18:47
GS1-6	Introduction to the Tribute lecture Fabio Ciceri (Milano, Italy) Paolo Muraro (London, United Kingdom of Great Britain and Northern Ireland (the))	18:47 - 18:55
GS1-7	Tribute lecture - HSCT in MS: from experimental procedure to standard of care Gianluigi Mancardi (Genova, Italy)	18:55 - 19:10
GS1-8	Introduction of the Keynote speakers Fabio Ciceri (Milano, Italy)	19:10 - 19:15
GS1-9	Keynote lecture - Gene therapy: from bench to bedside journey Luigi Naldini (Milan, Italy) Franco Locatelli (Rome, Italy)	19:15 - 19:45

Monday, 31. March 2025*Meetings*

07:00 - 08:45

R4

BM-IDWP - Business Meeting of the Infectious Diseases Working Party

Dina Averbuch (Jerusalem, Israel)

Meetings

07:00 - 08:45

R10

BM-SAAWP - Business Meeting of the Severe Aplastic Anaemia Working Party

Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the))

Meetings

07:00 - 08:45

R11

BM-PDWP - Business Meeting of the Paediatric Diseases Working Party

Krzysztof Kalwak (WROCLAW, Poland)

Meetings

07:00 - 08:45

R12

BM-CMWP - Business Meeting of the Chronic Malignancies Working Party

Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the))

Meet the Expert

07:45 - 08:45

R16

MTE-2 - Meet-the-Expert: Respiratory viruses including SARS-CoV-2

MTE-2

Respiratory viruses including SARS-CoV-2

07:45 - 08:45

Jaap Van Doesum (Groningen, Netherlands (the))

Maria Teresa Lupo-Stanghellini (Milano, Italy)

Meet the Expert

07:45 - 08:45

R16

MTE-3 - Meet-the-Expert: Donor Choice in 2025

MTE-3

Donor Choice in 2025

07:45 - 08:45

Katharina Fleischhauer (Essen, Germany)

Marco Andreani (Rome, Italy)

Meet the Expert

07:45 - 08:45

R16

MTE-4 - Meet-the-Expert: Endothelial complications

MTE-4

Endothelial complications

07:45 - 08:45

Rafael Duarte (Madrid, Spain)

Selim Corbacioglu (Regensburg, Germany)

Meet the Expert

07:45 - 08:45

R16

MTE-5 - Meet-the-Expert: Chronic GVHD - is there a first-line alternative to standard therapy?

MTE-5

Chronic GVHD: is there a first-line alternative to standard therapy?

07:45 - 08:45

Alessandra Picardi (Naples, Italy)

Meet the Expert

07:45 - 08:45

R16

MTE-6 - Meet-the-Expert: Allografts in older AML patient

MTE-6

Allografts in older AML patient

07:45 - 08:45

Adriano Venditti (Rome, Italy)

Marie Robin (Paris, France)

Meet the Expert

07:45 - 08:45

R16

MTE-7 - Meet-the-Expert: VEXAS from biology to clinics

MTE-7

VEXAS from biology to clinics

07:45 - 08:45

Carmelo Gurnari (Rome, Italy)

Meet the Expert

07:45 - 08:45

R16

MTE-8 - Meet-the-Expert: Allo-SCT in Plasma cell leukemia

MTE-8

Allo-SCT in Plasma cell leukemia

07:45 - 08:45

Francesca Patriarca (Udine, Italy)

Luca Castagna (Palermo, Italy)

Meet the Expert

07:45 - 08:45

R16

MTE-1 - Meet-the-Expert: HSCT in AML/MDS secondary to Multiple Myeloma treatments and haematological secondary malignancies after CAR-T therapy for lymphomas

MTE-1

HSCT in AML/MDS secondary to Multiple Myeloma treatments and haematological secondary malignancies after CAR-T therapy for lymphomas

07:45 - 08:45

Benedetto Bruno (Torino, Italy)

Marco Ladetto (Italy)

Meet the Expert

07:45 - 08:45

R16

MTE - Breakfast Meet the Expert - Monday*Meet the Expert*

07:45 - 08:45

R16

QM-MTE-1 - Quality Management Meet the Expert: IEC Accreditation: extending the scope or a standalone accreditation?

QM-MTE-1

IEC Accreditation: extending the scope or a standalone accreditation?

07:45 - 08:45

Carla Sánchez (Barcelona, Spain)

Louisa McDonald (London, United Kingdom of Great Britain and Northern Ireland (the))

Meet the Expert

07:45 - 08:45

R16

QM-MTE-2 - Quality Management Meet the Expert: Management of Occurrences: A risk based approach to quality improvement

QM-MTE-2

Management of Occurrences: A risk-based approach to quality improvement

07:45 - 08:45

Laurel Anderson (Johannesburg, South Africa)

Olivier Urbain (Brussels, Belgium)

Meetings

08:00 - 08:50

R15

IM-2 - Internal Meeting 2 - National Registries meeting*ePoster*

08:30 - 18:00

R18

ePoster Viewing*Plenary Session*

09:00 - 10:30

R1

P01 - Relapse in acute leukemia

Simona Pagliuca (NANCY, France)

Christoph Schmid (Augsburg, Germany)

- | | | |
|-------|---|---------------|
| P01-1 | Mechanisms of leukemia relapse after allogeneic transplantation: from biology to treatment (and back)
Luca Vago (Milano, Italy) | 09:00 - 09:30 |
| P01-2 | Relapsed B-ALL post CAR T-cell therapy
Alessandro Rambaldi (Bergamo, Italy) | 09:30 - 10:00 |
| P01-3 | Relapse therapy
Christoph Schmid (Augsburg, Germany) | 10:00 - 10:30 |

Cell Therapy Day

09:00 - 10:20

R2

CTD1 - Cell Therapy Day 1 | New insight on CAR-T

Annalisa Ruggeri (Italy)

Jurgen Kuball (Utrecht, Netherlands (the))

- | | | |
|--------|---|---------------|
| CTD1-0 | Welcome | 09:00 - 09:05 |
| CTD1-1 | CAR-T Hematotoxicity
Marion Subklewe (Munich, Germany) | 09:05 - 09:30 |
| CTD1-2 | Single-cell multiomic dissection of response and resistance to CAR-T
Maximillian Merz (New York City, United States of America (the)) | 09:30 - 09:55 |
| CTD1-3 | Bispecific and CAR-T cell therapy in Multiple Myeloma
Monique Minnema (Utrecht, Netherlands (the)) | 09:55 - 10:20 |

Educational

09:00 - 10:30

R3

E01 - GVHD prophylaxis across different donors

Helene Schoemans (Leuven, Belgium)

Ivan Moiseev (Saint-Petersburg, Russian Federation (the))

- | | | |
|-------|--|---------------|
| E01-1 | Extensive graft manipulation 2.0
Antonio Pierini (Perugia, Italy) | 09:00 - 09:30 |
| E01-2 | In vivo TCD
Nicolaus Kröger (Hamburg, Germany) | 09:30 - 10:00 |
| E01-3 | Novel Approaches to GVHD Prevention
Benjamin Watkins (New Orleans, United States of America (the)) | 10:00 - 10:30 |

Working Party Session

09:00 - 10:15

R4

IDWP - Infectious Diseases Working Party SessionDina Averbuch (Jerusalem, Israel)
Jan Styczynski (Bydgoszcz, Poland)

IDWP-1	State of the art: CMV management 2025: new ECIL guidelines Per Ljungman (Stockholm, Sweden)	09:00 - 09:18
IDWP-2	Challenges in the management of mold infections Martin Hoenigl (Graz, Austria)	09:18 - 09:36
IDWP-3	How shall I manage neutropenic patient with severe sepsis? Murat Akova (Ankara, Turkey)	09:36 - 09:54
IDWP-4	TOP 10 publications in HCT infections 2024 - 2025 Malgorzata Mikulska (Genoa, Italy) Dionysios Neofytos (Geneva, Switzerland)	09:54 - 10:12

Educational

09:00 - 10:30

R5

E02 - Hot topics for allogeneic HSCT in MDS and MPNAlessandro Vannucchi (Florence, Italy)
Kavita Raj (London, United Kingdom of Great Britain and Northern Ireland (the))

E02-1	Timing of allo-HCT in Myelofibrosis: not too early, not too late Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the))	09:00 - 09:30
E02-2	Allo in CMML Francesco Onida (Milano, Italy)	09:30 - 10:00
E02-3	Prevention and management of poor graft function after allo-SCT in MFI Nicola Polverelli (Pavia, Italy)	10:00 - 10:30

Workshop

09:00 - 10:30

R6

W01 - MicrobiomeGiorgia Battipaglia (Naples, Italy)
Zachariah DeFilipp (Boston, United States of America (the))

W01-1	New frontiers: present and future in new therapies Daniela Weber (Regensburg, Germany)	09:00 - 09:30
W01-2	Longitudinal change of microbiome during pediatric and adult HSCT Riccardo Masetti (Bologna, Italy)	09:30 - 10:00
W01-3	Microbiome modulation Florent Malard (Paris, France)	10:00 - 10:30

Nurses Group

09:00 - 10:30

R7

NG06 - Nurses Group Opening SessionMichelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))
Claudia Boglione (Florence, Italy)

NG06-1	Welcome and overview	09:00 - 09:10
NG06-2	Welcome to Florence	09:10 - 09:15
NG06-3	Presentation of the 17th Distinguished Merit Award	09:15 - 09:30

NG06-4	Keynote lecture: Lessons learned from a sibling Jade Sercu (Ghent, Belgium)	09:30 - 10:00
NG06-5	Keynote lecture: Donor confidentiality Nicoletta Sacchi (Genova, Italy)	10:00 - 10:30
<i>How do I... ?</i>		
09:00 - 10:15		R8
HDI1 - How Do I... Select CAR-T or Bispecific for relapsed DLBCL patients Supported through an unrestricted educational grant by Genmab		
Carmelo Carlo-Stella (Milano, Italy) Pier Luigi Zinzani (Bologna, Italy)		
HDI1-1	How I treat DLBCL patients relapsed after CAR T Marta Canelo-Vilaseca (Paris, France)	09:00 - 09:25
HDI1-2	Challenges associated with prescribing CAR T cell therapy after Bispecifics in DLBCL Mohamed Kharfan-Dabaja (Jacksonville, United States of America (the))	09:25 - 09:50
HDI1-3	Panel Discussion	09:50 - 10:15
<i>Joint Sessions</i>		
09:00 - 10:30		R9
JS01 - Joint Session EBMT - ISCT Strengthening Partnerships, Standards, and Talent in the ATMP Ecosystem		
Anna Sureda (Barcelona, Spain) Fermin Sanchez-Guijo (Salamanca, Spain)		
JS01-1	European regulatory challenges and opportunities for the development of ATMPs can we envision successful public-private collaborations? Miguel Forte (Rixensart, Belgium)	09:00 - 09:20
JS01-2	Challenges and perspectives for quality certification of ATMP therapy centers: role of JACIE Tuula Rintala (London, United Kingdom of Great Britain and Northern Ireland (the))	09:20 - 09:40
JS01-3	Education & Workforce development for manufacturing and clinical management of ATMPs Jaap Jan Zwaginga (Leiden, Netherlands (the))	09:40 - 10:00
JS01-4	Q&A	10:00 - 10:30
<i>Working Party Session</i>		
09:00 - 10:15		R10
SAAWP - Severe Aplastic Anaemia Working Party Session		
Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the)) Carlo Dufour (Genova, Italy)		
SAAWP-1	SAAWP Activities Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the))	09:00 - 09:10
SAAWP-2	Impact of age and donor type in transplant for SAA in the decade 2011-2020: a retrospective SAAWP study Carlo Dufour (Genova, Italy)	09:10 - 09:20
SAAWP-3	HSCT vs IST as front line therapy for SAA: option for retrospective and prospective comparative studies Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the))	09:20 - 09:30
SAAWP-4	Round Table: How I treat SAA in real life: burning question 1- How do I role out inherited BMF?	09:30 - 09:45

	Flore Sicre de Fontbrune (Paris, France)	
SAAWP-5	Round Table: How I treat SAA in real life: burning question 2- Do I offer haplo HSCT upfront? To which patients?	09:45 - 10:00
	Amy De Zern (Baltimore, United States of America (the))	
SAAWP-6	Round Table: How I treat SAA in real life: burning question 3- How do I manage Tpo-mimetics long-term in patients lacking/losing complete response	10:00 - 10:15
	Beatrice Drexler (Basel, Switzerland)	

Working Party Session

09:00 - 10:30

R11

HWP - Haemoglobinopathies Working Party Session

Emanuele Angelucci (Genova, Italy)

Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the))

HWP-1	Welcome and introduction	09:00 - 09:05
HWP-2	Clinical sign of VOC in SCD. Review of available literature Valeria Pinto (Genova, Italy)	09:05 - 09:20
HWP-3	Conditioning regimens for HSCT in Sickle Cell Disease: from myeloablative to immuno-ablative? Erfan Nur (Amsterdam, Netherlands (the))	09:20 - 09:35
HWP-4	Conditioning regimen for HCT in TDT: Review of available literature Mohammed Essa (Riyadh, Saudi Arabia)	09:35 - 09:50
HWP-5	Iron and the stem cell Federica Pilo (Cagliari, Italy)	09:50 - 10:05
HWP-6	HWP initiative for the low income countries: what has been done so far Miguel R. Abboud (Beirut, Lebanon)	10:05 - 10:20
HWP-7	Q&A	10:20 - 10:30

Patient Advocacy Session

09:00 - 10:15

R12

PAS1 - Patient Advocacy Committee Session 1 | CAR-T Cell Therapy: Advancing Access or Deepening Disparities?

Christian Chabannon (Marseille, France)

Natacha Bolaños (Madrid, Spain)

PAS1-1	Introduction	09:00 - 09:05
PAS1-2	Advancements in point-of-care approach to CAR-T cell manufacturing Arnon Nagler (Tel Aviv, Israel)	09:05 - 09:25
PAS1-3	Panel Discussion Arnon Nagler (Tel Aviv, Israel) Carmen Sanges (Würzburg, Germany) Christian Chabannon (Marseille, France)	09:25 - 10:10
PAS1-4	Conclusions	10:10 - 10:15

Special Session

09:00 - 10:15

R13

SS2 - Equality, Diversity, and Inclusion Session | How to preserve EDI values without compromising efficacy in a complex international environment: is scientific/academic boycott an option?

Nada Hamad (Newtown, Australia)

SS2-1

Panel Discussion (Trainee, Patients & EHA representatives)

09:00 - 10:15

Nihar Desai (Toronto, Canada)

Adele Fielding (York, United Kingdom of Great Britain and Northern Ireland (the))

Lorna Warwick (Mississauga, Canada)

Pharmacists Day

09:00 - 10:30

R14

Pharm1 - Pharmacists Day 1 | Clinical Update

Nick Duncan (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))

Agnès Bonnin (Paris, France)

Pharm1-1.1

Welcome from the EBMT Pharmacist committee

09:00 - 09:05

Nick Duncan (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))

Pharm1-1.2

Welcome from the oncology group of the Italian Society of Hospital Pharmacists

09:05 - 09:10

Aldo De Luca (Florence, Italy)

Pharm1-2

Haematopoietic stem cell transplantation and CAR-T therapy for autoimmune diseases

09:10 - 09:35

John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))

Pharm1-3

Nutrition for transplant patients

09:35 - 10:00

Stéphane Schneider (Nice, France)

Pharm1-4

The role of post-transplant maintenance in patients allografted for AML

10:00 - 10:25

Charles Craddock (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))

Data Management

09:00 - 10:25

R15

DM1 - Data Management Session 1 | The EBMT Registry: data reporting and the activity survey

Annelot van Amerongen (Den Haag, Netherlands (the))

Ignacio Garcia (Eindhoven, Netherlands (the))

DM1-1

Welcome

09:00 - 09:10

DM1-2

The EBMT Activity survey

09:10 - 09:30

Anja van Biezen (Netherlands (the))

DM1-3

Summary and demonstration of EBMT Registry functionalities added in 2023-2024

09:30 - 09:50

Nadiia Dyba (Dnipro, Ukraine)

DM1-4

EBMT data collection form revision 2024 update

09:50 - 10:10

Alina Kuliesh (Leiden, Netherlands (the))

DM1-5

Q&A

10:10 - 10:25

Breaks

10:30 - 11:00

R1

Coffee Break, ePoster Viewing, Visit Exhibition

Plenary Session

11:00 - 12:30

R1

P02 - Multidisciplinary approach in HSCT and IEC

Alice Mariottini (Florence, Italy)

John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))

P02-01	How to build a multidisciplinary team Francesco Maisano (milano, Italy)	11:00 - 11:23
P02-02	ICU MDT approach in hematology Suzanne van Dorp (Nijmegen, Netherlands (the))	11:23 - 11:46
P02-03	Immunomonitoring and translational diagnostics in CAR T-cell therapies Sophie Caillat-Zucman (Paris, France)	11:46 - 12:09
P02-04	Panel Discussion	12:09 - 12:30

Cell Therapy Day

11:00 - 12:15

R2

CTD2 - Cell Therapy Day 2 | How to find the best donor

Arnon Nagler (Tel Aviv, Israel)

Mary Eapen (Milwaukee, United States of America (the))

CTD2-1	HLA Immunopeptidome Katharina Fleischhauer (Essen, Germany)	11:00 - 11:25
CTD2-2	Donor selection for non-malignant disease Mary Eapen (Milwaukee, United States of America (the))	11:25 - 11:50
CTD2-3	Anti HLA antibodies in HCT outcomes Annalisa Ruggeri (Italy)	11:50 - 12:15

Educational

11:00 - 12:30

R3

E03 - New frontiers in acute and chronic GVHD

Attilio Olivieri (Ancona, Italy)

Daniel Wolff (Regensburg, Germany)

E03-0	Introduction Attilio Olivieri (Ancona, Italy) Daniel Wolff (Regensburg, Germany)	11:00 - 11:00
E03-1	New insight in pathogenesis of GVHD Robert Zeiser (Freiburg, Germany)	11:00 - 11:30
E03-2	Challenges and opportunities of biomarkers in GVHD Hildegard T. Greinix (Graz, Austria)	11:30 - 12:00
E03-3	Management of Ruxolitinib-refractory GVHD Corey S. Cutler (Boston, United States of America (the))	12:00 - 12:30

Working Party Session

11:00 - 12:15

R4

CMWP - Chronic Malignancies Working Party Session

Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the))

Joanna Drozd-Sokolowska (Warsaw, Poland)

CMWP-1	Harnessing Machine Learning to predict outcomes post allogeneic HCT for chronic myeloid malignancies Adrian Mosquera-Orgeira (Santiago de Compostela, Spain)	11:00 - 11:10
CMWP-2	Future thinking Strategies to optimise outcomes in allogeneic HCT	11:10 - 11:20

	for Myelofibrosis	
	Juan Carlos Hernández-Boluda (Valencia, Spain)	
CMWP-3	Role of allogeneic HCT for CML in 2025: a Latin America perspective	11:20 - 11:30
	Natalia Aranguiz García (Santiago, Chile)	
CMWP-4	Optimising outcomes in allogeneic HCT for CMML in 2025: a Latin America perspective	11:30 - 11:40
	Fernando Barroso Duarte (Fortaleza, Brazil)	
CMWP-5	The who, when and how: allogeneic HCT in Advanced Systemic Mastocytosis: an EBMT perspective	11:40 - 11:50
	Deepti Radia (London, United Kingdom of Great Britain and Northern Ireland (the))	
CMWP-6	Role of allogeneic HCT in Atypical MPN and overlap syndromes: a consensus on behalf of the Practice Guidelines and Harmonisation Committee	11:50 - 12:00
	Nicola Polverelli (Pavia, Italy)	
CMWP-7	Discussion	12:00 - 12:15
<i>Educational</i>		
11:00 - 12:30		R5
E04 - Conditioning regimen, pre/post transplant strategies		
Alessandro Rambaldi (Bergamo, Italy)		
Annoek Broers (Rotterdam, Netherlands (the))		
E04-1	Challenges of AML CAR T cell therapy	11:00 - 11:18
	Sara Ghorashian (London, United Kingdom of Great Britain and Northern Ireland (the))	
E04-2	Defining the optimal conditioning regimen in adults allografted for AML	11:18 - 11:36
	Charles Craddock (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	
E04-3	Should Conditioning regimens be tailored for each disease?	11:36 - 11:54
	Anna Sureda (Barcelona, Spain)	
E04-4	HSC engineering enables antibody-based posttransplant therapy	11:54 - 12:12
	Lukas Jeker (Basel, Switzerland)	
E04-5	Panel Discussion	12:12 - 12:30
<i>Workshop</i>		
11:00 - 12:30		R6
W02 - Vaccine and other prevention strategies		
Livio Pagano (Roma, Italy)		
Mette Hazenberg (Amsterdam, Netherlands (the))		
W02-1	Locally endemic infections: pre-transplant evaluation and post-transplant evaluation and prevention	11:00 - 11:30
	Clarisse Machado (São Paulo, Brazil)	
W02-2	What is new in vaccination after HCT	11:30 - 12:00
	Corrado Girmenia (Rome, Italy)	
W02-3	Adoptive cellular therapy	12:00 - 12:30
	Patrizia Comoli (Pavia, Italy)	

Nurses Group

11:00 - 12:30

R7

NG07 - Oral Adult - Best Abstract Award Finalist

Sandra Schoenfeld (Basel, Switzerland)

Letizia Galgano (florence, Italy)

NG07-01	FACTORS PREDICTING THE INCIDENCE RATE OF RETURNING TO WORK FOR PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE COHORT STUDY Meng-Kuan Chiang (Taipei, Taiwan (Province of China))	11:00 - 11:15
NG07-02	PERCEPTION OF "PATIENT SAFETY CULTURE" AMONG HEALTHCARE PROFESSIONALS IN THE FIELD OF HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CAR-T: A MULTICENTER CROSS-SECTIONAL OBSERVATIONAL STUDY BY GITMO Marco Cioce (Rome, Italy)	11:15 - 11:30
NG07-03	ADHERENCE TO IMMUNOSUPPRESSORS AND QUALITY OF LIFE: A SUB-ANALYSIS OF THE NURSING INTERVENTION TO STRENGTHEN MEDICATION ADHERENCE AFTER ALLOGENEIC TRANSPLANTATION (NISMAT) TRIAL Chiara Visintini (Udine, Italy)	11:30 - 11:45
NG07-04	QUALITY OF LIFE, ANXIETY, AND DEPRESSION REPORTED BY PATIENTS DURING THE FIRST 24 MONTHS FOLLOWING CAR-T CELL THERAPY Mercedes Montoro-Lorite (Barcelona, Spain)	11:45 - 12:00
NG07-05	LONGITUDINAL IMPLICATIONS OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ON PHYSICAL AND FUNCTIONAL HEALTH: A SINGLE-SERVICE REVIEW OF PHYSIOTHERAPY OUTCOME MEASURES James Williams (Cardiff, United Kingdom of Great Britain and Northern Ireland (the))	12:00 - 12:15

How do I... ?

11:00 - 12:15

R8

HDI2 - How Do I... deliver best practice in CAR T cell therapy? | Supported through an unrestricted educational grant by Gilead and Kite

Chiara Cannici (Alessandria, IT, Italy)

Maaïke de Ruijter (Haarlem, Netherlands (the))

HDI2-1	Fostering smooth transitions in care Charlotte Mestdagh (Belgium)	11:00 - 11:15
HDI2-2.1	In or out - the right model, right patient, right time Hybrid/IP Marina Hernandez (Valencia, Spain)	11:15 - 11:30
HDI2-2.2	In or out - the right model, right patient, right time Ambulatory Nuria Ballestar (Barcelona, Spain)	11:30 - 11:45
HDI2-3	Keeping patients safe after CAR T - current strategies in side effect monitoring and management escalation Mathias Hellberg-Naegele (St. Gallen, Switzerland)	11:45 - 12:00
HDI2-4	Q&A	12:00 - 12:15

Joint Sessions

11:00 - 12:30

R9

JS02 - Joint Session EBMT - WBMT | Global perspective, addressing transplantation in the context of haematological malignancies

Damiano Rondelli (Chicago, United States of America (the))

Fabio Ciceri (Milano, Italy)

JS02-1	AML Dietger Niederwieser (Germany)	11:00 - 11:25
JS02-2	Disparities treating acute lymphoblastic leukemia Adriana Seber (Sao Paul, Brazil)	11:25 - 11:50
JS02-3	Myeloma Laurent Garderet (Paris, France)	11:50 - 12:15
JS02-4	Q&A	12:15 - 12:30

Special Session

11:00 - 12:30

R10

SS3 - EBMT Contest II - Machine Dreams: How can AI shape hematology now and in the future

Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the))

Nico Gagelmann (Hamburg, Germany)

Roni Shouval (New York, United States of America (the))

SS3-1	THE ALGORITHM OF LIFE: MACHINE MINDS AND HUMAN TOUCH - TRANSFORMING UNRELATED ALLOGENEIC BONE MARROW TRANSPLANTATION WITH AI Pinelopi Samara (Athens, Greece)	11:00 - 11:15
SS3-2	THE AMALGAMATION OF AI IN HEMATOLOGY: UPSCALING, COMPLEMENTING, AND GUIDING Nida Malik (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	11:15 - 11:30
SS3-3	USHERING IN THE ERA OF THE HEMATOLOGIST-AI ALLIANCE: THE DELICATE BALANCE OF HUMAN WISDOM AND ARTIFICIAL SYNTHESIS Manuela Spadea (Turin, Italy)	11:30 - 11:45
SS3-4	AI (Artificial Intelligence) vs RI (Real Intelligence): WHERE DO WE MEET? Cristobal Frutos-Ortiz (Asuncion, Paraguay)	11:45 - 12:00
SS3-5	ARTIFICIAL INTELLIGENCE IN ALLOGENEIC STEM CELL TRANSPLANTATION: TRANSFORMING RISK PREDICTION AND PATIENT CARE Gonzalo Bentolila (Ciudad Autónoma de Buenos Aires, Argentina)	12:00 - 12:15
SS3-6	Audience voting & Winner announcement	12:15 - 12:30

Nurses Group

11:00 - 12:30

R11

NG08 - Disease update

Iwona Przewozna (Poznan, Poland)

Claudia Boglione (Florence, Italy)

NG08-1	What is new in autoimmune disease? Raffaella Greco (Milano, Italy)	11:00 - 11:21
NG08-2	Immunodeficiencies Ignacio González (Madrid, Spain)	11:21 - 11:42
NG08-3	Aplastic anaemia Kelly Hennessy (London, United Kingdom of Great Britain and Northern Ireland (the))	11:42 - 12:03
NG08-4	Myelodysplastic neoplasms (MDS) Dominiek Mazure (Gent, Belgium)	12:03 - 12:24
NG08-5	Q&A	12:24 - 12:29

Patient Advocacy Session

11:00 - 12:15

R12

PAS2 - Patient Advocacy Committee Session 2 | Equitable Standards of Care in Bone Marrow Transplantation

Jurgen Kuball (Utrecht, Netherlands (the))

Natacha Bolaños (Madrid, Spain)

PAS2-1	Introduction	11:00 - 11:05
PAS2-2	Promoting equity in access to SoHO-based therapies: Bone Marrow Transplantation Nada Hamad (Newtown, Australia)	11:05 - 11:20
PAS2-3	Expectations and reality of access to BMT for autoimmune diseases Tobias Alexander (Berlin, Germany)	11:20 - 11:35
PAS2-4	Building Standards of Care in BMT for the treatment of MS and NMOSD Basil Sharrack (United Kingdom of Great Britain and Northern Ireland (the))	11:35 - 11:50
PAS2-5	Panel Discussion	11:50 - 12:10
PAS2-6	Conclusions	12:10 - 12:15

Statistics

11:00 - 12:00

R13

STATS 1 - Statistical Symposium

Hein Putter (Leiden, Netherlands (the))

Matthieu Resche-Rigon (Paris, France)

STATS 1-1	Use of external data for indirect comparison Jérôme Lambert (France)	11:00 - 11:20
STATS 1-2	Joint Models as a Tool for Modelling Immune Cell Kinetics and their Association with Allo-Immunological Events Liesbeth de Wreede (Leiden, Netherlands (the))	11:20 - 11:40
STATS 1-3	Regression model for duration of response after CAR-T cell therapy Kwang Woo Ahn (Milwaukee, WI, United States of America (the))	11:40 - 12:00

Pharmacists Day

11:00 - 12:15

R14

Pharm2 - Pharmacists Day 2 | Access to drugs

Claudia Langebrake (Hamburg, Germany)

Estela Moreno (Barcelona, Spain)

Pharm2-1	Changes in the Landscape for Drug Shortages across Europe Segundo Mariz (Netherlands (the))	11:00 - 11:25
Pharm2-2	Drug shortages and implications for transplant treatment schedules Sumantha Gabriel (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the))	11:25 - 11:50
Pharm2-3	Panel discussion - challenges in accessing new treatments and dealing with drug shortages Agnès Bonnin (Paris, France) Claudia Langebrake (Hamburg, Germany) Sumantha Gabriel (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) Segundo Mariz (Netherlands (the))	11:50 - 12:15

Data Management

11:00 - 12:15

R15

DM2 - Data Management Session 2 | OMOP in action: mapping, data transformation and data analysis

Annelot van Amerongen (Den Haag, Netherlands (the))

Hendrikus Bouwman (Putten, Netherlands (the))

DM2-1	The OMOP mapping process for EBMT data collection forms Nikolaos Glentis (Utrecht, Netherlands (the))	11:00 - 11:20
DM2-2	OMOP transformation: Behind the scenes Fernando Cid (Barcelona, Spain)	11:20 - 11:40
DM2-3	MicroStrategy for the EBMT Registry: process, functionalities and plans Ignacio Garcia (Eindhoven, Netherlands (the))	11:40 - 12:00
DM2-4	Q&A	12:00 - 12:15

Breaks

12:30 - 13:00

R1

Lunch Break, ePoster Viewing, Visit Exhibition*Meetings*

12:45 - 14:00

R11

BM-HWP - Business Meeting of the Haemoglobinopathies Working Party

Emanuele Angelucci (Genova, Italy)

Meetings

12:45 - 14:00

R13

BM-TCWP - Business Meeting of the Transplant Complications Working Party

Zinaida Peric (Rijeka, Croatia)

Industry Symposium

13:00 - 14:00

R1

IS19 - YOU VS. R/R DLBCL: NAVIGATING THE PATH TO A POTENTIAL CURE | Gilead & Kite

Fabio Ciceri (Milano, Italy)

IS19-1	You vs. R/R DLBCL: Navigating the path to a potential cure - Welcome and introduction Fabio Ciceri (Milano, Italy)	13:00 - 13:05
IS19-2	Case study 1: The patient who is responding to bridging therapy Annalisa Ruggeri (Italy)	13:05 - 13:17
IS19-3	Case study 2: The patient with high tumour volume Gloria Iacoboni (Barcelona, Spain)	13:17 - 13:29
IS19-4	Case study 3: The frail patient Miguel-Angel Perales (New York, United States of America (the))	13:29 - 13:41
IS19-5	Case study 4: The patient with refractory disease Kate Cwynarski (London, United Kingdom of Great Britain and Northern Ireland (the))	13:41 - 13:53
IS19-6	The quest continues Fabio Ciceri (Milano, Italy)	13:53 - 14:00

Industry Symposium

13:00 - 14:00

R2

IS20 - Harnessing the Power of Four: Optimizing Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapies in Newly Diagnosed Multiple Myeloma | Provided by Answers in CME Inc. (Supported by an educational grant from Sanofi)

Mohamad Mohty (Paris, France)

Maria Victoria Mateos (Salamanca, Spain)

IS20-1	Initial Considerations: Burden of Disease and the Case for Quadruplet Therapies in NDMM	13:00 - 13:10
	Mohamad Mohty (Paris, France) Maria Victoria Mateos (Salamanca, Spain)	
IS20-2	Optimizing Efficacy: Latest Evidence for Quadruplet Regimens in Transplant-Eligible Patients	13:10 - 13:20
	Mohamad Mohty (Paris, France) Maria Victoria Mateos (Salamanca, Spain)	
IS20-3	Expanding Options: Efficacy of Quadruplet Regimens in Transplant-Ineligible Patients	13:20 - 13:30
	Mohamad Mohty (Paris, France) Maria Victoria Mateos (Salamanca, Spain)	
IS20-4	Enhancing Safety: Managing Adverse Effects Across Patient Populations	13:30 - 13:40
	Mohamad Mohty (Paris, France) Maria Victoria Mateos (Salamanca, Spain)	
IS20-5	Collaborative Care: Communication, Shared Decision-Making, and Multidisciplinary Team (MDT) Approaches	13:40 - 13:50
	Mohamad Mohty (Paris, France) Maria Victoria Mateos (Salamanca, Spain)	
IS20-6	Audience Q&A and Closing Remarks	13:50 - 14:00
	Mohamad Mohty (Paris, France) Maria Victoria Mateos (Salamanca, Spain)	

Meetings

13:00 - 14:00

R7

BM-NG - EBMT Nurses Group overview opportunities and networking*Industry Theatre*

13:10 - 13:45

R17

IT1 - Navigating studies in evidence generation: The role of RWE| SANOFI

Corey S. Cutler (Boston, United States of America (the))

IT1-1	Welcome and Introduction	13:10 - 13:15
	Corey S. Cutler (Boston, United States of America (the)) Daniel Wolff (Regensburg, Germany)	
IT1-2	Speaker presentation	13:15 - 13:25
	Corey S. Cutler (Boston, United States of America (the))	
IT1-3	RWE: Unlocking the value of interventions in real-life settings	13:25 - 13:35
	Daniel Wolff (Regensburg, Germany)	
IT1-4	Discussion and Q&A	13:35 - 13:45
	Corey S. Cutler (Boston, United States of America (the)) Daniel Wolff (Regensburg, Germany)	

Breaks

14:00 - 14:30

R1

Break, ePoster Viewing, Visit Exhibition*Plenary Session*

14:30 - 16:00

R1

P03 - Next-generation sequencing in hematologic disorders

Carmelo Carlo-Stella (Milano, Italy)

Konstanze Doehner (Ulm, Germany)

P03-1	Role of liquid biopsy in T cell redirecting immunotherapy of lymphomas Paolo Corradini (Milan, Italy)	14:30 - 15:00
P03-2	Can NGS MRD better guide management of patients undergoing transplant of CAR T cell therapy for B ALL? Michael Pulsipher (Salt Lake City, United States of America (the))	15:00 - 15:30
P03-3	CHIP post CAR-T Frederik Damm (Berlin, Germany)	15:30 - 16:00

Cell Therapy Day

14:30 - 15:45

R2

CTD3 - Cell Therapy Day 3 | ATMPs for cancer (Beyond CAR-T)

Chiara Bonini (Milan, Italy)

Florent Malard (Paris, France)

CTD3-1	iNKT cell platform for CAR and TCR Giulia Casorati (Milano, Italy)	14:30 - 14:55
CTD3-2	gd T cells Jurgen Kuball (Utrecht, Netherlands (the))	14:55 - 15:20
CTD3-3	Enhancing TCR-based approaches for cancer immunotherapy Emma Morris (London, United Kingdom of Great Britain and Northern Ireland (the))	15:20 - 15:45

Oral Session

14:30 - 15:45

R3

OS01 - Oral Session 1 | Viral Infections

Jan Styczynski (Bydgoszcz, Poland)

Molly Fischer (Seattle, United States of America (the))

OS1-01	LETTERMOVIR PROPHYLAXIS GUIDED BY CYTOMEGALOVIRUS CELL-MEDIATED IMMUNITY IMPROVES THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Luxiang Wang (Shanghai, China)	14:30 - 14:39
OS1-02	USE OF VST CELLS FOR RELAPSED/REFRACTORY VIRAL INFECTIONS AFTER HSC AND ORGAN SOLID TRANSPLANT: RELEVANCE OF A THIRD PARTY DONOR REGISTRY FOR TREATMENT AVAILABILITY Nerea Castillo-Flores (Barcelona, Spain)	14:39 - 14:48
OS1-03	HERPES ZOSTER FREQUENCY IS SIMILAR WITH OR WITHOUT ADJUVANTED RECOMBINANT ZOSTER VACCINATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Jonas Mattsson (Toronto, Canada)	14:48 - 14:57
OS1-04	IMPACT OF DONOR AND RECIPIENT EBV-SEROSTATUS ON INCIDENCE OF ACUTE AND CHRONIC GVHD AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION:	14:57 - 15:06

	INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY	
	Jan Styczynski (Bydgoszcz, Poland)	
OS1-05	DIFFERENTIAL IMMUNE RECONSTITUTION PROFILES BETWEEN ORCA-T AND CD34 ALLOGRAFT RECIPIENTS PROVIDE INSIGHT FOR CONTROL OF VIRAL INFECTIONS	15:06 - 15:15
	Ioannis Politikos (New York, United States of America (the))	
OS1-06	RECIPIENT HERPES SIMPLEX VIRUS SEROSTATUS AND 1-YEAR SURVIVAL AMONG ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS	15:15 - 15:24
	Molly Fischer (Seattle, United States of America (the))	
OS1-07	IMPACT OF CYTOMEGALOVIRUS VIREMIA CLEARANCE ON POST-HEMATOPOIETIC-CELL TRANSPLANT MORTALITY: SOLSTICE POST-HOC ANALYSIS	15:24 - 15:33
	Johan Maertens (Leuven, Belgium)	
OS1-08	PRACTICES AND THE MANAGEMENT OF POST-TRANSPLANT HEMORRHAGIC CYSTITIS (HC) AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A SURVEY OF INFECTIOUS DISEASES WORKING PARTY OF EBMT	15:33 - 15:42
	Simone Cesaro (Verona, Italy)	
<i>Oral Session</i>		
	14:30 - 15:45	R4
OS02 - Oral Session 2 Haemoglobinopathy		
	Miguel R. Abboud (Beirut, Lebanon)	
	Mattia Algeri (Rome, Italy)	
OS2-01	DURABLE CLINICAL BENEFITS IN SEVERE SICKLE CELL DISEASE WITH EXAGAMGLOGENE AUTOTEMCEL	14:30 - 14:39
	Haydar Frangoul (Nashville, United States of America (the))	
OS2-02	ABATACEPT ABROGATES THE RISK OF ACUTE GVHD IN BOTH MATCHED AND MISMATCHED TRANSPLANTATION FOR HAEMOGLOBINOPATHIES AND BONE MARROW FAILURE	14:39 - 14:48
	Daniel Dexter (London, United Kingdom of Great Britain and Northern Ireland (the))	
OS2-03	ALLOGENEIC TRANSPLANTATION FOR SICKLE CELL DISEASE OFFERS HIGH RATES OF CURE WITH LOW INCIDENCE OF CHRONIC GVHD ACROSS ALL AGES: REAL WORLD DATA 2010-2021	14:48 - 14:57
	Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the))	
OS2-04	CS-101 TREATMENT IN PEDIATRIC TRANSFUSION-DEPENDENT B-THALASSEMIA LEADS TO RAPID, SUSTAINED FETAL HEMOGLOBIN PRODUCTION VIA EX VIVO EDITING OF AUTOLOGOUS CD34+ CELLS USING TRANSFORMER BASE EDITOR	14:57 - 15:06
	Zifeng Li (Shanghai, China)	
OS2-05	FLUDARABINE/TREOSULFAN/THIOTEPA/ATG CONDITIONING FOR SIBLING HAEMOPOIETIC STEM TRANSPLANTATION IN SICKLE CELL DISEASE LEADS TO EARLY AND SUSTAINED ENGRAFTMENT WITH LOW TOXICITY & GVHD	15:06 - 15:15
	Adam Gassas (London, United Kingdom of Great Britain and Northern Ireland (the))	
OS2-06	DURABLE CLINICAL BENEFITS IN TRANSFUSION-DEPENDENT B-THALASSEMIA WITH EXAGAMGLOGENE AUTOTEMCEL	15:15 - 15:24
	Franco Locatelli (Rome, Italy)	
OS2-07	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR ALPHA/BETA DEPLETION IN	15:24 - 15:33

	PEDIATRIC TRANSFUSION DEPENDENT THALASSEMIA AFTER PRE TRANSPLANT IMMUNOSUPPRESSION	
	Sunil Bhat (Bangalore, India)	
OS2-08	TREOSULFAN, THIOTEPA, AND FLUDARABINE-BASED REDUCED TOXICITY CONDITIONING REGIMEN IN CHILDREN WITH THALASSEMIA MAJOR: A REPORT FROM A TERTIARY CARE CENTER IN INDIA	15:33 - 15:42
	Ravi Joshi (Bengaluru, India)	
<i>Oral Session</i>		
14:30 - 15:45		
		R5
OS03 - Oral Session 3 ATMP preclinical and clinical		
Alice Bertaina (Stanford, United States of America (the))		
Fabian Freitag (Würzburg, Germany)		
OS3-01	THERAPEUTIC DOSES OF T-ALLO10 IMMUNOTHERAPY POST-ABDEPLETED HSCT ENHANCE IMMUNE RECONSTITUTION AND ACHIEVE 100% LEUKEMIA-FREE SURVIVAL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES	14:30 - 14:39
	Alice Bertaina (Stanford, United States of America (the))	
OS3-02	DISTINCT PREFERENCES OF CD8⁺ AND CD4⁺ CAR-T CELLS FOR TRANSCRIPTION FACTOR ENHANCEMENT	14:39 - 14:48
	Fabian Freitag (Würzburg, Germany)	
OS3-03	ENGINEERING INTERLEUKIN-12 SECRETING CHIMERIC ANTIGEN RECEPTOR (CAR) NATURAL KILLER CELLS TO TARGET HIGH-RISK ACUTE MYELOID LEUKEMIA	14:48 - 14:57
	Remy Dulery (Boston, United States of America (the))	
OS3-04	OBSERVATIONAL COMPARISON OF OVERALL SURVIVAL BETWEEN PHASE 1B ORCA-T® AND REGISTRY-BASED POST-TRANSPLANT CYCLOPHOSPHAMIDE PATIENTS	14:57 - 15:06
	Arpita P. Gandhi (Portland, United States of America (the))	
OS3-05	PRECLINICAL MODELLING AND MECHANISTIC INSIGHTS INTO CAR-T CELL INDUCED NEUROTOXICITY	15:06 - 15:15
	Rita El Khoury (Milan, Italy)	
OS3-06	LDHB IS A THERAPEUTIC TARGET TO OVERCOME SELINEXOR RESISTANCE IN ACUTE MYELOID LEUKEMIA	15:15 - 15:24
	Limengmeng Wang (Hangzhou, China)	
OS3-07	CD19.CAR-T DERIVED EXTRACELLULAR VESICLES: A NEW DYNAMIC BIOMARKER WITH A STRONG ANTILEUKEMIC ACTIVITY	15:24 - 15:33
	Paola Lanuti (Chieti, Italy)	
OS3-08	INHIBITION OF MITOCHONDRIAL TRANSLATION IMPROVES MITOCHONDRIA FITNESS AND ENHANCES ANTI-TUMOR EFFICACY OF CAR-T CELLS	15:33 - 15:42
	Mi Shao (Hangzhou, China)	
<i>Joint Sessions</i>		
14:30 - 15:45		
		R6
JS03 - Joint Session EBMT Trainee Committee & YoungEHA Do we need hemato-pathology training in 2025?		
Nico Gagelmann (Hamburg, Germany)		
Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the))		
Nuno Borges (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the))		
JS03-1	Introduction	14:30 - 14:35

JS03-2	YoungEHA Nuno Borges (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the))	14:35 - 14:45
JS03-3	The Trainee Committee Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) Nico Gagelmann (Hamburg, Germany)	14:45 - 14:55
JS03-4	Case challenges	14:55 - 15:45
<i>Nurses Group</i>		
14:30 - 16:00		R7
NG09 - Joint NG - PSY Session: Survivorship: Psychological and psychosocial care		
Marijke Quaghbeur (Ghent, Belgium) Surabhi Chaturvedi (London, United Kingdom of Great Britain and Northern Ireland (the))		
NG09-1	Surviving 2 stem cell transplantations - the aftermath Remy Frieden (Switzerland)	14:30 - 14:40
NG09-2	A new normal, a new "self": impact on identity post-transplant in chronic illness Helen Aiston (Southampton, United Kingdom of Great Britain and Northern Ireland (the))	14:40 - 15:00
NG09-3	Psychological aspects of survivorship : emotional distress, trauma & growth Alice Polomeni (PARIS 12alic, France)	15:00 - 15:20
NG09-4	Enabling transitions from home to health Trude Minnee (Leiden, Netherlands (the))	15:20 - 15:40
NG09-5	Panel Discussion	15:40 - 16:00
<i>Oral Session</i>		
14:30 - 15:45		R8
OS04 - Oral Session 4 Hemopoiesis and biology of cell therapy complications		
Parastoo B. Dahi (New York, United States of America (the)) Mathias Schäfersküpfer (Hamburg, Germany)		
OS4-01	RECONSTRUCTING SKELETAL HOMEOSTASIS THROUGH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS Mathias Schäfersküpfer (Hamburg, Germany)	14:30 - 14:39
OS4-02	CLONAL HAEMATOPOIESIS IN PATIENTS WITH AUTOIMMUNE DISEASE UNDERGOING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT David D. Ma (Sydney, Australia)	14:39 - 14:48
OS4-03	PROPHYLACTIC ANAKINRA FOR TOXICITY MITIGATION IN HIGH-RISK CD19-CAR-T PATIENTS: A REAL-WORLD DATA SET FROM THE ROYAL MARSDEN HOSPITAL Jack Taylor-Stuart (London, United Kingdom of Great Britain and Northern Ireland (the))	14:48 - 14:57
OS4-04	"REAL WORLD" INCIDENCE AND CHARACTERISTICS OF IMMUNE EFFECTOR CELL-ASSOCIATED HEMOPHAGOCYtic LYMPHOHISTOCYTOSIS: A GOCART COALITION STUDY ON BEHALF OF THE EBMT ADWP, CTIWP AND TCWP Matteo Doglio (Milan, Italy)	14:57 - 15:06
OS4-05	LATE HEMATOTOXICITY OF CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL IN PATIENTS WITH LARGE B CELL LYMPHOMA (LBCL): THE ANALYSIS OF CELL THERAPY CONSORTIUM Parastoo B. Dahi (New York, United States of America (the))	15:06 - 15:15

OS4-07	MICROBIAL METABOLITES: DUAL ROLES IN MODULATING CAR-T CELL THERAPY Markus Perl (Regensburg, Germany)	15:15 - 15:24
OS4-08	T-ICAH: A NOVEL GRADING SYSTEM TO CHARACTERIZE THROMBOCYTOPENIA AND ITS PROGNOSTIC RELEVANCE IN CAR-T THERAPY Jaime Sanz (Valencia, Spain)	15:24 - 15:33
<i>Working Party Session</i>		
14:30 - 15:45		R9
TCWP - Transplant Complications Working Party Session		
Zinaida Peric (Rijeka, Croatia)		
TCWP-1	Harmonization of response criteria in TA-TMA Ivan Moiseev (Saint-Petersburg, Russian Federation (the))	14:30 - 14:45
TCWP-2	Non-ICANS Neurological Complications after CAR-T-cell therapies: EBMT practice harmonization Charlotte Graham (London, United Kingdom of Great Britain and Northern Ireland (the))	14:45 - 15:00
TCWP-3	AI for the clinical decision making in infections and HSCT Carolina Garcia-Vidal (Barcelona, Spain)	15:00 - 15:15
TCWP-4	Communication - a prerequisite for personalized medicine? Helene Schoemans (Leuven, Belgium)	15:15 - 15:30
TCWP-5	Discussion	15:30 - 15:45
<i>Oral Session</i>		
14:30 - 15:45		R10
OS05 - Oral Session 5 Stem cell donor		
Arnon Nagler (Tel Aviv, Israel)		
Yishan Ye (Hangzhou, China)		
OS5-01	IMMUNOPEPTIDOME DIVERGENCE BETWEEN MISMATCHED HLA HAPLOTYPES AND SURVIVAL AFTER HAPLOIDENTICAL HCT: A RETROSPECTIVE STUDY FROM THE CIBMTR Pietro Crivello (Essen, Germany)	14:30 - 14:39
OS5-02	DO PATIENT OUTCOMES DIFFER BY DONOR TYPE IF POST TRANSPLANT CYCLOPHOSPHAMIDE IS USED FOR GVHD PROPHYLAXIS? A CIBMTR RETROSPECTIVE ANALYSIS Steven Devine (Minneapolis, United States of America (the))	14:39 - 14:48
OS5-03	LANDSCAPES OF HLA MISMATCHING IN UNRELATED HCT: A STUDY BY THE EBMT CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY Esteban Arrieta Bolaños (Essen, Germany)	14:48 - 14:57
OS5-04	PROSPECTIVE COMPARISON OF POST-TRANSPLANT OUTCOMES FOR MATCHED UNRELATED (MUD), MISMATCHED UNRELATED (MMUD) MISMATCHED RELATED (MMRD), UMBILICAL CORD BLOOD (UCB) DONORS: RESULTS FROM BMTCTN 1702 (NCT03904134) William Hogan (Rochester, United States of America (the))	14:57 - 15:06
OS5-05	SUPERIOR GRFS FOR HAPLOIDENTICAL TRANSPLANT WITH PTCY THAN MATCHED UNRELATED DONOR FOR AML PATIENTS TRANSPLANTED IN CR2: A STUDY FROM THE ALWP OF THE EBMT Yishan Ye (Hangzhou, China)	15:06 - 15:15
OS5-06	IS THERE A PREFERABLE DONOR FOR ALLOGENEIC	15:15 - 15:24

	TRANSPLANTATION IN SECONDARY ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION: A STUDY FROM THE ALWP/EBMT?	
	Arnon Nagler (Tel Aviv, Israel)	
OS5-07	CHANGING DONOR WAS CRITICAL FOR THE SUCCESS OF SECOND TRANSPLANTATIONS FOR PATIENTS WITH GRAFT FAILURE AFTER THE FIRST ALLOGENEIC STEM CELL TRANSPLANTATIONS	15:24 - 15:33
	Rui Ma (Beijing, China)	
OS5-08	HAPLOIDENTICAL, MSD OR MUD HCT FOR ADULT PATIENTS WITH TP53 MUTATED AML IN CR1: A COMPARATIVE STUDY FROM THE GLOBAL COMMITTEE AND ALWP OF EBMT	15:33 - 15:42
	Yuhua Ru (Suzhou, China)	
<i>Nurses Group</i>		
14:30 - 16:00		
		R11
NG10 - Oral Paediatric - Best Abstract Award Finalist		
Marco Deiana (Genoa, Italy)		
Maria Finch (London, United Kingdom of Great Britain and Northern Ireland (the))		
NG10-01	A SINGLE CENTRE STUDY OF FERTILITY PRESERVATION WITHIN A PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT UNIT	14:30 - 14:50
	Karen Nicholson (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the))	
NG10-02	OPTIMIZING CAREGIVER EDUCATION IN ADMINISTERING NUTRITION AND MEDICATION VIA A NASOGASTRIC TUBE IN PEDIATRIC PATIENTS FOLLOWING HSCT	14:50 - 15:10
	Jolanda Tijsterman-Kuijt (Leiden, Netherlands (the))	
NG10-03	DRESS FOR SUCCESS: POST THIOTEPA CENTRAL LINE CARE IN CHILDREN, WHAT DO WE DO?	15:10 - 15:30
	Andy Gooding (Glasgow, United Kingdom of Great Britain and Northern Ireland (the))	
NG10-04	SAFETY AND EFFECTIVITY OF NASAL BRIDLE FEEDING TUBE SECUREMENT IN PEDIATRIC ONCOLOGY PATIENTS: A SINGLE-CENTER EXPERIENCE AT THE PRINCESS MÁXIMA CENTER	15:30 - 15:50
	Agnes H. Vissers (Utrecht, Netherlands (the))	
<i>Oral Session</i>		
14:30 - 15:45		
		R12
OS06 - Oral Session 6 Deciphering the mechanisms of disease relapse		
Michele Malagola (Brescia, Italy)		
Anna Alonso-Saladrigues (Barcelona, Spain)		
OS6-01	MANAGEMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC PATIENTS RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: RESULTS OF THE GITMO AML/MDS-RELAPSE REGISTRY STUDY	14:30 - 14:39
	Michele Malagola (Brescia, Italy)	
OS6-02	TARGETING CATHEPSIN G WITH A DUAL HLA-RESTRICTED TCR: A PROMISING THERAPY FOR ACUTE MYELOID LEUKEMIA	14:39 - 14:48
	Francesca Marzuttini (Milan, Italy)	
OS6-03	DONOR-DERIVED CAR-T CELLS IN CHILDREN WITH B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REPORT OF 22 CASES	14:48 - 14:57
	M. Maschan (Moscow, Russian Federation (the))	
OS6-04	PRE-TRANSPLANT CR STATUS AND MOLECULAR MRD WITHIN 100 DAYS POST-TRANSPLANT WERE PREDICT SURVIVAL AND	14:57 - 15:06

	RELAPSE RISK FACTOR IN KMT2A-REARRANGED ACUTE LEUKEMIA	
	Yue Lu (Hebei, China)	
OS6-05	CLINICAL OUTCOMES OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE LEUKEMIA UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANT BASED ON GVHD PROPHYLAXIS (PTCY VS CALCINEURIN INHIBITORS)	15:06 - 15:15
	Aldo A. Acosta-Medina (Rochester, United States of America (the))	
OS6-06	HLA LOSS RELAPSES AFTER TRANSPLANTATION: TIME OF ORIGIN AND FACILITATION FROM EXPOSURE TO GANCICLOVIR	15:15 - 15:24
	Cristina Toffalori (Milano, Italy)	
OS6-07	SECOND INFUSION OF CAR T-CELLS IN RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: A GOCART COALITION ANALYSIS ON BEHALF OF THE PDWP, ALWP, AND CTIWP OF THE EBMT	15:24 - 15:33
	Anna Alonso-Saladrigues (Barcelona, Spain)	
OS6-08	ROLE OF FLOW-CYTOMETRY MINIMAL RESIDUAL DISEASE (FMRD) BEFORE ALLOGENEIC HSCT IN PEDIATRIC PATIENTS WITH AML: A RETROSPECTIVE STUDY BY ASSOCIAZIONE ITALIANA DI ONCOEMATOLOGIA PEDIATRICA (AIEOP)	15:33 - 15:42
	Pietro Merli (Rome, Italy)	
 <i>Oral Session</i>		
14:30 - 15:45		
		R13
OS07 - Oral Session 7 Predictive scores and biomarkers		
Sophie Paczesny (Charleston, United States of America (the))		
Sarah Weischendorff (Copenhagen, Denmark)		
OS7-01	TRENDS, PREVALENCE, AND MORTALITY PREDICTORS OF VTE IN POST-STEM CELL TRANSPLANT PATIENTS: A NATIONWIDE ANALYSIS	14:30 - 14:39
	Samridhi Sinha (Brooklyn, United States of America (the))	
OS7-02	CBFB-MYH11 RATIO AFTER THE SECOND CYCLE OF CHEMOTHERAPY: A GUIDE OF AML TO ALLOGENEIC STEM CELL TRANSPLANTATION	14:39 - 14:48
	Mingyang Wang (Tianjin, China)	
OS7-03	HIGH ACCURACY OF ST2 AS A RISK BIOMARKER FOR ACUTE GVHD II-IV BY D56 OR DEATH BY D100 POST-HCT IN A PROSPECTIVE MULTISITE STUDY	14:48 - 14:57
	Sophie Paczesny (Charleston, United States of America (the))	
OS7-04	DETERMINANTS AND OUTCOMES OF GRAFT FAILURE IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION FOR NON MALIGNANT DISORDERS: A COMPREHENSIVE ANALYSIS	14:57 - 15:06
	Rawad Rihani (Amman, Jordan)	
OS7-05	ALTERED DENDRITIC CELL RECONSTITUTION AND CYTOKINE DYNAMICS POST-HCT ARE ASSOCIATED WITH ACUTE GVHD DEVELOPMENT	15:06 - 15:15
	Kinga Hosszu (New York, United States of America (the))	
OS7-06	ELEVATED EARLY POST-TRANSPLANT REG3A LEVELS REFLECT LOWER GASTROINTESTINAL AGVHD BUT NOT GASTROINTESTINAL INFECTIONS	15:15 - 15:24
	Sarah Weischendorff (Copenhagen, Denmark)	
OS7-07	OUTCOME AND PROGNOSTIC FACTORS IN PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD TREATED WITH SECOND-LINE THERAPY: A GITMO REAL-WORLD STUDY	15:24 - 15:33

	Marta Lisa Battista (Udine, Italy)	
OS7-08	TRENDS OF EASIX SCORES IN PATIENTS RECEIVING PTCY OR METHOTREXATE FOR GVHD PROPHYLAXIS Hassan Alkhateeb (Rochester, United States of America (the))	15:33 - 15:42
<i>Pharmacists Day</i>		
	14:30 - 15:45	R14
Pharm3 - Pharmacists Day 3 Service Development and Research		
Vera Pires (Lisboa, Portugal)		
Vera Domingos (Lisboa, Portugal)		
Pharm3-1	Use of novel technologies to support transplant patients Estela Moreno (Barcelona, Spain)	14:30 - 15:00
Pharm3-2	REAL-WORLD EVALUATION OF ISAVUCONAZOLE IN PAEDIATRIC PATIENTS WITH CANCER AS PROPHYLAXIS AND THERAPY FOR INVASIVE FUNGAL DISEASE Janine Nijhuis (Utrecht, Netherlands (the))	15:00 - 15:10
Pharm3-3	THE IMPACT OF LYMPHODEPLETING CHEMOTHERAPY DOSE MODIFICATIONS ON AXICABTAGENE CILOLEUCEL EXPANSION AND TREATMENT OUTCOME IN PATIENTS WITH RELAPSED OR REFRACTORY CD19-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA Brijesh Gautama (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	15:10 - 15:20
Pharm3-4	BUSULFAN PHARMACOKINETICS IN ADULTS - REAL-WORLD DATA Claudia Langebrake (Hamburg, Germany)	15:20 - 15:30
Pharm3-5	Q&A	15:30 - 15:45
<i>Data Management</i>		
	14:30 - 15:45	R15
DM3 - Data Management Session 3 Malignant diseases: lymphoma and acute leukemia classifications		
Nikolaos Glentis (Utrecht, Netherlands (the))		
Alina Kuliesh (Leiden, Netherlands (the))		
DM3-1	Lymphomas classification in the EBMT Registry according to the 5th edition of the World Health Organisation Classification of Haematolymphoid Tumours Charalampia Kyriakou (London, United Kingdom of Great Britain and Northern Ireland (the))	14:30 - 15:10
DM3-2	Acute Leukemia Classification - Cytogenetics, Molecular Markers in the new Data Collection Form Emmanuelle Polge (PARIS, France)	15:10 - 15:30
DM3-3	Q&A	15:30 - 15:45
<i>Breaks</i>		
	16:00 - 16:30	R1
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>General</i>		
	16:30 - 18:00	R1
GS2 - Presidential Symposium		
Anna Sureda (Barcelona, Spain)		
Fabio Ciceri (Milano, Italy)		
GS2-1	Van Bekkum Award - Introduction	16:30 - 16:33

GS2-2	INITIAL RESULTS OF THE LUMINICE-203 STUDY INVESTIGATING ACIMTAMIG WITH OFF-THE-SHELF ALLOGENEIC NATURAL KILLER CELLS (ALLONK®) IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA Gunjan L. Shah (New York, United States of America (the))	16:33 - 16:48
GS2-3	Basic Science Award - Introduction	16:48 - 16:51
GS2-4	PREVALENCE AND ORIGIN OF CLONAL HEMATOPOIESIS IN LONG-TERM SURVIVORS OF PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION Konradin Müskens (Utrecht, Netherlands (the))	16:51 - 17:06
GS2-5	NSAIDS: A SIMPLE THERAPY FOR MANAGING GHOSAL HEMATODIAPHYSEAL DYSPLASIA, A RARE BONE MARROW FAILURE DIAGNOSIS WORTH CONSIDERING Jonathan Bordat (Paris, France)	17:06 - 17:15
GS2-6	COMPARISONS OF GLUCAGON-LIKE PEPTIDE-2 ANALOG APRAGLUTIDE IN COMBINATION WITH RUXOLITINIB FOR STEROID-REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE WITH MAGIC CONTROL COHORT: THE PHASE 2 STARGAZE TRIAL Robert Zeiser (Freiburg, Germany)	17:15 - 17:24
GS2-7	IMPACT OF DONOR TYPES IN ALLOGENEIC TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR SEVERE APLASTIC ANEMIA: A COMPARATIVE STUDY OF THE SAAWP EBMT Juan Montoro (Valencia, Spain)	17:24 - 17:33
GS2-8	TDI-01 IN THE TREATMENT OF MODERATE TO SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE: INTERIM RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE IB/II STUDY Xiaodong Mo (Beijing, China)	17:33 - 17:42
GS2-9	TRANSPLANTATION OUTCOMES AFTER TBI/EETOPOSIDE IN ADOLESCENTS AND YOUNG ADULTS COMPARED TO CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: DOES AGE MATTER? Charlotte Calvo (Paris, France)	17:42 - 17:51
GS2-10	LATE COMPLICATIONS AFTER AUTOLOGOUS HSCT FOR AUTOIMMUNE DISEASES: A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WP (ADWP) AND TRANSPLANT COMPLICATIONS WP (TCWP) OF THE EBMT Kirill Kirgizov (Moscow, Russian Federation (the))	17:51 - 18:00

Cell Therapy Day

16:30 - 17:45

R2

CTD4 - Cell Therapy Day 4 | Graft manipulation for HCT outcomes

Christian Chabannon (Marseille, France)

Nina Worel (Vienna, Austria)

CTD4-1	Ex vivo graft engineering in allo-HCT Moniek de Witte (Utrecht, Netherlands (the))	16:30 - 16:55
CTD4-2	Post allo CY Florent Malard (Paris, France)	16:55 - 17:20
CTD4-3	Does Campath have a role in conditioning regimens? Wendy Ingram (Cardiff, United Kingdom of Great Britain and Northern Ireland (the))	17:20 - 17:45

Nurses Group

16:30 - 18:00

R7

NG11 - Back to basics. Understanding...

Klára Kabátová Maxová (Pilsen, Czechia)

Stefano Botti (Reggio Emilia, Italy)

NG11-1	The principles of transfusion after transplant and cell therapy Shreyas Hanmantgad (London, United Kingdom of Great Britain and Northern Ireland (the))	16:30 - 16:51
NG11-2	The principles of related donor care Annika Kisch (Lund, Sweden)	16:51 - 17:12
NG11-3	The principles of nutritional support Sofia Cherici (Florence, Italy)	17:12 - 17:33
NG11-4	The principles of steroid in transplant and cell therapy Daphna Hutt (Tel Aviv, Israel)	17:33 - 17:54
NG11-5	Q&A	17:54 - 17:59

How do I... ?

16:30 - 17:45

R8

HDI3 - How Do I... Improve patient experience and understanding of GVHD impact | Supported through an unrestricted educational grant by Sanofi

Sophie Van Lancker (Gent, Belgium)

Chiara Visintini (Udine, Italy)

HDI3-1	Communicating complexity with ease Liana Abu Rumieleh (Jerusalem, Israel)	16:30 - 16:45
HDI3-2	Understanding information needs of patients Zinaida Peric (Rijeka, Croatia)	16:45 - 17:00
HDI3-3	Using GVHD literature to improve patient experience and understanding Francesca Palmisano (Alessandria, Italy)	17:00 - 17:15
HDI3-4	Living with GVHD - impact and experience Anna Barata (Boston, United States of America (the))	17:15 - 17:30
HDI3-5	Q&A	17:30 - 17:45

Nurses Group

16:30 - 18:00

R11

NG11B - Oral Session I

Ruth Clout (Manchester, United Kingdom of Great Britain and Northern Ireland (the))

Matteo Cosci (Firenze, Italy)

NG11B-01	EVALUATION OF COGNITIVE IMPAIRMENT AND NEUROTOXIC EFFECTS IN ADULT PATIENTS UNDERGOING CAR-T CELL THERAPY Evlampia Strongyli (Thessaloniki, Greece)	16:30 - 16:50
NG11B-02	STRENGTHENING CAREGIVERS' SAFETY AND PREPAREDNESS: THE STEM CELL TRANSPLANT CAREGIVERS NETWORK Alexandra Iosif (Munich, Germany)	16:50 - 17:10
NG11B-03	CLINICAL PREDICTORS OF NERVOUS SYSTEM TOXICITY ASSOCIATED WITH CAR-T CELL THERAPIES IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES Silvia Belloni (Pavia, Italy)	17:10 - 17:30
NG11B-04	CRITICAL CARE NURSE'S EXPERIENCES OF CARING FOR RECENT STEM CELL TRANSPLANT RECIPIENTS IN NEED OF INTENSIVE	17:30 - 17:50

CARE - A QUALITATIVE STUDY

Linnéa Abrahamsson (Stockholm, Sweden)

Pharmacists Day

16:30 - 17:45

R14

Pharm4 - Pharmacists Day 4 | CAR-T and other novel therapies

Katerina Nezvalova Henriksen (Oslo, Norway)

Rick Admiraal (Utrecht, Netherlands (the))

Pharm4-1 **How to incorporate CAR-T and BiTEs into the myeloma treatment pathway** 16:30 - 17:00

Thierry Facon (Lille, France)

Pharm4-2 **CAR T & Bridging Chemotherapy: UK and US Perspectives** 17:00 - 17:45

Daniel Schrum (Durham, United States of America (the))

Vaishali Dulobdas (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))

Data Management

16:30 - 17:45

R15

DM4 - Data Management Session 4 | How Do I... Navigate compliance, CTCAE, and other common Helpdesk Queries?

Annelot van Amerongen (Den Haag, Netherlands (the))

Tugce Demir (Barcelona, Spain)

DM4-1 **From Consent to Compliance: Data Reporting for Patients and Donors** 16:30 - 16:50

Iris Bargallo (Barcelona, Spain)

DM4-2 **Reporting CTCAE in the EBMT Registry for complications after HCT** 16:50 - 17:10

Ivan Moiseev (Saint-Petersburg, Russian Federation (the))

DM4-3 **Data entry in the EBMT Registry: frequently asked questions** 17:10 - 17:30

Per Ljungman (Stockholm, Sweden)

DM4-4 **Q&A** 17:30 - 17:45*Printed Poster*

18:00 - 19:00

R13

Nurses Posters - ResearchNP042 **RECOVERY IN A HOMELIKE ENVIRONMENT-PATIENTS' EXPERIENCES WITH HOSPITAL AT HOME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A QUALITATIVE STUDY** 18:00 - 18:00

Sigrid Cecilie Tinglum Skøyeneie (Oslo, Norway)

NP043 **EFFICACY OF A COMPLEX LYSOSTAPHIN GARGLE IN THE PREVENTION OF ORAL MUCOSITIS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY** 18:00 - 18:00

Xiaoyu Zhou (Hangzhou, China)

NP044 **CONSTRUCTION OF QUALITY EVALUATION SYSTEM FOR PREVENTION AND NURSING OF DRUG RESISTANT BACTERIAL INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS** 18:00 - 18:00

Erlie Jiang (Tianjin, China)

NP045 **STRESS PERCEIVED LEVELS BETWEEN PHYSICIANS AND NURSES IN COMMUNICATING BAD NEWS IN STEM CELL TRANSPLANTATION SETTINGS: A NATIONWIDE SURVEY BY THE GITMO NG** 18:00 - 18:00

	Stefano Botti (Reggio Emilia, Italy)	
NP046	ENHANCING OUTCOMES AFTER CAR-T THERAPY: A PATIENT SUPPORT INITIATIVE Luminita Keating (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP047	BREAKING BARRIERS: A SCOPING REVIEW OF FACTORS INFLUENCING WORK PARTICIPATION AFTER HEMATOPOIETIC CELL TRANSPLANTATION Karine Bilodeau (Montreal, Canada)	18:00 - 18:00
NP048	EXPERIENCES OF PATIENTS DEALING WITH CRS AND/OR ICANS DURING HOSPITALIZATION FOLLOWING CAR-T THERAPY Amaia Urcelay Ganzabal (Barcelona, Spain)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		R13
Nurses Posters - Paediatric		
NP034	UTILIZING DIGITAL THERAPEUTIC EDUCATION FOR ADOLESCENTS AND YOUNG ADULTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SCOPING REVIEW OF EVIDENCE AND STRATEGIES Simona Calza (Genoa, Italy)	18:00 - 18:00
NP035	SHIFTING PARADIGMS: IMPLEMENTATION OF THE FIRST PAEDIATRIC BMT & CELLULAR THERAPIES NURSE PRACTITIONER ROLE IN AUSTRALIA Maddie Gilsenan (Melbourne, Australia)	18:00 - 18:00
NP036	IMPLEMENTATION OF PATIENT SAFETY TOOLS AS A QUALITY STRATEGY IN A PEDIATRIC HEMATOPOIETIC STEM CELL, CELL THERAPY AND PEDIATRIC ONCOHEMATOLOGY UNIT Manuel Adrián Julbez Zamorano (Madrid, Spain)	18:00 - 18:00
NP037	VIRTUAL REALITY AS A NON-PHARMACOLOGICAL INTERVENTION IN PEDIATRIC ONCOLOGY: TWO SCOPING REVIEWS ON CLINICAL OUTCOMES, CAREGIVER EXPERIENCES, AND HEALTHCARE PROFESSIONAL PERSPECTIVES Simona Calza (Genoa, Italy)	18:00 - 18:00
NP038	THE PSYCHOLOGICAL IMPACT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION ON CHILDREN AND ADOLESCENTS: A PROSPECTIVE SINGLE-ARM STUDY FROM A PEDIATRIC BMT UNIT IN INDIA Jerlin Robin (Chennai, India)	18:00 - 18:00
NP039	ESCAPING THE FEAR OF SIMULATION - UTILISING ESCAPE ROOMS IN BMT NURSING EDUCATION AND TEAM BUILDING Johanna Lee (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP040	DRINKING WATER FOR ADULT AND PAEDIATRIC STEM CELL TRANSPLANT PATIENTS IN THE UK - THE NEED FOR GUIDANCE Rachel Protheroe (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP041	DEVELOPMENT OF A NURSE-LED PAEDIATRIC PHOTOBIO-MODULATION SERVICE Eleanor Leaney (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00

Printed Poster
18:00 - 19:00

R13

Non-infectious Late Effects, Quality of Life and Fertility

A308	COMPREHENSIVENESS VS SIMPLICITY VS OBJECTIVITY: A	18:00 - 18:00
------	--	---------------

	COMPARISON OF DIFFERENT COMORBIDITY INDICES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT)	
	Lorenzo Iovino (Seattle, United States of America (the))	
A309	SECOND CANCERS IN PATIENTS RECEIVING RUXOLITINIB FOR STEROID-REFRACTORY GVHD: IMPACT OF ACTIVE SURVEILLANCE IN 76 PATIENTS WITH 4 YEARS FOLLOW-UP	18:00 - 18:00
	Daniele Sannipoli (Milano, Italy)	
A310	DONOR CD8+ T CELLS DRIVE ATHEROSCLEROSIS IN MICE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	18:00 - 18:00
	Haroon Shaikh (Würzburg, Germany)	
A311	BONE HEALTH MONITORING AND FRACTURE RISK IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS	18:00 - 18:00
	Nabanita Bhunia (Columbus, United States of America (the))	
A312	DYNAMIC EASIX-DRI MODEL PREDICTS POST-TRANSPLANT SURVIVAL IN PATIENTS RECEIVING PTCY OR METHOTREXATE FOR GVHD PROPHYLAXIS	18:00 - 18:00
	Hassan Alkhateeb (Rochester, United States of America (the))	
A313	DETERMINANTS OF OUTCOMES AFTER ALLOGENEIC TRANSPLANTATION (ALLOHCT) IN PATIENTS ≥70 YEARS OF AGE - SINGLE CENTRE ANALYSIS	18:00 - 18:00
	Pavel Jindra (Pilsen, Czechia)	
A314	SECOND MALIGNANT NEOPLASMS INCIDENCE FOR CHILDREN UNDERGOING CYCLOPHOSPHAMIDE AND TBI CONDITIONED HSCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA OVER 10 YEARS FOLLOW-UP - A SINGLE CENTER EXPERIENCE	18:00 - 18:00
	Maharshi Trivedi (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	
A315	RURAL/REGIONAL PLACE OF RESIDENCE IMPACTS POST ALLOGENEIC BONE MARROW TRANSPLANT OVERALL SURVIVAL OF AUSTRALIAN PATIENTS WITH ACUTE MYELOID LEUKAEMIA: AN ANZTCT REGISTRY STUDY	18:00 - 18:00
	Zulekha Khan (Sydney, Australia)	
A316	SUCCESSFUL FERTILITY PRESERVATION IN PATIENTS WITH SICKLE CELL DISEASE PREPARING FOR HSCT AND GENE THERAPY: OOCYTE RETRIEVAL OUTCOMES AND ATTRITION RATES	18:00 - 18:00
	Hannah Maher (New York City, United States of America (the))	
A317	LONG-TERM METABOLIC DERANGEMENTS FOLLOWING HSCT IN PEDIATRICS: THE SIBLING DONOR-RECIPIENT DYAD AS AN IDEAL MODEL TO ASSESS THE DETRIMENTAL ROLE OF TBI ON IMMUNE-METABOLIC PATHWAYS	18:00 - 18:00
	Alessandro Cattoni (Monza, Italy)	
A318	STUDY PRESENTATION: TREATMENT ADHERENCE IN PATIENTS WITH STEM CELL TRANSPLANTATION FOR HEMATOLOGIC CANCER (TASK): A BICENTER OBSERVATIONAL STUDY	18:00 - 18:00
	Anne-Kathrin Köditz (Leipzig, Germany)	
A319	IMPACT OF A LONG-TERM FOLLOW-UP PROGRAM ON ADHERENCE TO SCREENING AND PREVENTION GUIDELINES IN SURVIVORS OF ALLOGENEIC BONE MARROW TRANSPLANTATION	18:00 - 18:00
	Vanderson Rocha (São Paulo, Brazil)	
A320	FERRITIN AS A BIOMARKER FOR RELAPSE, MORTALITY AND	18:00 - 18:00

	GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC STEM CELL TRANSPLANTATION	
	Caden Chiarello (Toronto, Canada)	
A321	CENTRAL NERVOUS SYSTEM RELAPSE AFTER ALLOGENEIC TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS: INCIDENCE AND PROGNOSTIC FACTORS	18:00 - 18:00
	Brenda Lizeth Acosta-Maldonado (Ciudad de México, Mexico)	
A322	ACCESS TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN A TRADITIONALLY AGE-INELIGIBLE POPULATION	18:00 - 18:00
	Dana Platt (Duarte, United States of America (the))	
A323	WHICH CRITERIA FOR RETURN TO WORK AFTER ALLOGENIC TRANSPLANTATION SHOULD BE RECOMMENDED? MIXED-METHODS SURVEY AMONG HEMATOLOGISTS OF AN ALLOGENIC STEM CELL TRANSPLANTATION NETWORK IN GERMANY	18:00 - 18:00
	Martina Crysandt (Aachen, Germany)	
A324	POST-ALLO HSCT ANXIETY, DEPRESSION AND COGNITIVE FUNCTIONS: CORRELATIONS WITH RETURN TO WORK AND DAILY LIVING ACTIVITIES - INSIGHTS FROM THE "SOPRALLO PROJECT"	18:00 - 18:00
	Fabio Andreozzi (Brussels, Belgium)	
A325	PATIENT REPORTED OUTCOMES IN AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS, PROSMM. SINGLE CENTRE PILOT STUDY	18:00 - 18:00
	Jose María Aspa Cilleruelo (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	
A326	MONOCLONAL GAMMOPATHY AFTER ALLO-HSCT: A SINGLE CENTER EXPERIENCE IN T-CELL DEPLETED TRANSPLANTS WITH TREG/TCON ADOPTIVE IMMUNOTHERAPY	18:00 - 18:00
	Valerio Viglione (Perugia, Italy)	
A327	PATIENT REPORTED OUTCOMES IN LONG TERM SURVIVORS POST-ALLOGENEIC STEM CELL TRANSPLANT WITH CD34+ POSITIVE SELECTION	18:00 - 18:00
	Alba Puyuelo (Barcelona, Spain)	
<i>Printed Poster</i>		
18:00 - 19:00		R13
Non-infectious Early Complications		
A273	RETROSPECTIVE ANALYSIS OF VENO-OCCLUSIVE DISEASE IN ADULT PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION: EARLY DEFIBROTIDE THERAPY AND PREDICTIVE RISK FACTORS FOR VENO-OCCLUSIVE DISEASE	18:00 - 18:00
	Alfredo Pacheco Reyes (Cordoba, Spain)	
A274	CYTOKINE PROFILING FOR DIFFERENTIATING CYTOKINE RELEASE SYNDROME FROM SEPSIS IN POST T CELL REPLETE HAPLO-HSCT AND CAR-T THERAPY SETTING	18:00 - 18:00
	Shreya Agrawal (Kochi, India)	
A275	RE-EVALUATING VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME ADULT DIAGNOSTIC CRITERIA: CHARACTERISATION OF DEFIBROTIDE-TREATED PATIENTS IN THE DEFIFRANCE REGISTRY	18:00 - 18:00
	Mohamad Mohty (Paris, France)	
A276	ABATACEPT LOWERS ENDOTHELIAL ACTIVATION-RELATED SERIOUS EVENTS IN CHILDREN UNDERGOING ALLOGENEIC TRANSPLANT FOR TRANSFUSION DEPENDENT BETA THALASSEMIA VIA NOVEL MECHANISM OF INHIBITING	18:00 - 18:00

	NEUTROPHIL EXTRACELLULAR TRAPS Pooja Khandelwal (Cincinnati, United States of America (the))	
A277	EASIX AND ENGRAFTMENT SYNDROME AFTER AT-HOME AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS María Queralt Salas (Barcelona, Spain)	18:00 - 18:00
A278	IMMUNE CYTOPENIA IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION - HALF MATCH LEADS TO DOUBLE THE TROUBLE Kavitha Ganesan (Chennai, India)	18:00 - 18:00
A279	REAL LIFE MANAGEMENT OF VENO-OCCLUSIVE DISEASE POST ALLOGENEIC TRANSPLANTATION: A NATIONAL SURVEY BY GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) Giorgia Mancini (Ancona, Italy)	18:00 - 18:00
A280	PRE-TRANSPLANT T-CELL RECEPTOR EXCISION CIRCLES (TRECS) PREDICT CLINICAL OUTCOMES POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Noa G. Holtzman (Miami, United States of America (the))	18:00 - 18:00
A281	EVALUATING THE EFFECT OF ENTERAL NUTRITION ON CLINICAL OUTCOMES AND MICROBIOME DYNAMICS IN HAEMATOPOIETIC TRANSPLANTATION RECIPIENTS Hannah Wardill (Adelaide, Australia)	18:00 - 18:00
A283	SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE Aitana Balaguer Roselló (Valencia, Spain)	18:00 - 18:00
A284	INCONSISTENT PRACTICE PATTERNS OF SGLT2 INHIBITOR USE ACROSS EBMT CELL THERAPY CENTERS: A SURVEY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY Christian Schultze-Florey (Hannover, Germany)	18:00 - 18:00
A285	OUTCOME OF PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC TRANSPLANTATION FROM UNRELATED DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Tel Aviv, Israel)	18:00 - 18:00
A286	FRAILTY SYNDROME AS A DETERMINANT OF ENDOTHELIAL ACTIVATION AND OUTCOMES IN ALLO-HCT PATIENTS María Queralt Salas (Barcelona, Spain)	18:00 - 18:00
A287	CARE BMT RISK SCORE: CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION, A REAL-LIFE EVALUATION Ambra Fumagalli (Milano, Italy)	18:00 - 18:00
A288	TRANSPLANT RELATED HEPATIC DYSFUNCTION AND MORTALITY AFTER MATCHED RELATED DONOR STEM CELL TRANSPLANT IN CHILDREN WITH ACUTE LEUKEMIA PREVIOUSLY TREATED WITH IMMUNOTHERAPY Aaron Ross (Houston, United States of America (the))	18:00 - 18:00
A289	ROOT CAUSE ANALYSIS OF GRAFT FAILURE IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT: A RETROSPECTIVE COHORT STUDY FROM A SINGLE CENTRE Gaurav Kharya (Delhi, India)	18:00 - 18:00
A290	CAN NEW HARMONIZED TA-TMA DIAGNOSTIC CRITERIA	18:00 - 18:00

	DISTINGUISH IT FROM OTHER ENDOTHELIAL INJURY SYNDROMES SUCH AS SOS/VOD?	
	Carlos de Miguel (Madrid, Spain)	
A291	PROGNOSTIC PLASMA BIOMARKERS FOR SINUSOIDAL OBSTRUCTION SYNDROME IN ALLOGENEIC HSCT WITH HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE	18:00 - 18:00
	Mi Kwon (., Spain)	
A292	OUTPATIENT CARE REDUCES COMPLICATIONS IN STEM CELL TRANSPLANTATION	18:00 - 18:00
	Javier Cornago Navascués (Madrid, Spain)	
A293	POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML PATIENTS UNDERGOING ALLO-HCT WITH CARDIAC MORBIDITY: IS IT SAFE?	18:00 - 18:00
	María Queralt Salas (Barcelona, Spain)	
A294	IMPACT OF INOTUZUMAB OZOGAMICIN ON SINUSOIDAL OBSTRUCTION SYNDROME INCIDENCE AND IDENTIFICATION OF RISK FACTORS IN ALLOGENEIC HSCT RECIPIENTS: MATCHED CASE-CONTROL STUDY WITH PROSPECTIVE LABORATORY MONITORING	18:00 - 18:00
	Dmitrii Evstratov (Moscow, Russian Federation (the))	
A295	REAL-WORLD OUTCOME OF DEFIBROTIDE FOR TREATMENT OF ADULT PATIENTS WITH SEVERE HEPATIC VOD/SOS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	18:00 - 18:00
	Jae Ho Yoon (Seoul, Korea (the Republic of))	
A296	CD36 AND CD326/EPCAM EXTRACELLULAR VESICLES MARKERS ASSOCIATED TO PERIPHERAL NEUROPATHY ONSET IN CHILDREN UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Francesca Gottardi (Bologna, Italy)	
A297	ENDOTHELIAL DYSFUNCTION IN PATIENTS BEFORE CELLULAR THERAPY - A PROSPECTIVE OBSERVATIONAL STUDY	18:00 - 18:00
	Laura Simons (Heidelberg, Germany)	
A298	EFFECT OF LUSPATERCEPT ON THE TREATMENT OF ANEMIA IN ALLO-HSCT FOR PATIENTS WITH HEMATOLOGICAL DISEASES	18:00 - 18:00
	Juan Wang (Zhengzhou, China)	
A299	STUDY OF PRIMARY GRAFT FAILURE AFTER A FIRST HSCT IN 10 PEDIATRIC UNITS: DO OUR PATIENTS SURVIVE ONE OF THE MOST FEARED COMPLICATIONS?	18:00 - 18:00
	Melissa Panesso (Barcelona, Spain)	
A300	HEMORRHAGIC CYSTITIS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN: A SINGLE PEDIATRIC CENTER EXPERIENCE	18:00 - 18:00
	Pauline Mazilier (Bruxelles, Belgium)	
A301	IDENTIFICATION OF VOD/SOS AND TMA RISK FACTORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE	18:00 - 18:00
	Aser Alonso (Palma, Spain)	
A302	CORTICAL BLINDNESS AND PROGRESSIVE TETRAPARESIS UNDER IMMUNOSUPPRESSION WITH THE CALCINEURIN INHIBITOR CICLOSPORIN A AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Anna Ruckdeschel (Würzburg, Germany)	
A303	A PROINFLAMMATORY TH1/TC1 ENVIRONMENT AND CYTOLYTIC	18:00 - 18:00

	ACTIVITY MEDIATE EARLY PULMONARY ENDOTHELIAL CELL (EC) APOPTOSIS AND DRIVE THE DEVELOPMENT OF EXPERIMENTAL IDIOPATHIC PNEUMONIA SYNDROME	
	Kenneth Cooke (Baltimore, United States of America (the))	
A304	INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF TOXIC EPIDERMAL NECROLYSIS AND ACUTE GRAFT VERSUS HOST DISEASE OF THE SKIN IN A PEDIATRIC COHORT	18:00 - 18:00
	April Rahrig (Indianapolis, United States of America (the))	
A305	INCREASED FREQUENCY OF ENGRAFTMENT SYNDROME FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WHO RECEIVED NIVOLUMAB-CONTAINING SALVAGE THERAPY	18:00 - 18:00
	Aikaterini Benekou (Athens, Greece)	
A306	SAFETY AND EFFICACY OF ROMIPLOSTIM FOR THE TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Yunchao Su (Beijing, China)	
A307	VON WILLEBRAND FACTOR (VWF) AND ENDOTHELIAL DYSFUNCTION SYNDROMES FOLLOWING PEDIATRIC HSCT	18:00 - 18:00
	Denise Horan (Copenhagen OE, Denmark)	
<i>Printed Poster</i>		
	18:00 - 19:00	R13
Infectious Complications		
A178	INVESTIGATIONAL LIVE BIOTHERAPEUTIC SER-155 : BIOMARKER INSIGHTS FROM A PHASE 1B STUDY IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT)	18:00 - 18:00
	Meghan Chafee (Cambridge, United States of America (the))	
A179	AN EVALUATION OF LATE CMV REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS RECEIVING LETERMOVIR PROPHYLAXIS	18:00 - 18:00
	Jessica Pealing (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
A180	EFFICACY AND SAFETY OF PRIMARY LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTION IN PAEDIATRIC PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTRE, RETROSPECTIVE, REAL-WORLD ANALYSIS	18:00 - 18:00
	Ye Guo (Tianjin, China)	
A182	CASE SERIES OF INVASIVE FUSARIOSIS IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH HIGHLY FAVORABLE OUTCOMES IN SETTING OF TREATMENT WITH FOSMANOGEPIX: A SINGLE-CENTER EXPERIENCE	18:00 - 18:00
	Avneet Kaur (Duarte, United States of America (the))	
A183	CMV INFECTIONS AND LETERMOVIR RESISTANCE IN FRANCE. DATA FROM THE NAVIRE, STEM-CELL RECIPIENTS REAL-LIFE COHORT	18:00 - 18:00
	Pascal Turlure (Limoges, France)	
A185	HIGH CMV IGG TITERS PRE-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ARE ASSOCIATED WITH CMV INFECTIONS WITH OR WITHOUT LETERMOVIR PROPHYLAXIS	18:00 - 18:00
	Léna Royston (Geneva, Switzerland)	
A186	EPSTEIN-BARR VIRUS-RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) IN	18:00 - 18:00

	SPAIN: TRENDS, CHARACTERISTICS, AND OUTCOMES IN A MULTICENTER GETH-TC STUDY	
	Irene García-Cadenas (Barcelona, Spain)	
A187	USE OF LETERMOVIR IN PAEDIATRIC AND YOUNG ADULT PATIENTS. A RETROSPECTIVE STUDY ON BEHALF OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH-TC)	18:00 - 18:00
	Maria Trabazo del Castillo (Barcelona, Spain)	
A188	IMPLIED PHYSICIAN PREFERENCES FOR MARIBAVIR VS VALGANCICLOVIR FOR TREATMENT OF POST-HCT CMV: RESULTS FROM A MULTI-CRITERIA DECISION ANALYSIS	18:00 - 18:00
	Miguel-Angel Perales (New York, United States of America (the))	
A189	HUMORAL VACCINE RESPONSES IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES FOLLOWING CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY	18:00 - 18:00
	Sigrun Einarsdottir (New York, United States of America (the))	
A191	NEGLECTED TROPICAL DISEASES (NTD) AND RELATED INFECTIONS IN HAEMATOPOIETIC CELLULAR THERAPY (HCT) IN ADULTS AND CHILDREN: A SURVEY FROM THE EBMT INFECTIOUS DISEASES WORKING PARTY	18:00 - 18:00
	John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	
A193	EFFECT OF LETERMOVIR ON CMV INFECTION AND IMMUNE RECONSTITUTION AFTER PTCY-BASED HAPLOIDENTICAL TRANSPLANTATION	18:00 - 18:00
	Su-Peng Yeh (Taichung, Taiwan (Province of China))	
A194	CMV REACTIVATIONS AFTER LETERMOVIR PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE	18:00 - 18:00
	Anna Grassi (Bergamo, Italy)	
A195	THE ROLE OF T-CELL RECOVERY AND CMV-SPECIFIC IMMUNE RECONSTITUTION THROUGH QUANTIFERON- CMV TEST IN PATIENTS RECEIVING LETERMOVIR PROPHYLAXIS	18:00 - 18:00
	Rosa Plos (Udine, Italy)	
A196	CMV REACTIVATION IN PATIENTS WITH LYMPHOMA AFTER CAR-T THERAPY: INTERNATIONAL STUDY ON BEHALF OF IDWP, LWP, AND CTIWP OF EBMT	18:00 - 18:00
	Dina Averbuch (Jerusalem, Israel)	
A197	TWO-STEP SCREENING STRATEGY FOR EARLY DETECTION OF VIRAL RESPIRATORY INFECTIONS IN PATIENTS UNDERGOING CAR T-CELL THERAPY. IS IT JUSTIFIED?	18:00 - 18:00
	Marina Sorribes Portella (Barcelona, Spain)	
A198	INCIDENCE AND RISK FACTORS FOR LATE CYTOMEGALOVIRUS INFECTION DEVELOPMENT BEYOND DAY 100 POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WHO HAVE NOT RECEIVED EXTENDED LETERMOVIR PROPHYLAXIS	18:00 - 18:00
	Israel Henig (Haifa, Israel)	
A199	PROGRESSIVE SUPPORTIVE CARE IMPROVEMENTS AND LETERMOVIR PROPHYLAXIS NEUTRALIZES THE HISTORICALLY INCREASED NON-RELAPSE MORTALITY ASSOCIATED WITH CMV SEROPOSITIVITY IN ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Radwan Massoud (Hamburg, Germany)	
A200	VIRAL ECHOES: NAVIGATING CMV AND EBV REACTIVATION IN	18:00 - 18:00

	THE LANDSCAPE OF STEM CELL TRANSPLANTS FOR AUTOIMMUNE DISEASES	
	Michele Dicataldo (Torino, Italy)	
A201	IMMUNE RECONSTITUTION ASSOCIATED WITH CMV REACTIVATION AFTER THE DISCONTINUATION OF LETERMОВIR PROPHYLAXIS - A PROSPECTIVE STUDY ON BEHALF OF THE POLISH ADULT LEUKEMIA GROUP	18:00 - 18:00
	Agnieszka Piekarska (Gdansk, Poland)	
A202	SURVEILLANCE AND PROPHYLAXIS OF INFECTIONS FOLLOWING CAR-T CELL THERAPY: INTERNATIONAL SURVEY ON BEHALF OF THE INFECTIOUS DISEASES WORKING PARTY AND GOCART COALITION EBMT	18:00 - 18:00
	Dina Averbuch (Jerusalem, Israel)	
A203	TIME EXPLORATION OF INITIATING LETERMОВIR FOR THE PREVENTION OF CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Ran Zhang (Zhengzhou, China)	
A204	INCIDENCE OF HERPES ZOSTER VIRUS INFECTION AFTER HZV VACCINATION IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER HZV VACCINATION	18:00 - 18:00
	María Suárez-Lledó (Barcelona, Spain)	
A205	LETERMОВIR PROVIDES PROTECTION AGAINST CLINICALLY SIGNIFICANT CMV INFECTIONS IN CMV-SERONEGATIVE RECIPIENTS OF AN ALLOTRANSPLANT FROM A CMV-SEROPOSITIVE DONOR	18:00 - 18:00
	Patrice Chevallier (Nantes, France)	
A207	EPIDEMIOLOGY OF BLOODSTREAM INFECTIONS IN ITALIAN PEDIATRIC HCT CENTERS: A NATIONWIDE OBSERVATIONAL ANALYSIS BY INFECTION WORKING GROUP OF THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION	18:00 - 18:00
	Francesco Baccelli (Bologna, Italy)	
A208	A MONOCENTRIC RETROSPECTIVE STUDY OF BREAKTHROUGH CANDIDEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, AND CORRELATION WITH GUT COLONIZATION	18:00 - 18:00
	Alienor Xhaard (Paris, France)	
A209	COST-EFFECTIVENESS OF LETERMОВIR PROPHYLAXIS IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANTATION: INSIGHTS FROM AN ITALIAN MONOCENTRIC EXPERIENCE	18:00 - 18:00
	Leonardo Amato (Pisa, Italy)	
A210	THE ROLE OF THE HUMORAL RESPONSE, MEMORY-LIKE NK CELLS, AND GAMMA-DELTA T CELLS IN HCMV CONTROL IN THE LETERMОВIR ERA	18:00 - 18:00
	Hannah Görge (Wuerzburg, Germany)	
A212	CLINICAL AND MICROBIOLOGICAL FEATURES OF <i>FUSARIUM</i> INFECTIONS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Krischan Braitsch (Munich, Germany)	
A213	IS PREEMPTIVE RITUXIMAB FOR EBV REACTIVATION POST-ALLOGENEIC TRANSPLANT BENEFICIAL? A COMPARATIVE STUDY OF CLINICAL OUTCOMES	18:00 - 18:00
	Eshrak Al-Shaibani (Toronto, Canada)	
A214	CLINICAL BURDEN OF LATE-ONSET CLINICALLY SIGNIFICANT	18:00 - 18:00

	CMV INFECTION AFTER LETERMOVIR CMV PROPHYLAXIS AMONG ALLOGENIC STEM CELL TRANSPLANT PATIENTS IN JAPAN	
	Rika Ohkubo (Chiyoda, Japan)	
A215	ASSOCIATION BETWEEN COLONIZATION AND MULTIDRUG-RESISTANT BACTEREMIA IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CAR-T THERAPY: A SINGLE-CENTER EXPERIENCE	18:00 - 18:00
	Alejandro Morales Curbelo (Las Palmas de Gran Canaria, Spain)	
A216	OPTIMIZATION OF PREVENTION STRATEGIES AGAINST SARS-COV2 INFECTION IN PATIENTS WITH HEMATOLOGIC DISEASES: AN EVIDENCE-BASED ANALYTIC HIERARCHY PROCESS.	18:00 - 18:00
	Corrado Girmenia (Rome, Italy)	
A217	INCIDENCE AND RISK FACTORS OF EBV REACTIVATION AND PTLD AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Yeqian Zhao (Hangzhou, China)	
A219	INCREASING INCIDENCE OF MULTIDRUG-RESISTANT (MDR) INFECTIONS IN PAEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE DEVELOPING WORLD	18:00 - 18:00
	Santanu Sen (Mumbai, India)	
A220	RECTAL COLONIZATION BY MULTIDRUG-RESISTANT BACTERIA IN ADULT ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT ON INFECTION RATE, GHVD INCIDENCE AND NONRELAPSE MORTALITY	18:00 - 18:00
	Edoardo Tamellini (Verona, Italy)	
A221	CHARACTERISTICS AND KEY DETERMINANTS OF RESPIRATORY SYNCYTIAL VIRUS SYMPTOMS DURATION IN POST-ALLOGENEIC STEM CELL TRANSPLANT	18:00 - 18:00
	Mireia Micó Cerdà (Valencia, Spain)	
A222	BURDEN OF ACYCLOVIR RESISTANT MUCOCUTANEOUS HUMAN HERPES SIMPLEX VIRUS INFECTION POST HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER US STUDY	18:00 - 18:00
	Genovefa Papanicolaou (New York, United States of America (the))	
A223	MONITORING AND MANAGEMENT OF EBV-ASSOCIATED COMPLICATIONS IN ALLOGENEIC TRANSPLANT RECIPIENTS: PRACTICES AND ACCESS TO ADOPTIVE CELLULAR THERAPY - 2024 SURVEY BY THE SPANISH GETH-TC GROUP	18:00 - 18:00
	Irene García-Cadenas (Barcelona, Spain)	
A224	AN 11-YEAR RETROSPECTIVE STUDY OF PNEUMOCYSTIS JIROVECHII PNEUMONIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Alienor Xhaard (Paris, France)	
A225	CHAGAS' DISEASE IN HAEMATOPOIETIC CELL TRANSPLANTATION PATIENTS AND DONORS	18:00 - 18:00
	Gregorio Jaimovich (Buenos Aires, Argentina)	
A226	DENGUE VIRUS INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Martin Eduardo Castro (Buenos Aires, Argentina)	
A227	PARADIGM SHIFT IN POST ALLOGENEIC-HSCT VIRAL INFECTIONS IN THE WIDESPREAD USE OF LETERMOVIR PROPHYLAXIS ERA. ONE SPANISH CENTER EXPERIENCE	18:00 - 18:00
	C. Blanco-Montes (Badalona, Spain)	

A228	FINAL ANALYSIS OF OUTCOMES IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH REFRACTORY CYTOMEGALOVIRUS INFECTION OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS TREATMENTS IN EUROPE, CANADA AND ISRAEL Johan Maertens (Leuven, Belgium)	18:00 - 18:00
A229	IMPACT OF CYTOMEGALOVIRUS VIREMIA CLEARANCE ON OUTCOMES IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH REFRACTORY OR RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS TREATMENTS Tien Bo (Lexington, United States of America (the))	18:00 - 18:00
A230	A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Anna Nordlander (Stockholm, Sweden)	18:00 - 18:00
A231	CD45RA-DEPLETED DLI FOR REFRACTORY CMV INFECTION IN PEDIATRIC HSCT RECIPIENTS: A PROMISING THERAPEUTIC STRATEGY Ho Joon Im (Seoul, Korea (the Republic of))	18:00 - 18:00
A232	IMPACT OF LETERMIVIR PROPHYLAXIS ON CYTOMEGALOVIRUS OUTCOMES AND RESOURCE USE IN HIGH- RISK ALLOGENEIC HSCT RECIPIENTS ACCORDING TO THE REIMBURSEMENT CRITERIA IN SPAIN Carlos de Miguel (Madrid, Spain)	18:00 - 18:00
A233	TRENDS IN ICU ADMISSIONS FOR ALLOGENEIC HEMATOPOIETIC TRANSPLANT RECIPIENTS: PATIENT PROFILES AND OUTCOMES Camilla Dao Vo (Oslo, Norway)	18:00 - 18:00
A234	LETERMIVIR PRIMARY PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) REACTIVATION IN EX-VIVO TCRAB-DEPLETED HAPLOIDENTICAL ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION WITH MEMORY T CELL ADD-BACK Ao Ran Boo (Singapore, Singapore)	18:00 - 18:00
A235	ASSESSMENT OF INACTIVATED VACCINE COVERAGES IN THE REVACCINATION PROGRAM OF HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AFTER THE SECOND YEAR OF TRANSPLANTATION Clarisse Machado (São Paulo, Brazil)	18:00 - 18:00
A236	CLINICAL VALIDATION OF A URINARY ANTIGEN TEST AS AN AID TO DIAGNOSE INVASIVE ASPERGILLOSIS IN HEMATOLOGY PATIENTS Yuri Vanbiervliet (Leuven, Belgium)	18:00 - 18:00
A237	IMPACT OF PROPHYLACTIC GRANULOCYTE TRANSFUSIONS ON REDUCING BLOOD CULTURE POSITIVITY AND TRANSPLANT-RELATED MORTALITY IN PAEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTS Anjali Yadav (Gurugram, India)	18:00 - 18:00
A238	NGS-BASED PATHOGEN DETECTION IN BRONCHOALVEOLAR LAVAGE FLUID OBTAINED FROM PATIENTS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION WITH PULMONARY INFECTIONS Anna Ruckdeschel (Würzburg, Germany)	18:00 - 18:00
A239	PRE-TRANSPLANT POSITIVE CMV PCR IS ASSOCIATED WITH POST-TRANSPLANT CMV INFECTIONS WITH OR WITHOUT LETERMIVIR PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	18:00 - 18:00

	Léna Royston (Geneva, Switzerland)	
A240	SURVEY ON THE INCIDENCE AND MANAGEMENT OF TOXOPLASMOSIS AMONG THE CENTERS OF ITALIAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (GITMO) Katia Perruccio (Perugia, Italy)	18:00 - 18:00
A242	CLINICAL SIGNIFICANCE OF REACTIVATION OF HUMAN HERPESVIRUS 6 IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS M. Emilia Mas (Córdoba, Argentina)	18:00 - 18:00
A243	INFLUENCE OF GRAFT IMMUNE CELL COMPOSITION AND IMMUNE RECONSTITUTION ON CMV REACTIVATION AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION Valle Gómez García de Soria (Madrid, Spain)	18:00 - 18:00
A244	IDENTIFICATION OF PRIORITIZED HIGH-RISK CRITERIA AND PATIENT POPULATION SIZES FOR EXTENDED CMV PROPHYLAXIS IN ALLO-HSCT PATIENTS Maša Morsan (Zagreb, Croatia)	18:00 - 18:00
A245	ASSESSMENT OF T-CELL-MEDIATED, SARS-COV-2-SPECIFIC IMMUNE RESPONSES IN PATIENTS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE DIAGNOSTIC STUDY Anna Ruckdeschel (Würzburg, Germany)	18:00 - 18:00
A246	IMPACT OF LETERMIVIR PROPHYLAXIS ON CMV REACTIVATION AND IMMUNE RECONSTITUTION IN CMV-SEROPOSITIVE ALLOGENEIC HSCT RECIPIENTS: A SINGLE-CENTRE ANALYSIS Ilaria Cutini (Florence, Italy)	18:00 - 18:00
A247	INVASIVE FUNGAL DISEASES CAUSED BY RARE PATHOGENS IN ADULT PATIENTS AFTER HEMATOPOIETIC CELL TRANSPLANTATION AND CHEMOTHERAPY Marina Popova (Saint Petersburg, Russian Federation (the))	18:00 - 18:00
A248	COLONIZATION BY CARBAPENEM-RESISTANT BACTERIA IS ASSOCIATED WITH CARBAPENEM-RESISTANT BLOODSTREAM INFECTIONS WITH DISMAL OUTCOME IN THE IMMEDIATE POST-TRANSPLANT PHASE Francesco Baccelli (Bologna, Italy)	18:00 - 18:00
A249	NEW INSIGHTS IN CURRENT PRACTICE IN THE MANAGEMENT OF DNA VIRUSES IN CHILDREN FOLLOWING ALLOGENEIC HSCT AT EBMT CENTERS Jan Styczynski (Bydgoszcz, Poland)	18:00 - 18:00
A250	INSIGHTS FROM A DISCRETE CHOICE EXPERIMENT: HOW BENEFITS AND RISKS AFFECT PHYSICIAN PREFERENCES FOR PRE-EMPTIVE CMV TREATMENT IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS Miguel-Angel Perales (New York, United States of America (the))	18:00 - 18:00
A251	SEPSIS AND ORGAN FAILURE REMAIN THE MAJOR RISK FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE POST- OR LATE ENGRAFTMENT PHASE ADMITTED TO THE INTENSIVE CARE UNIT Michael Serries (Bonn, Germany)	18:00 - 18:00
A252	RESPIRATORY TRACT INFECTIONS CAUSED BY RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA VIRUS TREATED WITH RIBAVIRIN IN PATIENTS THAT HAVE UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTATION Maria Stamouli (Athens, Greece)	18:00 - 18:00

A253	TOO MUCH ANTIBIOTIC USE IN ALLO-HCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE DURING THE CRS-RISK PERIOD? Björn Reijnders (Nijmegen, Netherlands (the))	18:00 - 18:00
A254	MOBILIZED GRANULOCYTES TRANSFUSION FOR SEVERE INFECTIONS IN NEUTROPENIC PEDIATRIC PATIENTS Federica Galaverna (Roma, Italy)	18:00 - 18:00
A256	SAFETY AND EFFECTIVENESS OF THE RECOMBINANT ZOSTER VACCINE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL-WORLD SETTING Isabel Izquierdo (Zaragoza, Spain)	18:00 - 18:00
A257	IMPACT OF LEVOFLOXACIN PROPHYLAXIS ON BLOODSTREAM INFECTION, CLOSTRIOIDES DIFFICILE INFECTION AND 30-DAY MORTALITY IN RECIPIENTS OF HEMATOPOIETIC CELL TRANSPLANTATION - A SINGLE CENTER EXPERIENCE Taylor Ackling (Duarte, United States of America (the))	18:00 - 18:00
A258	CMV RNA MONITORING IN HEMATOPOIETIC STEM CELL TRANSPLANT Giovanna Travi (Milan, Italy)	18:00 - 18:00
A259	SYMPTOMATIC HEPATITIS E VIRUS INFECTION IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Martina Crysandt (Aachen, Germany)	18:00 - 18:00
A261	CMV RETINITIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN Musa Karakukcu (Kayseri, Turkey)	18:00 - 18:00
A262	IMPACT OF LETERMIVIR PROPHYLAXIS AND VALIDATION OF CMV SCORE RISK IN ALLOGENEIC STEM CELL PATIENTS Cristina Rotolo (Palermo, Italy)	18:00 - 18:00
A263	INCIDENCE AND RISK FACTORS FOR INFECTION WITHIN THE FIRST 5 DAYS AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION USING CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS Marjorie Batista (Sao Paulo, Brazil)	18:00 - 18:00
A264	THE RELATIONSHIP BETWEEN BLOOD CONCENTRATION OF ISAVUCONAZOLE AND TREATMENT EFFICACY AND ADVERSE EVENTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Asami Kataoka (Kyoto, Japan)	18:00 - 18:00
A265	USE OF ANIDULAFUNGIN AS ANTIFUNGAL PROPHYLAXIS IN MISMATCHED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A PROSPECTIVE SINGLE TRANSPLANT PROGRAM EXPERIENCE Angela Carobene (Napoli, Italy)	18:00 - 18:00
A266	ADENOVIRUS INFECTION IN ADULT PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT: INCIDENCE AND OUTCOME DURING THE COVID-19 AND POST-COVID-19 YEARS Malgorzata Mikulska (Genoa, Italy)	18:00 - 18:00
A267	USEFULNESS OF WHOLE BLOOD MULTIPLEX REAL-TIME PCR IN PATIENTS WITH SUSPECTED SEPSIS: AN EXPERIENCE FROM A TERTIARY PEDIATRIC HEMATOLOGY-ONCOLOGY AND TRANSPLANT CENTER IN SOUTH INDIA Stalin Ramprakash (Bangalore, India)	18:00 - 18:00

A268	INCIDENCE, TYPE AND OUTCOME OF HEMORRHAGIC CYSTITIS (HC) AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A SURVEY OF INFECTIOUS DISEASES WORKING PARTY OF EBMT Simone Cesaro (Verona, Italy)	18:00 - 18:00
A269	POOLED BUFFY COAT PREPARATION AS A COST-EFFECTIVE METHOD OF GRANULOCYTE TRANSFUSION IN MANAGING INFECTIONS POST HSCT: AN EFFICACY ANALYSIS Rakesh Reddy Boya (Visakhapatnam, India)	18:00 - 18:00
A270	LEVERAGING FRENCH COMPASSIONATE PROGRAM DATA IN REFRACTORY CMV TO FURTHER DESCRIBE MARIBAVIR EFFECTIVENESS AND RESISTANCE PROFILE Catherine Cordonnier (Créteil, France)	18:00 - 18:00
A271	COMPARATIVE GENOMIC PROFILING OF SEVERE BACTERIAL INFECTIONS IN IMMUNOCOMPROMISED BONE MARROW TRANSPLANT RECIPIENTS AT A TERTIARY REFERRAL CENTER Marat Kazanov (Moscow, Russian Federation (the))	18:00 - 18:00
A272	PREVALENCE OF CLINICALLY SIGNIFICANT VIRAL AND BACTERIAL ENTERIC PATHOGENS IN HAEMOPOIETIC STEM CELL TRANSPLANT RECIPIENTS AND ALLOGENIC DONORS FROM LOW AND MIDDLE INCOME COUNTRY Manaswinee Mallik (Chandigarh, India)	18:00 - 18:00
<i>Printed Poster</i> 18:00 - 19:00		R13
Stem Cell Source		
A171	THE APPLICATION OF UMBILICAL CORD BLOOD TRANSPLANTATION IN PAEDIATRIC INBORN ERRORS OF IMMUNITY Xiaowen Zhai (Shanghai, China)	18:00 - 18:00
A172	ADHERENCE TO CB GUIDELINES IMPROVES TRANSPLANT OUTCOMES IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES Filippo Milano (Seattle, United States of America (the))	18:00 - 18:00
A173	THE COMPARISON OF BONE MARROW (BM) PLUS PERIPHERAL BLOOD (PB) VERSUS PB AS GRAFT SOURCE IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR ELDERLY PATIENTS Wei Zhao (Beijing, China)	18:00 - 18:00
A174	THE HAPLOID HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH UMBILICAL CORD BLOOD TRANSFUSION IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES - A MULTICENTER, SINGLE-ARM PROSPECTIVE TRIAL Jiejing Qian (Hangzhou, China)	18:00 - 18:00
A175	ADAMII™-CD34: INSTRUMENTAL QUALIFICATION IN THE CHARACTERIZATION PROCESS OF THE LEUKAPHERESIS PRODUCT FOR HSC TRANSPLANTATION Serena Urbani (Firenze, Italy)	18:00 - 18:00
A176	EARLY LOW-DOSE ATG CONDITIONING FOR SINGLE UNIT CORD BLOOD TRANSPLANT IN HIGH-RISK MALIGNANCIES: GOOD ENGRAFTMENT, REDUCED GVHD, AND LOW NRM Marta Castelli (Bergamo, Italy)	18:00 - 18:00
A177	COMPARATIVE ANALYSIS OF STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH HLA-HOMOZYGOUS HAPLOTYPES Noriyoshi Yoshinaga (Kyoto, Japan)	18:00 - 18:00

Printed Poster

18:00 - 19:00

R13

New Drugs and Cell-based Immune Therapies

- | | | |
|------|--|---------------|
| A162 | BONE MARROW TRANSPLANTATION AND MITOCHONDRIAL TRANSFER ALLEVIATE THE SYMPTOMS OF LEIGH SYNDROME
Takafumi Yokota (Osaka, Japan) | 18:00 - 18:00 |
| A163 | SYNERGIZING MDM2 INHIBITION WITH ANTI-TIM-3 ANTIBODY THERAPY TO ENHANCE THE GRAFT-VERSUS-LEUKEMIA EFFECT
Andrea Acerbis (Freiburg, Germany) | 18:00 - 18:00 |
| A164 | T CELL RECEPTOR GENE THERAPY TARGETING MUTANT NPM1 IN ACUTE MYELOID LEUKEMIA
Eva Argiro (Leiden, Netherlands (the)) | 18:00 - 18:00 |
| A165 | EBV INFECTION RISK OF BLINATUMOMAB IN B-ALL PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hailu Sun (Beijing, China) | 18:00 - 18:00 |
| A166 | A NOVEL SKP2 INHIBITOR TRIGGERS PYROPTOSIS IN PH⁺ ALL VIA DYSREGULATION OF GLYCEROPHOSPHOLIPID METABOLISM
Xioalong Tian (Chongqing, China) | 18:00 - 18:00 |
| A167 | PREVENTION OF RELAPSE WITH ORAL AZACITIDINE AND VENETOCLAX AFTER ALLO-HCT FOR AML AND MDS
Antoine Capes (Paris, France) | 18:00 - 18:00 |
| A169 | A SINGLE CENTRE EXPERIENCE WITH DARATUMUMAB IN RELAPSED REFRACTORY T-ALL
Sandra Easdale (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A170 | LUSPATERCEPT TREATMENT FOR ERYTHROID POOR GRAFT FUNCTION OCCURRING POST HEMATOPOIETIC STEM CELL TRANSPLANTATION
Qing Zhao (Shanghai, China) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R13

Experimental Transplantation and Gene Therapy

- | | | |
|------|---|---------------|
| A156 | BASE EDITING OF HEMATOPOIETIC STEM CELLS AND T CELLS RESTORES PI3K SIGNALLING IN APDS1 AND APDS2 PATIENTS
Kate Orf (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A157 | GENE THERAPY FOR SICKLE CELL DISEASE AND TRANSFUSION DEPENDENT BETA THALASSEMIA: REAL WORLD DATA, SINGLE CENTER EXPERIENCE
Mohammed Essa (Riyadh, Saudi Arabia) | 18:00 - 18:00 |
| A159 | CHARACTERISATION OF THE DIFFERENTIAL B CELL TRANSCRIPTOME EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WHO DEVELOP CHRONIC GVHD OR DISEASE RELAPSE
Ali Gazwani (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A161 | ALLOGENEIC HSCT FOLLOWING LUNG TRANSPLANT: SECOND REPORTED CASE IN THE LITERATURE
Irene Bernareggi (Siena, Italy) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R13

Nurses Posters - Adult

NP001	SCHOOL OF HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS BASED ON PEER-TO-PEER EDUCATION METHOD María Soledad Jiménez Picazo (Córdoba, Spain)	18:00 - 18:00
NP002	ADVANCE CARE PLANNING IN CAR-T THERAPY PATIENTS: DEMOGRAPHIC INFLUENCES AND ENGAGEMENT RATES - A RETROSPECTIVE SINGLE-CENTRE STUDY Andres Sebastian Moya Davila (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP003	ADHERENCE TO IMMUNOSUPPRESSORS AFTER HSCT: A CROSS-SECTIONAL STUDY Chiara Visintini (Udine, Italy)	18:00 - 18:00
NP004	IMPLEMENTATION OF USE OF PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) FOR ADMINISTRATION OF PERIPHERAL BLOOD STEM CELLS (PBSC) IN PATIENTS RECEIVING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) Yu Ting Ngo (Singapore, Singapore)	18:00 - 18:00
NP005	NURSE LED PRE-HABILITATION FOR PATIENTS UNDERGOING STEM CELL TRANSPLANTATION Jo Preston (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP006	PATIENT FEEDBACK ON LYMPHOMA END OF TREATMENT SESSION Katherine Taylor (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP007	PROPHYLACTIC NASOGASTRIC TUBE FEEDING IN MYELOABLATIVE STEM CELL TRANSPLANT: A SERVICE EVALUATION Julie Beckerson (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP008	'BACK TO SCHOOL': CAN A STEM CELL TRANSPLANT EDUCATION PROGRAM ENHANCE PATIENT EXPERIENCES? Christina Paula Tejada (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP009	HAEMATOLOGY EMERGENCY DEPARTMENT UTILIZATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE Cristina Canaleta (Barcelona, Spain)	18:00 - 18:00
NP010	NURSE LED CLINIC HEMATOLOGY: DREAMWORK OR TEAMWORK Maaïke de Ruijter (Haarlem, Netherlands (the))	18:00 - 18:00
NP011	IMPROVING HAEMATOLOGY ONCOLOGY PATIENT'S TREATMENT RECALL PRIOR TO STARTING CONDITIONING PRE-AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT AND PRIMARY SYSTEMIC ANTI-CANCER THERAPY: IMPLEMENTATION OF "TEACH-BACK METHOD" Ana Goncalves (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP012	IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY (ICAHT) FOLLOWING CD19 CAR T-CELL THERAPY IN LBCL, A SINGLE CENTER EXPERIENCE Nicole O'Leary (Melbourne, Australia)	18:00 - 18:00
NP013	HOW DOES PREMATURE OVARIAN INSUFFICIENCY AFFECT QUALITY OF LIFE IN WOMEN THAT HAVE RECEIVED A HAEMATOPOIETIC STEM CELL TRANSPLANT? A LITERATURE REVIEW Francesca Toselli (Oxford, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP014	HOME SELF-ADMINISTRATION IN PATIENTS RECEIVING CELL THERAPY AND INTENSIVE CHEMOTHERAPY. A UNICENTRIC EXPERIENCE	18:00 - 18:00

	Marta Torres Torres (Barcelona, Spain)	
NP015	FEASIBILITY ASSESSMENT OF IMPLEMENTING AN EARLY WARNING SYSTEM FOR VENO-OCCLUSIVE DISEASE IN ALLOGENIC STEM CELL TRANSPLANTATION: A PILOT STUDY Angela Rodriguez-Rodriguez (Salamanca, Spain)	18:00 - 18:00
NP016	AN OCCUPATIONAL SAFETY PROJECT FOR CANCER CARE NURSES, USING SURFACE WIPE SAMPLING FOR HAZARDOUS DRUGS IN A HAEMATOLOGY AND ONCOLOGY SETTING Audrey O'Halloran (Dublin, Ireland)	18:00 - 18:00
NP017	ADDRESSING BARRIERS IN ACCESSING SUITABLE STEM CELL DONORS: HAEMATOLOGY NURSE'S PERSPECTIVE ON SOUTH ASIAN DONOR AWARENESS IN THE UK Sinju Thomas (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP019	OPTIMIZING STEM CELL HARVESTING FOR MYELOMA PATIENTS: REDUCING NHS COSTS AND ENHANCING PATIENT EXPERIENCE THROUGH SINGLE TRANSPLANT STRATEGY Annabelle Annis (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP020	THE ROLE AND IMPACT OF NURSE SPECIALISTS IN THE ASSESSMENT AND MANAGEMENT OF GRAFT VERSUS HOST DISEASE AT THE GVHD CLINIC Mohsen Alzahrani (Riyadh, Saudi Arabia)	18:00 - 18:00
NP021	IMPROVING THE ADMINISTRATION OF ALEMTUZUMAB FOR THE CONDITIONING OF ALLOGENEIC TRANSPLANT PATIENTS Sara Rush (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP022	COMPARISON OF HOSPITALIZATIONS IN PATIENTS UNDERGOING REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT BASED ON GVHD PROPHYLAXIS (PTCY VS METHOTREXATE) IN HOSPITAL BASED OUTPATIENT PRACTICE Kendall Solinger (Rochester, United States of America (the))	18:00 - 18:00
NP023	BONE MARROW TRANSPLANTATION IN COVID-19 PATIENTS: A QUALITATIVE STUDY ON THE HEALTHCARE PROFESSIONALS' EXPERIENCE Nicole Cassinari (Piacenza, Italy)	18:00 - 18:00
NP024	DELAYED ADMISSION MODEL IN THE WARD EVALUATING THE SAFETY AND EFFICACY OF OUTPATIENT LYMPHODEPLETING CHEMOTHERAPY: AN ANALYSIS IN PATIENTS UNDERGOING CAR-T THERAPY Sabrina Castiglione (Firenze, Italy)	18:00 - 18:00
NP025	'WHERE NOW': A HEALTH AND WELLBEING COURSE SUPPORTING THE NEEDS OF SURVIVORS POST ALLOGENEIC STEM CELL TRANSPLANTATION Janet O'Doherty (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP026	NURSING CARE IN CAR-T THERAPY FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Laura Tierno Marti (Barcelona, Spain)	18:00 - 18:00
NP027	MOBILE HEALTH TECHNOLOGIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SCOPING REVIEW Zhengwen Pan (Hangzhou, China)	18:00 - 18:00
NP028	A QUALITY IMPROVEMENT PROJECT TO REDUCE 'TEMPERATURE SPIKE TO NEEDLE TIME' FOR FIRST DOSE ANTIBIOTICS TO WITHIN 60 MINUTES ON AN INPATIENT HAEMATOLOGY/AUTOLOGOUS TRANSPLANT UNIT	18:00 - 18:00

	Allison Ponsford (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	
NP029	THE TRANSPLANT COORDINATOR: A NEW APPROACH OF ORGANIZATION AND MANAGEMENT IN HSCT AND CELLULAR THERAPIES Roberta Lepori (Florence, Italy)	18:00 - 18:00
NP030	EMBEDDING PASTORAL SUPPORT NURSING IN CLINICAL HAEMATOLOGY: OUR EXPERIENCE Manelyn Castaneda (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP031	NURSE LED IMMUNE EFFECTOR CELL ENCEPHALOPATHY (ICE) SCORING: ADAPTING TO MEET THE INDIVIDUAL NEEDS OF PATIENTS RECEIVING CAR T-CELL THERAPY Emily John (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP032	IMPLEMENTATION OF GROUP AND SAVE & BLOOD TRANSFUSION PRODUCTS ORDERED NOTEBOOK TO REDUCE THE WASTAGE OF BLOOD COMPONENTS IN HAEMATOLOGY AND TRANSPLANT DAY UNIT (HTDU) Judith Lee (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP033	EFFECT OF CELLULAR THERAPY ON PATIENTS' QUALITY OF LIFE, A COHORT STUDY AT ABU DHABI STEM CELL CENTER, UAE CENTER OF EXCELLENCE FOR HSCT Dina El Mouzain (Abu Dhabi, United Arab Emirates (the))	18:00 - 18:00

Printed Poster

18:00 - 19:00

R13

Cellular Therapies other than CARs

A135	ADOPTIVE CELL THERAPY WITH MEMORY T LYMPHOCYTES TO TREAT INFECTIOUS DISEASES IN IMMUNCOMPROMISED PATIENTS Karima Al-Akioui Sanz (Madrid, Spain)	18:00 - 18:00
A136	UTILIZING T REGULATORY AND T MEMORY CELL PRODUCTS IN THE TREATMENT OF PATIENTS WITH GVHD AND ASSOCIATED INFECTIOUS COMPLICATIONS: INSIGHTS FROM A CLINICAL EXPERIENCE Dmitry Pershin (Moscow, Russian Federation (the))	18:00 - 18:00
A139	ADOPTIVE IMMUNOTHERAPY WITH DONOR-DERIVED VIRUS-SPECIFIC T LYMPHOCYTE FOR THE TREATMENT OF SEVERE, TREATMENT-REFRACTORY VIRAL INFECTIONS IN CHILDREN UNDERGOING HLA-HAPLOIDENTICAL T-ALPHA/BETA AND B-DEPLETED TRANSPLANTATION Federica Galaverna (Roma, Italy)	18:00 - 18:00
A140	AN INNOVATIVE PLATFORM APPROACH FOR THE PARALLEL DEVELOPMENT OF HEMATOPOIETIC STEM AND PROGENITOR CELL-GENE THERAPIES (HSPC-GT) FOR RARE/ULTRA-RARE LYSOSOMAL STORAGE DISORDERS WITH SEVERE SKELETAL MANIFESTATIONS Maria Ester Bernardo (Milano, Italy)	18:00 - 18:00
A141	T- AND B-CELL NEOGENESIS RECOVERS EFFICIENTLY IN CHILDREN WITH ACUTE LEUKEMIA GIVEN AN ALPHA-BETA T-CELL DEPLETED HAPLO-HSCT FOLLOWED BY INFUSION OF GENETICALLY MODIFIED DONOR T-CELLS Marialuigia Catanoso (Rome, Italy)	18:00 - 18:00
A142	POST-TRANSPLANT MAINTENANCE THERAPY WITH AZACITIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) IN PATIENTS WITH JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) AT HIGH RISK OF RELAPSE	18:00 - 18:00

	Luca Vinci (Freiburg, Germany)	
A143	DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A SINGLE CENTER LONGITUDINAL RETROSPECTIVE STUDY Veronika Valkova (Prague 2, Czechia)	18:00 - 18:00
A144	MERIT OF A HIGH-VOLUME DONOR LYMPHOCYTE INFUSION PRACTICE IN MODERN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION Micheal Brennan (Dublin, Ireland)	18:00 - 18:00
A145	SAFETY AND EFFICACY OF AN ADVANCED THERAPY PROPHYLAXIS WITH CMV-SPECIFIC CYTOTOXIC T LYMPHOCYTES AFTER FAMILIAL ALLOGENEIC TRANSPLANTATION Arancha Bermudez (Santander, Spain)	18:00 - 18:00
A147	FEASIBILITY OF GENERATION AND EXPANSION OF HEMATOPOIETIC STEM CELL-DERIVED NATURAL KILLER CELLS FOR A POTENTIAL ALTERNATIVE CELL SOURCE OF CANCER IMMUNOTHERAPY Suppanut Komjakraphan (Hat Yai, Thailand)	18:00 - 18:00
A148	IMPLEMENTING A DATABASE ON ATMP-RELATED TRIALS IN EUROPE - INSIGHTS FROM THE JOIN4ATMP PROJECT Stephanie Winter (Vienna, Austria)	18:00 - 18:00
A149	DONOR-DERIVED ANTI-LEUKEMIA CTL FOR THE CONTROL OF LEUKEMIA RELAPSE IN HIGH-RISK CHILDREN AFTER HAPLO-HSCT Daniela Montagna (Pavia, Italy)	18:00 - 18:00
A150	ABATACEPT(CTLA4-IG) PRIMING AND ITS ROLE IN MODULATING NKCELL FUNCTION AND GRAFT-VERSUS-LEUKEMIA EFFECT IN PATIENTS UNDERGOING HAPLOIDENTICAL HCT: A PROMISING APPROACH TO DISSOCIATE GVH AND GVL Sarita Jaiswal (New Delhi, India)	18:00 - 18:00
A152	LEUKAPHERESIS FOR CD45RA-DEPLETED DONOR LYMPHOCYTE INFUSIONS: REPORT FROM A SINGLE PEDIATRIC CENTER Blanca Molina (Madrid, Spain)	18:00 - 18:00
A153	2 YEARS OF CAR-T IN A TERTIARY PEDIATRIC CENTER: RESULTS AND RESPONSE TO TREATMENT Antonella Zanette (Curitiba, Brazil)	18:00 - 18:00
A154	THE ADDITION OF CD28 SIGNALLING MOTIFS TO CD3Z ENHANCES TCR T CELL FUNCTION Emma Morris (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
A155	SUCCESSFUL LONG-TERM USE OF DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD Bernd Gruhn (Jena, Germany)	18:00 - 18:00

Printed Poster

18:00 - 19:00

R13

Chronic Leukaemia and Other Myeloproliferative Disorders

A364	DASATINIB AS TARGETED THERAPY FOR POST-TRANSPLANT EXTRAMEDULLARY RELAPSE. AN OBSERVATIONAL STUDY Isabel Cunningham (New York, United States of America (the))	18:00 - 18:00
------	---	---------------

Printed Poster

18:00 - 19:00

R13

CAR-based Cellular Therapy - Clinical

A082	THE OPTIMIZED HINGE CD19/20 CAR-T SHOWED DURABLE EFFICACY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA: INTERIM RESULTS FROM A MULTICENTER PHASE I/II TRIAL Jia Wei (Wuhan, China)	18:00 - 18:00
A083	THE ROLE OF FUNCTIONAL RESPIRATORY TESTS IN PRE-CAR T-CELL THERAPY SCREENING: NECESSITY OR REDUNDANCY? Giulia Losi (Pavia, Italy)	18:00 - 18:00
A085	EDITED ALLOGENEIC BCMA-CAR NK CELLS AS INNOVATIVE THERAPEUTIC CONCEPT FOR MULTIPLE MYELOMA Evelyn Ullrich (Frankfurt, Germany)	18:00 - 18:00
A086	PROLONGED CAR-T CELL EXPANSION AND STEMNESS IN HEAVILY PRETREATED RELAPSED/REFRACTORY B-ALL AND B-NHL PATIENTS TREATED WITH PSU CD19CAR INCORPORATED CD28/CD40 CO-STIMULATORY MOLECULE: A PRELIMINARY OUTCOME Jakrawadee Julamanee (Hat Yai, Thailand)	18:00 - 18:00
A087	ANALYSIS OF RESIDUAL CELLULAR AND HUMORAL VACCINE RESPONSE IN PATIENTS TREATED WITH ANTI-CD19 CAR-T CELLS Ana Llorens (Nantes, France)	18:00 - 18:00
A088	MOLECULAR TUMOR BURDEN AND CLONAL DYNAMICS ARE ASSOCIATED WITH TREATMENT FAILURE RISK IN LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH CAR-T CELL THERAPY Mariana Bastos Oreiro (Madrid, Spain)	18:00 - 18:00
A089	COMPARING T-CELL PHENOTYPE OF CD28 VS 4-1BB CD19 SPECIFIC CAR T-CELLS IN B-ALL PATIENTS Alexandre G. Troullioud Lucas (New York, United States of America (the))	18:00 - 18:00
A090	CAR-T CELL DYNAMICS AND MYELOID-CELL ALTERED PROFILE ARE ASSOCIATED WITH CLINICAL OUTCOME IN ANTI-CD19 CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL MALIGNANCIES: A REAL-LIFE COHORT STUDY Edoardo Campodonico (Milan, Italy)	18:00 - 18:00
A091	A RETROSPECTIVE STUDY OF RECIPIENT-DERIVED VERSUS DONOR-DERIVED CAR-T CELL THERAPY IN RELAPSED B-ALL PATIENTS AFTER TRANSPLANTATION Xiaoqi Wang (ChongQing, China)	18:00 - 18:00
A092	THE CD62L⁺ PROPORTION AND CD4/CD8 RATIO OF BCMA-CART PRODUCTS AS A PROGNOSTIC INDICATOR FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Longyuan Wu (Hangzhou, China)	18:00 - 18:00
A093	SIX-YEAR FOLLOW-UP INDICATES THE CURATIVE POTENTIAL OF COCKTAIL CAR-T OR IN COMBINATION WITH ASCT IN TP53-ALTERED RELAPSED/REFRACTORY B-NHL Jia Wei (Wuhan, China)	18:00 - 18:00
A094	HIGHER DOSES OF FLUCY LYMPHODEPLETION IN HIGH-RISK PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL) TREATED WITH TISAGENLEUCEL ARE ASSOCIATED WITH HIGHER CAR-T EXPANSION AND BETTER RESPONSE Marta Canelo-Vilaseca (Paris, France)	18:00 - 18:00
A095	DECIPHERING THE COMPLEX INTERTWINING BETWEEN	18:00 - 18:00

	CYTOPENIA AND TRANSFUSION NEEDS AFTER CAR T-CELL THERAPY FOR B-CELL MALIGNANCIES	
	Luciana Teofili (Rome, Italy)	
A097	PATIENTS WITH NON-REMISSION AT LYMPHODYPLETING CHEMOTHERAPY AND SEVERE CYTOKINE RELEASE SYNDROME AFTER TREATMENT WITH TISAGENLEUCEL SHOW HIGH RATES OF CD19-NEGATIVE RELAPSES AND POOR SURVIVAL	18:00 - 18:00
	Martin Hutter (Frankfurt am Main, Germany)	
A098	AUTOLOGOUS STEM CELL TRANSPLANTATION COMBINED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR REFRACTORY/RELAPSED B-CELL LYMPHOMA: SALVAGE THERAPY VS. CONSOLIDATION THERAPY	18:00 - 18:00
	Fan Yang (Beijing, China)	
A099	BCMA/CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ANTI-HLA ANTIBODY SENSITIZATION IN PATIENTS WITH ACUTE LEUKEMIA: A PILOT CLINICAL STUDY	18:00 - 18:00
	Houli Zhao (Hangzhou, China)	
A100	NOVEL SIGNATURE OF BASELINE INFLAMMATION IDENTIFIES PATIENTS AT HIGH RISK OF RELAPSE AFTER BCMA CAR-T IN MULTIPLE MYELOMA	18:00 - 18:00
	Eugene Brailovski (New York City, United States of America (the))	
A102	EFFICACY AND SAFETY OF CAR-T CELL THERAPY IN B-ALL PATIENTS PREVIOUSLY TREATED WITH BLINATUMOMAB	18:00 - 18:00
	Yurou Chu (Suzhou, China)	
A103	DISTINCT EXPANSION, PHENOTYPE, FUNCTION, AND TOXICITY OF CILTA-CEL VS. IDE-CEL CAR T CELLS IN THE REAL WORLD	18:00 - 18:00
	Djordje Atanackovic (Baltimore, United States of America (the))	
A104	CD19.CAR-T CELL THERAPY FOR PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS OR RHEUMATOID ARTHRITIS	18:00 - 18:00
	Michael Schmitt (Heidelberg, Germany)	
A105	VIRAL REACTIVATION IN MULTIPLE MYELOMA PATIENTS RECEIVING ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY	18:00 - 18:00
	Shlomo Elias (Jerusalem, Israel)	
A106	CAR-T CELL RECEPTOR ASSOCIATED TREMOR - AN OBSERVATIONAL STUDY	18:00 - 18:00
	Sara Lozano Cerrada (London, United Kingdom of Great Britain and Northern Ireland (the))	
A108	CLINICAL OUTCOMES OF PATIENTS WITH LYMPHOID BLASTIC PHASE OF CHRONIC MYELOID LEUKEMIA TREATED WITH CAR T-CELL THERAPY: A MULTICENTER REAL WORLD STUDY	18:00 - 18:00
	Yujie Liu (Suzhou, China)	
A109	LYMPHODEPLETION WITH SINGLE AGENT BENDAMUSTINE PRIOR TO CAR T-CELL THERAPY IN PATIENTS WITH IMPAIRED RENAL FUNCTION	18:00 - 18:00
	Georg-Nikolaus Franke (Leipzig, Germany)	
A110	UNLOCKING THE ROLE OF CRP AND IL-10 SERUM LEVELS ON CAR-T CELL THERAPY OUTCOME. A SINGLE CENTRE EXPERIENCE	18:00 - 18:00
	Ilaria Cutini (Florence, Italy)	
A111	ELECTROENCEPHALOGRAPH FEATURES IN PATIENTS WITH IMMUNE EFFECTOR-CELL ASSOCIATED NEUROTOXICITY SYNDROME (ICANS): A MONOCENTRIC EXPERIENCE	18:00 - 18:00

	Michele Wieczorek (Vicenza, Italy)	
A112	CLINICALLY SIGNIFICANT HYPOFIBRINOGENEMIA AS A FREQUENT ADVERSE EVENT IN CAR-T-CELL THERAPY RECEPTORS WITH CYTOKINE RELEASE SYNDROME Maria Huguet (Badalona, Spain)	18:00 - 18:00
A113	ANALYSIS OF MAJOR ADVERSE CARDIAC EVENTS (MACE) AND SURVIVAL OUTCOMES BY CAR-T SUBTYPE: CD-19 VERSUS BCMA DIRECTED THERAPY IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS Anup Kumar Trikannad Ashwini Kumar (Little Rock, United States of America (the))	18:00 - 18:00
A114	INITIAL ANALYSIS OF TISAGENLEUCEL THERAPY USING FORMSNET3 IN JAPAN: REAL-WORLD EFFICACY AND SAFETY IN PEDIATRIC AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA Itaru Kato (Kyoto, Japan)	18:00 - 18:00
A115	SINGLE-CELL TRANSCRIPTOMICS UNCOVERS THE IMPACT OF IMMUNE RECONSTITUTION DYNAMICS ON EBV/CMV REACTIVATION IN RELAPSED/REFRACTORY T-ALL/LBL PATIENTS TREATED WITH AUTOLOGOUS NANOBODY-DERIVED FRATRICIDE-RESISTANT CD7 CAR-T THERAPY Meng Lv (Beijing, China)	18:00 - 18:00
A116	THE PATIENT JOURNEY AND TREATMENT OUTCOMES COMPARING INPATIENT VERSUS OUTPATIENT AXICABTAGENE CILOLEUCEL IN NON-HODGKIN'S LYMPHOMA (NHL) - A LARGE, MULTICENTER STUDY Minoo Battiwalla (Nashville, United States of America (the))	18:00 - 18:00
A117	CLINICAL RESOLUTION OF AUTOIMMUNE CHOROIDITIS AND MULTIORGAN INVOLVEMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT TREATED WITH CD19CAR-T INCORPORATED CD28/CD40 SIGNALING MOLECULES Jakrawadee Julamanee (Hat Yai, Thailand)	18:00 - 18:00
A118	EASIX SCORE AS PREDICTOR FOR SURVIVAL OUTCOMES AFTER ANTI-CD19 CAR-T CELL THERAPY: A STUDY ON BEHALF OF THE GRUPO ESPAÑOL DE TRASPLANTE Y TERAPIA CELULAR Alberto Mussetti (Barcelona, Spain)	18:00 - 18:00
A119	SERUM AMYLOID-A (SAA) IS AN OPTIMAL ACUTE PHASE PROTEIN FOR CYTOKINE RELEASE SYNDROME IN CAR-T PATIENTS EXPOSED TO TOCILIZUMAB Eugenio Galli (Rome, Italy)	18:00 - 18:00
A120	FIRST-LINE SALVAGE THERAPIES AFTER ANTI-BCMA CAR-T FAILURE IN PATIENTS WITH MULTIPLE MYELOMA: A META-ANALYSIS OF RESPONSE RATES Jaromir Tomasik (Warsaw, Poland)	18:00 - 18:00
A121	ICANS PREDICTORS IN CAR-T CELL THERAPY: BASELINE CLINICAL, BIOCHEMICAL, AND EEG FINDINGS Eugenio Galli (Rome, Italy)	18:00 - 18:00
A122	LOW DISEASE BURDEN BEFORE CAR-T CELL INFUSION HIGHLY REDUCES THERAPY-RELATED TOXICITIES Paweł Marschollek (Wrocław, Poland)	18:00 - 18:00
A123	INFECTIONS AFTER CAR T-CELL THERAPY WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA Ana Benzaquén (Valencia, Spain)	18:00 - 18:00
A124	DISEASE PATTERNS AND RESOURCE UTILIZATION OF LATE IMMUNE CELL-ASSOCIATED HEMATOLOGIC TOXICITY (ICAHT)	18:00 - 18:00

	AFTER CD19-DIRECTED CAR-T THERAPY Philippe Giguère (Ottawa, Canada)	
A125	IMPACT OF WEIGHT CHANGE ON OUTCOMES AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR B-CELL LYMPHOMAS Shaykhah Alotaibi (Jacksonville, United States of America (the))	18:00 - 18:00
A126	OUTCOMES AFTER CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELLS FOR B-CELL MALIGNANCIES: A SINGLE CENTER EXPERIENCE Giorgia Battipaglia (Naples, Italy)	18:00 - 18:00
A127	THIRD LINE (3L) CAR T-CELL THERAPY IN THE GOLDEN YEARS: A SINGLE-CENTER EXPERIENCE ON OUTCOMES FOR ELDERLY PATIENTS IN LARGE B-CELL LYMPHOMA Majed Altareb (Toronto, Canada)	18:00 - 18:00
A128	IMPORTANCE OF INFLAMMATORY BIOMARKERS ON PREDICTION OF RESPONSE TO CAR-T IN LYMPHOMA PATIENTS Nicolás De Lucas Torres (Oviedo, Spain)	18:00 - 18:00
A130	EXPANDING CAR T-CELL THERAPY BOUNDARIES: DEVELOPING A MIXED OUTPATIENT-AT HOME MODEL Beatriz Merchán Muñoz (Barcelona, Spain)	18:00 - 18:00
A131	ESTABLISHMENT OF THE FIRST PROGRAM FOR LOCAL CD19-CAR-T PRODUCTION AND TREATMENT OF LYMPHOMA IN THE UAE AND GULF REGION Inas El-Najjar (Abu-Dhabi, United Arab Emirates (the))	18:00 - 18:00
A132	SEQUENTIAL BCMA CAR-T CELL THERAPY IS SAFE AND EFFICACIOUS IN REFRACTORY MULTIPLE MYELOMA IN A REAL-WORLD SETTING Philipp Gödel (Cologne, Germany)	18:00 - 18:00
A133	CYTOKINE PROFILE AS A PREDICTOR OF CELLULAR EXPANSION AND ICANS IN CAR-T CELL THERAPY FOR B-CELL LYMPHOMAS Giuseppe Petruzzellis (Udine, Italy)	18:00 - 18:00
A134	USE OF RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IMPROVE THROMBOCYTOPENIA IN CAR-T CELL-TREATED PATIENTS Jia Wei (Wuhan, China)	18:00 - 18:00

Printed Poster

18:00 - 19:00

R13

CAR-based Cellular Therapy - Preclinical

A073	THE EXPRESSION OF PD-1 ON T CELLS IN ACUTE GRAFT-VERSUS-HOST DISEASE AND PRELIMINARY EXPLORATION OF PD-1.ICAR-TREG CELLS IN THE TREATMENT OF AGVHD Xiaopeng Tian (Suzhou, China)	18:00 - 18:00
A074	QUINOLONES ENHANCE ANTI-TUMOR EFFICACY OF CAR T CELL THERAPY Qiqi Zhang (□□, China)	18:00 - 18:00
A076	LOW-AFFINITY ANTIHER2-CAR T CELLS EFFICIENTLY ERADICATE HER2+ AND HER2LOW CANCER CELLS WITH REDUCED TOXICITY ON HEALTHY TISSUE Markus Perl (Regensburg, Germany)	18:00 - 18:00
A077	CD19-CAR REDIRECTED NK CELLS SECRETE CYTOTOXIC EXTRACELLULAR VESICLES EXPRESSING CAR MOLECULES WITH A POWERFUL ANTI-LEUKEMIC ACTIVITY IN VIVO	18:00 - 18:00

	Giulia Corradi (Pescara, Italy)	
A078	ON THE WAY TO IMPROVE NKG2D CAR-T AS A TREATMENT FOR PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS Karima Al-Akioui Sanz (Madrid, Spain)	18:00 - 18:00
A079	ENGINEERING CAR-T CELLS FOR EFFECTIVE THERAPY AMID JAK INHIBITION Alexandros Rampotas (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
A080	ENHANCED LLAMA-DERIVED V_HH CLEC12A-CAR-NK CELLS FOR TREATMENT ACUTE MYELOID LEUKEMIA Evelyn Ullrich (Frankfurt, Germany)	18:00 - 18:00
A081	NEXT-DAY CAR-T MANUFACTURING: IMPROVING TRANSDUCTION EFFICIENCY AND CELL PHENOTYPE WITH MICROFLUIDIC SYSTEMS Marina Popova (Saint Petersburg, Russian Federation (the))	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		R13
Stem Cell Mobilization, Collection and Engineering		
A050	DARATUMUMAB-CONTAINING INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EFFECTS ON STEM CELL MOBILIZATION, COLLECTION AND ENGRAFTMENT (DILEMMA STUDY) Luciana Teofili (Rome, Italy)	18:00 - 18:00
A051	TREATMENT STRATEGIES AIMED AT MOBILIZING ALLOGENEIC AND AUTOLOGOUS HSC IN ADULTS AND CHILDREN: EVIDENCE-BASED RECOMMENDATIONS BY THE GRUPPO ITALIANO TRAPIANTI MIDOLLO OSSEO (GITMO) Massimo Martino (Reggio Calabria, Italy)	18:00 - 18:00
A052	NEW METHOD FOR BONE MARROW SEPARATION AND BUFFY COAT ENRICHMENT: QUICK TO USE, SAFE AND COST-EFFECTIVE Martina Brandl (Gauting, Germany)	18:00 - 18:00
A053	INFANTS AND YOUNG CHILDREN PERIPHERAL BLOOD STEM CELL COLLECTION FOR EX-VIVO HEMATOPOIETIC STEM CELL GENE THERAPY: FEASIBILITY AND EFFICACY IN 37 PATIENTS WEIGHING 7-15 KG Alessia Orsini (Milan, Italy)	18:00 - 18:00
A054	POSITIVE SELECTION OF CD34+ FROM CRYOPRESERVED STEM CELL (SC) SOURCE TO TREAT POOR GRAFT FUNCTION (PGF): PRELIMINARY DATA FROM TWO ITALIAN TRANSPLANT CENTERS Giorgia Mancini (Ancona, Italy)	18:00 - 18:00
A055	IMPACT OF PREEMPTIVE USE OF PLERIXAFOR ON MOBILIZATION, GRAFT COMPOSITION AND CLINICAL OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER PROPENSITY SCORE MATCHING ANALYSIS Ling Wang (Shanghai, China)	18:00 - 18:00
A056	SAFETY, EFFICACY AND FEASIBILITY OF GCSF AND PLERIXAFOR BASED CD34 MOBILIZATION FOR AUTOLOGOUS BACKUP IN PATIENTS UNDERGOING ALTERNATE DONOR HSCT FOR SICKLE CELL DISEASE Vaibhav Chadha (Delhi, India)	18:00 - 18:00
A057	STEM CELL BOOST WITH IMMUNOMAGNETIC SELECTION IS SUCCESSFUL IN THE THERAPY OF 60% PATIENTS WITH ALLOGENEIC POOR GRAFT FUNCTION- RESULTS OF RETROSPECTIVE POLISH STUDY	18:00 - 18:00

	Jowita Frączkiewicz (Wroclaw, Poland)	
A059	MACHINE LEARNING IDENTIFIES KEY FACTORS INFLUENCING APHERESIS YIELD FOR CAR-T CELL THERAPY IN B-CELL LYMPHOMA PATIENTS Natalia Lorente (Madrid, Spain)	18:00 - 18:00
A060	IMMUNOMAGNETIC SELECTION OF ALLOGENEIC CD34+ CELLS FOR STEM CELL BOOST - SINGLE CENTRE EXPERIENCE Darija Bogdanić (Zagreb, Croatia)	18:00 - 18:00
A061	PREDICTIVE MODEL OF THE EFFICIENCY OF HAEMATOPOIETIC PROGENITOR CELL MOBILISATION FOR HEALTHY DONORS MOBILISED WITH G-CSF Tania Dexter (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
A062	IS EXCEPTIONALLY HIGH PRE-TRANSPLANT CD34+ CELL YIELD IN SINGLE APHERESIS PREDICTIVE OF POOR PROGNOSIS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION? Sinem Civriz Bozdag (Istanbul, Turkey)	18:00 - 18:00
A063	HEMATOPOIETIC STEM CELL COLLECTION IN HEALTHY PEDIATRIC ALLOGENEIC DONORS FOR ADULT RECIPIENTS: PREDICTING FACTORS FOR OPTIMAL CD34+ COLLECTION Mohammed Essa (Riyadh, Saudi Arabia)	18:00 - 18:00
A064	IMMUNOPHENOTYPIC ANALYSIS OF ANTI-CD38 TREATMENT ON HEMATOPOIETIC PROGENITOR CELLS DURING APHERESIS IN PATIENTS WITH PLASMA CELL DYSCRASIAS Natalia Lorente (Madrid, Spain)	18:00 - 18:00
A065	FROM DELHI TO TBILISI: A TALE OF TWO CITIES AND TWO TRANSPLANT PROGRAMS Maia Ananiashvili (Tbilisi, Georgia)	18:00 - 18:00
A066	SUBSTITUTION OF THE CLINIMACS PRODIGY TO THE CLINIMACS PLUS DEVICE SUPPORTS EQUIVALENT PERFORMANCES FOR THE IMMUNO-SELECTION OF CD34+ CELLS FROM FRESH OR THAWED APHERESIS PRODUCTS Boris Calmels (Marseille, France)	18:00 - 18:00
A067	DARATUMUMAB: DOES IT INFLUENCE AUTOLOGOUS STEM CELL COLLECTION AND ENGRAFTMENT? Raquel García-Talavera Hernández (Las Palmas de Gran Canaria, Spain)	18:00 - 18:00
A068	SAFETY OF BONE MARROW HARVESTING IN BONE MARROW SIBLING DONORS WITH THALASSEMIA CARRIER Pornpun Sripornsawan (Hat Yai, Thailand)	18:00 - 18:00
A069	OPERATOR AND NON-OPERATOR BASED FACTORS THAT AFFECT HEMATOPOIETIC STEM CELL COLLECTION EFFICIENCY Eleni Lalou (Athens, Greece)	18:00 - 18:00
A070	RETROSPECTIVE ANALYSIS TO EVALUATE MOBILISATION EFFECTIVENESS OF G-CSF + PLERIXAFOR VS G-CSF ± CHEMOTHERAPY IN PATIENTS WITH MULTIPLE MYELOMA Sung-Hoon Jung (Hwasun, Korea (the Republic of))	18:00 - 18:00
A071	THE IMPACT OF TOTAL HANDLING TIME AND SUBSEQUENT CRYOPRESERVATION OF ALLOGENEIC STEM CELLS ON ENGRAFTMENT KINETICS Malgorzata Sobczyk-Kruszelnicka (Gliwice, Poland)	18:00 - 18:00
A072	COMPLETE RECOVERY FROM CYTOPENIAS AFTER CHEMOTHERAPY, CART CELL INFUSION OR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CD34+	18:00 - 18:00

SELECTED STEM CELL BOOST

Marta Pérez Laencina (Murcia, Spain)

Printed Poster

18:00 - 19:00

R13

Multiple Myeloma

- | | | |
|------|--|---------------|
| A347 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER RECEIVING CAR-T THERAPY: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
Martin Vogel (Neuss, Germany) | 18:00 - 18:00 |
| A348 | MULTICENTER PROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF DARATUMUMAB INCLUDED IN A MELPHALAN 200 MG/M2 CONDITIONING REGIMEN IN PATIENTS WITH PLASMA CELL MYELOMA (PM)
Denis Fedorenko (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| A349 | ANALYSIS OF DIFFERENT MODALITIES OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE PROVINCE OF GRANADA (SPAIN)
Manuel Jurado Chacón (Granada, Spain) | 18:00 - 18:00 |
| A350 | IMPROVED SURVIVAL IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT
Victor Wei Teik Ling (Singapore, Singapore) | 18:00 - 18:00 |
| A351 | AN ANALYSIS OF REAL-WORLD MEDICAL HISTORY, CILTACABTAGENE AUTOLEUCEL PRODUCT CHARACTERISTICS, AND PATIENT OUTCOMES
Raphaëlle Parker (New Brunswick, United States of America (the)) | 18:00 - 18:00 |
| A352 | EXPLORATORY MULTIVARIABLE ANALYSES SHOW DIFFERENTIAL IMPACT OF DUFFY GENOTYPE ON PROGRESSION-FREE SURVIVAL (PFS) WITH LENALIDOMIDE-BORTEZOMIB-DEXAMETHASONE (RVD) ALONE OR RVD+ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
Lauren E. Merz (Boston, United States of America (the)) | 18:00 - 18:00 |
| A353 | DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: A POOLED ANALYSIS OF PATIENTS AGED ≥65 YEARS FROM PERSEUS AND GRIFFIN STUDIES
Roberto Mina (Torino, Italy) | 18:00 - 18:00 |
| A354 | IMPACT OF DIFFERENT TREATMENT AND DISEASE CHARACTERISTICS ON ACHIEVING MINIMAL RESIDUAL DISEASE NEGATIVITY AFTER AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA
Ana Pilar Gonzalez-Rodriguez (Oviedo, Spain) | 18:00 - 18:00 |
| A355 | AHSCT WITH NON-CRYOPRESERVED COMPARED TO CRYOPRESERVED HPSC YIELDS FASTER NEUTROPHIL ENGRAFTMENT AND LESS TRANSFUSION NEED AMONG PATIENTS WITH MULTIPLE MYELOMA
Ramazan Öcal (Ankara, Turkey) | 18:00 - 18:00 |
| A356 | LENALIDOMIDE VS NO MAINTENANCE IN MULTIPLE MYELOMA POST-AUTOLOGOUS TRANSPLANT IN A REAL WORLD SETTING: A PROPENSITY SCORE MATCHING ANALYSIS IN A COHORT FROM LATAM
Cristobal Frutos-Ortiz (Asuncion, Paraguay) | 18:00 - 18:00 |

A357	COMBINED MINIMAL RESIDUAL DISEASE EVALUATION IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION TO IMPROVE OUTCOME PREDICTION: BONE MARROW AND APHERESIS SAMPLES ANALYSIS Ludovica Pengue (Florence, Italy)	18:00 - 18:00
A359	A SINGLE-CENTER EXPERIENCE OF ALLOGENEIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA OVER A PERIOD OF 20 YEARS Tim Mayer (Würzburg, Germany)	18:00 - 18:00
A360	STRESS-INDUCED MITOPHAGY AND MITOCHONDRIAL DYSFUNCTION DRIVE NK CELL IMMUNE IMPAIRMENT IN MULTIPLE MYELOMA Katia Beider (Ramat Gan, Israel)	18:00 - 18:00
A361	TREATMENT ATTRITION IN MYELOMA PATIENTS IN FINLAND: A REAL-WORLD STUDY Anu Partanen (Kuopio, Finland)	18:00 - 18:00
A362	UP-FRONT AUTOLOGOUS TRANSPLANTATION IN STANDARD-RISK MULTIPLE MYELOMA: NO NEED FOR CRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS Ahmad Ibrahim (Beirut, Lebanon)	18:00 - 18:00

Printed Poster

18:00 - 19:00

R13

Haemoglobinopathy

A328	TREOSULFAN, THIOTEPA AND FLUDARABIN REPRESENTS A SAFE AND EFFICIENT ALTERNATIVE CONDITIONING IN T CELL DEPLETED HAPLOIDENTICAL AND MSD HSCT FOR PATIENTS WITH TDT Anja Troeger (Regensburg, Germany)	18:00 - 18:00
A329	HAEMOPOIETIC CELL TRANSPLANTATION FOR TRANSFUSION DEPENDENT THALASSAEMIA: REAL WORLD DATA FROM 2010-2021. AGE , DONOR TYPE AND YEAR OF TRANSPLANT AFFECT THE OUTCOME Donatella Barionciani (Pesaro, Italy)	18:00 - 18:00
A330	RISK ADAPTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH HIGH-RISK HEMOGLOBINOPATHIES: INSIGHTS FROM KING HUSSEIN CANCER CENTER Rawad Rihani (Amman, Jordan)	18:00 - 18:00
A331	HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH TRANSFUSION DEPENDENT THALASSEMIA-COMPARISON BASED ON DIFFERENT DONOR TYPES Sunil Bhat (Bangalore, India)	18:00 - 18:00
A332	PEDIATRIC TRANSPLANT AND CELLULAR THERAPY CONSORTIUM (PTCTC) SURVEY ASSESSING PRACTICE PREFERENCES FOR ALLOGENEIC STEM CELL TRANSPLANTATION OR GENE THERAPY FOR PATIENTS WITH SICKLE CELL DISEASE Niketa C. Shah (New Brunswick, United States of America (the))	18:00 - 18:00
A333	OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR TRANSFUSION-DEPENDENT ANAEMIAS IN HONG KONG Wilson Chan (Hong Kong, Hong Kong)	18:00 - 18:00
A334	FEASIBILITY OF SECOND ALLOGENEIC HEMATOPOIETIC CELL	18:00 - 18:00

	TRANSPLANTATION IN CHILDREN WITH HEMOGLOBINOPATHIES	
	Marco Zecca (Pavia, Italy)	
A335	TERRITORY-WIDE RETROSPECTIVE REVIEW ON OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR HAEMOGLOBIN BART'S HYDROPS FETALIS SYNDROME IN HONG KONG	18:00 - 18:00
	Wilson Chan (Hong Kong, Hong Kong)	
A337	DURABLE ENGRAFTMENT AFTER RADIATION FREE REDUCED INTENSITY CONDITIONING AND HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH SEVERE SICKLE CELL DISEASE	18:00 - 18:00
	Alexander Ngwube (Houston, United States of America (the))	
A338	OUTCOME OF TCR ALPHA / BETA AND CD19⁺ DEPLETION VS. POST-TRANSPLANT CYCLOPHOSPHAMIDE HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT IN PATIENT WITH THALASSEMIA MAJOR : A COMPARATIVE ANALYSIS	18:00 - 18:00
	Anjali Yadav (Gurugram, India)	
A339	REDUCED-TOXICITY MYELOABLATIVE CONDITIONING REGIMEN IN HLA-IDENTICAL SIBLING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE	18:00 - 18:00
	Thalita Cristina de Mello Costa (Ribeirão Preto, Brazil)	
A340	FLUDARABINE/TREOSULFAN/THIOTEPA/ATG CONDITIONING FOR SIBLING TRANSPLANTATION TRANSFUSION DEPENDENT THALASSAEMIA LEADS TO EARLY AND SUSTAINED ENGRAFTMENT WITH LOW INCIDENCE OF VOD AND GVHD	18:00 - 18:00
	Leena Karnik (London, United Kingdom of Great Britain and Northern Ireland (the))	
A341	SIGNIFICANT GROWTH IN HCT USE FOR HAEMOGLOBINOPATHIES IN THE LAST DECADE DRIVEN BY SICKLE CELL DISEASE ACROSS ALL AGES WITH EXCELLENT OUTCOMES: EBMT ANALYSIS	18:00 - 18:00
	Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the))	
A342	EXCELLENT THALASSEMIA-FREE SURVIVAL IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN OLDER CHILDREN WITH ANTIBODIES AND TRANSFUSION-DEPENDENT THALASSEMIA	18:00 - 18:00
	Kavitha Ganesan (Chennai, India)	
A344	HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS WITH SICKLE CELL DISEASE AND RECURRENT VASO-OCCLUSIVE CRISES OR BETA-THALASSEMIA WHO RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS IN THE US	18:00 - 18:00
	Duncan Brown (Boston, United States of America (the))	
A345	GRAFT VS HOST DISEASE IN PATIENTS WITH BETA-THALASSEMIA MAJOR AFTER STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE	18:00 - 18:00
	Alphan Küpesiz (Antalya, Turkey)	

Printed Poster

18:00 - 19:00

R13

Haematopoietic Stem Cells

A001	MYELODYSPLASIA-RELATED GENETIC MUTATIONS ARE ASSOCIATED WITH IMPROVED SURVIVAL FOLLOWING HMA MAINTENANCE TREATMENT AFTER ALLO-HSCT IN ADULT AML PATIENTS WITH ADVERSE-RISK	18:00 - 18:00
	Luxiang Wang (Shanghai, China)	

A002	MULTICENTER VALIDATION OF THE NEWLY DEVELOPED CONCISE OBJECTIFIABLE RISK EVALUATION (CORE) SCORE FOR NON-RELAPSE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Gunnar Weise (Hamburg, Germany)	18:00 - 18:00
A003	IMPACT OF FLT3-INHIBITOR MAINTENANCE POST ALLOGENEIC STEM CELL TRANSPLANT ON ACUTE MYELOID LEUKEMIA PATIENTS WITH FLT3-ITD AND ASSOCIATED NPM1/DNMT3A MUTATIONS - MULTI-CENTER RETROSPECTIVE STUDY Dennis Dong Hwan Kim (Toronto, Canada)	18:00 - 18:00
A004	PHARMACOLOGICAL SUPPRESSION OF SEX HORMONES PROMOTES LYMPHOPOIESIS AND MEGAKARYOPOIESIS IN A LUTEINIZING HORMONE-DEPENDENT MANNER Enrico Velardi (Rome, Italy)	18:00 - 18:00
A005	DEEP IMMUNOPHENOTYPING EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION REVEALS NOVEL ASSOCIATIONS BETWEEN FUNCTIONAL IMMUNE CELL RECONSTITUTION, IMMUNE-STIMULATED WHOLE BLOOD FUNCTION AND CLINICAL OUTCOMES Patrick Terrence Brooks (Copenhagen, Denmark)	18:00 - 18:00
A006	POST-TRANSPLANT MAINTENANCE THERAPY IN WILD-TYPE FLT3 ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: A BICENTRIC REAL-LIFE EXPERIENCE Alessandra Cipiciani (Ancona, Italy)	18:00 - 18:00
A007	EARLY B CELL IMMUNE RECONSTITUTION AS A PREDICTOR OF NON-RELAPSE MORTALITY IN T CELL DEPLETED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Alexandre G. Troullioud Lucas (New York, United States of America (the))	18:00 - 18:00
A008	HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER CAR19 T-CELL THERAPY IN B-ALL: A GOCART COALITION STUDY ON BEHALF OF THE PDWP, ALWP, AND CTIWP OF THE EBMT Adriana Balduzzi (Monza, Italy)	18:00 - 18:00
A009	EARLY SECONDARY CANCERS AFTER HAPLO-IDENTICAL ALLOGRAFT TRANSPLANTATION: RETROSPECTIVE MULTICENTER STUDY BY THE SFGM-TC Thomas Fatrara (Saint-Etienne, France)	18:00 - 18:00
A010	GERIATRIC ASSESSMENT SCORE FOR PREDICTING THE OUTCOME FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS AGED OVER 50 YEARS: RESULTS FROM A PROSPECTIVE ITALIAN SINGLE-CENTER STUDY Eugenia Accorsi Buttini (Brescia, Italy)	18:00 - 18:00
A011	EVOLVING TRENDS IN MORBIDITY AND MORTALITY OF IDIOPATHIC PNEUMONIA SYNDROME AND DIFFUSE ALVEOLAR HEMORRHAGE IN POST-STEM CELL TRANSPLANT PATIENTS WITH PRE-EXISTING PULMONARY DISEASE Samridhi Sinha (Brooklyn, United States of America (the))	18:00 - 18:00
A012	THE INFLUENCE OF BONE DISEASES ON MORBIDITY, MORTALITY, AND HEALTHCARE COSTS IN POST-STEM CELL TRANSPLANT PATIENTS Samridhi Sinha (Brooklyn, United States of America (the))	18:00 - 18:00
A013	THE IMPACT OF HLA-DQ8 HAPLOTYPE ON RELAPSE RISK AND GRAFT-VERSUS-LEUKEMIA EFFECT FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER ANALYSIS ON 400 PATIENTS	18:00 - 18:00

	Giulia Losi (Pavia, Italy)	
A015	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH MDS AND AML SECONDARY TO INHERITED BONE MARROW FAILURE SYNDROMES AND INBORN ERRORS OF IMMUNITY Tatiana Bykova (Saint-Petersburg, Russian Federation (the))	18:00 - 18:00
A016	NON-REMOVAL DSA PROTOCOL PROMOTES HEMATOPOIETIC RECONSTRUCTION IN HAPLOIDENTICAL AND MMUD HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH POSITIVE DSA: A RETROSPECTIVE MULTICENTER CASE-CONTROL STUDY Jian Zhou (Zhengzhou, China)	18:00 - 18:00
A017	PREDICTIVE FACTORS AND IMPACT OF MIXED CHIMERISM ON OUTCOME AFTER ALLOGENEIC HSCT FOR ACQUIRED APLASTIC ANEMIA: A RETROSPECTIVE MULTICENTRIC STUDY Flore Sicre de Fontbrune (Paris, France)	18:00 - 18:00
A019	SHAPING THE FUTURE OF FRAILTY CARE IN ALLO-HCT CANDIDATES: A PROSPECTIVE TELE-PREHABILITATION PROJECT Raquel Salinas González (Barcelona, Spain)	18:00 - 18:00
A021	DETERMINATION OF THE CORRELATION BETWEEN SERUM VCAM-1, ANGPT-1, ANGPT-2, S1P AND OPN LEVELS AND ENGRAFTMENT AFTER AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION Nur Soyer (Izmir, Turkey)	18:00 - 18:00
A022	LONG-TERM EFFICACY AND SAFETY OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL). REAL-WORLD REPORT OF POLISH LYMPHOMA RESEARCH GROUP (PLRG) Beata Ostrowska (Warsaw, Poland)	18:00 - 18:00
A023	THE DIRE NEED OF ESTABLISHING ADULT AND PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER IN A RESOURCE LIMITED SETUP: A NEEDS ASSESSMENT STUDY Eden Biltibo (Nashville, United States of America (the))	18:00 - 18:00
A025	OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION IN TP53-MUTATED MYELOID MALIGNANCIES: A MULTICENTER CANADIAN STUDY Jonas Mattsson (Toronto, Canada)	18:00 - 18:00
A026	IMPACT OF INCREASING DOSES OF TREOSULFAN IN DOUBLE-ALKYLATING CONDITIONING REGIMEN ON LONG TERM OUTCOME IN ABTCR/CD19 DEPLETED HAPLOIDENTICAL HSCT IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES Lucia Prezioso (Parma, Italy)	18:00 - 18:00
A027	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) IN ADULTS WITH HEREDITARY MYELOID MALIGNANCIES, A SINGLE-CENTER STUDY Alejandro Morales Curbelo (Las Palmas de Gran Canaria, Spain)	18:00 - 18:00
A028	A COMPARATIVE STUDY OF THE EFFECT ON THE OUTCOMES OF HAPLO HSCT USING HEMATOPOIETIC STEM CELL MOBILIZING REGIMENS CONTAINING PLERIXAFOR PLUS G-CSF VERSUS G-CSF ALONE Jing Long (Beijing, China)	18:00 - 18:00
A030	OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN PATIENTS WITH CHEDIAK HIGASHI SYNDROME ON BEHALF OF IEWP: PRELIMINARY REPORT	18:00 - 18:00

	Reem Elfeky (London, United Kingdom of Great Britain and Northern Ireland (the))	
A031	GOLD STANDARD UNDER PRESSURE: THE UKRAINIAN EXPERIENCE OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS Nazarii Shokun (Kyiv, Ukraine)	18:00 - 18:00
A032	COMPARATIVE OUTCOMES OF AIRBORNE INFECTION CONTROL IN HEPA-FILTERED ROOMS WITHOUT POSITIVE PRESSURE VERSUS POSITIVE PRESSURE ROOMS FOR STEM CELL TRANSPLANTATION Michael W. Sunga (Taguig, Philippines (the))	18:00 - 18:00
A033	LONG-TERM SURVIVAL AFTER SEQUENTIAL CONDITIONING WITH FLAMSA AND TOTAL BODY IRRADIATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA Paula Kessler (Düsseldorf, Germany)	18:00 - 18:00
A034	COMPARISON OF SEQUENTIAL CONDITIONING REGIMENS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA - A MULTICENTER RETROSPECTIVE STUDY OF THE SFGM-TC Victoria Volpari (Grenoble, France)	18:00 - 18:00
A035	LONG-TERM SURVIVAL POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: ASSESSING PREDICTIVE RISK TOOLS IN A COLOMBIAN COHORT Claudia Sossa-Melo (Floridablanca, Colombia)	18:00 - 18:00
A036	LONG-TERM OUTCOMES OF PATIENTS WITH CALM::MLLT10 POSITIVE HEMATOLOGICAL MALIGNANCIES FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Gai ling Zhang (Langfang, China)	18:00 - 18:00
A037	NOVEL FLOW CYTOMETRIC KIT FOR THE IDENTIFICATION, CHARACTERIZATION AND ENUMERATION OF HEMATOPOIETIC STEM CELLS FROM DIFFERENT BLOOD SOURCES Julia Dzionek (Bergisch Gladbach, Germany)	18:00 - 18:00
A038	VALIDATION AND CLINICAL APPLICATION OF GELOFUSINE AS AN ALTERNATIVE TO DEXTRAN40-BASED SOLUTIONS FOR WASHING CRYOPRESERVED HEMATOPOIETIC STEM CELLS Stefania Nappo (Naples, Italy)	18:00 - 18:00
A040	RISK ASSESSMENT AND SURVIVAL IN AUTO-HCT: 13-YEAR EXPERIENCE IN A COLOMBIAN CENTRE Claudia Sossa-Melo (Floridablanca, Colombia)	18:00 - 18:00
A041	PATIENT'S OUTCOME AFTER DONOR LYMPHOCYTE INFUSION ACCORDING TO DIFFERENT INDICATION: SAFETY AND FEASIBILITY Micheline Karam (Lille, France)	18:00 - 18:00
A042	AUTOLOGOUS VS. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOBLASTIC LYMPHOMA:ALLOGENEIC TRANSPLANTATION---A PREFERENTIAL SELECTION, BUT NO SIGNIFICANT ADVANTAGES Qian Cheng (Suzhou, China)	18:00 - 18:00
A043	FEASABILITY AND TOLERABILITY OF FLT3 INHIBITORS AS MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN AML WITH MUTATED FLT3 Rosa Plos (Udine, Italy)	18:00 - 18:00
A044	EFFICACY OF A PHARMACOKINETICS-GUIDED BUSULFAN-CONTAINING CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH MYELOID	18:00 - 18:00

HEMATOLOGIC MALIGNANCIES

Cristina Astrid Tentori (Milano, Italy)

- A045 **THE SHORT-TERM CARDIOTOXICITY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER EXPERIENCE** 18:00 - 18:00
Jean El Cheikh (Beirut, Lebanon)
- A047 **IMPACT OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE ON GUT MICROBIOTA AND IMMUNE RECONSTITUTION: A COMPARATIVE ANALYSIS WITH MATCHED DONOR TRANSPLANTS** 18:00 - 18:00
Su-Peng Yeh (Taichung, Taiwan (Province of China))
- A048 **COMPARING THE CLINICAL OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS IN PATIENTS WITH APLASTIC ANEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS** 18:00 - 18:00
Sirichai Puttirangsan (Chiangmai, Thailand)
- A049 **EFFECT OF DONOR AND RECIPIENT HLA GENOTYPE ON GVHD (GRAFT VERSUS HOST DISEASE) AND RELAPSE-FREE SURVIVAL (GRFS) IN MYELODYSPLASTIC SYNDROME AND ACUTE LEUKEMIA** 18:00 - 18:00
Meltem Kurt Yüksel (Ankara, Turkey)

Printed Poster

18:00 - 19:00

R13

Poster Session in Spadolini 1

Tuesday, 01. April 2025*General*

07:45 - 08:45

R13

GS3 - EBMT General Assembly

Anna Sureda (Barcelona, Spain)

GS3-1	President's Report Anna Sureda (Barcelona, Spain)	07:45 - 08:10
GS3-2	Treasurer's Financial Report Mette Hazenberg (Amsterdam, Netherlands (the))	08:10 - 08:20
GS3-3	Secretary's Report Raffaella Greco (Milano, Italy)	08:20 - 08:30
GS3-4	Election Results 2025 Raffaella Greco (Milano, Italy)	08:30 - 08:35
GS3-5	Outgoing Board Members Anna Sureda (Barcelona, Spain)	08:35 - 08:40
GS3-6	Q&A	08:40 - 08:45

Meet the Expert

07:45 - 08:45

R16

MTE - Breakfast Meet the Expert - Tuesday*Meet the Expert*

07:45 - 08:45

R16

MTE-13 - Meet-the-Expert: Infections after CAR-T

MTE-13	Infections after CAR-T Eleftheria Kampouri (Lausanne, Switzerland)	07:45 - 08:45
--------	--	---------------

Meet the Expert

07:45 - 08:45

R16

MTE-15 - Meet-the-Expert: Rescue Strategies after failure of HCT in MFI

MTE-15	Rescue Strategies after failure of HCT in MFI Francesco Passamonti (Milano, Italy) Samah Alimam (London, United Kingdom of Great Britain and Northern Ireland (the))	07:45 - 08:45
--------	---	---------------

Meet the Expert

07:45 - 08:45

R16

QM-MTE-4 - Quality Management Meet the Expert: Closing the loop: Managing audits and adverse events

QM-MTE-4	Closing the loop: Managing audits and adverse events Lea Brandt Kristensen (Aarhus, Denmark) Olga López (Salamanca, Spain)	07:45 - 08:45
----------	---	---------------

Meet the Expert

07:45 - 08:45

R16

MTE-9 - Meet-the-Expert: Difficult to treat chronic GVHD

MTE-9	Difficult to treat chronic GVHD Carmen Martínez (Barcelona, Spain) Drazen Pulanic (Zagreb, Croatia)	07:45 - 08:45
-------	--	---------------

Meet the Expert

07:45 - 08:45

R16

MTE-14 - Meet-the-Expert: Transplanting patients with advanced AML

MTE-14

Transplanting patients with advanced AML

07:45 - 08:45

Jaime Sanz (Valencia, Spain)
Arnon Nagler (Tel Aviv, Israel)*Meet the Expert*

07:45 - 08:45

R16

MTE-10 - Meet-the-Expert: Advances in non-transplant therapies for AA

MTE-10

Advances in non-transplant therapies for AA

07:45 - 08:45

Flore Sicre de Fontbrune (Paris, France)
Beatrice Drexler (Basel, Switzerland)*Meet the Expert*

07:45 - 08:45

R16

MTE-11 - Meet-the-Expert: HSCT in hemoglobinopathies: how to prepare eligible patients

MTE-11

HSCT in hemoglobinopathies: how to prepare eligible patients

07:45 - 08:45

Lawrence Faulkner (Firenze, Italy)
Erfan Nur (Amsterdam, Netherlands (the))*Meet the Expert*

07:45 - 08:45

R16

QM-MTE-3 - Quality Management Meet the Expert: First time for JACIE? JACIE Process, roles and responsibilities

QM-MTE-3

First time for JACIE? JACIE Process, roles and responsibilities

07:45 - 08:45

Anne Emmett (London, United Kingdom of Great Britain and Northern Ireland (the))
Raquel Espada (Barcelona, Spain)*Meet the Expert*

07:45 - 08:45

R16

MTE-12 - Meet-the-Expert: GVHD in paediatrics

MTE-12

GVHD in paediatrics

07:45 - 08:45

Marco Zecca (Pavia, Italy)

ePoster

08:30 - 18:00

R18

ePoster Viewing*Plenary Session*

09:00 - 10:30

R1

P04 - Gene lesions in normal and impaired hematopoiesis

Carlo Dufour (Genova, Italy)

Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the))

P04-1

Evolution of clonal hematopoiesis

09:00 - 09:30

Elsa Bernard (Villejuif, France)

P04-2

Germline genetic lesions defining novel inherited BMF

09:30 - 10:00

Charlotte Niemeyer (Freiburg i. Br., Germany)

P04-3

Somatic genetic lesions in acquired AA: understanding clonal hematopoiesis

10:00 - 10:30

Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the))

Paediatrics Day

09:00 - 10:15

R2

Paed1 - Paediatrics Diseases Working Party Session

Krzysztof Kalwak (WROCLAW, Poland)

Katharina Kleinschmidt (Regensburg, Germany)

Paed1-1	ALL SCT FORUM 1/Forum 2 Update Christina Peters (Vienna, Austria) Anita Lawitschka (vienna, Austria)	09:00 - 09:15
Paed1-2	Refining Busulfan Conditioning in Pediatric ALL Through Exposure-Outcome Analysis: Critical Insights from the International Prospective FORUM Study Marc Ansari (Geneva, Switzerland)	09:15 - 09:30
Paed1-3	Between Scylla and Charybdis: overcoming the challenges of loss of persistence and antigen negative relapse after CAR-T cell therapy for ALL Persis Amrolia (London, United Kingdom of Great Britain and Northern Ireland (the))	09:30 - 09:45
Paed1-4	Recent progress in CAR-T cell therapy in children with solid tumors Franco Locatelli (Rome, Italy)	09:45 - 10:00
Paed1-5	Dietrich Niethammer Award - Introduction	10:00 - 10:06
Paed1-6	Dietrich Niethammer Award Peter Bader (Frankfurt, Germany)	10:06 - 10:15

Educational

09:00 - 10:30

R3

E05 - Established indications for cellular therapy strategies in patients with lymphoma

Pier Luigi Zinzani (Bologna, Italy)

Annalisa Chiappella (Milano, Italy)

E05-1	Allotransplant in TCL Philipp Berning (Muenster, Germany)	09:00 - 09:30
E05-2	CAR-T Cell in Lymphomas Mariana Bastos Oreiro (Madrid, Spain)	09:30 - 10:00
E05-3	Allo-HCT in HL Ali Bazarbachi (Beirut, Lebanon)	10:00 - 10:30

Workshop

09:00 - 10:30

R4

W03 - Long-term survivors

Franca Fagioli (Turin, Italy)

Helene Schoemans (Leuven, Belgium)

W03-1	The long way across late-effects: the lesson learned from HSCT, useful insight for CAR-T Zinaida Peric (Rijeka, Croatia)	09:00 - 09:30
W03-2	The cardio-metabolic issue in 2025: take home message for kids and adults Fabio Turazza (Firenze, Italy)	09:30 - 10:00
W03-3	The second cancer issue in 2025: take home message for patients and oncologist Maria Teresa Lupo-Stanghellini (Milano, Italy)	10:00 - 10:30

Educational

09:00 - 10:30

R5

E06 - MDR bacterial and fungal pathogens in 2025

Rafael de la Camara (Madrid, Spain)

Gianmaria Rossolini (Florence, Italy)

E06-1	What is new in diagnosis of resistant infections Patricia Muñoz (Madrid, Spain)	09:00 - 09:18
E06-2	Treatment of multi-drug resistant gram-negatives Dina Averbuch (Jerusalem, Israel)	09:18 - 09:36
E06-3	Antifungal prophylaxis and treatment Malgorzata Mikulska (Genoa, Italy)	09:36 - 09:54
E06-4	Novel therapies from the clinical pharmacologist's point of view Federico Pea (Bologna, Italy)	09:54 - 10:12
E06-5	Panel Discussion	10:12 - 10:30

Workshop

09:00 - 10:30

R6

W04 - Pulmonary complications

Adriana Balduzzi (Monza, Italy)

Eolia Brissot (Paris, France)

W04-1	Is it infection? Optimal diagnostic strategies in evaluation of lung lesions Anne Bergeron (Geneva, Switzerland)	09:00 - 09:30
W04-2	Challenges in diagnosis of lung GvHD: a multidisciplinary approach Saskia Bos (Leuven, Belgium)	09:30 - 10:00
W04-3	Lung fibrosis in SSc after HCT and MSC Dominique Farge (PARIS, France)	10:00 - 10:30

Nurses Group

09:00 - 10:30

R7

NG12 - Infections

Polona Klanscek (Ljubljana, Slovenia)

Francesca Palmisano (Alessandria, Italy)

NG12-1	Vaccinations Angela van Klaveren (Leiden, Netherlands (the))	09:00 - 09:21
NG12-2	Central nervous system infection Ilaria Cutini (Florence, Italy)	09:21 - 09:42
NG12-3	Gut infections and microbiome recovery Esther Martínez (Madrid, Spain)	09:42 - 10:03
NG12-4	Post-transplant lymphoproliferative disease Marzia Rahman (London, United Kingdom of Great Britain and Northern Ireland (the))	10:03 - 10:24
NG12-5	Q&A	10:24 - 10:29

Working Party Session

09:00 - 10:15

R8

CTIWP - Cellular Therapy & Immunobiology Working Party Session

Annalisa Ruggeri (Italy)

Florent Malard (Paris, France)

CTIWP-1	Introduction of the Jon J. Van Rood Award	09:00 - 09:05
---------	--	---------------

CTIWP-2.1	Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome Janaki Manoj Vinnakota (Germany)	09:05 - 09:25
CTIWP-2.2	Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation Nicoletta Cieri (United States of America (the))	09:25 - 09:45
CTIWP-3	Practice and harmonisation in Cellular Therapy - on behalf of the EBMT Practice Harmonisation and Guidelines Committee Ibrahim Yakoub-Agha (Lille, France)	09:45 - 10:05
CTIWP-4	Q&A	10:05 - 10:15

Oral Session

09:00 - 10:15

R9

OS08 - Oral Session 8 | Acute leukemia (I)

Alexandros Spyridonidis (Patra, Greece)

Christoph Schmid (Augsburg, Germany)

OS8-01	A HOLISTIC APPROACH TO ASSESS POST ALLO-HCT SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA ACCORDING TO VALIDATED INDICES Alexandros Spyridonidis (Patra, Greece)	09:00 - 09:09
OS8-02	OBECABTAGENE AUTOLEUCEL (OBE-CEL) FOR RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): THE IMPACT OF INOTUZUMAB-CONTAINING BRIDGING THERAPY ON TREATMENT OUTCOMES Deborah Yallop (London, United Kingdom of Great Britain and Northern Ireland (the))	09:09 - 09:18
OS8-03	OUTCOMES OF ELN 2022 ADVERSE CYTOGENETIC SUBGROUPS IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST REMISSION: FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY Ali Bazarbachi (Beirut, Lebanon)	09:18 - 09:27
OS8-04	SECOND ALLOGENEIC SCT (ALLOSCT2) FOR AML IN ACTIVE DISEASE: FEASIBILITY, OUTCOME, AND RISK FACTORS - A STUDY ON BEHALF OF THE ALWP OF THE EBMT Giuliano Filippini Velázquez (Augsburg, Germany)	09:27 - 09:36
OS8-05	PHASE I TRIAL OF EX VIVO EXPANDED DONOR-DERIVED GAMMA DELTA T CELL IMMUNOTHERAPY TO PREVENT ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENEIC TRANSPLANTATION Nelli Bejanyan (Tampa, United States of America (the))	09:36 - 09:45
OS8-06	OUTCOMES OF ACUTE MYELOID LEUKEMIA WITH KMT2A (MLL) REARRANGEMENT: A MULTICENTER STUDY OF TROPHY GROUP Ruoxuan Zhang (Wuhan, China)	09:45 - 09:54
OS8-07	ACUTE MYELOID LEUKEMIA OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: VALIDATION OF CURRENT PROGNOSTIC MODELS AND PROPOSAL FOR A NOVEL PROGNOSTIC RISK SCORING SYSTEM Garret Leung (Hong Kong, Hong Kong)	09:54 - 10:03
OS8-08	DONOR IMPACT ON ADVERSE-RISK AML IN FIRST COMPLETE REMISSION ACCORDING TO EUROPEAN LEUKEMIANET 2022 RISK STRATIFICATION: A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY Marta Villalba Montaner (Valencia, Spain)	10:03 - 10:12

Transplant and Search Coordinators Day

09:00 - 10:15

R10

TSCD1 - EBMT-WMDA Transplant and Search Coordinators Day 1 | Challenging Search Cases

Matthew Seftel (Vancouver, Canada)

Silvia Montoto (London, United Kingdom of Great Britain and Northern Ireland (the))

TSCD1-1	International search case using WMDA Search and Match Service 1: mismatched donor Timo Olieslagers (Maastricht, Netherlands (the))	09:00 - 09:20
TSCD1-2	International search case using WMDA Search and Match Service 2: finding a second donor after leukemia relapse with HLA-loss Simona Piemontese (Milan, Italy)	09:20 - 09:40
TSCD1-3	International search case using WMDA Search and Match Service 3: non-HLA factors Bronwen Shaw (Milwaukee, United States of America (the))	09:40 - 10:00
TSCD1-4	Q&A	10:00 - 10:15

Nurses Group

09:00 - 10:30

R11

NG13 - Apheresis

Natalia Lorente (Madrid, Spain)

Giorgia Gobbi (MILAN, Italy)

NG13-1	Apheresis procedure in the intensive care Elisa Rino (Reggio Calabria, Italy)	09:00 - 09:21
NG13-2	Red cell exchange programme in haemoglobinopathy Haili Cui (London, United Kingdom of Great Britain and Northern Ireland (the))	09:21 - 09:42
NG13-3	Nurse consultation, vein assessment and low body weight challenges Angela Leather (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	09:42 - 10:03
NG13-4	Related donor experience of cell collection Michele Baioni (Firenze, Italy)	10:03 - 10:24
NG13-5	Q&A	10:24 - 10:29

Special Session

09:00 - 10:30

R12

SS4 - Global Committee Session

Norbert-Claude Gorin (Paris, France)

Gregorio Jaimovich (Buenos Aires, Argentina)

EGC-1	Introduction Norbert-Claude Gorin (Paris, France)	09:00 - 09:01
EGC-2	A global vision of maintenance therapy for Acute Myelocytic leukemia post stem cell transplantation Iman Abou Dalle (Beirut, Lebanon)	09:01 - 09:16
EGC-3	How Indian oncology centers inspired action against anti microbial resistance (AMR) in India Abdul Ghafur (Chennai, India)	09:16 - 09:31
EGC-4	Comparison of haploidentical transplants for Acute myeloid leukemias in China versus European centers Yuhua Ru (Suzhou, China)	09:31 - 09:46
EGC-5	Novel strategies for cellular therapy and hematopoietic cell transplantation	09:46 - 10:01

	Huang He (Hangzhou, China)	
EGC-6	The global aspects of the cost of new therapies Mohamad Mohty (Paris, France)	10:01 - 10:16
EGC-7	Discussion & Conclusion Anna Sureda (Barcelona, Spain)	10:16 - 10:30
 <i>Working Party Session</i>		
09:00 - 10:15		R13
ADWP - Autoimmune Diseases Working Party Session		
Tobias Alexander (Berlin, Germany) Elisa Roldan Galvan (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))		
ADWP-1	Welcome	09:00 - 09:05
ADWP-2	Patient selection and best conditioning regimen for HSCT in MS Alice Mariottini (Florence, Italy)	09:05 - 09:20
ADWP-3	Current position of HSCT in the treatment landscape of systemic sclerosis Nicoletta Del Papa (Milano, Italy)	09:20 - 09:35
ADWP-4	Emerging indications for CAR T cell therapy in autoimmune diseases Fabian Müller (Erlangen, Germany)	09:35 - 09:50
ADWP-5	Autologous HCT in rheumatic indications: consensus and best practice recommendations from the EBMT practice harmonization and guidelines committee. Elisa Roldan Galvan (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	09:50 - 10:05
ADWP-6	Q&A	10:05 - 10:15
 <i>Quality Management</i>		
09:00 - 10:15		R14
QM1 - Quality Management 1 Developing a Safety Culture & QM Award		
Olivier Urbain (Brussels, Belgium) Aurora Vassanelli (Verona, Italy)		
QM1-1	Understanding SoHO Regulation: Implications for Cellular Therapies Rita Piteira (Brussels, Belgium)	09:00 - 09:15
QM1-2	Enhancing Patient Safety: 10 Years of JACIE Journey in Tertiary Care Center in Saudia Arabia Mohamed Bayoumy (Jeddah, Saudi Arabia)	09:15 - 09:30
QM1-3	Learning from Incidents to improving patient safety Lorraine Schwanberg (Dublin, Ireland)	09:30 - 09:44
QM1-4	QUALITY IMPROVEMENT THROUGH DIGITISING EXCEPTIONAL RELEASE: STANDARDISATION FOR UNPREDICTABILITY Anna Sargent (London, United Kingdom of Great Britain and Northern Ireland (the))	09:44 - 09:59
QM1-5	Q&A	09:59 - 10:14

Joint Sessions

09:00 - 10:30 R15

JS04 - EBMT - T2EVOLVE roundtable | Implementing Patient-Friendly Informed Consent Forms in CAR-T Clinical Studies: Insights and Solutions

Carmen Sanges (Würzburg, Germany)

Hilda Mekelenkamp (Leiden, Netherlands (the))

JS04-1 **Opening remarks** 09:00 - 09:05

Carmen Sanges (Würzburg, Germany)

JS04-2 **Survey Results on ICFs in CAR-T Clinical Studies** 09:05 - 09:15

Lutgart Roux-Opstale (Boulogne-Billancourt, France)

JS04-3 **Ethical and Regulatory Challenges in ICF Implementation** 09:15 - 09:25

Jan von Hassel (Obertraubling, Germany)

JS04-4 **Collaborative Efforts for ICF Harmonization** 09:25 - 09:35

Barbara Huber (Würzburg, Germany)

JS04-5 **Panel Discussion: Moving Towards Actionable Solutions** 09:35 - 10:20

Sabrina Kraus (Würzburg, Germany)

Natacha Bolaños (Madrid, Spain)

Jan von Hassel (Obertraubling, Germany)

Martin Dreyling (Munich, Germany)

Carsten Ferfer-Gerdemann (Neuss, Germany)

JS04-6 **Conclusion and Next Steps** 10:20 - 10:30*Breaks*

10:30 - 11:00 R1

Coffee Break, ePoster Viewing, Visit Exhibition*Special Session*

11:00 - 12:30 R1

SS5 - Cell manipulation/processing

Francesco Lanza (ravenna, Italy)

Maria Bianchi (Rome, Italy)

SS5-1 **Cryopreservation, thawing and washing of PBSC** 11:00 - 11:25

Serena Urbani (Firenze, Italy)

SS5-2 **Alternative source and genetic tools for cellular therapy with engineered lymphocytes** 11:25 - 11:50

Chiara Bonini (Milan, Italy)

SS5-3 **Impact of leukapheresis products characteristics on ATMP manufacturing** 11:50 - 12:15

Boris Calmels (Marseille, France)

SS5-4 **Panel Discussion** 12:15 - 12:30*Paediatrics Day*

11:00 - 12:15 R2

Paed2 - Inborn Errors Working Party Session

Bénédicte Neven (paris, France)

Claire Booth (London, United Kingdom of Great Britain and Northern Ireland (the))

Paed2-1 **Diagnosis and Treatment of SCID in the era of newborn screening** 11:00 - 11:20

Manfred Hoenig (Ulm, Germany)

Paed2-2 **Personalised serotherapy: are we there?** 11:20 - 11:40

Arjan Lankester (Leiden, Netherlands (the))

Paed2-3	To transplant or not to transplant - A prospective observational study on combined immunodeficiencies	11:40 - 12:00
	Stephan Ehl (Freiburg, Germany)	
Paed2-4	Discussion	12:00 - 12:15
<i>Educational</i>		
11:00 - 12:30		R3
E07 - Viral infections		
Corrado Girmenia (Rome, Italy)		
Jan Styczynski (Bydgoszcz, Poland)		
E07-1	Controversies in HHV6 - 1: What is the clinical impact in HCT and CAR-T?	11:00 - 11:18
	Eleftheria Kampouri (Lausanne, Switzerland)	
E07-2	Controversies in HHV6 - 2: How to monitor and treat HHV6	11:18 - 11:36
	Raffaella Greco (Milano, Italy)	
E07-3	Treatment of CARVs in 2025	11:36 - 11:54
	Marie von Lilienfeld-Toal (Bochum, Germany)	
E07-4	Management of BKV and ADV infections	11:54 - 12:12
	Simone Cesaro (Verona, Italy)	
E07-5	Panel Discussion	12:12 - 12:30
<i>Joint Sessions</i>		
11:00 - 12:15		R4
JS05 - Joint Session EBMT - EHA How do we optimise bridging therapies before CART?		
Anna Sureda (Barcelona, Spain)		
Antonio Almeida (Lisbon, Portugal)		
JS05-1	Lymphomas	11:00 - 11:15
	Marion Subklewe (Munich, Germany)	
JS05-2	ALL	11:15 - 11:30
	Maeve O'Reilly (London, United Kingdom of Great Britain and Northern Ireland (the))	
JS05-3	Multiple myeloma	11:30 - 11:45
	Carlos Fernández de Larrea (Barcelona, Spain)	
JS05-4	Panel Discussion	11:45 - 12:00
<i>Special Session</i>		
11:00 - 12:30		R5
SS8 - EUROCORD & Cord Blood Association Joint Session		
Eliane Gluckman (Paris, France)		
Gesine Koegler (Düsseldorf, Germany)		
Colleen Delaney (Seattle, United States of America (the))		
SS8-1	How I did the first CBT 30+ years ago	11:00 - 11:20
	Eliane Gluckman (Paris, France)	
SS8-2	Novel applications of Cord Blood and Birthing Tissues	11:20 - 11:40
	Beth Shaz (Durham, United States of America (the))	
SS8-3	CBT in ped patients	11:40 - 12:00
	Robert Wynn (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
SS8-4	Use of Cord blood for cellular therapy	12:00 - 12:20

	Elizabeth Shpall (Houston, United States of America (the))	
SS8-5	Round table: Bright future of CB - a hype or hope?	12:20 - 12:30
	Tomasz Baran (Warsaw, Poland)	
	Robert Wynn (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
	Elizabeth Shpall (Houston, United States of America (the))	
	Colleen Delaney (Seattle, United States of America (the))	
	Gesine Koegler (Düsseldorf, Germany)	
	Eliane Gluckman (Paris, France)	

Working Party Session

11:00 - 12:15

R6

ALWP - Acute Leukaemia Working Party Session | Advances in acute leukemia: an update by the ALWP

Fabio Ciceri (Milano, Italy)

Eolia Brissot (Paris, France)

ALWP-0	Introduction	11:00 - 11:15
ALWP-1	Predicting post-allo-HSCT survival of pts with acute leukemia	11:15 - 11:35
	Alexandros Spyridonidis (Patra, Greece)	
ALWP-2	NGS profiling in AML undergoing allo HSCT	11:35 - 11:55
	Ali Bazarbachi (Beirut, Lebanon)	
ALWP-3	Chemo-free therapy for Ph+ ALL: what is the role of transplant?	11:55 - 12:15
	Eolia Brissot (Paris, France)	

Nurses Group

11:00 - 12:30

R7

NG14 - Next Generation Session: challenges of care

Daniel Kisielewski (Stuttgart, Germany)

Frederico Pastorini (Firenze, Italy)

NG14-1	Supporting patient care through digital technology and AI	11:00 - 11:21
	Matteo Steduto (San Giovanni Rotondo, Italy)	
NG14-2	Supporting the expert patient and caregiver	11:21 - 11:42
	Lucie Cottarel (Nantes, France)	
NG14-3	Supporting the patient receiving bad news	11:42 - 12:03
	Surabhi Chaturvedi (London, United Kingdom of Great Britain and Northern Ireland (the))	
NG14-4	Experiencing the sick patient	12:03 - 12:24
	Venescha Cameron (London, United Kingdom of Great Britain and Northern Ireland (the))	
	Diana Saguiguit (London, United Kingdom of Great Britain and Northern Ireland (the))	
NG14-5	Q&A	12:24 - 12:29

Oral Session

11:00 - 12:15

R8

OS09 - Oral Session 9 | Conditioning Regimen & maintenance

Charles Craddock (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))

Vera Radici (Brescia, Italy)

OS9-01	TBI/ETOPOSIDE VS. CHEMOCONDITIONING FOR ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): WEIGHING THE RISKS OF INCREASED TOXICITY	11:00 - 11:09
	Jan Robert Heusel (Frankfurt am Main, Germany)	
OS9-02	ASSOCIATION OF RABBIT ANTI-THYMOCYTE GLOBULIN (RATG) EXPOSURE AND OUTCOMES AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR MALIGNANT INDICATIONS: ANCILLARY	11:09 - 11:18

	ANALYSIS FROM BMT CTN 1202 Jaap Jan Boelens (New York, United States of America (the))	
OS9-03	BEAM VS. EAM, FEAM, BEEAM, AND TEAM: EXPLORING CONDITIONING STRATEGIES IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA A RETROSPECTIVE STUDY OF LWP Annalisa Paviglianiti (Barcelona, Spain)	11:18 - 11:27
OS9-04	SAFETY AND EFFICACY OF FLUDARABINE PLUS MYELOABLATIVE DOSE OF TREOSULFAN (FT14) CONDITIONING REGIMEN FOR AML - INTERIM ANALYSIS FROM THE FT14 STUDY GROUP Vera Radici (Brescia, Italy)	11:27 - 11:36
OS9-05	EXCELLENT LONG-TERM OUTCOMES OF ALEMTUZUMAB-BASED CONDITIONING FOR OLDER PATIENTS WITH APLASTIC ANAEMIA UNDERGOING PERIPHERAL BLOOD STEM CELL HAEMATOPOIETIC TRANSPLANTATION FROM UNRELATED DONORS Shreyas Hanmantgad (London, United Kingdom of Great Britain and Northern Ireland (the))	11:36 - 11:45
OS9-06	ALLOGENEIC STEM CELL TRANSPLANTATION IS EFFECTIVE AFTER PATHWAY INHIBITOR TREATMENTS IN CLL; A RETROSPECTIVE STUDY ON BEHALF OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT Michel Gelder (Maastricht, Netherlands (the))	11:45 - 11:54
OS9-07	THE SIGNIFICANCE OF BUSULFAN ADMINISTRATION INCLUDING THERAPEUTIC DRUG MONITORING IN THE CONDITIONING REGIMEN OF PEDIATRIC PATIENTS PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Bernd Gruhn (Jena, Germany)	11:54 - 12:03
OS9-08	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH BRIQUILIMAB (JSP191) ANTI-CD117 ANTIBODY-BASED NONMYELOABLATIVE CONDITIONING FOR GATA2 DEFICIENCY Danielle Arnold (Bethesda, United States of America (the))	12:03 - 12:12
<i>Oral Session</i> 11:00 - 12:15		R9
OS10 - Oral Session 10 Lymphomas		
Carmelo Carlo-Stella (Milano, Italy) Giulia Losi (Pavia, Italy)		
OS10-01	COMBATING IMMUNE EXHAUSTION: PD-1 BLOCKADE BOOSTS 7×19 CAR-T EFFICACY IN RELAPSED/REFRACTORY LBCL Lixia Sheng (Ningbo, China)	11:00 - 11:09
OS10-02	ALLOGENEIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA, A BENCHMARK STUDY FROM THE EBMT LYMPHOMA WORKING PARTY Yasmina Serroukh (Rotterdam, Netherlands (the))	11:09 - 11:18
OS10-03	EFFICACY AND TOXICITY OF DONOR-DERIVED CHIMERIC CD7 ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH T-CELL LYMPHOMA WHO RELAPSE AFTER ALLOGENEIC TRANSPLANTATION Fan Yang (Beijing, China)	11:18 - 11:27
OS10-04	COMPARATIVE OUTCOMES OF ALLOGENEIC VS. AUTOLOGOUS STEM CELL TRANSPLANTATION IN NATURAL KILLER/T-CELL LYMPHOMA: AN ANALYSIS BY THE LYMPHOMA WORKING PARTY Philipp Berning (Muenster, Germany)	11:27 - 11:36
OS10-05	COMPARING OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL	11:36 - 11:45

	TRANSPLANTATION VERSUS NON-CONSOLIDATION IN NON-HODGKIN LYMPHOMA PATIENTS TREATED WITH BISPECIFIC ANTIBODIES: A STUDY ON BEHALF OF GETH-TC	
	Giulia Losi (Pavia, Italy)	
OS10-06	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS CONSOLIDATION THERAPY IN PATIENTS WITH RELAPSED-REFRACTORY B-CELL LYMPHOMAS EXPOSED TO BISPECIFIC ANTIBODIES: A STUDY ON BELHALF OF GETH-TC	11:45 - 11:54
	Alberto Mussetti (Barcelona, Spain)	
OS10-07	STEM CELL TRANSPLANTATION FOR WALDENSTRÖM'S MACROGLOBULINEMIA (WM). UPDATED REPORT FROM THE LYMPHOMA WORKING PARTY OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION	11:54 - 12:03
	Charalampia Kyriakou (London, United Kingdom of Great Britain and Northern Ireland (the))	
OS10-08	CIRCULATING TUMOR DNA (CTDNA) AS AN EARLY OUTCOME PREDICTOR IN SECOND-LINE (2L) LARGE B-CELL LYMPHOMA (LBCL) AFTER LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS STANDARD OF CARE (SOC)	12:03 - 12:12
	Bertram Glass (Berlin, Germany)	
<i>Transplant and Search Coordinators Day</i>		
	11:00 - 12:15	R10
TSCD2 - EBMT-WMDA Transplant and Search Coordinators Day 2 Revolutionizing Collection - What are European initiatives, taking the new SOHO regulation into account?		
	Nicoletta Sacchi (Genova, Italy)	
	Christian Chabannon (Marseille, France)	
TSCD2-1	A novel good reason for collecting cord blood units	11:00 - 11:20
	Luciana Teofili (Rome, Italy)	
TSCD2-2	Bone marrow as a source of hematopoietic cells: Where we are now? Overview of safety and efficacy of BM donation in unrelated donors	11:20 - 11:40
	Tigran Torosian (Warsaw, Poland)	
TSCD2-3	A nation-wide consent for the collection of donor stem cells, endorsed by all transplant centres for both family donors and unrelated donors	11:40 - 12:00
	Mirjam Fechter (Leiden, Netherlands (the))	
TSCD2-4	Q&A	12:00 - 12:15
<i>Nurses Group</i>		
	11:00 - 12:30	R11
NG15 - Best Research Abstracts Finalists		
	Isabel Salcedo (Madrid, Spain)	
	Simona Calza (Genoa, Italy)	
NG15-01	ON THE INSIDE OF HOSPITAL AT HOME: FAMILY CAREGIVERS' EXPERIENCES OF HOSPITAL AT HOME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A QUALITATIVE STUDY	11:00 - 11:15
	Sigrid Cecilie Tinglum Skøyeneie (Oslo, Norway)	
NG15-02	CO-DESIGNING THE CARE PATHWAY FOR ADOPTIVE CELL THERAPIES WITH TUMOR-INFILTRATING LYMPHOCYTES FROM THE STAKEHOLDERS' EXPERIENCES AND PERSPECTIVES	11:15 - 11:30
	Nina Canova (Lausanne, Switzerland)	
NG15-03	NUTRITIONAL IMPACT OF BRIDGING TREATMENT AND ICANS IN PATIENTS RECEIVING CAR T-CELL THERAPY	11:30 - 11:45

	Catherine Green (Southampton, United Kingdom of Great Britain and Northern Ireland (the))	
NG15-04	PRIORITIZING RESEARCH DIRECTIONS IN STEM CELL TRANSPLANTATION: A COMPREHENSIVE SCOPING REVIEW Ozgun Gokmen Kaya (Istanbul, Turkey)	11:45 - 12:00
NG15-05	SYMPTOM DISTRESS EVOLUTION OVER THE FIRST YEAR AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – A PROSPECTIVE OBSERVATIONAL SUBSTUDY OF THE SMILE PROJECT Anja Schmid (Freiburg im Breisgau, Germany)	12:00 - 12:15
 <i>Oral Session</i>		
11:00 - 12:15		
R12		
OS11 - Oral Session 11 GVHD (I)		
Robert Zeiser (Freiburg, Germany) Francesca Patriarca (Udine, Italy)		
OS11-01	IMPACT OF PERI-TRANSPLANTATION RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Janny Yao (Duarte, United States of America (the))	11:00 - 11:09
OS11-02	SAFETY AND EFFICACY OF THE GLUCAGON-LIKE PEPTIDE 2 ANALOG APRAGLUTIDE IN COMBINATION WITH RUXOLITINIB IN STEROID-REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: THE PHASE 2 STARGAZE TRIAL Robert Zeiser (Freiburg, Germany)	11:09 - 11:18
OS11-03	EFFICACY AND SAFETY OF BELUMOSUDIL AS COMPARED WITH BEST AVAILABLE THERAPY FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE IN THE US POPULATION Edmund K. Waller (Atlanta, United States of America (the))	11:18 - 11:27
OS11-04	EFFICACY AND SAFETY OF RUXOLITINIB IN GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR PBSC-ONLY ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS: A PROSPECTIVE PHASE II STUDY Xiaoyu Zhang (Tianjin, China)	11:27 - 11:36
OS11-05	IMPACT OF RUXOLITINIB CONCENTRATIONS IN CALCINEURIN-FREE POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND RUXOLITINIB GVHD PROPHYLAXIS REGIMEN Ivan Moiseev (Saint-Petersburg, Russian Federation (the))	11:36 - 11:45
OS11-06	COSBLR-AGVHD SYNDROME: A UNIQUE PATTERN OF ACUTE GVHD PHENOTYPE IN HAPLOIDENTICAL HCT WITH T CELL COSTIMULATION BLOCKADE WITH ABATACEPT AND PTCY Sarita Jaiswal (New Delhi, India)	11:45 - 11:54
OS11-07	INCIDENCE OF GRAFT VERSUS HOST DISEASE ACCORDING TO PROPHYLAXIS STRATEGY IN MATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL-WORLD EXPERIENCE OF GETH-TC Leyre Bento (Palma, Spain)	11:54 - 12:03
OS11-08	CSA VERSUS CSA+MMF IN RIC ALLO-SCT FOR INTERMEDIATE-RISK-AML: A RANDOMIZED STUDY FROM THE ACUTE LEUKEMIA FRENCH INTERGROUP, ON BEHALF OF THE FILO, ALFA, AND SFGM-TC Edouard Forcade (Pessac, France)	12:03 - 12:12

Oral Session

11:00 - 12:15

R13

OS12 - Oral Session 12 | Aplastic Anaemia & Autoimmune Diseases

Flore Sicre de Fontbrune (Paris, France)

Giorgio Orofino (Milan, Italy)

OS12-01	EFFECTIVENESS OF NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS PATIENTS (MS) AND FACTORS ASSOCIATED WITH BETTER OUTCOMES Denis Fedorenko (Moscow, Russian Federation (the))	11:00 - 11:09
OS12-02	CO-INFUSION OF CD19/BCMA-TARGETED CAR-T CELLS ERADICATES AUTOANTIBODY-PRODUCING CELLS IN SLE PATIENTS:A PHASE 1 CLINICAL TRIAL Jingjing Feng (Hangzhou, China)	11:09 - 11:18
OS12-03	OUTCOMES OF PATIENTS WITH ACQUIRED APLASTIC ANEMIA RECEIVING MATCHED RELATED DONOR TRANSPLANT: A MULTICENTER STUDY ON BEHALF OF PAKISTAN BLOOD AND MARROW TRANSPLANT GROUP Natasha Ali (Karachi, Pakistan)	11:18 - 11:27
OS12-04	COMPARISON OF DIFFERENT ANTI-HUMAN T CELL GLOBULINS ON IMMUNE RECONSTITUTION AND EARLY INFECTIONS AFTER CYCLOPHOSPHAMIDE-BASED CONDITIONING FOLLOWED BY AUTOLOGOUS TRANSPLANT IN PATIENTS WITH MULTIPLE SCLEROSIS Johanna Richter (Hamburg, Germany)	11:27 - 11:36
OS12-05	HLA HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA: A GATMO-TC EXPERIENCE Ana Lisa Basquiera (Córdoba, Argentina)	11:36 - 11:45
OS12-06	EARLY MORBIMORTALITY IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION PERFORMED ON OUTPATIENT BASIS IN PATIENTS WITH AUTOIMMUNE DISEASES: EXPERIENCE IN 1700 PATIENTS Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	11:45 - 11:54
OS12-07	ADENOSINE DEAMINASE 2 DEFICIENCY: A NOVEL GENETIC CAUSE OF BONE MARROW FAILURE SYNDROMES Federica Barzaghi (Milan, Italy)	11:54 - 12:03
OS12-08	FRESH AUTOLOGOUS CD19-TARGETING CAR T CELLS (CD19-CART) FOR PEDIATRIC PATIENTS WITH SEVERE/REFRACTORY AUTOIMMUNE DISEASE (AD) Marco Becilli (Rome, Italy)	12:03 - 12:12

Quality Management

11:00 - 12:15

R14

QM2 - Quality Management 2 | Challenges at Inspections

Carlos Torrico Leon (Barcelona, Spain)

Laura Lombardi (Rome, Italy)

QM2-1	JACIE Activity Update and Common Deficiencies at Inspections Raquel Espada (Barcelona, Spain)	11:00 - 11:15
QM2-2	Understanding the inspection burden by hospitals in ATMP context: Results of the QMC/GoCART Survey Nick Van Sinderen (Venray, Netherlands (the)) Julie Dolva (Oslo, Norway)	11:15 - 11:30
QM2-3	Managing time during the onsite inspection: time management	11:30 - 11:45

tips for centers and Inspectors

Dania Arabi (Jeddah, Saudi Arabia)

QM2-4 **Assessing IEC Standards: Standards to apply and how to assess them** 11:45 - 12:00

Martin Bornhäuser (Dresden, Germany)

QM2-5 **Q&A** 12:00 - 12:15

GoCART Coalition

11:00 - 12:15

R15

GCC1 - GoCART Coalition 1 | Turning the power of cells and genes into actual treatments

Jurgen Kuball (Utrecht, Netherlands (the))

Martin Dreyling (Munich, Germany)

GCC1-1 **Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models** 11:00 - 11:15

Arezoo Jamali (Langen, Germany)

GCC1-2 **Bench to bedside and back with CAR-T for heme malignancies** 11:15 - 11:30

Marcela Maus (Boston, United States of America (the))

GCC1-3 **Harnessing CD3 diversity to optimize CAR T cells** 11:30 - 11:44

Susanna Minguet (Freiburg, Germany)

GCC1-4 **Harnessing cytotoxic cells with intracellular immunotherapy** 11:44 - 11:59

Geoffrey Guittard (Marseille, France)

GCC1-5 **Payload-delivering for engineered $\gamma\delta$ T cells** 11:59 - 12:14

Jonathan Fisher (London, United Kingdom of Great Britain and Northern Ireland (the))

Breaks

12:30 - 13:00

R1

Lunch Break, ePoster Viewing, Visit Exhibition*Meetings*

12:45 - 14:00

R10

BM-ALWP - Business Meeting of the Acute Leukaemia Working Party

Fabio Ciceri (Milano, Italy)

Meetings

12:45 - 14:00

R11

BM-IEWP - Business Meeting of the Inborn Errors Working Party

Béatrice Neven (Paris, France)

Meetings

12:45 - 14:00

R12

BM-LWP - Business Meeting of the Lymphoma Working Party

Ali Bazarbachi (Beirut, Lebanon)

Meetings

12:45 - 14:00

R13

BM-CTIWP - Business Meeting of the Cellular Therapy & Immunobiology Working Party

Annalisa Ruggeri (Italy)

Industry Symposium

13:00 - 14:00

R7

IS21 - Supporting patients with haemoglobinopathies through the transplant journey: The role of the multidisciplinary team | VERTEX

Hilda Mekelenkamp (Leiden, Netherlands (the))

IS21-1	Welcome and introduction: Role of the multidisciplinary team Hilda Mekelenkamp (Leiden, Netherlands (the))	13:00 - 13:10
IS21-2	Supporting patients with their treatment decision: Let's talk Marjola Gjergji (Roma, Italy) Kofi Anie (London, United Kingdom of Great Britain and Northern Ireland (the))	13:10 - 13:30
IS21-3	Practical transplant tips and tricks: The nurse's perspective Kelly Hennessy (London, United Kingdom of Great Britain and Northern Ireland (the))	13:30 - 13:45
IS21-4	Panel discussion and Q&A: How can we work together to ensure success through the transplant journey? - All faculty, moderated by Chair	13:45 - 13:55
IS21-5	Summary and close Hilda Mekelenkamp (Leiden, Netherlands (the))	13:55 - 14:00

Industry Symposium

13:00 - 14:00

R8

IS22 - Integrated approaches for monitoring and diagnosing HSCT-TMA| ALEXION

Daniele Avenoso (Brescia, Italy)

IS22-1	Introductions Daniele Avenoso (Brescia, Italy)	13:00 - 13:05
IS22-2	HSCT-TMA: Pathophysiology and the role of complement Daniele Avenoso (Brescia, Italy) Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))	13:05 - 13:15
IS22-3	Diagnostic Challenges in HSCT-TMA Daniele Avenoso (Brescia, Italy) Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))	13:15 - 13:25
IS22-4	Multidisciplinary approaches to the monitoring and recognition of HSCT-TMA Daniele Avenoso (Brescia, Italy) Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))	13:25 - 13:35
IS22-5	Discussion Daniele Avenoso (Brescia, Italy) Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))	13:35 - 13:55
IS22-6	Closing remarks Daniele Avenoso (Brescia, Italy)	13:55 - 14:00

Industry Meet the Expert

13:00 - 14:00

R16

S-MTE1 - How does CART fit into 2L and DLBCL Treatment | Bristol Myers Squibb

Bastian von Tresckow (Essen, Germany)

Industry Meet the Expert

13:00 - 14:00

R16

S-MTE - Meet the Expert

Breaks

14:00 - 14:30

R1

Break, ePoster Viewing, Visit Exhibition*Special Session*

14:30 - 16:00

R1

SS6 - Artificial Intelligence and Machine Learning: AI for next-generation clinical trials in hematology

Matteo Della Porta (Milan, Italy)

Alejandro Madrigal (United Kingdom of Great Britain and Northern Ireland (the))

SS6-1	Generative and distributed AI to improve access and use of real-world data to accelerate clinical research in hematology Federico Alvarez (Madrid, Spain)	14:30 - 15:00
SS6-2	A legal perspective from AI ACT on the use of generative AI in medicine Nathan Lea (Ghent, Belgium)	15:00 - 15:30
SS6-3	Innovative design of clinical trials in hematology for rare/complex diseases Jurjen Versluis (Rotterdam, Netherlands (the))	15:30 - 16:00

Paediatrics Day

14:30 - 15:45

R2

Paed3 - Paediatric Diseases Oral Session

Adriana Balduzzi (Monza, Italy)

Marianne Ifversen (Copenhagen, Denmark)

Paed3-01	LETMOVIR PROPHYLAXIS VERSUS PRE-EMPTIVE THERAPY IN CHILDREN: FASTER IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Manuela Spadea (Turin, Italy)	14:30 - 14:39
Paed3-02	REAL-WORLD MULTICENTER INTERNATIONAL EXPERIENCE OF FLT3-INHIBITORS POST-TRANSPLANT MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA WITH FLT3-ITD Charlotte Calvo (Paris, France)	14:39 - 14:48
Paed3-03	TCRαB+/CD19+ CELL-DEPLETED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH FANCONI ANEMIA: AN UPDATE OF A SINGLE CENTER EXPERIENCE Daria Pagliara (Roma, Italy)	14:48 - 14:57
Paed3-04	SINGLE UNRELATED CORD-BLOOD VERSUS UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION USING PT-CY IN PEDIATRIC AML: A RETROSPECTIVE STUDY ON BEHALF OF THE EBMT-PDWP AND CTIWP Benedetta Elena Di Majo (Monza, Italy)	14:57 - 15:06
Paed3-05	CD34+ SELECTED STEM CELL BOOST IN PAEDIATRIC PATIENTS WITH POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION. A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF GETH-TC Maria Isabel Benitez Carabante (Barcelona, Spain)	15:06 - 15:15
Paed3-06	TBI VERSUS CHEMOTHERAPY CONDITIONING BEFORE ALLOHSCT FOR PEDIATRIC ALL PATIENTS AGED 2 TO 4 YEARS: A RETROSPECTIVE STUDY OF THE EBMT PEDIATRIC DISEASES WORKING PARTY Anna Eichinger (Munich, Germany)	15:15 - 15:24
Paed3-07	BELUMOSUDIL FOR REFRACTORY CHRONIC GVHD IN CHILDREN:	15:24 - 15:33

	A NATIONAL ISRAELI REAL-WORLD STUDY	
	Etai Adam (Ramat Gan, Israel)	
Paed3-08	NAÏVE T CELL DEPLETED HAPLOIDENTICAL DONOR HCT WITH SELECTED USE OF BLINATUMOMAB FOR PEDIATRIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES RELAPSED AFTER PRIOR TRANSPLANTATION	15:33 - 15:42
	Rebecca Epperly (Memphis, United States of America (the))	
<i>Educational</i>		
14:30 - 16:00		R3
	E08 - Innovations in CBU transplant	
	Robert Wynn (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) Vanderson Rocha (São Paulo, Brazil)	
E08-1	Conditioning regimen and GVHD prophylaxis in CBU	14:30 - 15:00
	Patrizia Chiusolo (Roma, Italy)	
E08-2	Improving stem cell quality with UM171 for better transplant outcome	15:00 - 15:30
	Guy Sauvageau (Montreal, Canada)	
E08-3	UCB activity in Japan	15:30 - 16:00
	Takanori Teshima (Sapporo, Japan)	
<i>Workshop</i>		
14:30 - 16:00		R4
	W05 - New treatment and cell therapy in MM	
	Chiara Nozzoli (Florence, Italy) Massimo Martino (Reggio Calabria, Italy)	
W05-1	New therapies	14:30 - 14:48
	Francesca Gay (Torino, Italy)	
W05-2	CAR-T - Clinical applications	14:48 - 15:06
	Mohamad Mohty (Paris, France)	
W05-3	Auto allo	15:06 - 15:24
	Thierry Facon (Lille, France)	
W05-4	CAR T cell for MM in the Real World Setting	15:24 - 15:42
	Marcelo Pasquini (Milwaukee, United States of America (the))	
W05-5	Panel Discussion	15:42 - 16:00
<i>Educational</i>		
14:30 - 16:00		R5
	E09 - MRD strategies and relapse	
	Simona Sica (Rome, Italy) Peter Bader (Frankfurt, Germany)	
E09-1	MRD in Myeloma as surrogate marker for outcomes	14:30 - 15:00
	Maria Victoria Mateos (Salamanca, Spain)	
E09-2	MRD in myelofibrosis	15:00 - 15:30
	Nico Gagelmann (Hamburg, Germany)	
E09-3	MRD driven treatment in AML, update 2025	15:30 - 16:00
	Francesco Buccisano (Rome, Italy)	

<i>Workshop</i>		
14:30 - 16:00		R6
W06 - Regulatory aspects in HSCT and IEC		
Fermin Sanchez-Guijo (Salamanca, Spain) Aurora Vassanelli (Verona, Italy)		
W06-1	Potency Tests for CAR/TCR T Cell Products: The T2EVOLVE Perspective	14:30 - 15:00
	Concetta Quintarelli (Rome, Italy)	
W06-2	Impact of regulatory changes on access to HSCT and IECs	15:00 - 15:30
	Christian Chabannon (Marseille, France)	
W06-3	Innovations in regulatory aspects of gene therapy	15:30 - 16:00
	Alessandro Aiuti (Milan, Italy)	
<i>Nurses Group</i>		
14:30 - 16:00		R7
NG16 - Cell and Gene Therapy		
Sandrine Bremathas (London, United Kingdom of Great Britain and Northern Ireland (the)) Valentina de Cecco (Roma, Italy)		
NG16-1	The science of cell and gene therapy	14:30 - 14:51
	Victoria Potter (London, United Kingdom of Great Britain and Northern Ireland (the))	
NG16-2	Cell and gene therapy patient care	14:51 - 15:12
	Ruth Clout (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
NG16-3	Late malignant and immunological effects	15:12 - 15:33
	Marjola Gjergji (Roma, Italy)	
NG16-4	Ethical challenges of evolving therapies	15:33 - 15:54
	Hilda Mekelenkamp (Leiden, Netherlands (the))	
NG16-5	Q&A	15:54 - 15:59
<i>Special Session</i>		
14:30 - 16:00		R8
SS7 - Joint physician-nurse session Achieving best outcomes in transplant and cell therapy for autoimmune disease. Opportunities and optimisation		
Raffaella Greco (Milano, Italy) Claudia Boglione (Florence, Italy)		
	Panel discussion session on achieving the best outcomes in transplant and cell therapy for autoimmune disease:	14:30 - 14:30
SS7-1	HSCT in neurological ADs	14:30 - 14:50
SS7-2	Transplant outcome	14:50 - 15:10
SS7-3	Infections focus and long-term complication	15:10 - 15:30
SS7-4	The future of HSCT and other treatments	15:30 - 15:50
	Patient perspective	15:50 - 15:50
	Noelle Tassy (Marseilles, France) Susanne Baerlin (Berlin, Germany)	
	Physiotherapist perspective	15:50 - 15:50
	Cristina Bozzolini (Firenze, Italy)	
	Nurse perspective	15:50 - 15:50

	Claudia Boglione (Florence, Italy) Davide Bonomi (Milan, Italy)	
	Disease specialist perspective	15:50 - 15:50
	Basil Sharrack (United Kingdom of Great Britain and Northern Ireland (the))	
	HSCT specialist perspective	15:50 - 15:50
	Richard Burt (United States of America (the))	
SS7-5	Closing remarks	15:50 - 16:00
	<i>How do I... ?</i>	
	14:30 - 15:45	R9
	HDI4 - How do I ... evolve GVHD treatment strategies for unique cases? A focus on ECP Supported through an unrestricted educational grant by Therakos	
	Francesca Patriarca (Udine, Italy) Olaf Penack (Berlin, Germany)	
HDI4-1	ECP-ruxolitinib combination treatment for refractory severe cGVHD	14:30 - 14:55
	Attilio Olivieri (Ancona, Italy)	
HDI4-2	ECP positioning in the treatment algorithm for GvHD in 2025	14:55 - 15:20
	Daniel Wolff (Regensburg, Germany)	
HDI4-3	Panel Discussion	15:20 - 15:45
	<i>Transplant and Search Coordinators Day</i>	
	14:30 - 15:45	R10
	TSCD3 - EBMT-WMDA Transplant and Search Coordinators Day 3 Managing the first mile from collection to cryopreservation - understanding the donor perspective for collection	
	Eefke van Eerden (Leiden, Netherlands (the)) Boris Calmels (Marseille, France)	
TSCD3-1	The impact of the COVID-19 pandemic on the cryopreservation of hematopoietic cells of unrelated donors from the Czech National Marrow Donor Registry	14:30 - 14:50
	Katerina Steinerova (Plilsen, Czechia)	
TSCD3-2	Adult Donor Cryopreserved Units - a new product on the match list	14:50 - 15:10
	Alexander Platz (Dresden, Germany)	
TSCD3-3	Which components are most critical to select the best cryopreserved cord blood unit?	15:10 - 15:30
	Jesús Fernandez Sojo (Barcelona, Spain)	
TSCD3-4	Q&A	15:30 - 15:45
	<i>Nurses Group</i>	
	14:30 - 16:00	R11
	NG17 - Oral session II	
	Matteo Steduto (San Giovanni Rotondo, Italy) Ozgun Gokmen Kaya (Istanbul, Turkey)	
NG17-01	SICKLE CELL DISEASE PATIENT REPORTED OUTCOMES POST NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION	14:30 - 14:45
	Samer Ghazi (Toronto, Canada)	
NG17-02	CHALLENGES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A QUALITATIVE SURVEY AS A BASIS FOR OUTPATIENT NURSING CONSULTATIONS	14:45 - 15:00
	Ronja Titze (Ulm, Germany)	

NG17-03	A DECADE OF LONG-TERM FOLLOW UP CARE AFTER ALLOGENEIC STEM CELL TRANSPLANT: RETROSPECTIVE ANALYSIS FROM AN AUSTRALIAN NURSE-LED LONG-TERM FOLLOW-UP SERVICE Teresa Garcia (Parkville, Australia)	15:00 - 15:15
NG17-04	IDENTIFICATION OF FACILITATING FACTORS AND PREPARATORY DIALOUGE ON SELF-CARE IN ALLO-HCT Katarina Holmberg (Stockholm, Sweden)	15:15 - 15:30
NG17-05	EARLY EVALUATION AND IMMUNIZATION IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS Elizabeth Swift (Memphis, United States of America (the))	15:30 - 15:45

Joint Sessions

14:30 - 15:30

R12

JS06 - Joint Session EBMT - KSBMT | How to use DLI in 2025?

Anna Sureda (Barcelona, Spain)

Jae Ho Yoon (Seoul, Korea (the Republic of))

JS06-1	Korean perspective: Differential Effects of DLI Based on Relapse Levels and Donor Types in Patients with MDS Silvia Park (Seoul, Korea (the Republic of))	14:30 - 14:50
JS06-2	European perspective Simona Pagliuca (NANCY, France)	14:50 - 15:10
JS06-3	Panel Disucssion Silvia Park (Seoul, Korea (the Republic of)) Simona Pagliuca (NANCY, France) Jae Ho Yoon (Seoul, Korea (the Republic of)) Anna Sureda (Barcelona, Spain)	15:10 - 15:30

Statistics

14:30 - 15:30

R13

STATS 2 - Statistical Workshop

Simona Iacobelli (Rome, Italy)

Allain-Thibeault Ferhat Berland (Paris, France)

STATS 2-1	Auto-HCT in older multiple myeloma patients: relative survival and comparison to non-transplant treatment Luuk Gras (Leiden, Netherlands (the)) Laurent Garderet (Paris, France)	14:30 - 15:30
-----------	---	---------------

Quality Management

14:30 - 15:45

R14

QM3 - Quality Management 3 | 9th Edition Standards: Key changes

Lynn Manson (Edinburgh, United Kingdom of Great Britain and Northern Ireland (the))

Remy Dulery (Boston, United States of America (the))

QM3-1	Clinical Standards Charles Crawley (United Kingdom of Great Britain and Northern Ireland (the))	14:30 - 14:42
QM3-2	Collection Standards Nina Worel (Vienna, Austria)	14:42 - 14:54
QM3-3	Processing Standards Ivan Van Riet (Brussels, Belgium)	14:54 - 15:06
QM3-4	Quality management Standards	15:06 - 15:18

	Anne Emmett (London, United Kingdom of Great Britain and Northern Ireland (the))	
QM3-5	IEC Standards	15:18 - 15:30
	Jaap Jan Zwaginga (Leiden, Netherlands (the))	
QM3-6	Q&A	15:30 - 15:45
<i>GoCART Coalition</i>		
	14:30 - 15:45	R15
GCC2 - GoCART Coalition 2 GoCART Scientific Excellence Research Studies		
Annalisa Ruggeri (Italy)		
Martin Dreyling (Munich, Germany)		
GCC2-1	Conducting studies using the EBMT Registry	14:30 - 14:42
	Annalisa Ruggeri (Italy)	
GCC2-2	Surveillance and prophylaxis of infections following CAR-T cell therapy: International survey on behalf of the Infectious Diseases Working Party and GoCART coalition EBMT	14:42 - 14:54
	Dina Averbuch (Jerusalem, Israel)	
GCC2-3	The role of bridging therapy before CAR-T cell therapy in diffuse large B-cell lymphoma	14:54 - 15:05
	Philipp Berning (Muenster, Germany)	
GCC2-4	Impact of prior B-cell directed immunotherapy on the outcome of CD19 CAR-T cell therapy in aggressive B-cell malignancies	15:05 - 15:16
	Jan Schröder (Tuebingen, Germany)	
GCC2-5	Engineered T cells: the challenge of solid tumors	15:16 - 15:28
	Fabio Ciceri (Milano, Italy)	
GCC2-6	Q&A	15:28 - 15:43
<i>Breaks</i>		
	16:00 - 16:30	R1
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>Plenary Session</i>		
	16:30 - 18:00	R1
P05 - Prognostic impact of updated classification for hematologic malignancies in allogeneic HSCT		
Valeria Santini (Florence, Italy)		
Paola Guglielmelli (Florence, Italy)		
P05-1	AML and MDS	16:30 - 17:00
	Maria Teresa Voso (Rome, Italy)	
P05-2	MPN	17:00 - 17:30
	Ibrahim Yakoub-Agha (Lille, France)	
P05-3	ALL	17:30 - 18:00
	Sebastian Giebel (Gliwice, Poland)	
<i>Paediatrics Day</i>		
	16:30 - 17:45	R2
Paed4 - Inborn Errors Oral Session		
Béatrice Neven (Paris, France)		
Maria Ester Bernardo (Milano, Italy)		

Paed4-01	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN OSTEOPETROSIS: AN IEWP STUDY OF 715 CHILDREN Robert Chiesa (London, United Kingdom of Great Britain and Northern Ireland (the))	16:30 - 16:39
Paed4-02	BUSULFAN-FLUDARABINE VERSUS TREOSULFAN-FLUDARABINE CONDITIONING FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY: A RETROSPECTIVE MULTICENTER STUDY Filippo Consonni (Florence, Italy)	16:39 - 16:48
Paed4-03	POST-TRANSPLANT INFUSION OF RIVO-CEL IMPROVES OUTCOME OF T-CELL RECEPTOR AB+(TCRAB+)/CD19+CELL-DEPLETED HAPLOIDENTICAL TRANSPLANTATION (TCRAB-HAPLOHSCT) FOR INBORN ERRORS OF IMMUNITY (IEIS): FINAL RESULTS OF BP-004-EU MULTICENTER TRIAL Mattia Algeri (Rome, Italy)	16:48 - 16:57
Paed4-04	CORD VERSUS HAPLOIDENTICAL DONOR HSCT FOR INBORN ERRORS OF IMMUNITY, WHICH IS PREFERRED IN 2025? Su Han Lum (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the))	16:57 - 17:06
Paed4-05	MULTIMODAL THERAPY WITH HSCT, ENZYME REPLACEMENT AND DIETARY SUBSTRATE REDUCTION FOR WOLMAN DISEASE- A GLOBAL SUCCESS STORY TRANSFORMING THE THERAPEUTIC LANDSCAPE OF THIS RARE DISORDER Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	17:06 - 17:15
Paed4-06	EXTENSIVE DETOXIFICATION AND FAVORABLE EFFECTS ON SYSTEMIC CLINICAL OUTCOMES AFTER HEMATOPOIETIC STEM CELL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE I-HURLER (OTL-203) Maria Ester Bernardo (Milano, Italy)	17:15 - 17:24
Paed4-07	EX VIVO LENTIVIRAL-BASED GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE I-HURLER: FOCUS ON SKELETAL DAMAGE AND CROSS-CORRECTION MECHANISM Ludovica Santi (Milano, Italy)	17:24 - 17:33
Paed4-08	TIMING IS EVERYTHING: ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS WITH INBORN ERRORS OF IMMUNITY Kate Orf (London, United Kingdom of Great Britain and Northern Ireland (the))	17:33 - 17:42

Educational

16:30 - 18:00

R3

E10 - CAR-T complications

Annalisa Ruggeri (Italy)

Catherine Thieblemont (France)

E10-1	Secondary malignancies Fabio Ciceri (Milano, Italy)	16:30 - 16:53
E10-2	Models predicting ICANS after CAR-T cell therapy Francesca Bonifazi (BOLOGNA, Italy)	16:53 - 17:16
E10-3	Cardiac complications of CAR-T therapy Roni Shouval (New York, United States of America (the))	17:16 - 17:39
E10-4	Panel Discussion	17:39 - 18:00

Workshop

16:30 - 18:00

R4

W07 - New IEC approaches

Dominique Farge (PARIS, France)

Alina Daniela Tanase (Bucharest, Romania)

W07-1	New and dual CAR Targeting Marcela Maus (Boston, United States of America (the))	16:30 - 17:00
W07-2	CAR in autoimmune diseases Johanna Richter (Hamburg, Germany)	17:00 - 17:30
W07-3	CAR-T in solid tumors Monica Casucci (Milano, Italy)	17:30 - 18:00

Joint Sessions

16:30 - 18:00

R5

JS07 - Joint Session EBMT - ASTCT - CIBMTR - APBMT - LABMT | GVHD prophylaxis

Anna Sureda (Barcelona, Spain)

Bronwen Shaw (Milwaukee, United States of America (the))

Cristobal Frutos-Ortiz (Asuncion, Paraguay)

Corey S. Cutler (Boston, United States of America (the))

Alok Srivastava (Bengaluru, India)

JS07-1	Introduction	16:30 - 16:35
JS07-2	PTCy for GVHD prevention in Asia Pacific - Different shades: With and without partners APBMT experience part I Alok Srivastava (Bengaluru, India)	16:35 - 16:40
JS07-3	Evidence based management of pulmonary GVHD APBMT experience part II Su-Peng Yeh (Taichung, Taiwan (Province of China))	16:40 - 16:45
JS07-4	Haploidentical Stem Cell Transplantation in Latin America LABMT experience part I Cristobal Frutos-Ortiz (Asuncion, Paraguay)	16:45 - 16:50
JS07-5	Full or Reduced Doses of PTCy for Haploidentical Stem Cell Transplantation LABMT experience part II Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	16:50 - 16:55
JS07-6	Beyond standard of care PTCy: matched donor setting US experience ASTCT Corey S. Cutler (Boston, United States of America (the))	16:55 - 17:05
JS07-7	Beyond standard of care PTCy: mismatched donor setting US experience CIBMTR Bronwen Shaw (Milwaukee, United States of America (the))	17:05 - 17:15
JS07-8	ATG vs PTCy in HLA matched setting EBMT experience Jaime Sanz (Valencia, Spain)	17:15 - 17:25
JS07-9	Panel Discussion	17:25 - 18:00

Oral Session

16:30 - 17:45

R6

OS13 - Oral Session 13 | Acute leukemia (II)

Udit Nangia (Parma, United States of America (the))

Eolia Brissot (Paris, France)

OS13-01	COMPARABLE RESULTS OF ALLO-HCT FROM MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH ALL. A	16:30 - 16:39
---------	--	---------------

	STUDY FROM ALWP OF THE EBMT	
	Sebastian Giebel (Gliwice, Poland)	
OS13-02	OUTCOMES OF CAR T-CELL THERAPY (CART19) FOR B-ALL: A GOCART COALITION REPORT ON BEHALF OF THE PDWP, ALWP, AND CTIWP OF THE EBMT	16:39 - 16:48
	Sebastian Giebel (Gliwice, Poland)	
OS13-03	LONG-TERM FOLLOW-UP OF CAR-T THERAPY FOLLOWED BY HAPLOIDENTICAL HSCT FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER RETROSPECTIVE STUDY	16:48 - 16:57
	Houli Zhao (Hangzhou, China)	
OS13-04	OBECABTAGENE AUTOLEUCEL (OBE-CEL) VERSUS EXTERNAL CONTROL ARM (ECA) MATCHED COMPARISONS IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL)	16:57 - 17:06
	Max S. Topp (Würzburg, Germany)	
OS13-05	FRAILTY IN ACUTE LEUKEMIA PATIENTS - ACCOUNTING FOR THE UNOBSERVED RISK FACTORS IN HSCT PATIENTS	17:06 - 17:15
	Udit Nangia (Parma, United States of America (the))	
OS13-06	OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL) TREATED WITH OBECABTAGENE AUTOLEUCEL (OBE-CEL) WITH OR WITHOUT CONSOLIDATIVE ALLOGENEIC STEM CELL TRANSPLANTATION (SCT)	17:15 - 17:24
	Karamjeet S. Sandhu (Duarte, United States of America (the))	
OS13-07	YOUNGER HAPLOIDENTICAL VERSUS OLDER MATCHED SIBLING DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY FROM THE ALWP OF EBMT	17:24 - 17:33
	Eolia Brissot (Paris, France)	
OS13-08	LATE EVENTS AND LONG-TERM OUTCOMES AFTER POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: AN ALWP-EBMT STUDY	17:33 - 17:42
	Eduardo Rodríguez-Arbolí (Seville, Spain)	
<i>Nurses Group</i>		
	16:30 - 18:00	R7
NG18 - Delivering equitable and equal care in an unequal world		
Julia Ruiz Pato (Madrid, Spain)		
Liana Abu Rumieleh (Jerusalem, Israel)		
NG18-1	A holistic approach to equity in health	16:30 - 16:51
	Nada Hamad (Newtown, Australia)	
NG18-2	Transcultural care	16:51 - 17:12
	Seham Aweida (Lund, Sweden)	
NG18-3	The sustainability of nursing	17:12 - 17:33
	Virpi Sulosaari (Kaarina, Finland)	
NG18-4	LGBTQIA+ delivering appropriate care	17:33 - 17:54
	Jay Swinnerton (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
NG18-5	Q&A	17:54 - 17:59

Working Party Session

16:30 - 18:00

R8

LWP - Lymphoma Working Party Session

Ali Bazarbachi (Beirut, Lebanon)

LWP-1	Report of LWP activities + Introduction Jian Jian Luan award Ali Bazarbachi (Beirut, Lebanon)	16:30 - 16:45
LWP-2	COMPREHENSIVE GENOMIC AND PHENOTYPIC PROFILING OF CD19 IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CAR-T THERAPY Magdalena Corona (New York, United States of America (the))	16:45 - 17:00
LWP-3	EBMT Consensus on allogeneic transplantation in T-cell lymphoma Gandhi Damaj (caen, France)	17:00 - 17:15
LWP-4	Controversy on CAR-T versus auto-HSCT for chemo-sensitive DLBCL in first relapse	17:15 - 17:15
LWP-4.1	In favor of CAR-T Anna Ossami Saidy (Berlin, Germany)	17:15 - 17:22
LWP-4.2	In favor of auto-HSCT Christopher Fox (Nottingham, United Kingdom of Great Britain and Northern Ireland (the))	17:22 - 17:29
LWP-4.3	Discussion	17:29 - 17:37
LWP-5	Should we autograft MCL in CR1?	17:37 - 17:37
LWP-5.1	Should we autograft MCL in CR1? - YES Olivier Hermine (Paris, France)	17:37 - 17:44
LWP-5.2	Should we autograft MCL in CR1? - NO Eva Giné (Barcelona, Spain)	17:44 - 17:51
LWP-5.3	Discussion	17:51 - 17:59

Oral Session

16:30 - 17:45

R9

OS14 - Oral Session 14 | Multiple Myeloma

Chiara Nozzoli (Florence, Italy)

Nico Gagelmann (Hamburg, Germany)

OS14-01	(DARA)/BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE (D-VRD) WITH D-R MAINTENANCE (MAINT) IN TRANSPLANT-ELIGIBLE (TE) NEWLY DIAGNOSED MYELOMA (NDMM): ANALYSIS OF PERSEUS BASED ON CYTOGENETIC RISK Mario Boccadoro (Torino, Italy)	16:30 - 16:39
OS14-02	OVERALL SURVIVAL (OS) WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VERSUS STANDARD OF CARE (SOC) IN LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM): PHASE 3 CARTITUDE-4 STUDY UPDATE Maria Victoria Mateos (Salamanca, Spain)	16:39 - 16:48
OS14-03	CILTA-CEL OR IDE-CEL AND RESPONSE DYNAMICS IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A REAL-WORD ANALYSIS OF DRST/DSMM/GMMG Nico Gagelmann (Hamburg, Germany)	16:48 - 16:57
OS14-04	A LONGITUDINAL MULTI-OMIC SINGLE-CELL LANDSCAPE OF CRS IN MULTIPLE MYELOMA PATIENTS AFTER ANTI-BCMA CAR-T CELL THERAPY Xia Li (Hang Zhou, China)	16:57 - 17:06

OS14-05	CILTACABTAGENE AUTOLEUCCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AFTER 1-3 LINES OF THERAPY: MINIMAL RESIDUAL DISEASE NEGATIVITY IN PHASE 3 CARTITUDE-4 TRIAL Michele Cavo (Bologna, Italy)	17:06 - 17:15
OS14-06	SUCCESSFUL TREATMENT OF PATIENTS WITH HEAVILY PRETREATED SYSTEMIC LIGHT CHAIN AL AMYLOIDOSIS AND MULTIPLE MYELOMA WITH THE NOVEL MDC-BCMA-CAR001 Kivasch Mohammad Nejad Farid (Heidelberg, Germany)	17:15 - 17:24
OS14-07	G-CSF VERSUS NON G-CSF PROPHYLAXIS IN AUTOLOGOUS STEM CELL POST-TRANSPLANTATION FOR MULTIPLE MYELOMA: ONE CENTER EXPERIENCE Adolfo Fernandez Sanchez (Salamanca, Spain)	17:24 - 17:33
OS14-08	OUTCOMES OF AUTOLOGOUS STEM-CELL TRANSPLANT AS PER MELPHALAN DOSE IN PATIENTS WITH MULTIPLE MYELOMA - A 15-YEAR RETROSPECTIVE INSTITUTIONAL ANALYSIS Sumeet Mirgh (Mumbai, India)	17:33 - 17:42

Transplant and Search Coordinators Day

16:30 - 17:45

R10

TSCD4 - EBMT-WMDA Transplant and Search Coordinators Day 4 | Point of Care Transport: Risk of transportation of products

Tigran Torosian (Warsaw, Poland)

Tuula Rintala (London, United Kingdom of Great Britain and Northern Ireland (the))

TSCD4-1	Serious Adverse Events in Transport - transport incidents reported to WMDA Gabriela Marti Fankhauser (3097 Liebefeld, Switzerland)	16:30 - 16:50
TSCD4-2	Root cause analysis on a transport incident Thilo Mengling (Cologne, Germany)	16:50 - 17:10
TSCD4-3	Certification of your courier process - WMDA's approach Hirasine Sengomona (London, United Kingdom of Great Britain and Northern Ireland (the))	17:10 - 17:30
TSCD4-4	Q&A	17:30 - 17:45

Nurses Group

16:30 - 18:00

R11

NG19 - Advanced Clinical Practice

Kelly Hennessy (London, United Kingdom of Great Britain and Northern Ireland (the))

Claudia Boglione (Florence, Italy)

NG19-1	Nurse-led bone marrow assessment Gabriella Rennick (London, United Kingdom of Great Britain and Northern Ireland (the))	16:30 - 16:51
NG19-2	Nurse prescribing Maaïke de Ruijter (Haarlem, Netherlands (the))	16:51 - 17:12
NG19-3	Nurse-led line placement Liesbeth Raymakers (Nieuwegein, Netherlands (the))	17:12 - 17:33
NG19-4	Professional issues: trial by social media Thomas Jezequel (Nantes, France)	17:33 - 17:54
NG19-5	Q&A	17:54 - 17:59

Joint Sessions

16:30 - 17:45

R12

JS08 - Joint Session EBMT - EFI | The role of Immunogenetics in HSCT

Marco Andreani (Rome, Italy)

Luca Vago (Milano, Italy)

JS08-1	HLA mismatching in the PTCy era: have we overcome the barriers? Esteban Arrieta Bolaños (Essen, Germany)	16:30 - 16:55
JS08-2	How KIR diversity can impact hematopoietic stem cell transplantation Jean Villard (Geneva, Switzerland)	16:55 - 17:20
JS08-3	Immunogenetics in NK cell immunotherapies Lotte Wietten (Maastricht, Netherlands (the))	17:20 - 17:45

Special Session

16:30 - 17:30

R13

SS1 - From Page to Podium: Mastering Publication and Presentation in Hematology

Mohamad Mohty (Paris, France)

Iman Abou Dalle (Beirut, Lebanon)

SS1-1	From Page to Podium: Mastering Publication and Presentation in Hematology Mohamad Mohty (Paris, France) Iman Abou Dalle (Beirut, Lebanon)	16:30 - 17:30
-------	--	---------------

Quality Management

16:30 - 17:45

R14

QM4 - Quality Management 4 | How to...

Ivana Ferrero (Turin, Italy)

QM4-1	How to.... When, what and how to validate? John Fitzgerald (Dublin, Ireland)	16:30 - 16:45
QM4-2	How to.... Manage the written agreements? Carlos Torrico Leon (Barcelona, Spain)	16:45 - 17:00
QM4-3	How to... Set up Internal Audit programme? Lea Brandt Kristensen (Aarhus, Denmark)	17:00 - 17:15
QM4-4	How to... meet the Standards for Outcome analysis in Clinical, Collection and Processing Facilities? Olga López (Salamanca, Spain)	17:15 - 17:30
QM4-5	Q&A	17:30 - 17:45

GoCART Coalition

16:30 - 17:45

R15

GCC3 - GoCART Coalition 3 | Collect once, use often: how RWD can inform decisions

Christian Chabannon (Marseille, France)

Chiara Bonini (Milan, Italy)

GCC4-1	Updating the EBMT Cellular Therapy form Jurgen Kuball (Utrecht, Netherlands (the))	16:30 - 16:42
GCC4-2	Data Harmonisation - CART-CD Bjoern Chapuy (Berlin, Germany)	16:42 - 16:54

GCC4-3	European CAR T-Cell Handbook Christian Chabannon (Marseille, France)	16:54 - 17:06
GCC4-4	GoCART passport Chiara Bonini (Milan, Italy)	17:06 - 17:18
GCC4-5	Access to CAR T-Cell Therapy in Eastern Europe Krzysztof Kalwak (WROCLAW, Poland)	17:18 - 17:30
GCC4-6	Q&A	17:30 - 17:45
<i>Printed Poster</i>		
18:00 - 19:00		R13
Non-haematopoietic Stem Cells and Regenerative Medicine		
B001	EFFECT OF CONDITIONING TOXICITY ON THE BONE MARROW MESENCHYMAL STROMA CELL-NICHE AND ITS IMPACT ON ENGRAFTMENT AND RELAPSE OF MYELOID NEOPLASIA Sara Garaali (Halle (Saale), Germany)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		R13
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution		
B140	PREDICTORS FOR THYMIC RECONSTITUTION AFTER PEDIATRIC AND YOUNG ADULT HCT: A MULTICENTER ANALYSIS Devin McAvoy (New York, United States of America (the))	18:00 - 18:00
B141	PROTECTIVE ROLE OF NAÏVE VD2 GD T-CELL AGAINST RELAPSE IN ABHAPLO-HSCT Giulia Barbarito (Palo Alto, United States of America (the))	18:00 - 18:00
B144	ATLG IMPAIR CD4+ NAÏVE T CELLS AFTER HEMATOPOIETIC STEM CELL TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA Silvia Nucera (Monza, Italy)	18:00 - 18:00
B145	DECIPHERING THE IMPACT OF LETERMIVIR ON THE IMMUNE-RECONSTITUTION OF CMV-SPECIFIC T LYMPHOCYTES REVEALED BY DEXTRAMERS IN THE PT-CY ERA Elena Tassi (Milan, Italy)	18:00 - 18:00
B147	THE IMPACT OF VITAMIN D RECEPTOR POLYMORPHISMS AND PRE-TRANSPLANT VITAMIN D STATUS ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML, MDS, AND ALL PATIENTS Lina Kolloch (Muenster, Germany)	18:00 - 18:00
B148	DISTINCT IMMUNE RECONSTITUTION PATTERNS CORRELATE WITH OUTCOMES FOLLOWING PEDIATRIC AB T-CELL/CD19 B-CELL DEPLETED HAPLOIDENTICAL HSCT Linda Oppizzi (Palo Alto, United States of America (the))	18:00 - 18:00
B149	RECONSTITUTION AND LICENSING OF NATURAL KILLER CELLS FOLLOWING T-CELL REplete HAPLOIDENTICAL STEM CELL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN Maxime Jullien (Nantes, France)	18:00 - 18:00
B151	THE IMPACT OF MONOCYTE RECOVERY ON OUTCOMES OF MATCHED UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS	18:00 - 18:00

	Nihar Desai (Toronto, Canada)	
B152	IMPLEMENTATION OF FLOW CYTOMETRY IN MONITORING POST-HSCT CHIMERISM IN PATIENTS WITH CERTAIN INBORN ERRORS OF IMMUNITY (IEI) Dmitry Pershin (Moscow, Russian Federation (the))	18:00 - 18:00
B153	RETROSPECTIVE ANALYSIS OF CHIMERISM MONITORING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: EVALUATION OF THE PREDICTIVE VALUE OF ULTRA-LOW THRESHOLDS FOR EARLY RELAPSE DETECTION Karolin Weber (Munich, Germany)	18:00 - 18:00
B154	REDUCED-INTENSITY POST-CYCLOPHOSPHAMIDE DECREASED EARLY IMMUNE REACTIONS IN UNRELATED CORD BLOOD TRANSPLANTATION Yuntian Ding (Shenzhen, China)	18:00 - 18:00
B155	DIAGNOSTIC NGS PANEL-BASED SERIAL MRD MONITORING AS A PROGNOSTIC TOOL IN ACUTE MYELOID LEUKEMIA Hyeoung-Joon Kim (Jeollanam-do, Korea (the Republic of))	18:00 - 18:00
B156	DISTINCT PATTERNS OF CHIMERISM DYNAMICS IN THE PATIENTS RECEIVED POST-TRANSPLANT CYCLOPHOSPHAMIDE GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS BASED REGIMEN FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) Majed Altareb (Toronto, Canada)	18:00 - 18:00
B157	CD4⁺ T-CELL RECONSTITUTION AT DAY 90 PREDICTS FAVORABLE OUTCOMES AFTER CONVENTIONAL T-CELL REPLETE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS Milena Todorović Balint (Belgrade, Serbia)	18:00 - 18:00
B158	CHARACTERIZATION OF IMMUNE CELL SUBPOPULATIONS IN PATIENTS WITH RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Wei Zhao (Beijing, China)	18:00 - 18:00
B159	ALLOGENEIC STEM CELL TRANSPLANTATION AFTER BRIDGING WITH AZACITIDINE[CT1] - VENETOCLAX FOR MOLECULAR RELAPSE OF NPM1 MUTATED AML Martina Crysandt (Aachen, Germany)	18:00 - 18:00
B160	PHENOTYPIC AND GENOTYPIC PROFILES OF PERSISTENT GRAFT T CELLS MAY IMPACT THE POST-TRANSPLANT RELAPSES IN PATIENTS WITH AML Evgeny Klyuchnikov (Hamburg, Germany)	18:00 - 18:00
B161	DONOR LYMPHOCYTE INFUSIONS FOR RECURRENCE OF MYELOID NEOPLASMS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF HYPOMETHYLATING AGENTS AND BCL2 INHIBITORS Miriam Mozaffari Jovein (Freiburg im Breisgau, Germany)	18:00 - 18:00
B162	IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS AFFECTED BY ACUTE MYELOID LEUKEMIA: ROLE OF GVHD PROPHYLAXIS Domenico D'Agostino (Verona, Italy)	18:00 - 18:00
B163	DETAILED FLOW CYTOMETRY-BASED ASSESSMENT OF EARLY B-CELL RECONSTITUTION DYNAMICS IN ACUTE LEUKEMIA PEDIATRIC PATIENTS AFTER HSCT Dmitry Pershin (Moscow, Russian Federation (the))	18:00 - 18:00

B164	DELAYED CD4 IMMUNE RECONSTITUTION ASSOCIATION WITH ACUTE GRAFT-VERSUS-HOST DISEASE AND NON-RELAPSE MORTALITY FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Benjamin McCormick (Birmingham, United States of America (the))	18:00 - 18:00
B165	INCREASING UTILITY OF MOLECULAR MRD MONITORING BY RT-QPCR IN PAEDIATRIC AML PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT Poulami Das (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
B166	MEASUREMENT OF ACTIVE ANTI-THYMOCYTE GLOBULIN (AATG) CONCENTRATION IN ALLOGENIC BONE MARROW TRANSPLANTATION (ABMT) OF PATIENTS WITH INBORN ERRORS OF IMMUNITY (IEI) BY FLOW CYTOMETRY (FC) Tatiana Sozonova (Moscow, Russian Federation (the))	18:00 - 18:00
B167	DISEASE STATUS AT ALLOGENEIC TRANSPLANT AFFECTS THE PROGNOSTIC VALUE OF POST-TRANSPLANT MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA Chiara Camerini (Florence, Italy)	18:00 - 18:00

Printed Poster

18:00 - 19:00

R13

Lymphoma and Chronic Lymphocytic Leukaemia

B339	LONG-TERM FOLLOW-UP RESULTS OF NONREMISSION RELAPSED/REFRACTORY DLBCL WITH CAR T-CELL COCKTAIL THERAPY ALONE OR IN COMBINATION WITH ASCT Xiaoying Zhang (Wuhan, China)	18:00 - 18:00
B340	IMPROVEMENTS IN OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOMA BETWEEN 2002-2022: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY Evgenii Shumilov (Münster, Germany)	18:00 - 18:00
B341	UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK T-CELL LYMPHOMA: INTERIM ANALYSIS OF A PROSPECTIVE STUDY FengRong Wang (Beijing, China)	18:00 - 18:00
B342	INTERIM ANALYSIS OF SECOND-LINE PROLGOLIMAB THERAPY IN CLASSIC HODGKIN LYMPHOMA: A STEP TOWARD TRANSPLANT-FREE TREATMENT (PROLGO-HL) Liudmila Fedorova (Saint Petersburg, Russian Federation (the))	18:00 - 18:00
B343	CLINICAL OUTCOMES OF HTLV-1-ASSOCIATED ADULT T-CELL LEUKEMIA/LYMPHOMA (ATL) PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION (SCT): AN EBMT LWP RETROSPECTIVE ANALYSIS Patricia López-Pereira (Barcelona, Spain)	18:00 - 18:00
B344	CAR-T AND ALLOGENIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA (THRLBCL): AN EBMT LYMPHOMA WORKING PARTY STUDY Simon Renders (Heidelberg, Germany)	18:00 - 18:00
B345	LONG-TERM SURVIVAL OUTCOMES OF T-CELL LYMPHOMAS: NATIONWIDE STATISTICAL ANALYSIS OF KOREA Dong Won Baek (Daegu, Korea (the Republic of))	18:00 - 18:00
B346	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR RELAPSED AND/OR REFRACTORY CLASSICAL HODGKIN	18:00 - 18:00

	LYMPHOMA, A SINGLE CENTER 21-YEAR EXPERIENCE	
	André Antunes (Funchal, Portugal)	
B347	FRAILITY TRANSITIONS AND THEIR PROGNOSTIC SIGNIFICANCE IN CAR T-CELL THERAPY FOR NON-HODGKIN LYMPHOMA. PRELIMINARY RESULTS FROM A MULTICENTER STUDY CONDUCTED ON BEHALF OF THE GETH-TC	18:00 - 18:00
	María Queralt Salas (Barcelona, Spain)	
B348	OUTCOMES OF PATIENTS WITH HODGKIN LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN LATIN AMERICA: A MULTICENTER ANALYSIS BY GELL-LABMT	18:00 - 18:00
	Cristobal Frutos-Ortiz (Asuncion, Paraguay)	
B349	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND ABATACEPT GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS SHOWS IMPROVED OUTCOMES IN NORTH AMERICAN ADULT T-CELL LEUKEMIA/LYMPHOMA	18:00 - 18:00
	Alex Sica (New York, United States of America (the))	
B350	PATHWAY INHIBITOR-REFRACTORY HIGH-RISK CLL: WHICH CELLULAR THERAPY FIRST? A SINGLE-CENTER RETROSPECTIVE STUDY	18:00 - 18:00
	Michael Schmitt (Heidelberg, Germany)	
B351	IMPACT OF CENTER-EXPERIENCE ON TRANSPLANT OUTCOMES IN ADULT PATIENTS WITH LYMPHOMAS	18:00 - 18:00
	Mizuki Watanabe (Tokyo, Japan)	
B352	HIGH DOSE GEMCITABINE, BUSULFAN, AND THIOTEPA WITH AUTOLOGOUS STEM CELL TRANSPLANTATION SIGNIFICANTLY IMPROVE THE OUTCOME OF PRIMARY OR RELAPSED CENTRAL NERVOUS SYSTEM LYMPHOMA	18:00 - 18:00
	Jie Ji (Chengdu, China)	
B353	CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF 104 CASES OF EXTRANODAL NK/T-CELL LYMPHOMA UNDERGOING PRIMARY TREATMENT IN NOVEL AGENTS ERA	18:00 - 18:00
	Haiwen Huang (Suzhou, China)	
B354	BISPECIFIC ANTIBODIES FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: REAL-LIFE EXPERIENCE IN CART AND TARGET THERAPY ERA	18:00 - 18:00
	Gabriele Facchin (Udine, Italy)	
B355	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA: EFFECTIVE CONSOLIDATION POST-PD-1 INHIBITORS IN THIRD- AND FOURTH-LINE TREATMENT	18:00 - 18:00
	Liudmila Fedorova (Saint Petersburg, Russian Federation (the))	

Printed Poster

18:00 - 19:00

R13

Inborn Errors, Granulocyte and Osteoclast Disorders

B313	TREATMENT EFFECT OF ATIDARSAGENE AUTOTEMCEL (ARSA-CEL) IN AGE-MATCHED TREATED VS. UNTREATED SIBLING PAIRS WITH EARLY-ONSET METACHROMATIC LEUKODYSTROPHY (MLD)	18:00 - 18:00
	Valeria Calbi (Milan, Italy)	
B314	HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC NON-MALIGNANT DISEASES	18:00 - 18:00

	Tatiana Bykova (Saint-Petersburg, Russian Federation (the))	
B315	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR OSTEOPETROSIS: A SINGLE-CENTER EXPERIENCE Etai Adam (Ramat Gan, Israel)	18:00 - 18:00
B316	ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND 12-YEARS FOLLOW-UP IN TWO SIBLINGS AFFECTED BY FUCOSIDOSIS Virginia Meda Spaccamela (Zurich, Switzerland)	18:00 - 18:00
B317	PULMONARY COMPLICATIONS FOLLOWING ALLOGENIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCIES Victoria Bloch Blytt Sandstad (Copenhagen, Denmark)	18:00 - 18:00
<i>Printed Poster</i>		
	18:00 - 19:00	R13
Poster Session in Spadolini 1		
<i>Printed Poster</i>		
	18:00 - 19:00	R13
Autoimmune Diseases		
B299	BONE MARROW HEMOPOIESIS IN PRE-TREATED MULTIPLE SCLEROSIS BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION Edoardo Simonetti (Florence, Italy)	18:00 - 18:00
B300	HIGH DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS: QUALITY OF LIFE ANALYSIS Denis Fedorenko (Moscow, Russian Federation (the))	18:00 - 18:00
B301	EARLY THERAPEUTIC RESPONSE AS A PROGNOSTIC INDICATOR IN AUTOLOGOUS HSCT FOR MULTIPLE SCLEROSIS Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	18:00 - 18:00
B302	IMPACT OF BMI ON HEMATOPOIETIC STEM CELL TRANSPLANT OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	18:00 - 18:00
B303	ASSOCIATION OF SMOKING WITH DISEASE PROGRESSION IN PERSONS WITH MULTIPLE SCLEROSIS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	18:00 - 18:00
<i>Printed Poster</i>		
	18:00 - 19:00	R13
Nurses Posters - Adult		
NP001	SCHOOL OF HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS BASED ON PEER-TO-PEER EDUCATION METHOD María Soledad Jiménez Picazo (Córdoba, Spain)	18:00 - 18:00
NP002	ADVANCE CARE PLANNING IN CAR-T THERAPY PATIENTS: DEMOGRAPHIC INFLUENCES AND ENGAGEMENT RATES - A RETROSPECTIVE SINGLE-CENTRE STUDY Andres Sebastian Moya Davila (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP003	ADHERENCE TO IMMUNOSUPPRESSORS AFTER HSCT: A CROSS-	18:00 - 18:00

SECTIONAL STUDY		
	Chiara Visintini (Udine, Italy)	
NP004	IMPLEMENTATION OF USE OF PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) FOR ADMINISTRATION OF PERIPHERAL BLOOD STEM CELLS (PBSC) IN PATIENTS RECEIVING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)	18:00 - 18:00
	Yu Ting Ngo (Singapore, Singapore)	
NP005	NURSE LED PRE-HABILITATION FOR PATIENTS UNDERGOING STEM CELL TRANSPLANTATION	18:00 - 18:00
	Jo Preston (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
NP006	PATIENT FEEDBACK ON LYMPHOMA END OF TREATMENT SESSION	18:00 - 18:00
	Katherine Taylor (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP007	PROPHYLACTIC NASOGASTRIC TUBE FEEDING IN MYELOABLATIVE STEM CELL TRANSPLANT: A SERVICE EVALUATION	18:00 - 18:00
	Julie Beckerson (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP008	'BACK TO SCHOOL': CAN A STEM CELL TRANSPLANT EDUCATION PROGRAM ENHANCE PATIENT EXPERIENCES?	18:00 - 18:00
	Christina Paula Tejada (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP009	HAEMATOLOGY EMERGENCY DEPARTMENT UTILIZATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE	18:00 - 18:00
	Cristina Canaleta (Barcelona, Spain)	
NP010	NURSE LED CLINIC HAEMATOLOGY: DREAMWORK OR TEAMWORK	18:00 - 18:00
	Maaïke de Ruijter (Haarlem, Netherlands (the))	
NP011	IMPROVING HAEMATOLOGY ONCOLOGY PATIENT'S TREATMENT RECALL PRIOR TO STARTING CONDITIONING PRE-AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT AND PRIMARY SYSTEMIC ANTI-CANCER THERAPY: IMPLEMENTATION OF "TEACH-BACK METHOD"	18:00 - 18:00
	Ana Goncalves (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP012	IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY (ICAHT) FOLLOWING CD19 CAR T-CELL THERAPY IN LBCL, A SINGLE CENTER EXPERIENCE	18:00 - 18:00
	Nicole O'Leary (Melbourne, Australia)	
NP013	HOW DOES PREMATURE OVARIAN INSUFFICIENCY AFFECT QUALITY OF LIFE IN WOMEN THAT HAVE RECEIVED A HAEMATOPOIETIC STEM CELL TRANSPLANT? A LITERATURE REVIEW	18:00 - 18:00
	Francesca Toselli (Oxford, United Kingdom of Great Britain and Northern Ireland (the))	
NP014	HOME SELF-ADMINISTRATION IN PATIENTS RECEIVING CELL THERAPY AND INTENSIVE CHEMOTHERAPY. A UNICENTRIC EXPERIENCE	18:00 - 18:00
	Marta Torres Torres (Barcelona, Spain)	
NP015	FEASIBILITY ASSESSMENT OF IMPLEMENTING AN EARLY WARNING SYSTEM FOR VENO-OCCLUSIVE DISEASE IN ALLOGENIC STEM CELL TRANSPLANTATION: A PILOT STUDY	18:00 - 18:00
	Angela Rodriguez-Rodriguez (Salamanca, Spain)	
NP016	AN OCCUPATIONAL SAFETY PROJECT FOR CANCER CARE NURSES, USING SURFACE WIPE SAMPLING FOR HAZARDOUS DRUGS IN A HAEMATOLOGY AND ONCOLOGY SETTING	18:00 - 18:00

	Audrey O'Halloran (Dublin, Ireland)	
NP017	ADDRESSING BARRIERS IN ACCESSING SUITABLE STEM CELL DONORS: HAEMATOLOGY NURSE'S PERSPECTIVE ON SOUTH ASIAN DONOR AWARENESS IN THE UK	18:00 - 18:00
	Sinju Thomas (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP019	OPTIMIZING STEM CELL HARVESTING FOR MYELOMA PATIENTS: REDUCING NHS COSTS AND ENHANCING PATIENT EXPERIENCE THROUGH SINGLE TRANSPLANT STRATEGY	18:00 - 18:00
	Annabelle Annis (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	
NP020	THE ROLE AND IMPACT OF NURSE SPECIALISTS IN THE ASSESSMENT AND MANAGEMENT OF GRAFT VERSUS HOST DISEASE AT THE GVHD CLINIC	18:00 - 18:00
	Mohsen Alzahrani (Riyadh, Saudi Arabia)	
NP021	IMPROVING THE ADMINISTRATION OF ALEMTUZUMAB FOR THE CONDITIONING OF ALLOGENEIC TRANSPLANT PATIENTS	18:00 - 18:00
	Sara Rush (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
NP022	COMPARISON OF HOSPITALIZATIONS IN PATIENTS UNDERGOING REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT BASED ON GVHD PROPHYLAXIS (PTCY VS METHOTREXATE) IN HOSPITAL BASED OUTPATIENT PRACTICE	18:00 - 18:00
	Kendall Solinger (Rochester, United States of America (the))	
NP023	BONE MARROW TRANSPLANTATION IN COVID-19 PATIENTS: A QUALITATIVE STUDY ON THE HEALTHCARE PROFESSIONALS' EXPERIENCE	18:00 - 18:00
	Nicole Cassinari (Piacenza, Italy)	
NP024	DELAYED ADMISSION MODEL IN THE WARD EVALUATING THE SAFETY AND EFFICACY OF OUTPATIENT LYMPHODEPLETING CHEMOTHERAPY: AN ANALYSIS IN PATIENTS UNDERGOING CAR-T THERAPY	18:00 - 18:00
	Sabrina Castiglione (Firenze, Italy)	
NP025	'WHERE NOW': A HEALTH AND WELLBEING COURSE SUPPORTING THE NEEDS OF SURVIVORS POST ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Janet O'Doherty (London, United Kingdom of Great Britain and Northern Ireland (the))	
NP026	NURSING CARE IN CAR-T THERAPY FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	18:00 - 18:00
	Laura Tierno Marti (Barcelona, Spain)	
NP027	MOBILE HEALTH TECHNOLOGIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SCOPING REVIEW	18:00 - 18:00
	Zhengwen Pan (Hangzhou, China)	
NP028	A QUALITY IMPROVEMENT PROJECT TO REDUCE 'TEMPERATURE SPIKE TO NEEDLE TIME' FOR FIRST DOSE ANTIBIOTICS TO WITHIN 60 MINUTES ON AN INPATIENT HAEMATOLOGY/AUTOLOGOUS TRANSPLANT UNIT	18:00 - 18:00
	Allison Ponsford (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	
NP029	THE TRANSPLANT COORDINATOR: A NEW APPROACH OF ORGANIZATION AND MANAGEMENT IN HSCT AND CELLULAR THERAPIES	18:00 - 18:00
	Roberta Lepori (Florence, Italy)	
NP030	EMBEDDING PASTORAL SUPPORT NURSING IN CLINICAL HAEMATOLOGY: OUR EXPERIENCE	18:00 - 18:00
	Manelyn Castaneda (London, United Kingdom of Great Britain and Northern Ireland (the))	

NP031	NURSE LED IMMUNE EFFECTOR CELL ENCEPHALOPATHY (ICE) SCORING: ADAPTING TO MEET THE INDIVIDUAL NEEDS OF PATIENTS RECEIVING CAR T-CELL THERAPY Emily John (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP032	IMPLEMENTATION OF GROUP AND SAVE & BLOOD TRANSFUSION PRODUCTS ORDERED NOTEBOOK TO REDUCE THE WASTAGE OF BLOOD COMPONENTS IN HAEMATOLOGY AND TRANSPLANT DAY UNIT (HTDU) Judith Lee (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP033	EFFECT OF CELLULAR THERAPY ON PATIENTS' QUALITY OF LIFE, A COHORT STUDY AT ABU DHABI STEM CELL CENTER, UAE CENTER OF EXCELLENCE FOR HSCT Dina El Mouzain (Abu Dhabi, United Arab Emirates (the))	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		R13
Nurses Posters - Paediatric		
NP034	UTILIZING DIGITAL THERAPEUTIC EDUCATION FOR ADOLESCENTS AND YOUNG ADULTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SCOPING REVIEW OF EVIDENCE AND STRATEGIES Simona Calza (Genoa, Italy)	18:00 - 18:00
NP035	SHIFTING PARADIGMS: IMPLEMENTATION OF THE FIRST PAEDIATRIC BMT & CELLULAR THERAPIES NURSE PRACTITIONER ROLE IN AUSTRALIA Maddie Gilsenan (Melbourne, Australia)	18:00 - 18:00
NP036	IMPLEMENTATION OF PATIENT SAFETY TOOLS AS A QUALITY STRATEGY IN A PEDIATRIC HEMATOPOIETIC STEM CELL, CELL THERAPY AND PEDIATRIC ONCOHEMATOLOGY UNIT Manuel Adrián Julbez Zamorano (Madrid, Spain)	18:00 - 18:00
NP037	VIRTUAL REALITY AS A NON-PHARMACOLOGICAL INTERVENTION IN PEDIATRIC ONCOLOGY: TWO SCOPING REVIEWS ON CLINICAL OUTCOMES, CAREGIVER EXPERIENCES, AND HEALTHCARE PROFESSIONAL PERSPECTIVES Simona Calza (Genoa, Italy)	18:00 - 18:00
NP038	THE PSYCHOLOGICAL IMPACT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION ON CHILDREN AND ADOLESCENTS: A PROSPECTIVE SINGLE-ARM STUDY FROM A PEDIATRIC BMT UNIT IN INDIA Jerlin Robin (Chennai, India)	18:00 - 18:00
NP039	ESCAPING THE FEAR OF SIMULATION - UTILISING ESCAPE ROOMS IN BMT NURSING EDUCATION AND TEAM BUILDING Johanna Lee (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP040	DRINKING WATER FOR ADULT AND PAEDIATRIC STEM CELL TRANSPLANT PATIENTS IN THE UK - THE NEED FOR GUIDANCE Rachel Protheroe (Bristol, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP041	DEVELOPMENT OF A NURSE-LED PAEDIATRIC PHOTOBIO-MODULATION SERVICE Eleanor Leaney (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00

Printed Poster
18:00 - 19:00

R13

Nurses Posters - Research

NP042	RECOVERY IN A HOMELIKE ENVIRONMENT-PATIENTS' EXPERIENCES WITH HOSPITAL AT HOME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A QUALITATIVE STUDY Sigrid Cecilie Tinglum Skøyeneie (Oslo, Norway)	18:00 - 18:00
NP043	EFFICACY OF A COMPLEX LYSOSTAPHIN GARGLE IN THE PREVENTION OF ORAL MUCOSITIS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY Xiaoyu Zhou (Hangzhou, China)	18:00 - 18:00
NP044	CONSTRUCTION OF QUALITY EVALUATION SYSTEM FOR PREVENTION AND NURSING OF DRUG RESISTANT BACTERIAL INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS Erjie Jiang (Tianjin, China)	18:00 - 18:00
NP045	STRESS PERCEIVED LEVELS BETWEEN PHYSICIANS AND NURSES IN COMMUNICATING BAD NEWS IN STEM CELL TRANSPLANTATION SETTINGS: A NATIONWIDE SURVEY BY THE GITMO NG Stefano Botti (Reggio Emilia, Italy)	18:00 - 18:00
NP046	ENHANCING OUTCOMES AFTER CAR-T THERAPY: A PATIENT SUPPORT INITIATIVE Luminita Keating (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
NP047	BREAKING BARRIERS: A SCOPING REVIEW OF FACTORS INFLUENCING WORK PARTICIPATION AFTER HEMATOPOIETIC CELL TRANSPLANTATION Karine Bilodeau (Montreal, Canada)	18:00 - 18:00
NP048	EXPERIENCES OF PATIENTS DEALING WITH CRS AND/OR ICANS DURING HOSPITALIZATION FOLLOWING CAR-T THERAPY Amaia Urcelay Ganzabal (Barcelona, Spain)	18:00 - 18:00
<i>Printed Poster</i> 18:00 - 19:00		R13
Graft-versus-host Disease - Preclinical and Animal Models		
B019	TISSUE-ADAPTED TREGS HARNESS INFLAMMATORY SIGNALS TO PROMOTE INTESTINAL REPAIR FROM THERAPY-RELATED INJURY Sascha Götttert (Regensburg, Germany)	18:00 - 18:00
B020	GUT MICROBIOME ALTERATIONS AND FUNCTIONAL PATHWAYS ASSOCIATED WITH SEVERE AGVHD IN PEDIATRIC ALLO-HSCT RECIPIENTS: THE ROLE OF RUMINOCOCCUS GNAVUS AND LACTOBACILLUS RHAMNOSUS Francesco Baccelli (Bologna, Italy)	18:00 - 18:00
B021	MAST CELL DEFICIENCY IS ASSOCIATED WITH POOR GLUCOCORTICOID RESPONSE IN ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE Lukas Gaksch (Graz, Austria)	18:00 - 18:00
B022	TREGS DERIVED EXTRACELLULAR VESICLES ARE ASSOCIATED WITH A STRONG IMMUNOSUPPRESSIVE ACTIVITY AND PREVENT GVHD IN MURINE MODELS Francesco Guardalupi (Chieti, Italy)	18:00 - 18:00
B023	POST-TRANSPLANT CYCLOPHOSPHAMIDE FACILITATES PRESERVATION OF TISSUE-RESIDENT IL-22-PRODUCING LYMPHOCYTES AND INTESTINAL STEM CELLS	18:00 - 18:00

	Guillermo Ortí (New York City, United States of America (the))	
B024	NON-RADIOACTIVE METABOLIC IMAGING OF GRAFT-VERSUS HOST DISEASE BY DEUTERIUM MAGNETIC RESONANCE SPECTROSCOPY Nataliya Buxbaum (Buffalo, United States of America (the))	18:00 - 18:00
B025	TIMED INHIBITION OF THE STING PATHWAY IMPROVES TISSUE REGENERATION AND PREVENTS GVHD FOLLOWING ALLO-HSCT Chiara Suriano (Regensburg, Germany)	18:00 - 18:00
B027	DYNAMIC CHANGES OF EXTRACELLULAR VESICLES ORIGINATED FROM PLATELETS, ENDOTHELIAL CELLS AND LEUKOCYTES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CORRELATION WITH ACUTE GVHD Federica Ferrando (Torino, Italy)	18:00 - 18:00
B028	MICROBIOME CHIMERISM - A NEW FRONTIER IN GVHD PATHOGENESIS? Anna Li (Adelaide, Australia)	18:00 - 18:00
B029	SERUM EXTRACELLULAR VESICLES AND MIRNA CARGO AS PREDICTIVE MARKERS FOR ACUTE-GRAFT-VS.-HOST DISEASE Federica Ferrando (Torino, Italy)	18:00 - 18:00
<i>Printed Poster</i> 18:00 - 19:00		R13
Stem Cell Donor		
B002	PEPTIDE BINDING MOTIF MISMATCHES AND OUTCOME IN EX-VIVO T-CELL DEPLETED HLA-HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC PATIENTS AFFECTED BY ACUTE LEUKEMIA Pietro Merli (Rome, Italy)	18:00 - 18:00
B003	HAPLOIDENTICAL VS MISMATCHED UNRELATED DONOR HCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE PROPHYLAXIS: DONOR AGE MATTERS MORE THAN DONOR TYPE Yosra Aljawai (Houston, United States of America (the))	18:00 - 18:00
B005	HAPLOIDENTICAL TRANSPLANT USING SELECTIVE EX-VIVO TCR-AB DEPLETED AND UPFRONT MEMORY T-CELL ADD-BACK YIELDS COMPARABLE OUTCOME AS MATCHED RELATED AND UNRELATED DONOR TRANSPLANT FOR ELDERLY ADULTS Ian Wu (Singapore, Singapore)	18:00 - 18:00
B006	DROP-OUTS OF STEM CELL DONATION - AN ANALYSIS OF THE AUSTRIAN STEM CELL REGISTER Sophia Oesterreicher (Vienna, Austria)	18:00 - 18:00
B007	ALTERNATIVE DONOR SELECTION FOR PTCY HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT Jaime Sanz (Valencia, Spain)	18:00 - 18:00
B008	CHANCES OF FINDING MATCHED RELATED DONORS AND UNDERGOING TRANSPLANT FOR SAUDI PATIENTS WITH SICKLE CELL DISEASE IN NEED OF HEMATOPOIETIC STEM CELL TRANSPLANTATION Mohsen Alzahrani (Riyadh, Saudi Arabia)	18:00 - 18:00
B009	OUTCOMES OF SECOND-DEGREE RELATIVE HAPLOIDENTICAL DONORS FOR ALLOGENEIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR HEMATOLOGICAL MALIGNANCIES	18:00 - 18:00

	Shukaib Arslan (Duarte, United States of America (the))	
B010	COMPARISON OF THE RESULTS OF HSCT BETWEEN UNRELATED CORD BLOOD DONORS AND HAPLOIDENTICAL DONORS FOR THE TREATMENT OF APLASTIC ANEMIA IN PEDIATRIC PATIENTS Zhang Jianping (Langfang, China)	18:00 - 18:00
B012	BUILDING RECOMMENDATIONS FOR RELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A DELPHI STUDY BY THE LATIN AMERICAN BONE MARROW TRANSPLANTATION GROUP (LABMT) Cristobal Frutos-Ortiz (Asuncion, Paraguay)	18:00 - 18:00
B013	DISTRIBUTION OF GRAFT TYPES AND TIME TO HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA (AML) IN DIFFERENT ETHNIC GROUPS IN ISRAEL Shlomo Elias (Jerusalem, Israel)	18:00 - 18:00
B014	HEALING BONDS: THE COMPLEX EXPERIENCES OF PEDIATRIC SIBLING STEM CELL DONORS Victoria Bordon (Ghent, Belgium)	18:00 - 18:00
B015	SAFETY OF HEMATOPOIETIC STEM CELL DONATION FROM YOUNG RELATED DONORS DUE TO THE LOWERED ADULT AGE IN JAPAN Tsuneaki Hirakawa (Tokyo, Japan)	18:00 - 18:00
B016	THE EFFECT OF ABO INCOMPATIBILITY BETWEEN DONOR AND RECIPIENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, SINGLE CENTER STUDY Mohammed Essa (Riyadh, Saudi Arabia)	18:00 - 18:00
B017	DOES ONE HLA MISMATCH INFLUENCE TRANSPLANT SUCCESS? A COMPARATIVE ANALYSIS ON GVHD AND MORTALITY Mehmet Sinan Dal (Ankara, Turkey)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		R13
Graft-versus-host Disease - Clinical		
B030	EFFICACY AND SAFETY OF BELUMOSUDIL FOR TREATMENT OF CGVHD: MULTICENTER RETROSPECTIVE ANALYSIS OF THE FRENCH COHORT OF THE COMPASSIONATE USE PROGRAM Michael Loschi (Nice, France)	18:00 - 18:00
B031	CLINICALLY MEANINGFUL IMPROVEMENT OF MODIFIED LEE SYMPTOM SCALE IN PATIENTS TREATED WITH BELUMOSUDIL FOR STEROID-REFRACTORY CHRONIC GVHD: EVIDENCE FROM REAL-WORLD OUTCOMES Dennis Dong Hwan Kim (Toronto, Canada)	18:00 - 18:00
B032	SPANISH REAL WORLD EXPERIENCE (GETH-TC) OF BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER 2 OR MORE PRIOR LINES OF THERAPY Mi Kwon (., Spain)	18:00 - 18:00
B033	MESENCHYMAL STROMAL CELLS AS A SAFE AND EFFECTIVE TREATMENT OPTION FOR HEAVILY PRE-TREATED AGVHD PATIENTS IN A REAL-WORLD SETTING Robert Zeiser (Freiburg, Germany)	18:00 - 18:00
B034	IMPACT OF BELUMOSUDIL TREATMENT IN ADVANCED CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): INSIGHTS INTO RESPONSE-BASED T- AND B-CELL SUBPOPULATION DYNAMICS	18:00 - 18:00

	Doris Ponce (New York, United States of America (the))	
B035	CORRELATIONS OF CLINICIAN-REPORTED RESPONSES WITH OTHER RESPONSE MEASURES IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE: AN ANALYSIS FROM THE AGAVE-201 TRIAL Annie Im (Pittsburgh, United States of America (the))	18:00 - 18:00
B036	IMPACT OF TGF-FSMP AND MICROBIOME IN OBESE ALLO-HSCT PATIENTS: POSSIBLE REDUCTION OF GASTROINTESTINAL ACUTE GVHD RISK AND IMPROVEMENT OF OS Enrico Morello (Brescia, Italy)	18:00 - 18:00
B037	ASSESSING PRACTICE PATTERNS AND FUTURE PARADIGMS IN GRAFT VERSUS HOST DISEASE PROPHYLAXIS Brittany Knick Ragon (Charlotte, United States of America (the))	18:00 - 18:00
B038	DEVELOPMENT OF A VALIDATED CLINICAL RISK SCORE TO PREDICT ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A CIBMTR ANALYSIS Wael Saber (Milwaukee, United States of America (the))	18:00 - 18:00
B039	THE EFFECTS OF PRIOR LINES OF THERAPY ON CLINICAL OUTCOMES FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE RECEIVING AXATILIMAB: A POST HOC ANALYSIS OF AGAVE-201 John Galvin (Wilmington, United States of America (the))	18:00 - 18:00
B040	DYNAMICS OF OVERALL AND ORGAN-SPECIFIC RESPONSES TO AXATILIMAB IN CHRONIC GRAFT-VERSUS-HOST DISEASE: ANALYSIS FROM THE AGAVE-201 STUDY Amandeep Salhotra (Duarte, United States of America (the))	18:00 - 18:00
B041	A PROSPECTIVE OBSERVATIONAL STUDY USING BUDESONIDE, ADDED TO PTCY-BASED GVHD PROPHYLAXIS, FOR PREVENTION OF ACUTE GI GVHD AFTER ALLOGENEIC TRANSPLANTATION AND COMPARISON WITH CIBMTR CONTROL Stefan Ciurea (Orange, United States of America (the))	18:00 - 18:00
B042	POST-TRANSPLANT TELOMERE LENGTH IS ASSOCIATED WITH CHRONIC GVHD IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Kirk Schultz (Vancouver, Canada)	18:00 - 18:00
B043	HLA-DRB1 ALLELE MISMATCH IS ASSOCIATED WITH ENGRAFTMENT AND ACUTE GVHD AFTER HLA-HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A NATIONWIDE RETROSPECTIVE ANALYSIS IN JAPAN Hiroyuki Muranushi (Kurashiki, Japan)	18:00 - 18:00
B044	PRECISION DOSING OF PREEMPTIVE ADD-ON PROPHYLACTIC MEDICATION AGAINST SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE: A PROSPECTIVE INTERVENTIONAL TRIAL OF A MACHINE LEARNING MODEL Erlic Jiang (Tianjin, China)	18:00 - 18:00
B045	THIRD-PARTY FECAL MICROBIOTA TRANSPLANTATION AS ADDITIONAL TREATMENT TO STANDARD THERAPY EARLY IN THE COURSE OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST-DISEASE Olga Pankratova (Helsinki, Finland)	18:00 - 18:00
B046	RESULTS OF HOVON 112 TRIAL RANDOMIZING MSC VS PLACEBO IN SEVERE ACUTE GVHD AS FIRST-LINE TREATMENT	18:00 - 18:00

	L.E. van der Wagen (Utrecht, Netherlands (the))	
B047	PRE-TRANSPLANT HLA AND TISSUE RESIDENT MEMORY NK/T EXTRACELLULAR VESICLES ASSOCIATE WITH GVHD IN PEDIATRIC STEM CELL TRANSPLANTATION Francesca Gottardi (Bologna, Italy)	18:00 - 18:00
B048	40 MG/KG/DAY CYCLOPHOSPHAMIDE: A STEP FORWARD IN REDUCING TOXICITY IN GVHD PROPHYLAXIS FOR ALLO-HCT FROM HLA-MATCHED DONORS Filipe R. Pinto (Porto, Portugal)	18:00 - 18:00
B049	POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT, AND SHORT COURSE TACROLIMUS AS GVHD PROPHYLAXIS IN MATCHED, MISMATCHED UNRELATED DONOR AND HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT - MAYO CLINIC EXPERIENCE Hassan Alkhateeb (Rochester, United States of America (the))	18:00 - 18:00
B050	SHORT-TERM SUBSTITUTION OF CALCINEURIN INHIBITORS (CNIS) WITH RECOMBINANT HUMANIZED ANTI-CD25 MONOCLONAL ANTIBODY (DACLIZUMAB) AS AGVHD PROPHYLAXIS IN CNIS INTOLERANT PATIENTS AFTER ALLO-HSCT Shan Shao (Shanghai, China)	18:00 - 18:00
B051	ASSESSING THE CLINICAL AND ECONOMIC IMPACT OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ENGLAND: A RETROSPECTIVE COHORT ANALYSIS Francesca Kinsella (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
B052	LETMOVIR PROPHYLAXIS MAY INCREASE THE RISK OF GVHD AND DECREASE GRFS IN PATIENTS AFTER EX-VIVO AB⁺T-CELL DEPLETED HAPLOHCT Dominik Turkiewicz (Lund, Sweden)	18:00 - 18:00
B053	DESLOSINE AS A NOVEL BIOMARKER FOR PULMONARY AND CUTANEOUS MANIFESTATIONS IN CHRONIC GRAFT-VERSUS-HOST DISEASE Noa G. Holtzman (Miami, United States of America (the))	18:00 - 18:00
B054	CLUSTER ANALYSIS IDENTIFIES THREE DISTINCT BIOLOGIC SUBTYPES OF CHRONIC GVHD IN A LARGE PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION COHORT Kirk Schultz (Vancouver, Canada)	18:00 - 18:00
B055	THE MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM (MAGIC) COMPOSITE RESPONSE: A NOVEL ENDPOINT INTEGRATING CLINICAL AND BIOMARKER PARAMETERS FOR ACUTE GVHD James Ferrara (United States of America (the))	18:00 - 18:00
B056	REAL-WORLD OUTCOMES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN FOR GVHD PROPHYLAXIS Cornelia Baden (Kiel, Germany)	18:00 - 18:00
B057	PHASE 1 STUDY OF PACRITINIB, A CSF1R/JAK2/IRAK1 INHIBITOR, FOR REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: A PRELIMINARY ANALYSIS Noa G. Holtzman (Miami, United States of America (the))	18:00 - 18:00
B058	BARICITINIB IN THE GVHD PREVENTION REGIMEN WITH REDUCED DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT AND VEDOLIZUMAB IN CHILDREN WITH ACUTE LEUKEMIA: RESULTS OF A PROSPECTIVE STUDY	18:00 - 18:00

	Margarita Perminova (Moscow, Russian Federation (the))	
B059	NOVEL QUADRUPLET GVHD PROPHYLAXIS WITH RABBIT ATG, PTCY, TACROLIMUS, AND MMF IN RIC ALLOGENEIC HSCT: A REAL WORLD DATA FROM A SINGLE CENTER IN INDIA Ganesh Jaishetwar (Hyderabad, India)	18:00 - 18:00
B061	NOVEL GVHD PROPHYLAXIS COMBINING REDUCED DOSE CYTOXAN AND ABATACEPT RESULTS IN LOW RATES OF ACUTE AND CHRONIC GVHD AND LOW TRANSPLANT RELATED TOXICITY Yuliya Shestovska (Philadelphia, United States of America (the))	18:00 - 18:00
B062	BELUMOSUDIL IS EFFICACIOUS FOR THE MANAGEMENT OF HEAVILY PRETREATED AND PROLONGED CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE MULTI-CENTER STUDY BY THE ISRAEL BONE MARROW TRANSPLANTATION ASSOCIATION Tsila Zuckerman (Haifa, Israel)	18:00 - 18:00
B064	ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) AS A RISK FACTOR OF RUXOLITINIB FAILURE FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE TREATMENT Nihar Desai (Toronto, Canada)	18:00 - 18:00
B065	THE EASIX SCORE IN PEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE COHORT ANALYSIS Francesco Baccelli (Bologna, Italy)	18:00 - 18:00
B066	VALIDATION OF MANHATTAN RISK SCORE TO PREDICT AGVHD SEVERITY IN PTCY-BASED PROPHYLAXIS: A STUDY ON 459 CONSECUTIVE HSCT PATIENTS Alessandro Criscimanna (Milan, Italy)	18:00 - 18:00
B067	DIFFERENT MONOCYTE SUBPOPULATIONS IN ALLOGENEIC STEM TRANSPLANTATION RECIPIENTS WITH AND WITHOUT GVHD: IMMUNOPHENOTYPES AND THE EXPRESSION OF HLA-DR AND CD300E Igor Age Kos (Homburg, Germany)	18:00 - 18:00
B068	EFFICACY AND SAFETY OF RUXOLITINIB IN CHILDREN WITH ACUTE AND CHRONIC STEROID-REFRACTORY OR STEROID-DEPENDENT GVHD Maria Gabelli (Padova, Italy)	18:00 - 18:00
B070	GRADE YOUR GVHD YOURSELF - DEVELOPMENT OF AN APP TO DOCUMENT CHRONIC GRAFT-VERSUS-HOST DISEASE BY PATIENTS AND CAREGIVERS Alexander Denk (Regensburg, Germany)	18:00 - 18:00
B073	A SINGLE-CENTER PROSPECTIVE STUDY OF SOLUBLE CHRONIC GRAFT-VERSUS-HOST DISEASE BIOMARKERS EVALUATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS Giorgos Karavalakis (Thessaloniki, Greece)	18:00 - 18:00
B074	REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE WHO RECEIVED 3 OR MORE LINES OF TREATMENT IN THE UNITED STATES Jingbo Yu (Wilmington, United States of America (the))	18:00 - 18:00
B075	CALCINEURIN INHIBITOR ALONE OR IN COMBINATION WITH METHOTREXATE FOR GVHD PROPHYLAXIS IN ACQUIRED APLASTIC ANEMIA:A REPORT ON BEHALF OF PAKISTAN BLOOD AND MARROW TRANSPLANT GROUP Natasha Ali (Karachi, Pakistan)	18:00 - 18:00

B076	ROLE OF PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES IN GRAFT-VERSUS-HOST DISEASE AFTER CORD BLOOD TRANSPLANTATION - A RETROSPECTIVE STUDY Harish Selvaraj (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
B079	THE IMPACT OF RUXOLITINIB ON STEROID-REFRACTORY CGVHD: ASSESSING CUTANEOUS RESPONSES AND LONG-TERM PROGNOSTIC FACTORS ACROSS PHENOTYPES Maria Helena Parrinello (Milano, Italy)	18:00 - 18:00
B080	COMPARATIVE SINGLE CENTRE OBSERVATIONAL ANALYSIS OF GVHD PROPHYLAXIS WITH GRAFALON (RATLG) AND THYMOGLOBULIN (RATG) IN THALASSEMIA MAJOR PATIENTS UNDERGOING STEM CELL TRANSPLANTATION Santanu Sen (Mumbai, India)	18:00 - 18:00
B081	AGVHDTRACKR AND CGVHDTRACKR: SHINY APPLICATIONS FOR GRAFT VERSUS HOST DISEASE MANAGEMENT AND CLINICAL DATA COLLECTION Silvia Nucera (Monza, Italy)	18:00 - 18:00
B082	PHENOTYPIC CHANGES IN SYSTEMIC IMMUNE CELLS IN RESPONSE TO AXATILIMAB IN HEALTHY MALE JAPANESE VOLUNTEERS Michael Pratta (Wilmington, United States of America (the))	18:00 - 18:00
B084	TRANSPORTABILITY TO THE EU POPULATION OF EFFICACY OF BELUMOSUDIL AS COMPARED WITH BEST AVAILABLE THERAPY FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE Daniel Wolff (Regensburg, Germany)	18:00 - 18:00
B085	ANTI-CD25 MONOCLONAL ANTIBODY AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA Jian Zhou (Zhengzhou, China)	18:00 - 18:00
B086	EXTRACORPOREAL PHOTOPHERESIS TREATMENT IN PEDIATRIC PATIENTS WITH GVHD: INSIGHTS FROM A CASE SERIES Marina Rierola (Barcelona, Spain)	18:00 - 18:00
B087	SAFETY AND EFFICACY OF REDUCED-DOSE POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN HLA-IDENTICAL RELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: A COHORT STUDY Alejandro Luna de Abia (Madrid, Spain)	18:00 - 18:00
B088	GUT MICROBIOTA AND IMMUNOSUPPRESSION DOSING AFTER ALLO-HSCT Mikhail Uss (Minsk, Belarus)	18:00 - 18:00
B089	EFFICACY OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM AN UNRELATED MISMATCHED DONOR Lea Jukić (Zagreb, Croatia)	18:00 - 18:00
B090	EFFICACY AND SAFETY OF REDUCED-DOSES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED (10/10) PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Irene García-Cadenas (Barcelona, Spain)	18:00 - 18:00
B091	THE IMPACT OF MDSCS IN PBSC ON THE OCCURRENCE OF PATIENT GVHD Man Chen (Langfang, China)	18:00 - 18:00

B093	LIVER BIOPSY IN THE DIFFERENTIAL DIAGNOSIS OF LIVER TOXICITY AFTER TRANSPLANTATION: A CLINICO-PATHOLOGICAL STUDY OF 43 CONSECUTIVE PATIENTS Maria Teresa Lupo-Stanghellini (Milano, Italy)	18:00 - 18:00
B094	DOES THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION AFFECT UNRELATED DONOR ALLO-HCT OUTCOMES? A RETROSPECTIVE ANALYSIS ON BEHALF OF THE POLISH ADULT LEUKEMIA GROUP Ugo Giordano (Wrocław, Poland)	18:00 - 18:00
B096	IS IT POSSIBLE TO REDUCE THE DOSE OF CYPT IN <u>HLA-IDENTICAL</u> DONOR HSCT IN A SAFE WAY? RETROSPECTIVE UNICENTRE EXPERIENCE Marta Luque Garrido (Málaga, Spain)	18:00 - 18:00
B097	REAL-WORLD PATIENT CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE RECEIVING BELUMOSUDIL IN THE UNITED STATES Jingbo Yu (Wilmington, United States of America (the))	18:00 - 18:00
B098	POST-TRANSPLANT CYCLOPHOSPHAMIDE AND CARDIOTOXICITY: INSIGHTS FROM A RETROSPECTIVE STUDY IN ALLOGENEIC HSCT PATIENTS Claudia Sossa-Melo (Floridablanca, Colombia)	18:00 - 18:00
B099	TREG SELECTION FROM G-CSF STIMULATED DONORS IMPROVES OUTCOMES OF IMMUNE-SUPPRESSION FREE HLA-HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH T CELL ADOPTIVE IMMUNOTHERAPY Rebecca Sembenico (Perugia, Italy)	18:00 - 18:00
B100	SUBSTANTIAL REDUCTION IN THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE WITH THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN MATCHED UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: A COMPARATIVE CASE-CONTROL STUDY Sotirios Bristogiannis (Athens, Greece)	18:00 - 18:00
B101	GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE STUDY Omur Gokmen Sevindik (Istanbul, Turkey)	18:00 - 18:00
B102	ASSESSMENT OF GASTROINTESTINAL GRAFT VERSUS HOST DISEASE USING ¹⁸F-FDG PET-CT AND SELECTED BIOMARKERS Joanna Kujawska (Poznan, Poland)	18:00 - 18:00
B103	IMPACT OF GRAFT CD3 AND CD34 CELL DOSES ON ACUTE GVHD RISK AND OUTCOMES: INSIGHTS FROM A SINGLE-CENTRE STUDY Alina Daniela Tanase (Bucharest, Romania)	18:00 - 18:00
B104	SINGLE CENTRE OBSERVATIONAL ANALYSIS OF GVHD PROPHYLAXIS WITH ANTI HUMAN T LYMPHOCYTE IMMUNOGLOBULIN (RATLG) IN THALASSEMIA MAJOR PATIENTS UNDERGOING STEM CELL TRANSPLANTATION Santanu Sen (Mumbai, India)	18:00 - 18:00
B105	EFFICACY AND SAFETY OF RUXOLITINIB FOR THERAPY OF CHRONIC STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN Nikita Levkovsky (Saint Petersburg, Russian Federation (the))	18:00 - 18:00

Printed Poster

18:00 - 19:00

R13

Myeloproliferative Neoplasm

- B304 **PREDICTORS OF SURVIVAL OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELOYDYSPLASTIC SYNDROME** 18:00 - 18:00
Nelli Bejanyan (Tampa, United States of America (the))
- B305 **CLINICAL IMPACT OF SPLANCHNIC VEIN THROMBOSIS IN PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 18:00 - 18:00
Maria Chiara Finazzi (Bergamo, Italy)
- B307 **ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH MYELOFIBROSIS: THE DONOR TYPE EFFECT ON SURVIVAL** 18:00 - 18:00
Patrizia Chiusolo (Roma, Italy)
- B308 **DISRUPTION OF MECHANOTRANSDUCTION PATHWAY EFFICIENTLY INHIBITS FIBROTIC RESPONSE OF MESENCHYMAL STROMAL CELLS DERIVED FROM MYELOFIBROSIS PATIENTS** 18:00 - 18:00
Weronika Lebowa (Kraków, Poland)
- B309 **OVERALL SURVIVAL AND DURATION OF TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR BEST AVAILABLE THERAPY IN A REAL-WORLD SETTING** 18:00 - 18:00
Andreas Reiter (Mannheim, Germany)
- B310 **ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS: A COMPARISON BETWEEN DONOR TYPES** 18:00 - 18:00
Ana Lisa Basquiera (Córdoba, Argentina)
- B311 **SPLENIC MANAGEMENT AND ITS IMPACT ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT OUTCOMES IN MYELOFIBROSIS** 18:00 - 18:00
Urmimala Bhattacharjee (Bristol, United Kingdom of Great Britain and Northern Ireland (the))
- B312 **POST-TRANSPLANT SPLENECTOMY WAS A POTENTIAL EFFECTIVE OPTION TO TREATING POOR GRAFT FUNCTION IN PATIENTS WITH MYELOFIBROSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION** 18:00 - 18:00
Yi Liao (Beijing, China)

Printed Poster

18:00 - 19:00

R13

Aplastic Anaemia

- B285 **COMPARISON OF OUTCOMES OF IMMUNOSUPPRESSIVE THERAPY WITH RABBIT VS. HORSE ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE A IN PATIENTS WITH REFRACTORY CYTOPENIA OF CHILDHOOD** 18:00 - 18:00
Ayami Yoshimi (Freiburg,, Germany)
- B286 **THE DOSE OPTIMIZATION OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE [PTCY] IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR APLASTIC ANEMIA PATIENTS** 18:00 - 18:00
Na Wang (Wuhan, China)
- B287 **MIXED T-CELL CHIMERISM IN SAA HSCT RECIPIENTS IS LINKED TO VIRUS INFECTION, DOES NOT PREDICT GRAFT FAILURE, AND REQUIRES NO PROLONGED IMMUNOSUPPRESSION OR DLI** 18:00 - 18:00
Kainat Memon (Manchester, United Kingdom of Great Britain and Northern Ireland (the))

B288	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR VEXAS SYNDROME: INTERIM RESULTS FROM A PHASE II STUDY Emma Groarke (Bethesda, United States of America (the))	18:00 - 18:00
B289	DANICOPAN AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: LONG-TERM PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 ALPHA TRIAL Hubert Schrezenmeier (Ulm, Germany)	18:00 - 18:00
B290	IN VIVO EFFECTS AND PHARMACODYNAMICS OF ATGAM IN ACQUIRED APLASTIC ANEMIA PATIENTS Emma Pool (Leiden, Netherlands (the))	18:00 - 18:00
B291	ASSESSMENT OF CHARACTERISTICS AND TREATMENT PATTERNS OF ADULT PATIENTS WITH ACQUIRED APLASTIC ANAEMIA IN TURKIYE (PLANE-TR STUDY) Mehmet Sinan Dal (Ankara, Turkey)	18:00 - 18:00
B292	LOW-DOSE TREOSULFAN-BASED CONDITIONING WITH PTCY GVHD PROPHYLAXIS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SEVERE APLASTIC ANEMIA Anna Lifshits (Moscow, Russian Federation (the))	18:00 - 18:00
B293	OUTCOME OF ACQUIRED APLASTIC ANAEMIA IN CHILDREN UNDER SIX YEARS: A STUDY FROM A COHORT ON BEHALF OF THE FRENCH REFERENCE CENTER FOR APLASTIC ANEMIA Cecile Renard (Lyon, France)	18:00 - 18:00
B294	EVALUATION OF HAEMATOLOGY PHYSICIANS' AWARENESS OF AND REFERRAL TO APLASTIC ANAEMIA PATIENT ADVOCACY GROUPS Raj Gokani (Walton Oaks, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
B295	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACQUIRED APLASTIC ANEMIA WITH CYCLOPHOSPHAMIDE AND ANTI-THYMOCYTE GLOBULIN CONDITIONING REGIMEN Malek Benakli (Algiers, Algeria)	18:00 - 18:00
B296	OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR BONE MARROW FAILURE SYNDROMES IN PAEDIATRIC POPULATION - A RESOURCE-LIMITED COUNTRY - SRI LANKA Shanika Vitharana (Colombo, Sri Lanka)	18:00 - 18:00
B297	OUTCOME AFTER AUTOLOGOUS CORD BLOOD TRANSPLANTATION FOR PEDIATRIC ACQUIRED APLASTIC ANEMIA:A RETROSPECTIVE ANALYSIS OF MULTICENTER STUDY IN CHINA Jiao Chen (Beijing, China)	18:00 - 18:00

Printed Poster

18:00 - 19:00

R13

Myelodysplastic Syndromes

B356	OUTCOME OF PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MDS/MPN OVERLAP SYNDROMES - A REAL WORLD ANALYSIS ACROSS 12 CENTERS IN GERMANY Marek Werth (Frankfurt am Main, Germany)	18:00 - 18:00
B357	VALIDATION OF MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM FOR POST-TRANSPLANT PROGNOSIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA DEFINED BY INTERNATIONAL CONSENSUS	18:00 - 18:00

CLASSIFICATION 2022

Yiming Cai (Suzhou, China)

- | | | |
|------|---|---------------|
| B358 | SEQUENTIAL FLAMSA-FB CONDITIONING IMPROVES PFS IN UNTREATED MDS PATIENTS UNDERGOING ALLOGENEIC HSCT COMPARED TO ALTERNATIVE REGIMENS
Radwan Massoud (Hamburg, Germany) | 18:00 - 18:00 |
| B359 | OUTCOMES OF ALLO-HCT PERFORMED WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED PROPHYLAXIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME. STUDY CONDUCTED ON BEHALF OF GETH-TC
María Queralt Salas (Barcelona, Spain) | 18:00 - 18:00 |
| B360 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME ASSOCIATED WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - A STUDY ON BEHALF OF THE CMWP AND SAAWP OF THE EBMT
Joanna Drozd-Sokolowska (Warsaw, Poland) | 18:00 - 18:00 |
| B362 | INFLUENCE OF MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-M) STRATIFICATION ON BONE MARROW TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME(MDS): LATIN AMERICAN REGISTRY
Fernando Barroso Duarte (Fortaleza, Brazil) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R13

Immunodeficiency Diseases and Macrophages

- | | | |
|------|---|---------------|
| B318 | CLINICAL OUTCOME AND QUALITY OF LIFE IN PATIENTS WITH ARPC1B-DEFICIENCY MANAGED CONSERVATIVELY OR WITH ALLOGENEIC STEM CELL TRANSPLANTATION ON BEHALF OF INBORN ERRORS WORKING PARTY
Maura Faraci (Genova, Italy) | 18:00 - 18:00 |
| B319 | HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR VERY EARLY-ONSET INFLAMMATORY BOWEL DISEASE CAUSED BY INTERLEUKIN-10 RECEPTOR DEFICIENCY
Ping Wang (Shanghai, China) | 18:00 - 18:00 |
| B320 | POST-TRANSPLANT AUTOIMMUNE DISORDERS IN PATIENTS TRANSPLANTED FOR PRIMARY IMMUNODEFICIENCY OR IMMUNE DYSREGULATION
Hannah Lust (Chicago, United States of America (the)) | 18:00 - 18:00 |
| B321 | EXPERIENCE WITH T-CELL DEPLETED ALLOGENEIC HSCT FOR REFRACTORY SJIA ASSOCIATED WITH LUNG DISEASE
Eleanor Cook (Cincinnati, United States of America (the)) | 18:00 - 18:00 |
| B322 | NEWBORN SCREENING SAVES LIVES, AND OTHER LESSONS LEARNED FROM ONE HUNDRED TRANSPLANTS IN SCID
Etai Adam (Ramat Gan, Israel) | 18:00 - 18:00 |
| B323 | TREOSULFAN-BASED CONDITIONING REGIMEN WITH PLERIXAFOR AND G-CSF BEFORE TCRAB+/CD19+ GRAFT DEPLETED HSCT IN WISKOTT-ALDRICH SYNDROME PATIENTS: AN UPDATE OF 8 YEARS' EXPERIENCE
Evelina Lyudovskikh (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| B324 | EXCELLENT SURVIVAL AFTER ALLO-HSCT FROM ANY DONOR SOURCE IN SCREENED SCID PATIENTS - A SINGLE CENTER ANALYSIS
Kajetan Trojovsky (Düsseldorf, Germany) | 18:00 - 18:00 |

B325	IMPROVED SURVIVAL AFTER ALLOGENEIC HSCT IN SCID PATIENTS AFTER INTRODUCTION OF NEWBORN SCREENING IN RUSSIA Alexandra Laberko (Moscow, Russian Federation (the))	18:00 - 18:00
B326	IMPACT OF MIXED CHIMERISM ON DISEASE CONTROL IN PATIENTS WITH INBORN ERRORS OF IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION Alexandra Laberko (Moscow, Russian Federation (the))	18:00 - 18:00
B327	EXPANDING THE LANDSCAPE OF INBORN ERRORS OF IMMUNITY IN HEMATOLOGICAL DISORDERS: A PROSPECTIVE STUDY ON HIDDEN IEI AND IEI PHENOCOPIES Eleonora Gambineri (Florence, Italy)	18:00 - 18:00
B328	THE JANUS KINASE INHIBITOR RUXOLITINIB RESOLVED RECURRENT CNS DISEASE POST-HEMATOPOIETIC STEM CELL TRANSPLANT IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS Yue Song (Suzhou, China)	18:00 - 18:00
B330	SECOND ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH INBORN ERRORS OF IMMUNITY Vedat Uygun (Istanbul, Turkey)	18:00 - 18:00
B331	ALLOPLUS: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV), UPDATE OF A RETROSPECTIVE STUDY OF THE SFGM TC Ana Berceanu (Reims, France)	18:00 - 18:00
B332	CLINICAL EFFICACY AND SAFETY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TREATING X-LINKED AGAMMAGLOBULINEMIA Jun Li Zhu (Beijing, China)	18:00 - 18:00
B335	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN FOR PRIMARY IMMUNE DEFICIENCIES: THE EXPERIENCE OF SINGLE CENTER Ilgen Sasmaz (Adana, Turkey)	18:00 - 18:00
B336	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR WISKOTT-ALDRICH SYNDROME - A REPORT FROM INDIA Satya Prakash Yadav (Gurgaon, India)	18:00 - 18:00
B337	HSCT IN CHILDREN WITH INBORN ERRORS OF IMMUNITY: A SINGLE-CENTER EXPERIENCE FROM SOUTHERN INDIA Sagar Bhattad (Bangalore, India)	18:00 - 18:00
B338	THE IMPACT OF PRE-TRANSPLANT COMORBIDITIES AND IMMUNE RECONSTITUTION ON HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN CHILDREN WITH INBORN ERRORS OF IMMUNITY Rafaella Muratori (Curitiba, Brazil)	18:00 - 18:00

Printed Poster
18:00 - 19:00

R13

Solid Tumours

B363	EXTRAMEDULLARY DISEASE OF MYELOID MALIGNANCIES: A RELIABLE INDICATOR FOR TREATMENT WITH ALLOSCT AT ANY STAGE? Alexander Hölscher (Düsseldorf, Germany)	18:00 - 18:00
------	--	---------------

B364	HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANTATION IN ADULT EWING SARCOMA PATIENTS - A RETROSPECTIVE EBMT REGISTRY STUDY Paolo Pedrazzoli (Pavia, Italy)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		R13
Acute Leukaemia		
B216	SAFETY, EFFICACY AND CAR T-CELL PERSISTENCE OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PATIENTS ≥55 YEARS OLD, WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL) Deborah Yallop (London, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
B217	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH <i>NUP98</i>-REARRANGED ACUTE MYELOID LEUKEMIA: A REAL-WORLD MULTICENTER EXPERIENCE Shixuan Zhang (Hangzhou, China)	18:00 - 18:00
B218	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SHOULD BE OFFERED TO OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION: A STUDY FROM THE EBMT ALWP Ali Bazarbachi (Beirut, Lebanon)	18:00 - 18:00
B219	HAPLOIDENTICAL VERSUS MUD HCT FOR ADULT PATIENTS WITH R/R ALL: A STUDY FROM THE GLOBAL COMMITTEE AND THE ALWP OF THE EBMT Yuhua Ru (Suzhou, China)	18:00 - 18:00
B220	ALLOGENEIC TRANSPLANTATION OUTCOMES OF MDS/AML: A MULTICENTER STUDY OF RISK VERIFICATION AND MATCHED ANALYSIS Yuhua Ru (Suzhou, China)	18:00 - 18:00
B221	CLONAL EVOLUTION IN AML PATIENTS AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Olga Blau (Berlin, Germany)	18:00 - 18:00
B222	PROGNOSTIC SIGNIFICANCE OF CYTOGENETIC RISK SCORE IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC TRANSPLANTATION FROM HLA MATCHED DONORS: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Tel Aviv, Israel)	18:00 - 18:00
B223	SAFETY AND EFFICACY OF AFM28, A CD123-TARGETING INNATE CELL ENGAGER IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKAEMIA: INTERIM RESULTS FROM A PHASE 1 STUDY Lydia Wunderle (Mannheim, Germany)	18:00 - 18:00
B224	HYPOMETHYLATING AGENTS AND VENETOCLAX WITH OR WITHOUT DLI IN RELAPSED AML AND MDS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REAL LIFE MULTICENTRIC STUDY Patrizia Chiusolo (Roma, Italy)	18:00 - 18:00
B225	CONSOLIDATIVE ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION VS. WATCH AND WAIT APPROACH FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH EARLY LOSS OF B-CELL APLASIA AFTER CAR T-CELL THERAPY Sergi Camarillas (Barcelona, Spain)	18:00 - 18:00
B226	AUTO-HCT IN CR1 VERSUS ALLO-HCT IN CR2 FOR ADULT	18:00 - 18:00

	PATIENTS WITH INTERMEDIATE-RISK AML. ON BEHALF OF THE EBMT GLOBAL COMMITTEE AND ACUTE LEUKEMIA WORKING PARTY	
	Jia Chen (Suzhou, China)	
B227	ALLOGENEIC TRANSPLANTATION FOR WILMS TUMOR 1 (WT1) MUTATED COMPARED TO NON-MUTATED ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ALWP/EBMT	18:00 - 18:00
	Arnon Nagler (Tel Aviv, Israel)	
B228	OUTCOMES OF MIXED PHENOTYPE ACUTE LEUKEMIA IN THE POST-TRANSPLANT CYCLOPHOSPHAMIDE ERA: A RETROSPECTIVE STUDY OF THE ALWP OF EBMT	18:00 - 18:00
	Annalisa Paviglianiti (Barcelona, Spain)	
B229	ALLOGENEIC STEM CELL TRANSPLANTATION AFTER CAR-T CELL FOR R/R B-ALL IN PAEDIATRIC AND YOUNG ADULT PATIENTS. A RETROSPECTIVE STUDY ON BEHALF OF THE SPANISH GETH-TC	18:00 - 18:00
	Júlia Marsal-Ricomà (Barcelona, Spain)	
B230	VENETOCLAX PLUS HYPOMETHYLATING AGENT COMBINATION AS EFFECTIVE BRIDGE THERAPY TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AML PATIENTS: A SUB-ANALYSIS OF THE AVALON STUDY	18:00 - 18:00
	Elisabetta Todisco (Busto Arsizio, Italy)	
B233	ENDOTHELIAL DYSFUNCTION IN AML PATIENTS PREVAILS FROM INITIAL DIAGNOSIS AND ASSOCIATES WITH OUTCOME	18:00 - 18:00
	Thomas Luft (Heidelberg, Germany)	
B234	OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ADULTS WITH INHERITED MYELOID MALIGNANCIES - A MULTICENTER ANALYSIS ON BEHALF OF THE GERMAN COOPERATIVE TRANSPLANT STUDY GROUP	18:00 - 18:00
	Tim Lohmann (Essen, Germany)	
B235	EXPRESSION OF BONE MARROW INFILTRATING NK CELLS (BINK) AND PERIPHERAL BLOOD NK CELL (PBNK) RECEPTORS IN PAEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA	18:00 - 18:00
	Carmen Mestre Durán (Madrid, Spain)	
B237	VENETOCLAX-DECITABINE FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANT IMPROVES THE OUTCOME OF ELDERLY HIGH-RISK ACUTE MYELOID LEUKAEMIA: VEN-DEC-GITMO STUDY MID-TERM UPDATE OF ALLO-TRANSPLANTED PATIENTS	18:00 - 18:00
	Daniele Avenoso (Brescia, Italy)	
B238	ALLO-HCT OUTCOMES FOR AML PATIENTS WITH TP53 MUTATIONS IN ACTIVE DISEASE: A STUDY ON BEHALF OF THE GLOBAL COMMITTEE AND THE ALWP OF THE EBMT	18:00 - 18:00
	Yishan Ye (Hangzhou, China)	
B239	FLT3-ITD MRD MEASUREMENT WITH A SENSITIVE NGS-BASED METHOD IN AML PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Adriane Halik (Berlin, Germany)	
B240	LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA	18:00 - 18:00
	Maria Klimentova (Moscow, Russian Federation (the))	
B241	DECREASING RISK TO DIE FROM ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN,	18:00 - 18:00

ADOLESCENTS AND YOUNG ADULTS

Jochen J. Frietsch (Jena, Germany)

B242	INVESTIGATING THE ROLE OF BONE MARROW MICROENVIRONMENT IN LEUKEMIA RELAPSE AFTER ALLOGENEIC TRANSPLANTATION	18:00 - 18:00
	Cristina Toffalori (Milano, Italy)	
B243	RELAPSED/REFRACTORY ACUTE MYELOBLASTIC LEUKEMIA: HIGH EFFICIENCY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING SALVAGE THERAPY COMBINING 7 DAYS VENETOCLAX AND G-CSF, FLUDARABINE, HIGH-DOSE CYTARABINE, AND MITOXANTRONE	18:00 - 18:00
	Ahmad Ibrahim (Beirut, Lebanon)	
B244	IMPACT OF TP53 MUTATION ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MDS/AML NOT IN COMPLETE REMISSION	18:00 - 18:00
	Normann Steiner (Innsbruck, Austria)	
B245	ALLOGENEIC STEM CELL TRANSPLANTATION IN <i>DE NOVO</i> CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA IN <i>ACTIVE DISEASE</i>: A STUDY FROM THE ALWP OF THE EBMT	18:00 - 18:00
	Sara Tarantino (Milan, Italy)	
B246	ACUTE MYELOID LEUKEMIA (AML) BLASTS IMPAIR HUMAN MAIT CELL FUNCTION	18:00 - 18:00
	Charlotte Calvo (Paris, France)	
B250	OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PRIMARY REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE ANALYSIS FROM THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION REGISTRY	18:00 - 18:00
	Gloria Catalano (Milan, Italy)	
B251	COMPARING THE EFFICACY AND SAFETY OF VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY AS INDUCTION THERAPY IN CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA PATIENTS	18:00 - 18:00
	Jingyi Shen (Suchow, China)	
B253	IMPACT OF MUTATED TP53 ALLELIC BURDEN ON OUTCOMES OF ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A STUDY FROM THE ALWP OF THE EBMT	18:00 - 18:00
	Xavier Poiré (Brussels, Belgium)	
B254	OPTIMIZATION STRATEGIES FOR TRANSPLANT RECOMMENDATION FOR ADULT AML PATIENTS WITH <i>CBFB::MYH11</i> FUSION	18:00 - 18:00
	Luxiang Wang (Shanghai, China)	
B255	COMPARATIVE OUTCOMES OF AZACITIDINE-VENETOCLAX VERSUS LENALIDOMIDE-AZACITIDINE AS SALVAGE THERAPY IN RELAPSED MYELOID MALIGNANCIES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Inna Shaforostova (Muenster, Germany)	
B256	LONG-TERM OUTCOME OF DLI-BASED TREATMENT STRATEGY IN PATIENTS WITH RELAPSED AML AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Jule Bergsma (Leiden, Netherlands (the))	
B258	REAL-WORLD ANALYSIS OF FLT3 INHIBITOR MAINTENANCE THERAPY ON POST-TRANSPLANT OUTCOMES IN FLT3-MUTATED AML PATIENTS FROM THE GERMAN HEMATOPOIETIC STEM CELL TRANSPLANTATION REGISTRY (DRST)	18:00 - 18:00

	Radwan Massoud (Hamburg, Germany)	
B259	B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH RELAPSED/REFRACTORY OR PERSISTENT MRD BENEFIT FROM BLINATUMOMAB BRIDGING PRIOR TO ALLO-HSCT Luxiang Wang (Shanghai, China)	18:00 - 18:00
B260	IMPACT OF COMPLETE REMISSION WITH PARTIAL AND INCOMPLETE HEMATOLOGIC RECOVERY AFTER VENETOCLAX-BASED THERAPY ON ALLOHCT OUTCOMES IN AML PATIENTS Dmitrii Zhogolev (St. Petersburg, Russian Federation (the))	18:00 - 18:00
B261	A PHASE I/II STUDY OF TAFASITAMAB FOR THE PREVENTION OF RELAPSE AFTER STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ALL Peter Lang (Tübingen, Germany)	18:00 - 18:00
B263	FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN OLDER AML AND MDS PATIENTS: A SINGLE-CENTER EXPERIENCE Anna Grassi (Bergamo, Italy)	18:00 - 18:00
B264	SORAFENIB MAINTENANCE MODULATES IMMUNE RECONSTITUTION AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION REDUCING PD-1 EXPRESSION ON CD8 T CELLS Sarah Morin (Geneva, Switzerland)	18:00 - 18:00
B265	KAT6A INHIBITION AS A NOVEL STRATEGY TO OVERCOME IDH INHIBITOR RESISTANCE IN ACUTE MYELOID LEUKEMIA Mengbao Du (Hangzhou, China)	18:00 - 18:00
B266	DONOR LYMPHOCYTE INFUSIONS FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS Fabio Serpenti (Milano, Italy)	18:00 - 18:00
B267	SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE SINGLE CENTER ANALYSIS Michalis Kastamoulas (Athens, Greece)	18:00 - 18:00
B268	CLINICAL OUTCOMES OF AZACITIDINE AND VENETOCLAX TREATMENT WITH OR WITHOUT CELLULAR THERAPY IN RELAPSED AML POST-ALLOHCT Candela Ceballos (San Sebastian, Spain)	18:00 - 18:00
B269	EFFICACY AND SAFETY OF AZACITIDINE AND VENETOCLAX IN RELAPSED ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES POST-ALLO-HCT: A POLISH ACUTE LEUKEMIA GROUP (PALG) ANALYSIS Agnieszka Szeremet (Wroclaw, Poland)	18:00 - 18:00
B270	DAY +100 BONE MARROW MEGAKARYOCYTE RESERVE PREDICTS SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ACUTE LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Zeynep Arzu Yegin (Ankara, Turkey)	18:00 - 18:00
B271	PREEMPTIVE DONOR LYMPHOCYTE INFUSION FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA - AN ANALYSIS ON BEHALF OF POLISH ACUTE LEUKEMIA GROUP (PALG) Anna Lojko-Dankowska (Poznan, Poland)	18:00 - 18:00
B272	PRE-TRANSPLANT MRD DOUBLE POSITIVE DETECTION BY MOLECULAR AND MFC WERE THE INDEPENDENT DISMAL	18:00 - 18:00

	PROGNOSTIC FACTOR IN KMT2A-TRANSLOCATION PARTNER GENES AND KMT2A-PTD AML IN CR1	
	Na Zhang (Hebei, China)	
B274	MO-TRANS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE III STUDY OF MOCRAVIMOD (MOC) AS ADJUNCTIVE AND MAINTENANCE TREATMENT IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	18:00 - 18:00
	Elisabeth Kueenburg (Saint-Louis, France)	
B275	A SOUTH WALES PERSPECTIVE OF OUTCOMES IN ACUTE MYELOID LEUKAEMIA (AML) IN FIRST COMPLETE REMISSION (CR1): A RETROSPECTIVE ANALYSIS OF PRE-TRANSPLANT BONE MARROW ASSESSMENT	18:00 - 18:00
	Abigail Downing (Cardiff, United Kingdom of Great Britain and Northern Ireland (the))	
B276	EFFICACY AND SAFETY OF REDUCED DOSE POST TRANSPLANT CYCLOPHOSPHAMIDE REGIMES IN HAPLOIDENTICAL STEM CELL TRANSPLANT IN PATIENTS WITH ACUTE LEUKAEMIA, A SINGLE CENTRE STUDY	18:00 - 18:00
	Tien Gen Wong (Ampang Jaya, Malaysia)	
B277	IMPACT OF T(9;11) AND DEL(7Q) AS INTERMEDIATE-RISK ABNORMALITIES IN AML AFTER ALLO-TRANSPLANT: ANALYSIS BASED ON THE ELN 2022 CLASSIFICATION - AN EBMT ALWP STUDY	18:00 - 18:00
	Iman Abou Dalle (Beirut, Lebanon)	
B278	AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS MAINTENANCE THERAPY AS A POST-CONSOLIDATION THERAPY IN PATIENTS WITH STANDARD RISK ACUTE LYMPHOBLASTIC LEUKEMIA	18:00 - 18:00
	Sebastian Giebel (Gliwice, Poland)	
B279	OUTCOME OF AML PATIENTS WITH POSTTRANSPLANT EXTRAMEDULLARY RELAPSE	18:00 - 18:00
	Cort Hendrik Claassen (Essen, Germany)	
B281	IMPLEMENTATION OF CLINICAL ROUTINE USE OF NEXT-GENERATION SEQUENCING AND VENETOCLAX IN ACUTE MYELOID LEUKAEMIA TREATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION, A REAL-LIFE SINGLE-CENTRE STUDY	18:00 - 18:00
	Riccardo Boncompagni (Florence, Italy)	
B282	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN CHILDREN WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: AMBULATORY OR IN-HOSPITAL?	18:00 - 18:00
	Guillermo J. Ruiz-Argüelles (Puebla, Mexico)	
B283	CONDITIONING REGIMEN COMBINING LOW DOSE TBI, POST TRANSPLANTATION CYCLOPHOSPHAMIDE AND STANDARD PROPHYLACTIC DLI LEADS TO EXCELLENT 2 YEARS OUTCOME IN FRAIL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	18:00 - 18:00
	Constantijn Halkes (Leiden, Netherlands (the))	
B284	IMPACT OF TACROLIMUS EXPOSURE ON CLINICAL OUTCOMES IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	Andreas Ralfs (Düsseldorf, Germany)	

Printed Poster
18:00 - 19:00

Paediatric Issues

R13

B168	<p>CUMULATIVE INCIDENCE AND OUTCOME OF SECONDARY NEOPLASMS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN. A SINGLE CENTER EXPERIENCE</p> <p>Daria Pagliara (Roma, Italy)</p>	18:00 - 18:00
B169	<p>LONG-TERM OUTCOMES OF HSCT FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA, SINGLE CENTER EXPERIENCE.</p> <p>L. Shelikhova (Moscow, Russian Federation (the))</p>	18:00 - 18:00
B170	<p>DISRUPTION OF THE GUT MICROENVIRONMENT AND BLOOD-BRAIN BARRIER PREDICTS COGNITIVE IMPAIRMENT IN PAEDIATRIC HSCT</p> <p>Maya Davies (Adelaide, Australia)</p>	18:00 - 18:00
B171	<p>HEPATIC VENO-OCCLUSIVE DISEASE IN PATIENTS UNDER 3 YEARS OLD RECEIVING A HSCT. A MULTICENTER SURVEY STUDY OF SPANISH GROUP FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (GETH-TC)</p> <p>Iván López-Torija (Barcelona, Spain)</p>	18:00 - 18:00
B172	<p>VEDOLIZUMAB PREVENTS LOWER GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC NON-MALIGNANT DISEASE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</p> <p>Karin Toews (Berlin, Germany)</p>	18:00 - 18:00
B173	<p>SPECIFIC HLA CLASS I GENOTYPES DO NOT PREDICT PROGNOSIS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC APLASTIC ANEMIA</p> <p>Kotaro Narita (Nagoya, Japan)</p>	18:00 - 18:00
B174	<p>PROSPECTIVE EVALUATION OF TREOSULFAN EXPOSURE IMPACT ON THE OUTCOMES OF PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</p> <p>Francesco Delle Cave (Pavia, Italy)</p>	18:00 - 18:00
B175	<p>EASIX SCORE PREDICTS OVERALL SURVIVAL, EVENT-FREE SURVIVAL AND NON-RELAPSE MORTALITY FOR PEDIATRIC PATIENTS AFTER ALLOST</p> <p>Burak Caliskan (Vienna, Austria)</p>	18:00 - 18:00
B176	<p>AGE IS A STRONG INFLUENCE ON THE GUT MICROBIOME IN CHILDREN UNDERGOING HEMATOPOIETIC CELL TRANSPLANT</p> <p>Pooja Khandelwal (Cincinnati, United States of America (the))</p>	18:00 - 18:00
B177	<p>FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR DECOLONIZATION OF MULTI-DRUG RESISTANT MICROORGANISMS (MDRO) OR GVHD TREATMENT IN CHILDREN: A MULTICENTER RETROSPECTIVE ANALYSIS ON SAFETY AND EFFICACY</p> <p>Pietro Merli (Rome, Italy)</p>	18:00 - 18:00
B178	<p>DEVELOPMENT AND VALIDATION OF A PREDICTION MODEL FOR SEVERE PES DURING THE TREATMENT OF UNRELATED UCBT IN PEDIATRIC PATIENTS</p> <p>Fang Liu (Tianjin, China)</p>	18:00 - 18:00
B179	<p>OUTCOMES OF PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES GIVEN SECOND HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH EITHER TCRAB/CD19 DEPLETION OR POST-TRANSPLANT CYCLOPHOSPHAMIDE</p> <p>Riccardo Masetti (Bologna, Italy)</p>	18:00 - 18:00

B180	HAPLOIDENTICAL SIBLING DONOR FOR PEDIATRIC PATIENTS: THE PERFECT MISMATCH? Marta Gonzalez Vicent (Madrid, Spain)	18:00 - 18:00
B181	LONG-TERM OUTCOMES IN PATIENTS WITH HURLER SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION Melissa Panesso (Barcelona, Spain)	18:00 - 18:00
B182	PAEDIATRIC APHERESIS PROCEDURES USING HICKMAN CATHETERS: EXPERIENCE OF A UK CENTRE Gemma Barnard (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
B183	OUTCOMES OF THE FIRST COMPREHENSIVE PEDIATRIC PRIVATE HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER IN JORDAN: EXPERIENCE FROM A DEVELOPING COUNTRY. Ayad Ahmed Hussein (Amman, Jordan)	18:00 - 18:00
B184	NUTRITIONAL EVALUATION AND SUPPORT IN PEDIATRIC ALLO-HSCT: AN EXPERT CONSENSUS ON BEHALF OF THE INFECTIOUS DISEASE, NURSES, AND HEMATOPOIETIC CELL TRANSPLANT WORKING GROUPS OF AIEOP Francesco Baccelli (Bologna, Italy)	18:00 - 18:00
B185	HIGH TACROLIMUS TROUGH CONCENTRATIONS IS AN EARLY PREDICTOR OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN Rajinder Bajwa (Columbus, United States of America (the))	18:00 - 18:00
B186	USE OF ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION IN PEDIATRIC PATIENTS: A RETROSPECTIVE MULTICENTER STUDY Filomena Pierri (Genova, Italy)	18:00 - 18:00
B187	MULTICENTER REPORT ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH TRISOMY 21 AND ACUTE LEUKEMIAS IN CHILE, 2000-2024 Paula Catalán (Santiago, Chile)	18:00 - 18:00
B188	ENHANCING PEDIATRIC OUTCOMES IN STEM CELL TRANSPLANTATION: INTEGRATING SCREENING TOOLS FOR COMPREHENSIVE QUALITY OF LIFE ASSESSMENT Flannery Bowman (Durham, United States of America (the))	18:00 - 18:00
B189	EFFICACY OF AUTOLOGOUS CORD BLOOD TRANSPLANTATION IN TREATING CHILDREN WITH ACQUIRED APLASTIC ANEMIA: A SINGLE-CENTER COMPARATIVE STUDY AND INDIVIDUAL PATIENT DATA META-ANALYSIS Ye Guo (Tianjin, China)	18:00 - 18:00
B190	PHYSICAL CAPACITY AND METABOLIC SYNDROME IN LONG-TERM SURVIVORS OF PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - THE IMPACT OF LIFESTYLE Anne Nissen (Copenhagen, Denmark)	18:00 - 18:00
B191	THE USE OF CONTINUOUS MILRINONE THERAPY AS A HEMODYMANIC BRIDGE TO ALLOGENEIC HEMATOPOEITIC CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ANTHRACYCLINE-RELATED CARDIOTOXICITY Deepak Chellapandian (St Petersburg, United States of America (the))	18:00 - 18:00
B192	ARTIFICIAL INTELLIGENCE HELPS IN THE EARLY DIAGNOSIS OF VENO-OCCLUSIVE DISEASE IN CHILDREN WITH 100% ACCURACY	18:00 - 18:00

	Rajinder Bajwa (Columbus, United States of America (the))	
B193	TCI-SCORE: EXPLORATION FOR FUTURE VALIDATION IN A PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION COHORT, FIRST REPORT Paula Catalán (Santiago, Chile)	18:00 - 18:00
B194	EFFICACY AND SAFETY ASSESSMENT OF ANTIFUNGAL PROPHYLAXIS WITH POSACONAZOLE USING THERAPEUTIC DRUG MONITORING IN PEDIATRIC PATIENTS WITH ONCOHEMATOLOGICAL DISORDERS - A SINGLE-CENTRE STUDY Karolina Liszka (Wrocław, Poland)	18:00 - 18:00
B195	IMPACT OF THE DASATINIB USED BEFORE ALLOHCT ON THE OUTCOME OF CHILDREN WITH CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA Fang Liu (Tianjin, China)	18:00 - 18:00
B196	SEVERE VANISHING BILE DUCT SYNDROME IN PEDIATRIC PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Maura Faraci (Genova, Italy)	18:00 - 18:00
B197	OUTCOMES OF AB T CELL DEPLETED HAPLO-HSCT FOR PEDIATRIC MDS Sung Han Kang (Seoul, Korea (the Republic of))	18:00 - 18:00
B198	IMPACT OF ABO MISMATCH ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS Luiz Guilherme Darrigo Junior (Ribeirão Preto, Brazil)	18:00 - 18:00
B199	ELEVATED PLASMA CXCL9 AND CHI3L1 PRIOR TO HCT PREDICTS POST-HCT PULMONARY COMPLICATIONS IN CHILDREN Hannah Walker (Parkville, Australia)	18:00 - 18:00
B200	MACROPHAGE ACTIVATION SYNDROME WITH POOR GRAFT FUNCTION OR REJECTION AS INDICATION FOR SECOND ALLOGENEIC HCT FROM HAPLOIDENTICAL DONOR IN CHILDREN WITH HIGH RISK ACUTE LEUKEMIA Polina Kozhokar (Saint-Petersburg, Russian Federation (the))	18:00 - 18:00
B201	THE USE OF POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN PEDIATRIC UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION Luca Marie Beermann (Hamburg, Germany)	18:00 - 18:00
B202	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM UNRELATED DONOR VERSUS HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK HEMATOLOGICAL MALIGNANCIES Maura Faraci (Genova, Italy)	18:00 - 18:00
B203	OUTCOME OF SECOND ALLOGENEIC STEM CELL TRANSPLANTATION OR BOOST FOR PEDIATRIC BONE MARROW FAILURE DISORDERS Alice Morin (Paris, France)	18:00 - 18:00
B204	CHARACTERIZING OUTCOMES AND RESOURCE UTILIZATION IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS MEETING ENHANCED CARE CRITERIA: A SINGLE CENTER EXPERIENCE Lev Gorfinkel (Boston, United States of America (the))	18:00 - 18:00
B205	HEMATOPOIETIC STEM CELL TRANSPLANTATION DISRUPTS AGE-RELATED GUT MICROBIOTA SIGNATURES IN PEDIATRIC AND ADULT PATIENTS	18:00 - 18:00

	Francesco Baccelli (Bologna, Italy)	
B207	SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOLLOWING GRAFT FAILURE IN CHILDREN Eun Sang Yi (Seoul, Korea (the Republic of))	18:00 - 18:00
B208	SECOND ALLOHCT FOR RELAPSES OF ACUTE LEUKEMIA ASSOCIATED WITH HLA LOSS OF HETEROZYGOSITY IN CHILDREN Polina Kozhokar (Saint-Petersburg, Russian Federation (the))	18:00 - 18:00
B210	USE OF SOMATIC NEXT-GENERATION SEQUENCING PANELS: NEW OPPORTUNITIES TO OPTIMIZE THE INDICATION FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION Aurora Pescini (Pisa, Italy)	18:00 - 18:00
B211	OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH DOWN SYNDROME AND ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GETH-TC Mercedes Plaza Fornieles (Murcia, Spain)	18:00 - 18:00
B212	ETHNIC DISPARITIES IN RESPONSE TO CMV IMMUNOTHERAPY USING INTRAVENOUS CMV HYPERIMMUNE GLOBULIN IN PEDIATRIC ALLO-HSCT RECIPIENTS Natalia Maximova (Trieste, Italy)	18:00 - 18:00
B213	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MALIGNANT NEOPLASMS IN CHILDREN: SINGLE CENTER EXPERIENCE FOR 560 PEDIATRIC PATIENTS Teimur Aliev (Moscow, Russian Federation (the))	18:00 - 18:00
B215	PHOTOBIMODULATION FOR PREVENTION AND TREATMENT OF MUCOSITIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE RESEARCH PROTOCOL AND PRELIMINARY RESULTS Giovanna Lucchini (Monza, Italy)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		R13
Conditioning Regimens		
B107	VENETOCLAX AND CLADRIBINE-BASED DEBULKING CHEMOTHERAPY SEQUENTIAL OR BRIDGING WITH REDUCED-INTENSITY CONDITIONING FOLLOWED BY ALLO-TRANSPLANTATION IN REFRACTORY MYELOID MALIGNANCIES: A SINGLE ARM PROSPECTIVE PHASE II STUDY Ling Wang (Shanghai, China)	18:00 - 18:00
B108	IN ALLOGENEIC TRANSPLANTATION WITH REDUCED DOSE POSTTRANSPLANTATION-CYCLOPHOSPHAMIDE NON-RELAPSE MORTALITY RISK-SCORES HAVE LIMITED (PATIENTS &GT;=65 YEARS) OR NO VALUE (PATIENTS &LT;65 YEARS) IN TRANSPLANTATION ELIGIBILITY PREDICTION P.A. von dem Borne (Leiden, Netherlands (the))	18:00 - 18:00
B109	PERIPHERAL BLOOD STEM CELL GRAFT BUT NOT CONDITIONING IMPROVES SIBLING OR UNRELATED DONOR TRANSPLANTATION OUTCOMES IN PATIENTS WITH AML ≥65YEARS. A STUDY OF EBMT ALWP Alexandros Kanellopoulos (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))	18:00 - 18:00
B110	CHOICE AND OUTCOME OF CONDITIONING REGIMENS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMA: AN ANALYSIS OF THE EBMT-LYMPHOMA WORKING PARTY	18:00 - 18:00

	Evgenii Shumilov (Münster, Germany)	
B111	TREOSULFAN VS BUSULFAN AS PART OF CLOFARABINE-BASED REDUCED-INTENSITY CONDITIONING REGIMEN BEFORE ALLOTRANSPLANT FOR MYELOID MALIGNANCIES Patrice Chevallier (Nantes, France)	18:00 - 18:00
B112	BUSULFAN LEVELS MONITORING IN ADULTS ENHANCING DOSING ADJUSTMENTS AND STEM CELL TRANSPLANTATION OUTCOMES Shlomo Elias (Jerusalem, Israel)	18:00 - 18:00
B113	COMPARISON OF <i>IN VIVO</i> GVHD PROPHYLAXIS REGIMENS IN PATIENTS WITH AML UNDERGOING ALLO-HCT WITH INTERMEDIATE TOXICITY PROTOCOLS: A STUDY ON BEHALF OF THE EBMT ALWP Jesus Duque-Afonso (Freiburg, Germany)	18:00 - 18:00
B114	COMPARABLE OS AND GFFS OF ATLG VS. RATG FOR GVHD PROPHYLAXIS IN PEDIATRIC AA PATIENTS UNDERGOING TRANSPLANTATION Li Nannan (Langfang, China)	18:00 - 18:00
B115	COMPARATIVE OUTCOMES OF CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A CIBMTR ANALYSIS Amy K. Keating (Boston, United States of America (the))	18:00 - 18:00
B116	GENOTYPE-SPECIFIC CYTOKINE PROFILES AND ENGRAFTMENT OUTCOMES IN REDUCED-TOXICITY HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PRE-TRANSPLANT IMMUNOSUPPRESSION FOR SICKLE CELL DISEASE Anna B. Pawlowska (Duarte, United States of America (the))	18:00 - 18:00
B117	CONDITIONING REGIMEN FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN ACUTE LEUKEMIA: EVIDENCE BASED GUIDELINES ON BEHALF OF THE ITALIAN STEM CELL TRANSPLANT GROUP (GITMO) Alessandra Picardi (Naples, Italy)	18:00 - 18:00
B118	TREOSULFAN/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMAS IN THE POST-TRANSPLANT CYCLOPHOSPHAMIDE ERA: A STUDY ON BEHALF OF GETH-TC Lorenzo Lazzari (Milano, Italy)	18:00 - 18:00
B119	OPTIMIZATION OF TBI-BASED MYELOABLATIVE REGIMEN INCORPORATING ATG AND PTCY IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: HISTORICAL COMPARISON WITH TBI/CY Jae Ho Yoon (Seoul, Korea (the Republic of))	18:00 - 18:00
B120	ALEMTUZUMAB-BASED ONE-DAY NONMYELOABLATIVE CONDITIONING REGIMEN FOR GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Nihar Desai (Toronto, Canada)	18:00 - 18:00
B121	FLUDARABINE AND TREOSULFAN CONDITIONING IS FEASIBLE AND LEADS TO HIGH OS AND LOW NRM Chiara Bernardi (Geneva, Switzerland)	18:00 - 18:00
B122	IMPACT OF GVHD PROPHYLAXIS WITH <i>IN VIVO</i> T-CELL DEPLETION ON HEMATOPOIETIC AND IMMUNE SYSTEM RECONSTITUTION IN PATIENTS WITH AML AFTER ALLOGENEIC	18:00 - 18:00

HEMATOPOIETIC CELL TRANSPLANTATION		
	Thomas Meyer (Freiburg, Germany)	
B123	HOSPITAL BASED OUTPATIENT ADMINISTRATION OF ONCE DAILY DOSING MYELOABLATIVE INTRAVENOUS PHARMACOKINETICALLY TARGETED BUSULFAN BASED CONDITIONING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT - SINGLE CENTER EXPERIENCE Hassan Alkhateeb (Rochester, United States of America (the))	18:00 - 18:00
B124	TBI-ATG BASED CONDITIONING REGIMEN IS A PROMISING APPROACH FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED PERIPHERAL T-CELL LYMPHOMA TREATED WITH ALLOGENEIC SCT Chuxian Zhao (Shanghai, China)	18:00 - 18:00
B125	ATG FREE CONDITIONING REGIMEN USING FLUDARABINE, BUSULFAN AND CYCLOPHOSPHAMIDE IN SIBLING DONOR TRANSPLANTATION FOR THALASSEMIA MAJOR AT A TERTIARY CENTRE IN INDIA D M Mohana Reddy (Bengaluru, India)	18:00 - 18:00
B126	LOW INCIDENCE OF GRAFT-VERSUS-HOST DISEASE AND SATISFACTORY EFFICACY OF VFM CONDITIONING REGIMEN FOR PATIENTS &GT; 50 YEARS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLO-HSCT Yi Luo (Hangzhou, China)	18:00 - 18:00
B127	POST-TRANSPLANT IMMUNOMODULATION WITH 5-AZACITIDINE-DLI IMPROVES SURVIVAL IN SEQUENTIAL CONDITIONING HSCT FOR HIGH-RISK AML AND MDS Audrey Da Rocha (Amiens, France)	18:00 - 18:00
B128	OPTIMIZED ALEMTUZUMAB DOSING AND ROUTE OF ADMINISTRATION MAY IMPROVE OUTCOMES IN PRIMARY HEMANGIOPATHIC LYMPHOHISTIOCYTOSIS Aaron Ross (Houston, United States of America (the))	18:00 - 18:00
B129	TANDEM CONDITIONING-BASED MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH MYELOID MALIGNANCIES NOT IN REMISSION Jae Won Yoo (Seoul, Korea (the Republic of))	18:00 - 18:00
B131	PROPORTIONAL BUT NOT EQUAL RELATION BETWEEN BUSULFAN DOSE ADJUSTMENTS AND RESULTING EXPOSURE VARIATIONS Daniele Canarutto (Milan, Italy)	18:00 - 18:00
B132	IMPACT OF IMMUNOSUPPRESSION INTENSIFIED CONDITIONING REGIMEN FOR PATIENTS WITH STRONG POSITIVE PRE-TRANSPLANTATION DONOR SPECIFIC ANTI-HLA ANTIBODIES (DSAS) UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION Huixia Liu (Shanghai, China)	18:00 - 18:00
B134	THIOTEPA ADDITION TO TREOSULFAN-FLUDARABINE REGIMEN EXHIBITED EFFECTIVENESS AND TOLERABILITY IN ELDERLY AND UNFIT PATIENTS UNDERGOING HSCT WITH ACTIVE MYELOID DISEASES: A REAL-WORLD STUDY Luca Tosoni (Udine, Italy)	18:00 - 18:00
B135	REAL WORLD EXPERIENCE OF TREOSULFAN IN ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH HEMATOLOGICAL DISEASES. THE SPANISH GROUP OF SCT AND CELL THERAPY (GETH-TC)	18:00 - 18:00

	Juan Manuel Cerezo Martín (Santander, Spain)	
B136	OUTCOMES OF SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH TOTAL MARROW AND LYMPHOID IRRADIATION WITH FLUDARABINE AND MELPHALAN Janny Yao (Duarte, United States of America (the))	18:00 - 18:00
B137	IMPACT OF ABSOLUTE LYMPHOCYTE COUNT AT ATG ADMINISTRATION ON OUTCOMES IN HAPLOIDENTICAL HSCT FOR ADULT AML Byung-Sik Cho (Seoul, Korea (the Republic of))	18:00 - 18:00
B138	TREOSULFAN CONDITIONING IN ALLO-HSCT AND DOSE CAPPING ACCORDING TO BODY SURFACE AREA Katerina Nezvalova Henriksen (Oslo, Norway)	18:00 - 18:00
B139	TOTAL MARROW AND LYMPHOID IRRADIATION VERSUS TOTAL BODY IRRADIATION AS CONDITIONING REGIMENS IN ALLOGENIC STEM CELL TRANSPLANTATION: TOXICITY AND OUTCOMES María Panizo-Inogés (Pamplona, Spain)	18:00 - 18:00

Wednesday, 02. April 2025*Educational*

08:30 - 10:00

R3

E11 - ATMPs

Marina Cavazzana (Paris, France)

Stephan Fricke (Leipzig, Germany)

E11-1	Non-Viral CARCIK Cells for AML: Challenges and Perspectives Andrea Biondi (Monza, Italy)	08:30 - 09:00
E11-2	CAR-T cell therapy in patients with T-ALL Franco Locatelli (Rome, Italy)	09:00 - 09:30
E11-3	Innovation in CAR T cell therapy of Multiple Myeloma Michael Hudecek (Würzburg, Germany)	09:30 - 10:00

Workshop

08:30 - 10:00

R6

W08 - Mechanism of disease: a focus on complement

John Lambris (Philadelphia, United States of America (the))

Fabio Ciceri (Milano, Italy)

W08-1	The biology of complement in HSCT: TAM and beyond Sonata Jodele (Cincinnati, United States of America (the))	08:30 - 08:55
W08-2	The complement system at the forefront of novel immunotherapies: Misconceptions, myths, and novel insights John Lambris (Philadelphia, United States of America (the))	08:55 - 09:20
W08-3	Can second-generation, proximal complement inhibitors improve treatment outcome? The lesson from PNH Morag Griffin (Leeds, United Kingdom of Great Britain and Northern Ireland (the))	09:20 - 09:45
W08-4	Panel Discussion	09:45 - 10:00

Nurses Group

08:30 - 10:00

R7

NG20 - Issues in supportive care

Cristina Baiana (Yvoir, Belgium)

Matteo Amicucci (Roma, Italy)

NG20-1	Alternative medicines Julia Ruiz Pato (Madrid, Spain)	08:30 - 08:51
NG20-2	Palliative care - when do we start Ellen de Nijs (Leiden, Netherlands (the))	08:51 - 09:12
NG20-3	Pre-habilitation and re-habilitation Virgile Pinelli (Toulouse, France)	09:12 - 09:33
NG20-4	Conception and pregnancy after transplant and cell therapy Iebe De Quick (Brussels, Belgium)	09:33 - 09:54
NG20-5	Q&A	09:54 - 09:59

Educational

08:30 - 10:00

R8

E12 - Hemoglobinopathies

Emanuele Angelucci (Genova, Italy)

Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the))

E12-1 **Indication and selection of Thalassemia patients for allogeneic transplant or genetic therapy** 08:30 - 09:00

Mattia Algeri (Rome, Italy)

E12-2 **Indication and selection of Sickle cell disease patients for allogeneic transplant or genetic therapy** 09:00 - 09:30

Haydar Frangoul (Nashville, United States of America (the))

E12-3 **Novel approaches of gene editing for patients with hemoglobinopathies** 09:30 - 10:00

Annarita Miccio (Paris, France)

Educational

08:30 - 10:00

R9

E13 - Biology and management of inherited BMF

Carlo Dufour (Genova, Italy)

Krzysztof Kalwak (WROCLAW, Poland)

E13-1 **Understanding leukemogenesis in FA and other inherited BMF** 08:30 - 09:00

Jean Soulier (Paris, France)

E13-2 **Biology and management of inborn errors of immunity with haematological presentations** 09:00 - 09:30

Emma Morris (London, United Kingdom of Great Britain and Northern Ireland (the))

E13-3 **Improving long term outcome of HSCT for Fanconi anemia** 09:30 - 10:00

Eliane Gluckman (Paris, France)

Special Session

08:30 - 10:00

R10

SS9 - Donor registries across different countries

Lydia Foeken (Leiden, Netherlands (the))

Nicoletta Sacchi (Genova, Italy)

SS9-1 **Role of the WMDA in harmonising Donor Registries in a Changing Environment** 08:30 - 08:55

Matthew Seftel (Vancouver, Canada)

SS9-2 **The Impact of (EU) regulation on unrelated HPC provision: the point of view of a registry** 08:55 - 09:20

Sergi Querol (Barcelona, Spain)

SS9-3 **The role of registries in cell and gene therapies** 09:20 - 09:45

Salmah Ahmed (London, United Kingdom of Great Britain and Northern Ireland (the))

SS9-4 **Panel Discussion** 09:45 - 10:00

Nurses Group

08:30 - 10:00

R11

NG21 - Paediatric Session

Ida Bremer Ophorst (Utrecht, Netherlands (the))

Marjola Gjergji (Roma, Italy)

NG21-1 **Join the online meeting How do You do It.. A summary** 08:30 - 08:45

Ida Bremer Ophorst (Utrecht, Netherlands (the))

NG21-2	Cultural differences in approaches to paediatric palliative care in BMT Julie Bayliss (London, United Kingdom of Great Britain and Northern Ireland (the))	08:45 - 09:10
NG21-3	Pediatric Palliative Care during Hematopoietic Stem Cell Transplantation: A Dutch initiative to support child and parents during the HSCT process Heidy Hollander Peggeman (Utrecht, Netherlands (the))	09:10 - 09:35
NG21-4	Advance Care Planning in Paediatric Palliative Nursing Care Maria Aviles Martínez (Madrid, Spain)	09:35 - 10:00
<i>ePoster</i>		
08:30 - 14:00		R18
ePoster Viewing		
<i>Breaks</i>		
10:00 - 10:30		R1
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>Workshop</i>		
10:30 - 11:45		R3
W09 - How to sequence cellular therapy strategies in lymphomas		
Luca Castagna (Palermo, Italy)		
Ali Bazarbachi (Beirut, Lebanon)		
W09-1	DLBCL Alberto Mussetti (Barcelona, Spain)	10:30 - 10:55
W09-2	FL Silvia Montoto (London, United Kingdom of Great Britain and Northern Ireland (the))	10:55 - 11:20
W09-3	MCL Nora Liebers (Duesseldorf, Germany)	11:20 - 11:45
<i>Special Session</i>		
10:30 - 12:00		R6
SS10 - The role of the Apheresis Unit		
Francesco Fiorin (Vicenza, Italy)		
Vanessa Agostini (Genoa, Italy)		
SS10-1	Use of plerixafor to mobilize hematopoietic progenitor cell donors Miquel Lozano (Barcelona, Spain)	10:30 - 11:00
SS10-2	Peripheral blood stem cell collection and megadose CD34 for gene therapy Giovanna Leone (Rome, Italy)	11:00 - 11:30
SS10-3	Leukocyte collection for CAR-T cell production Nina Worel (Vienna, Austria)	11:30 - 12:00
<i>Nurses Group</i>		
10:30 - 11:45		R7
NG22 - Multiprofessional care in transplantation and cell therapy		
Mathias Hellberg-Naegele (St. Gallen, Switzerland)		
Sara Errichiello (Udine, Italy)		
NG22-1	Frailty Anna Estanyol (Barcelona, Spain)	10:30 - 10:48

NG22-2	Neurocognitive disorder Rachel Davidson (London, United Kingdom of Great Britain and Northern Ireland (the))	10:48 - 11:06
NG22-3	Psychiatric conditions: collaborating with liaison psychiatry Hanne Vandewiele (Ghent, Belgium)	11:06 - 11:24
NG22-4	People with physical disability Matteo Cosci (Firenze, Italy)	11:24 - 11:42

Educational

10:30 - 11:45

R8

E14 - Optimizing HSCT in high risk AML/MDS

Michele Malagola (Brescia, Italy)

Marion Subklewe (Munich, Germany)

E14-1	Molecular profiling in MDS to anticipate HSCT Luca Malcovati (Pavia, Italy)	10:30 - 10:48
E14-2	Can we improve the HSCT outcome for TP53 mutated MDS/AML? Justin Loke (Boston, United States of America (the))	10:48 - 11:06
E14-3	Which AML patients should receive a chemo-free approach before allo-SCT? Gesine Bug (Frankfurt, Germany)	11:06 - 11:24
E14-4	Harnessing innate NK cell memory in high-risk AML/MDS Rizwan Romee (Boston, United States of America (the))	11:24 - 11:42

Workshop

10:30 - 11:45

R9

W10 - Optimizing transplantation in acquired BMF

Jakob Passweg (Basel, Switzerland)

Maria Teresa Lupo-Stanghellini (Milano, Italy)

W10-1	The FCC regimen for AA Victoria Potter (London, United Kingdom of Great Britain and Northern Ireland (the))	10:30 - 10:55
W10-2	Open questions in PTCY-based HSCT for AA: can we offer haplo upfront? Can we use for donor other than haplo? Haplo HSCT for AA: How and When Amy De Zern (Baltimore, United States of America (the))	10:55 - 11:20
W10-3	HSCT for PNH in the era of complement inhibitors Camilla Frieri (Avellino, Italy)	11:20 - 11:45

Oral Session

10:30 - 11:45

R10

OS15 - Oral Session 15 | GVHD (II)

Giorgia Battipaglia (Naples, Italy)

Stephanie Boisclair (Hempstead, United States of America (the))

OS15-01	ORCA-T® DEMONSTRATES IMPROVED SURVIVAL FREE OF CHRONIC GVHD COMPARED TO CONVENTIONAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT: A RANDOMIZED PHASE 3 TRIAL IN ADVANCED HEMATOLOGIC MALIGNANCIES Everett H. Meyer (Stanford, United States of America (the))	10:30 - 10:39
OS15-02	DUAL EFFECTS OF HUMAN AMNIOTIC EPITHELIAL STEM CELLS ON ANTI-INFLAMMATION AND FIBROSIS AND PROMOTING LIMBAL STEM CELL REGENERATION IN OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE Xiaoqi Wang (ChongQing, China)	10:39 - 10:48

OS15-03	PATIENT-REPORTED RESPONSE CAPTURES UNIQUE DIMENSION OF CLINICAL BENEFIT IN CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): AN ANALYSIS FROM THE RUXOLITINIB VERSUS BEST AVAILABLE THERAPY REACH3 TRIAL Annie Im (Pittsburgh, United States of America (the))	10:48 - 10:57
OS15-04	POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN IN HAPLOIDENTICAL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT Giorgia Battipaglia (Naples, Italy)	10:57 - 11:06
OS15-05	COMMENSAL BACTEROIDES T6SS ALLEVIATE GI-AGVHD VIA MEDIATING GUT MICROBIOTA COMPOSITION AND BILE ACIDS METABOLISM Pengfei Li (Soochow, China)	11:06 - 11:15
OS15-06	THE ABCS OF GVHD PROPHYLAXIS: A CALCINEURIN INHIBITOR-FREE REGIMEN Stephanie Boisclair (Hempstead, United States of America (the))	11:15 - 11:24
OS15-07	POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS ATG IN PATIENTS WITH CARDIOVASCULAR COMORBIDITY UNDERGOING HSCT FOR AML IN FIRST CR FROM UNRELATED DONORS: RETROSPECTIVE PAIR-MATCH ANALYSIS OF EBMT ALWP Jan Vydra (Prague, Czechia)	11:24 - 11:33

Nurses Group

10:30 - 11:45

R11

NG23 - Oral Flash Talks

Marijke Quaghbeur (Ghent, Belgium)

Patrizia Cornacchione (Rome, Italy)

NG23-01	ROUTES TO RESOURCES: A SURVEY OF NURSES' EBMT WEBSITE USE Julia Ruiz Pato (Madrid, Spain)	10:30 - 10:38
NG23-02	SUCCESSFUL POST-HEMATOPOIETIC CELL TRANSPLANTATION HEALTH PROMOTION AND VACCINATION CLINIC CONDUCTED BY THE REGISTERED NURSES IN RESOURCE-LIMITED COUNTRY Tidarat Pichedvanichok (Bangkok, Thailand)	10:38 - 10:46
NG23-03	COMPARATIVE ANALYSIS OF DRIP VERSUS PUMP INFUSION METHODS ON CAR-T CELL VIABILITY: INITIAL FINDINGS AND IMPLICATIONS FOR CLINICAL Shuyi Ding (Hangzhou, China)	10:46 - 10:54
NG23-05	UNDERSTAND THE SEXUAL LIFE AND INTIMATE RELATIONSHIP OF PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION Weiwei Zhou (Hangzhou, China)	10:54 - 11:02
NG23-06	ADVERSE EVENTS DUE TO CALCINEURIN INHIBITORS IN CHILDREN LESS THAN 2 YEARS OF AGE UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION Jerlin Robin (Chennai, India)	11:02 - 11:10
NG23-07	ARE PATIENTS AND THEIR FAMILIES/CARERS PREPARED FOR THE SLEEP DISTURBANCE DURING TRANSPLANT? AS NURSING STAFF CAN WE MINIMISE THE DISTURBANCE? Jodie Johnston (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	11:10 - 11:18

Breaks

11:45 - 12:30

R1

Lunch Break, ePoster Viewing, Visit Exhibition*Oral Session*

12:30 - 13:45

R3

OS16 - Oral Session 16 | Bacterial and fungal infections

Doris Ponce (New York, United States of America (the))

Yuqi Zhang (Suzhou, China)

- | | | |
|---------|---|---------------|
| OS16-01 | SAFETY AND EFFICACY OF SER-155, AN INVESTIGATIONAL LIVE BIOTHERAPEUTIC: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED COHORT 2 OF A PHASE 1B STUDY IN ADULTS UNDERGOING ALLO-HCT
Doris Ponce (New York, United States of America (the)) | 12:30 - 12:39 |
| OS16-02 | PRE-TRANSPLANT OROPHARYNGEAL ENTEROBACTER COLONIZATION AS A RISK FACTOR IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE CLINICAL ANALYSIS
Yuqi Zhang (Suzhou, China) | 12:39 - 12:48 |
| OS16-03 | PENTAGLOBIN® AS EARLY ADJUVANT TREATMENT FOR FEBRILE NEUTROPENIA IN HEMATOLOGICAL PATIENTS COLONIZED BY CARBAPENEM-RESISTANT ENTEROBACTERIACEAE OR PSEUDOMONAS AERUGINOSA: PRELIMINARY ANALYSIS OF GITMO STUDY "PENTALLO"
Daniela Clerici (Milano, Italy) | 12:48 - 12:57 |
| OS16-04 | NOT SO RARE: NON-ASPERGILLUS AND NON-MUCORALES MOULD INFECTIONS IN ALLOGENEIC STEM CELLS RECIPIENTS
Marie-Pierre Ledoux (Strasbourg, France) | 12:57 - 13:06 |
| OS16-05 | SURVEY ON ICU ORGANIZATION AND ADMISSION AFTER HAEMATOPOIETIC CELL TRANSPLANTATION WITH SPECIAL EMPHASIS ON INFECTIOUS CAUSES. A REPORT BY IDWP AND TCWP OF THE EBMT
Joanna Drozd-Sokolowska (Warsaw, Poland) | 13:06 - 13:15 |
| OS16-06 | DIFFERENTIAL DIAGNOSIS OF FEVER AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION TO REDUCE EMPIRICAL ANTIBIOTIC USE
Yuliya Rogacheva (Saint Petersburg, Russian Federation (the)) | 13:15 - 13:24 |
| OS16-07 | INVASIVE FUSARIOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT
Dina Averbuch (Jerusalem, Israel) | 13:24 - 13:33 |
| OS16-08 | THE EFFECT OF ANTIBACTERIAL PROPHYLAXIS ON EARLY POST-TRANSPLANT MORTALITY IN MYELOMA AND LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS HCT: A RETROSPECTIVE STUDY ON BEHALF OF THE EBMT-IDWP
Moshe Yeshurun (Petah Tikva, Israel) | 13:33 - 13:42 |

Oral Session

12:30 - 13:45

R6

OS17 - Oral Session 17 | CART and other cell therapies

Vanderson Rocha (São Paulo, Brazil)

Edoardo Campodonico (Milan, Italy)

- | | | |
|---------|---|---------------|
| OS17-01 | TANDEM CD19/CD22 CAR T-CELLS AS POTENTIAL THERAPY FOR CHILDREN AND YOUNG ADULTS WITH HIGH-RISK R/R B-ALL | 12:30 - 12:39 |
|---------|---|---------------|

	Jordi Minguillón (Madrid, Spain)	
OS17-02	OUTCOMES OF PATIENTS OVER 70 TREATED WITH BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED REFRACTORY MANTLE CELL LYMPHOMA: A STUDY ON BEHALF OF CTIWP OF EBMT	12:39 - 12:48
	Nicole Santoro (Pescara, Italy)	
OS17-03	UPDATED RESULTS: MULTICENTER OPEN-LABEL PH 3 STUDY OF TABELCLEUCEL FOR SOT OR HCT RECIPIENTS WITH EBV+PTLD AFTER FAILURE OF RITUXIMAB OR RITUXIMAB + CHEMOTHERAPY	12:48 - 12:57
	Sridhar Chaganti (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))	
OS17-04	IMPACT OF CLONAL HEMATOPOIESIS IN A SINGLE-CENTER COHORT OF PATIENTS AFFECTED BY PROLONGED CYTOPENIA AFTER ANTI-CD19 CAR T-CELL THERAPY	12:57 - 13:06
	Edoardo Campodonico (Milan, Italy)	
OS17-05	COMORBIDITIES DO NOT AFFECT NON-RELAPSE MORTALITY OR TOXICITY IN CD19 CAR-T THERAPY: INSIGHTS FROM A MULTICENTER REAL-WORLD ANALYSIS	13:06 - 13:15
	Eugenio Galli (Rome, Italy)	
OS17-06	COMPARISON OF OUTCOMES AFTER CAR-T CELL THERAPY (TISAGENLEUCEL OR AXICABTAGENE CIOLEUCEL) IN PATIENTS AGED >70 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA: CTIWP-EBMT	13:15 - 13:24
	Vanderson Rocha (São Paulo, Brazil)	
OS17-07	RELAPSE PATTERNS AND TREATMENTS AFTER ANTI-CD19 CAR T-CELL THERAPY IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A STUDY ON BEHALF THE GOCART COALITION AND THE EBMT LWP	13:24 - 13:33
	Aitana Balaguer Roselló (Valencia, Spain)	
OS17-08	AUTOLOGOUS CD7 CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY T CELL LYMPHOMA	13:33 - 13:42
	Shan Fu (Hangzhou, China)	
 <i>Nurses Group</i>		
	12:30 - 13:55	R7
NG24 - GVHD & NG Closing session		
Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))		
NG24-1	Skin GVHD: the view from the dermatologist	12:30 - 12:50
	Vieri Grandi (Prato - Pistoia, Italy)	
NG24-2	Gut GVHD: the view from the nurse	12:50 - 13:10
	Lynn Leppla (Freiburg, Germany, Germany)	
NG24-3	Male genital GVHD: the view from the patient	13:10 - 13:30
	Daniele Avenoso (Brescia, Italy)	
	Riccardo Tomasoni (LONDON, United Kingdom of Great Britain and Northern Ireland (the))	
NG24-4	Best of the best	13:30 - 13:40
NG24-5	Highlights of physicians sessions	13:40 - 13:50
	Chiara Nozzoli (Florence, Italy)	
NG24-6	Presentations of Annual Meeting 2026	13:50 - 13:55

Oral Session

12:30 - 13:45

R8

OS18 - Oral Session 18 | Early & Late complications

Elisa Roldan Galvan (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))
 Hassan Alkhateeb (Rochester, United States of America (the))

- | | | |
|---------|---|---------------|
| OS18-01 | OVARIAN TISSUE TRANSPLANTATION FOR FERTILITY RESTORATION IN WOMEN IN REMISSION OF ACUTE LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Florian Chevillon (Paris, France) | 12:30 - 12:39 |
| OS18-02 | TRACKING THE PATIENT QUALITY OF LIFE JOURNEY WITH PROMIS-29 AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
Victoria Korsos (Montreal, Canada) | 12:39 - 12:48 |
| OS18-03 | OUTCOMES OF A MULTICENTRE RANDOMISED TRIAL OF A VIRTUALLY-SUPERVISED TRAINING AND MOTIVATION PROGRAM FOR HCT SURVIVORS AT HOME
David D. Ma (Sydney, Australia) | 12:48 - 12:57 |
| OS18-04 | IMPACT OF BUSULFAN- VERSUS TREOSULFAN-BASED CONDITIONING ON THE INCIDENCE OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Lorenzo Lazzari (Milano, Italy) | 12:57 - 13:06 |
| OS18-05 | IMPACT OF CONDITIONING INTENSITY ON VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) SEVERITY/OUTCOMES IN ADULT HAEMATOPOIETIC CELL TRANSPLANT (HCT) PATIENTS: DEFIFRANCE AND EBMT PASS COMBINED ANALYSIS
Mohamad Mohty (Paris, France) | 13:06 - 13:15 |
| OS18-06 | EARLY CARDIAC EVENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE. SUBANALYSIS EXPLORING CARDIAC TOXICITY CONDUCTED ON BEHALF OF GETH-TC
Filipe R. Pinto (Porto, Portugal) | 13:15 - 13:24 |
| OS18-07 | LONG-TERM OUTCOMES AND LATE COMPLICATIONS OF ALLOGENEIC STEM CELL TRANSPLANTATION WITH T-CELL DEPLETION: EX VIVO (CD34+ POSITIVE SELECTION) VS IN VIVO (ALEMTUZUMAB-BASED CONDITIONING)
Elisa Roldan Galvan (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | 13:24 - 13:33 |
| OS18-08 | ECULIZUMAB IS ASSOCIATED WITH INCREASED BACTERIAL BLOOD INFECTION RATES IN CHILDREN WITH HEMATOPOIETIC CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY- A CASE- CONTROL STUDY
Michelle Schoettler (Atlanta, United States of America (the)) | 13:33 - 13:42 |

Oral Session

12:30 - 13:45

R9

OS19 - Oral Session 19 | Stem cell procurement and manipulation; solid tumors

Moniek de Witte (Utrecht, Netherlands (the))
 Selim Corbacioglu (Regensburg, Germany)

- | | | |
|---------|---|---------------|
| OS19-01 | BONE MARROW OR MOBILIZED PERIPHERAL BLOOD AS A STEM CELL SOURCE FOR HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN SECONDARY ACUTE MYELOID LEUKAEMIA: FROM THE ALWP/EBMT
Arnon Nagler (Tel Aviv, Israel) | 12:30 - 12:39 |
| OS19-02 | ANTI-SGSH ANTIBODIES FOLLOWING HAEMATOPOIETIC STEM CELL (HSC) GENE THERAPY IN MPSIIIA PATIENTS NEITHER | 12:39 - 12:48 |

	IMPACT ENGRAFTMENT OF GENETICALLY MODIFIED HSC NOR INTERFERE WITH MULTI-COMPARTMENT SUBSTRATE REDUCTION	
	Nathan Jeffreys (Manchester, United Kingdom of Great Britain and Northern Ireland (the))	
OS19-03	HAPLOIDENTICAL HSCT IN RELAPSED AND REFRACTORY NEUROBLASTOMA: RESULTS OF THE PROSPECTIVE, OPEN-LABEL RANDOMISED PHASE 2 RIST TRIAL	12:48 - 12:57
	Selim Corbacioglu (Regensburg, Germany)	
OS19-04	MEMORY CD4⁺ T CELLS RECOGNIZE DIVERGENT HLA-DP IMMUNOPEPTIDOMES AND CONTRIBUTE TO LEUKEMIA CONTROL AFTER ALLOGENEIC HCT	12:57 - 13:06
	Kulvara Kittisares (Essen, Germany)	
OS19-05	HLA-MATCHED, PARTIALLY TCRA⁺/CD19 DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION RESULTS IN COMPARABLE IMMUNOLOGICAL RECOVERY AND LOWER RATES OF GVHD COMPARED TO UNMANIPULATED BONE MARROW IN CHILDREN	13:06 - 13:15
	Tim Flaadt (Tübingen, Germany)	
OS19-06	IL-15 EX-VIVO-STIMULATED NK CELLS AS ADOPTIVE CELL THERAPY IN HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC ACUTE LEUKEMIA: A PHASE I/II TRIAL	13:15 - 13:24
	Carmen Mestre Durán (Madrid, Spain)	
OS19-07	VALIDATION OF SEPAX C-PRO (NON-MEDICAL CELL PROCESSING DEVICE) FOR CLINICAL USE	13:24 - 13:33
	Jesús Fernandez Sojo (Barcelona, Spain)	
OS19-08	COMPARISON OF CLINICAL OUTCOMES OF CAMPATH, ABTCR/CD19 DEPLETION AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN PATIENTS WITH ACUTE LEUKEMIA OR MDS/MPN, A STUDY OF CTIWP OF EBMT	13:33 - 13:42
	Moniek de Witte (Utrecht, Netherlands (the))	
<i>Oral Session</i>		
	12:30 - 13:45	R10
OS20 - Oral Session 20 Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution		
	Stefan Ciurea (Orange, United States of America (the))	
	Nicola Cecchi (London, United Kingdom of Great Britain and Northern Ireland (the))	
OS20-01	COMBINED KIDNEY AND HEMATOPOIETIC CELL TRANSPLANTATION FOR TOLERANCE INDUCTION BETWEEN HLA MATCHED SIBLINGS	12:30 - 12:39
	Moshe Yeshurun (Petah Tikva, Israel)	
OS20-02	CHARACTERIZING THYMIC FUNCTION IN PEDIATRIC AND YOUNG ADULT PATIENTS RECEIVING ALLO-HCT USING THE CD31 AND CD38 MARKERS	12:39 - 12:48
	Alessio Taviani (Rome, Italy)	
OS20-03	CHARACTERISATION OF IMMUNOMETABOLIC PROFILE AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEOPLE WITH MULTIPLE SCLEROSIS	12:48 - 12:57
	Malini Visweswaran (Sydney, Australia)	
OS20-04	FAILURE TO ESTABLISH A ROBUST T CELL REPERTOIRE IS ASSOCIATED WITH DEATH FROM INFECTION IN CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANT	12:57 - 13:06
	Caroline M. Bateman (Westmead, Sydney, Australia)	
OS20-05	LEUKEMIA STEM CELL BASED RESIDUAL DISEASE ASSAY FOR RELAPSE PREDICTION IN ACUTE MYELOID LEUKEMIA PATIENTS:	13:06 - 13:15

	A LONG-TERM FOLLOW-UP STUDY Siqi Li (Beijing, China)	
OS20-06	INFECTIONS AND IMMUNE RECONSTITUTION IN THE PHASE 3 CARTITUDE-4 TRIAL OF CILTACABTAGENE AUTOLEUCEL VS STANDARD CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AND 1-3 PRIOR LINES Roberto Mina (Torino, Italy)	13:15 - 13:24
OS20-07	ATG (GENZYME) LEADS TO FASTER IMMUNE RECONSTITUTION THAN ATLG (NEOVII) IMPROVING SURVIVAL IN SIBLING HAEMOPOIETIC STEM TRANSPLANTATION FOR HAEMOGLOBINOPATHIES Nicola Cecchi (London, United Kingdom of Great Britain and Northern Ireland (the))	13:24 - 13:33
OS20-08	ULTRASENSITIVE MICROCHIMERISM MONITORING ENABLES EARLY RELAPSE PREDICTION IN AML/MDS PATIENTS: INTERIM RESULTS FROM ACROBAT MULTICENTER STUDY Stefan Ciurea (Orange, United States of America (the))	13:33 - 13:42
 <i>Oral Session</i> 12:30 - 13:45		
		R11
	OS21 - Oral Session 21 MPD and MDS Yves Chalandon (Genève, Switzerland) Patrizia Chiusolo (Roma, Italy)	
OS21-01	IMPACT OF TP53 VARIANTS AND GERMLINE MUTATIONS ON ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES IN AML/MDS PATIENTS: A MULTI-CENTER COHORT STUDY Yeqian Zhao (Hangzhou, China)	12:30 - 12:39
OS21-02	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME IN YOUNG ADULTS: A RETROSPECTIVE STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT Antonio M. Jimenez Jimenez (Miami, United States of America (the))	12:39 - 12:48
OS21-03	ASSOCIATION OF CONDITIONING REGIMEN INTENSITY, STRATIFIED BY THE TRANSPLANT CONDITIONING INTENSITY (TCI) INDEX, AND OUTCOMES FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFIBROSIS Patrik Sobieralski (Gdańsk, Poland)	12:48 - 12:57
OS21-04	PTCY OR ATG GVHD PROPHYLAXIS FOR HLA-MATCHED TRANSPLANTATION IN MYELOFIBROSIS Patrizia Chiusolo (Roma, Italy)	12:57 - 13:06
OS21-05	DECREASED CHRONIC GVHD WITH PTCY COMPARED TO ATG IN PATIENTS WITH MYELOFIBROSIS ALLOGRAFTED WITH AN UNRELATED DONOR: A STUDY FROM THE CMWP OF THE EBMT Yves Chalandon (Genève, Switzerland)	13:06 - 13:15
OS21-06	ANALYSIS OF CHARACTERISTICS, OUTCOME AND RISK FACTORS OF PATIENTS WITH MDS UNDERGOING A SECOND ALLOGENEIC SCT (ALLOSCT2) - A STUDY ON BEHALF OF THE CMWP Giuliano Filippini Velázquez (Augsburg, Germany)	13:15 - 13:24
OS21-07	SUBGROUP OF MDS WITH VERY POOR-RISK CYTOGENETICS HARBORING A MORE FAVORABLE OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A STUDY FROM THE CMWP OF THE EBMT Xavier Poiré (Brussels, Belgium)	13:24 - 13:33
OS21-08	DEFINING REMISSION FOLLOWING HEMATOPOIETIC CELL	13:33 - 13:42

TRANSPLANTATION FOR MYELOFIBROSIS: AN INTERNATIONAL EXPERT PANEL CONSENSUS

Rachel Salit (Seattle, United States of America (the))

General

14:00 - 14:30

R3

GS4 - Closing Session

Anna Sureda (Barcelona, Spain)

Fabio Ciceri (Milano, Italy)

GS4-1	Presentation of the Springer Nature Poster Awards Anna Sureda (Barcelona, Spain)	14:00 - 14:05
GS4-2	Best Young Abstracts Mette Hazenberg (Amsterdam, Netherlands (the))	14:05 - 14:10
GS4-3	Congress Presidents closing remarks Fabio Ciceri (Milano, Italy) Anna Sureda (Barcelona, Spain)	14:10 - 14:15
GS4-4	Presentation of the 52nd Annual Meeting of the EBMT	14:15 - 14:25
GS4-5	EBMT President closing remarks Anna Sureda (Barcelona, Spain)	14:25 - 14:30